{"04a4b08224b045e039544b20ea5687985de22143": [["The development of a vaccine able to prevent infection or severe disease course of SARS-CoV-2 is a priority to stem the current COVID-19 pandemic and to be better prepared for future flare-ups.", [["infection", "DISEASE", 45, 54], ["SARS", "DISEASE", 83, 87], ["SARS-CoV-2", "ORGANISM", 83, 93], ["SARS-CoV", "SPECIES", 83, 91], ["a vaccine", "TREATMENT", 19, 28], ["infection", "PROBLEM", 45, 54], ["severe disease course of SARS", "PROBLEM", 58, 87], ["the current COVID", "TEST", 116, 133], ["pandemic", "PROBLEM", 137, 145], ["infection", "OBSERVATION", 45, 54], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["disease", "OBSERVATION", 65, 72]]], ["To accelerate T-cell immunogen design, many current approaches are employing epitope prediction strategies.", [["T-cell", "ANATOMY", 14, 20], ["T-cell", "CELL", 14, 20], ["T-cell immunogen design", "TREATMENT", 14, 37], ["epitope prediction strategies", "TREATMENT", 77, 106]]], ["Although such approaches have great merit, it is also important that unbiased approaches to characterizing the T-cell response to SARS-CoV-2 are incorporated into vaccine design, in order to generate a comprehensive picture of the total virus-specific T-cell response and to define correlates of protective immunity against the virus.", [["T-cell", "ANATOMY", 111, 117], ["T-cell", "ANATOMY", 252, 258], ["SARS", "DISEASE", 130, 134], ["T-cell", "CELL", 111, 117], ["SARS-CoV-2", "ORGANISM", 130, 140], ["T-cell", "CELL", 252, 258], ["SARS", "PROBLEM", 130, 134], ["CoV", "TEST", 135, 138], ["the total virus", "PROBLEM", 227, 242], ["protective immunity", "TREATMENT", 296, 315], ["the virus", "PROBLEM", 324, 333]]]], "168527e08cf88c12f7d5410bf0ab86ff6871d90c": [["This virus heterogeneously surges and abates across the country, and without a coordinated national response, it will continue indefinitely until a vaccine is available.", [["This virus heterogeneously surges", "PROBLEM", 0, 33], ["a vaccine", "TREATMENT", 146, 155], ["heterogeneously", "OBSERVATION_MODIFIER", 11, 26], ["surges", "OBSERVATION", 27, 33]]]], "5586a9e0d884dc39d90a1c4fd8f293459dd5f661": [["IntroductionEnglish springer spaniels (ESS) in the UK have an increased risk of chronic hepatitis (CH).", [["chronic hepatitis", "DISEASE", 80, 97], ["CH", "DISEASE", 99, 101], ["chronic hepatitis (CH)", "PROBLEM", 80, 102], ["increased", "OBSERVATION_MODIFIER", 62, 71], ["chronic", "OBSERVATION_MODIFIER", 80, 87], ["hepatitis", "OBSERVATION", 88, 97]]], ["1 CH is defined by the World Small Animal Veterinary Association (WSAVA) Liver Standardisation Project 2 as histological evidence of hepatocellular apoptosis, necrosis, regeneration, predominant mononuclear cell infiltration and fibrosis.", [["Liver", "ANATOMY", 73, 78], ["hepatocellular", "ANATOMY", 133, 147], ["mononuclear cell", "ANATOMY", 195, 211], ["necrosis", "DISEASE", 159, 167], ["fibrosis", "DISEASE", 229, 237], ["Liver", "ORGAN", 73, 78], ["hepatocellular", "CANCER", 133, 147], ["mononuclear cell", "CELL", 195, 211], ["hepatocellular apoptosis", "PROBLEM", 133, 157], ["necrosis", "PROBLEM", 159, 167], ["regeneration", "PROBLEM", 169, 181], ["predominant mononuclear cell infiltration", "PROBLEM", 183, 224], ["fibrosis", "PROBLEM", 229, 237], ["Small", "OBSERVATION_MODIFIER", 29, 34], ["Liver", "ANATOMY", 73, 78], ["evidence of", "UNCERTAINTY", 121, 132], ["hepatocellular apoptosis", "OBSERVATION", 133, 157], ["necrosis", "OBSERVATION", 159, 167], ["regeneration", "OBSERVATION_MODIFIER", 169, 181], ["predominant", "OBSERVATION_MODIFIER", 183, 194], ["mononuclear cell infiltration", "OBSERVATION", 195, 224], ["fibrosis", "OBSERVATION", 229, 237]]], ["The reported postmortem prevalence of CH in dogs in first-opinion practice is 12 per cent, suggesting this is a common disease which likely has a range of aetiologies including nutritional, environmental, genetic and infectious.", [["CH", "DISEASE", 38, 40], ["nutritional, environmental, genetic and infectious", "DISEASE", 177, 227], ["dogs", "ORGANISM", 44, 48], ["dogs", "SPECIES", 44, 48], ["a common disease", "PROBLEM", 110, 126], ["infectious", "OBSERVATION", 217, 227]]], ["3 There are several well-documented causes of canine CH, such as copper accumulation due to a defect in copper metabolism 4 and possible infectious causes due to Bartonella species, 5 Leptospira species 6 and Helicobacter species.", [["CH", "DISEASE", 53, 55], ["copper", "CHEMICAL", 65, 71], ["copper", "CHEMICAL", 104, 110], ["copper", "CHEMICAL", 65, 71], ["copper", "CHEMICAL", 104, 110], ["canine", "ORGANISM", 46, 52], ["copper", "SIMPLE_CHEMICAL", 65, 71], ["copper", "SIMPLE_CHEMICAL", 104, 110], ["Bartonella species", "ORGANISM", 162, 180], ["5", "ORGANISM", 182, 183], ["Leptospira species 6", "ORGANISM", 184, 204], ["Helicobacter species", "ORGANISM", 209, 229], ["canine", "SPECIES", 46, 52], ["canine CH", "PROBLEM", 46, 55], ["copper accumulation", "PROBLEM", 65, 84], ["a defect in copper metabolism 4", "PROBLEM", 92, 123], ["infectious causes", "PROBLEM", 137, 154], ["Bartonella species", "PROBLEM", 162, 180], ["5 Leptospira species", "PROBLEM", 182, 202], ["Helicobacter species", "PROBLEM", 209, 229], ["several", "OBSERVATION_MODIFIER", 12, 19], ["well-documented", "OBSERVATION_MODIFIER", 20, 35], ["canine CH", "OBSERVATION", 46, 55], ["defect", "OBSERVATION", 94, 100], ["possible", "UNCERTAINTY", 128, 136], ["infectious", "OBSERVATION", 137, 147], ["Bartonella species", "OBSERVATION", 162, 180], ["Helicobacter species", "OBSERVATION", 209, 229]]], ["7 Although previous studies have identified viral causes of CH, including canine adenovirus type I, 8 there is currently no substantial evidence to suggest viral causes are a significant aetiology for canine CH.", [["CH", "DISEASE", 60, 62], ["canine adenovirus type I", "DISEASE", 74, 98], ["CH", "DISEASE", 208, 210], ["canine adenovirus type I", "ORGANISM", 74, 98], ["canine", "ORGANISM", 201, 207], ["canine", "SPECIES", 74, 80], ["canine adenovirus type I", "SPECIES", 74, 98], ["canine", "SPECIES", 201, 207], ["previous studies", "TEST", 11, 27], ["viral causes of CH", "PROBLEM", 44, 62], ["canine adenovirus type I", "PROBLEM", 74, 98], ["viral causes", "PROBLEM", 156, 168], ["canine CH", "PROBLEM", 201, 210], ["viral", "OBSERVATION", 44, 49], ["no substantial evidence to suggest", "UNCERTAINTY", 121, 155], ["viral", "OBSERVATION", 156, 161]]], ["[9] [10] [11] [12] Studies have been performed which support an immune-mediated aetiology to CH in some breeds.", [["CH", "DISEASE", 93, 95]]], ["13 14 CH has a number of well-reported breed predispositions including the Labrador retriever, 15 American Cocker Spaniel, 16 English Cocker Spaniel, 17 ESS, 1 Dalmatian, 18 Doberman, 19 Great Dane, 20 Cairn Terrier and Samoyed; 1 however, the underlying aetiology is frequently unknown and therefore treatment often remains non-specific and supportive.", [["Labrador retriever", "DISEASE", 75, 93], ["Labrador retriever", "SPECIES", 75, 93]]], ["21 In a previous study of 68 ESS with biopsy confirmed idiopathic CH, only one was treated with prednisolone, and the median survival time of the whole cohort was 189 days (range: 1-1211 days).", [["idiopathic CH", "DISEASE", 55, 68], ["prednisolone", "CHEMICAL", 96, 108], ["prednisolone", "CHEMICAL", 96, 108], ["prednisolone", "SIMPLE_CHEMICAL", 96, 108], ["a previous study", "TEST", 6, 22], ["biopsy", "TEST", 38, 44], ["idiopathic CH", "PROBLEM", 55, 68], ["prednisolone", "TREATMENT", 96, 108], ["idiopathic", "OBSERVATION", 55, 65]]], ["22 This suggested that the underlying disease process in the ESS was aggressive and rapidly fatal in most cases, in contrast to a previous study looking at 79 dogs of various breeds with histologically confirmed CH which reported mean survival times of 21.1-36.4 months when cirrhosis was not present.", [["CH", "DISEASE", 212, 214], ["cirrhosis", "DISEASE", 275, 284], ["dogs", "ORGANISM", 159, 163], ["dogs", "SPECIES", 159, 163], ["the underlying disease process", "PROBLEM", 23, 53], ["a previous study", "TEST", 128, 144], ["cirrhosis", "PROBLEM", 275, 284], ["disease", "OBSERVATION", 38, 45], ["aggressive", "OBSERVATION_MODIFIER", 69, 79], ["cirrhosis", "OBSERVATION", 275, 284]]], ["23 Research investigating the disease in ESS and other breeds in the UK initially concentrated on attempts to find a viral cause for the disease because of the histological similarity to human viral hepatitis and canine acidophil cell hepatitis.", [["acidophil cell", "ANATOMY", 220, 234], ["viral hepatitis", "DISEASE", 193, 208], ["canine acidophil cell hepatitis", "DISEASE", 213, 244], ["human", "ORGANISM", 187, 192], ["canine acidophil cell hepatitis", "ORGANISM", 213, 244], ["human", "SPECIES", 187, 192], ["canine", "SPECIES", 213, 219], ["human", "SPECIES", 187, 192], ["canine", "SPECIES", 213, 219], ["the disease in ESS", "PROBLEM", 26, 44], ["a viral cause", "PROBLEM", 115, 128], ["the disease", "PROBLEM", 133, 144], ["human viral hepatitis", "PROBLEM", 187, 208], ["canine acidophil cell hepatitis", "PROBLEM", 213, 244], ["disease", "OBSERVATION", 30, 37], ["viral hepatitis", "OBSERVATION", 193, 208], ["acidophil cell hepatitis", "OBSERVATION", 220, 244]]], ["9 24 Corticosteroid treatment was not initially advised and cases were instead managed supportively.", [["Corticosteroid treatment", "TREATMENT", 5, 29]]], ["However, the progression of CH in these cases remained mostly rapid and short survival times were noted, 22 yet some clinicians reported improved survival when these cases were given corticosteroids.", [["CH", "DISEASE", 28, 30], ["corticosteroids", "CHEMICAL", 183, 198], ["the progression of CH in these cases", "PROBLEM", 9, 45], ["corticosteroids", "TREATMENT", 183, 198], ["progression", "OBSERVATION_MODIFIER", 13, 24], ["mostly", "OBSERVATION_MODIFIER", 55, 61], ["rapid", "OBSERVATION_MODIFIER", 62, 67]]], ["Despite the widespread use of corticosteroids in the general treatment of canine CH, only two previous studies have investigated their efficacy.", [["CH", "DISEASE", 81, 83], ["corticosteroids", "CHEMICAL", 30, 45], ["canine", "ORGANISM", 74, 80], ["canine", "SPECIES", 74, 80], ["corticosteroids", "TREATMENT", 30, 45], ["two previous studies", "TEST", 90, 110], ["widespread", "OBSERVATION_MODIFIER", 12, 22]]], ["25 26 One of those studies was published before the WSAVA Liver Standardisation Project, which generates concern that some patients were not truly idiopathic, and both studies included a range of canine breeds.", [["Liver", "ANATOMY", 58, 63], ["Liver", "ORGAN", 58, 63], ["patients", "ORGANISM", 123, 131], ["canine", "ORGANISM", 196, 202], ["patients", "SPECIES", 123, 131], ["canine", "SPECIES", 196, 202], ["those studies", "TEST", 13, 26], ["truly idiopathic", "PROBLEM", 141, 157], ["Liver", "ANATOMY", 58, 63], ["not truly", "UNCERTAINTY", 137, 146], ["idiopathic", "OBSERVATION", 147, 157]]], ["Although both studies identified some clinical and biochemical improvements in some cases of canine CH, it is likely that the study populations included a diverse range of underlying disease processes and therefore the results are likely difficult to interpret.", [["CH", "DISEASE", 100, 102], ["canine", "ORGANISM", 93, 99], ["canine", "SPECIES", 93, 99], ["both studies", "TEST", 9, 21], ["the study populations", "TEST", 122, 143], ["underlying disease processes", "PROBLEM", 172, 200], ["disease", "OBSERVATION", 183, 190]]], ["There are no currently published studies investigating the response to prednisolone in canine patients with CH in a single breed.", [["prednisolone", "CHEMICAL", 71, 83], ["CH", "DISEASE", 108, 110], ["prednisolone", "CHEMICAL", 71, 83], ["prednisolone", "SIMPLE_CHEMICAL", 71, 83], ["canine", "ORGANISM", 87, 93], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["canine", "SPECIES", 87, 93], ["published studies", "TEST", 23, 40], ["prednisolone", "TREATMENT", 71, 83], ["no", "UNCERTAINTY", 10, 12]]], ["Therefore, the authors instituted a prospective cohort study aimed at investigating the clinical and biochemical response to prednisolone and other supportive treatments in a group of ESS with histopathologically confirmed idiopathic CH.Materials and methodsESS being treated in first-opinion practice, or referred to the Queen's Veterinary School Hospital (University of Cambridge) with a histological diagnosis of idiopathic CH were enrolled prospectively between 2009 and 2017.", [["prednisolone", "CHEMICAL", 125, 137], ["idiopathic CH", "DISEASE", 223, 236], ["idiopathic CH", "DISEASE", 416, 429], ["prednisolone", "CHEMICAL", 125, 137], ["prednisolone", "SIMPLE_CHEMICAL", 125, 137], ["a prospective cohort study", "TEST", 34, 60], ["prednisolone", "TREATMENT", 125, 137], ["other supportive treatments", "TREATMENT", 142, 169], ["idiopathic CH", "PROBLEM", 223, 236], ["idiopathic CH", "PROBLEM", 416, 429], ["idiopathic", "OBSERVATION", 223, 233], ["idiopathic", "OBSERVATION", 416, 426]]], ["No cases had previously been involved in studies investigating CH in ESS.", [["CH", "DISEASE", 63, 65]]], ["A histopathological diagnosis was based on a predominantly lymphoplasmacytic, interface hepatitis and variable fibrosis, and according to WSAVA criteria for a diagnosis of CH.", [["hepatitis", "DISEASE", 88, 97], ["fibrosis", "DISEASE", 111, 119], ["CH", "DISEASE", 172, 174], ["A histopathological diagnosis", "TEST", 0, 29], ["a predominantly lymphoplasmacytic", "PROBLEM", 43, 76], ["interface hepatitis", "PROBLEM", 78, 97], ["variable fibrosis", "PROBLEM", 102, 119], ["predominantly", "OBSERVATION_MODIFIER", 45, 58], ["lymphoplasmacytic", "OBSERVATION", 59, 76], ["interface hepatitis", "OBSERVATION", 78, 97], ["variable", "OBSERVATION_MODIFIER", 102, 110], ["fibrosis", "OBSERVATION", 111, 119]]], ["All liver biopsies were stained with rhodanine for qualitative copper assessment using a previously published copper grading system.", [["liver biopsies", "ANATOMY", 4, 18], ["rhodanine", "CHEMICAL", 37, 46], ["copper", "CHEMICAL", 63, 69], ["copper", "CHEMICAL", 110, 116], ["rhodanine", "CHEMICAL", 37, 46], ["copper", "CHEMICAL", 63, 69], ["copper", "CHEMICAL", 110, 116], ["liver biopsies", "CANCER", 4, 18], ["rhodanine", "SIMPLE_CHEMICAL", 37, 46], ["copper", "SIMPLE_CHEMICAL", 63, 69], ["copper", "SIMPLE_CHEMICAL", 110, 116], ["All liver biopsies", "TEST", 0, 18], ["rhodanine", "TREATMENT", 37, 46], ["qualitative copper assessment", "TEST", 51, 80], ["liver", "ANATOMY", 4, 9], ["biopsies", "OBSERVATION", 10, 18]]], ["27 Samples were scored as grade 1: absence or few copper-containing granules in the cytoplasm of an occasional hepatocyte; grade 2: obvious copper-containing granules in some centrilobular hepatocytes; grade 3: numerous granules in most centrilobular hepatocytes (one-third of each lobule); grade 4: presence of numerous granules in all centrilobular and midzonal hepatocytes (approximately two-thirds of the hepatocytes in all lobules); grade 5: abundant granules in more than two-thirds of the liver cells in all lobules.", [["granules", "ANATOMY", 68, 76], ["cytoplasm", "ANATOMY", 84, 93], ["hepatocyte", "ANATOMY", 111, 121], ["granules", "ANATOMY", 158, 166], ["centrilobular hepatocytes", "ANATOMY", 175, 200], ["granules", "ANATOMY", 220, 228], ["centrilobular hepatocytes", "ANATOMY", 237, 262], ["lobule", "ANATOMY", 282, 288], ["granules", "ANATOMY", 321, 329], ["centrilobular", "ANATOMY", 337, 350], ["midzonal hepatocytes", "ANATOMY", 355, 375], ["hepatocytes", "ANATOMY", 409, 420], ["lobules", "ANATOMY", 428, 435], ["granules", "ANATOMY", 456, 464], ["liver cells", "ANATOMY", 496, 507], ["lobules", "ANATOMY", 515, 522], ["copper", "CHEMICAL", 50, 56], ["copper", "CHEMICAL", 50, 56], ["copper", "SIMPLE_CHEMICAL", 50, 56], ["granules", "ORGANISM_SUBSTANCE", 68, 76], ["cytoplasm", "ORGANISM_SUBSTANCE", 84, 93], ["hepatocyte", "CELL", 111, 121], ["granules", "ORGANISM_SUBSTANCE", 158, 166], ["centrilobular hepatocytes", "CELL", 175, 200], ["granules", "ORGANISM_SUBSTANCE", 220, 228], ["centrilobular hepatocytes", "TISSUE", 237, 262], ["lobule", "CANCER", 282, 288], ["granules", "ORGANISM_SUBSTANCE", 321, 329], ["centrilobular", "TISSUE", 337, 350], ["midzonal hepatocytes", "CELL", 355, 375], ["hepatocytes", "CELL", 409, 420], ["lobules", "CANCER", 428, 435], ["granules", "ORGANISM_SUBSTANCE", 456, 464], ["liver cells", "CELL", 496, 507], ["lobules", "MULTI-TISSUE_STRUCTURE", 515, 522], ["centrilobular hepatocytes", "CELL_TYPE", 175, 200], ["centrilobular hepatocytes", "CELL_TYPE", 237, 262], ["centrilobular and midzonal hepatocytes", "CELL_TYPE", 337, 375], ["hepatocytes", "CELL_TYPE", 409, 420], ["liver cells", "CELL_TYPE", 496, 507], ["few copper-containing granules", "PROBLEM", 46, 76], ["an occasional hepatocyte", "PROBLEM", 97, 121], ["obvious copper-containing granules in some centrilobular hepatocytes", "PROBLEM", 132, 200], ["numerous granules in most centrilobular hepatocytes", "PROBLEM", 211, 262], ["numerous granules in all centrilobular and midzonal hepatocytes", "PROBLEM", 312, 375], ["abundant granules", "PROBLEM", 447, 464], ["occasional", "OBSERVATION_MODIFIER", 100, 110], ["hepatocyte", "ANATOMY", 111, 121], ["copper-containing granules", "OBSERVATION", 140, 166], ["some", "ANATOMY_MODIFIER", 170, 174], ["centrilobular", "ANATOMY_MODIFIER", 175, 188], ["hepatocytes", "ANATOMY", 189, 200], ["grade 3", "OBSERVATION_MODIFIER", 202, 209], ["numerous", "OBSERVATION_MODIFIER", 211, 219], ["granules", "OBSERVATION", 220, 228], ["most", "ANATOMY_MODIFIER", 232, 236], ["centrilobular", "ANATOMY_MODIFIER", 237, 250], ["hepatocytes", "ANATOMY", 251, 262], ["lobule", "ANATOMY_MODIFIER", 282, 288], ["grade 4", "OBSERVATION_MODIFIER", 291, 298], ["numerous", "OBSERVATION_MODIFIER", 312, 320], ["granules", "OBSERVATION", 321, 329], ["all", "ANATOMY_MODIFIER", 333, 336], ["centrilobular", "ANATOMY_MODIFIER", 337, 350], ["midzonal", "ANATOMY_MODIFIER", 355, 363], ["hepatocytes", "ANATOMY", 364, 375], ["approximately", "OBSERVATION_MODIFIER", 377, 390], ["hepatocytes", "ANATOMY", 409, 420], ["all lobules", "ANATOMY", 424, 435], ["grade 5", "OBSERVATION_MODIFIER", 438, 445], ["abundant", "OBSERVATION_MODIFIER", 447, 455], ["granules", "OBSERVATION", 456, 464], ["liver", "ANATOMY", 496, 501], ["cells", "ANATOMY_MODIFIER", 502, 507], ["all lobules", "ANATOMY", 511, 522]]], ["The histopathology specimens were examined by several board-certified pathologists and were excluded if significant copper accumulation (grade 3-5) was documented.", [["histopathology specimens", "ANATOMY", 4, 28], ["copper", "CHEMICAL", 116, 122], ["copper", "CHEMICAL", 116, 122], ["histopathology specimens", "CANCER", 4, 28], ["copper", "SIMPLE_CHEMICAL", 116, 122], ["The histopathology specimens", "TEST", 0, 28], ["significant copper accumulation", "PROBLEM", 104, 135]]], ["Cases with evidence of pyogranulomatous hepatitis were also excluded.", [["pyogranulomatous hepatitis", "DISEASE", 23, 49], ["pyogranulomatous hepatitis", "PROBLEM", 23, 49], ["evidence of", "UNCERTAINTY", 11, 22], ["pyogranulomatous hepatitis", "OBSERVATION", 23, 49]]], ["No cases had been treated with corticosteroids within six months of the study.", [["corticosteroids", "CHEMICAL", 31, 46], ["corticosteroids", "TREATMENT", 31, 46], ["the study", "TEST", 68, 77]]], ["Attending veterinary surgeons gave prednisolone 1-2 mg/kg/day and submitted haematology and biochemistry samples and progress reports to the authors.", [["prednisolone", "CHEMICAL", 35, 47], ["prednisolone", "CHEMICAL", 35, 47], ["prednisolone", "SIMPLE_CHEMICAL", 35, 47], ["prednisolone", "TREATMENT", 35, 47], ["biochemistry samples", "TEST", 92, 112]]], ["The prednisolone starting dose range was based on two previous studies that investigated the response to prednisolone in various canine breeds with CH.", [["prednisolone", "CHEMICAL", 4, 16], ["prednisolone", "CHEMICAL", 105, 117], ["CH", "DISEASE", 148, 150], ["prednisolone", "CHEMICAL", 4, 16], ["prednisolone", "CHEMICAL", 105, 117], ["prednisolone", "SIMPLE_CHEMICAL", 4, 16], ["prednisolone", "SIMPLE_CHEMICAL", 105, 117], ["canine", "ORGANISM", 129, 135], ["canine", "SPECIES", 129, 135], ["The prednisolone", "TREATMENT", 0, 16], ["two previous studies", "TEST", 50, 70], ["prednisolone", "TREATMENT", 105, 117]]], ["25 26 Prednisolone is a wellreported treatment option for canine CH, and the decision to start the patients on this therapy was at the discretion of the clinician in charge of each case.", [["Prednisolone", "CHEMICAL", 6, 18], ["CH", "DISEASE", 65, 67], ["Prednisolone", "CHEMICAL", 6, 18], ["Prednisolone", "SIMPLE_CHEMICAL", 6, 18], ["canine", "ORGANISM", 58, 64], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["canine", "SPECIES", 58, 64], ["Prednisolone", "TREATMENT", 6, 18], ["a wellreported treatment option", "TREATMENT", 22, 53], ["this therapy", "TREATMENT", 111, 123]]], ["Informed owner consent was obtained for analysis of patient data.", [["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59], ["analysis of patient data", "TEST", 40, 64]]], ["All patients had their first recheck 2-4 weeks following initiation of prednisolone therapy, which included biochemical assessment of liver parameters.", [["liver", "ANATOMY", 134, 139], ["prednisolone", "CHEMICAL", 71, 83], ["prednisolone", "CHEMICAL", 71, 83], ["patients", "ORGANISM", 4, 12], ["prednisolone", "SIMPLE_CHEMICAL", 71, 83], ["liver", "ORGAN", 134, 139], ["patients", "SPECIES", 4, 12], ["prednisolone therapy", "TREATMENT", 71, 91], ["biochemical assessment", "TEST", 108, 130], ["liver parameters", "TEST", 134, 150], ["liver", "ANATOMY", 134, 139]]], ["Further blood samples were advised to be taken before any prednisolone dose reduction.", [["blood samples", "ANATOMY", 8, 21], ["prednisolone", "CHEMICAL", 58, 70], ["prednisolone", "CHEMICAL", 58, 70], ["blood samples", "ORGANISM_SUBSTANCE", 8, 21], ["prednisolone", "SIMPLE_CHEMICAL", 58, 70], ["Further blood samples", "TEST", 0, 21], ["any prednisolone dose reduction", "TREATMENT", 54, 85]]], ["The prednisolone dose was tapered by 25 per cent-50 per cent every 4 weeks according to the patient's clinical and biochemical response, focusing on alkaline phosphatase (ALKP), alanine aminotransferase (ALT) and bilirubin.", [["prednisolone", "CHEMICAL", 4, 16], ["alanine", "CHEMICAL", 178, 185], ["bilirubin", "CHEMICAL", 213, 222], ["prednisolone", "CHEMICAL", 4, 16], ["alanine", "CHEMICAL", 178, 185], ["bilirubin", "CHEMICAL", 213, 222], ["prednisolone", "SIMPLE_CHEMICAL", 4, 16], ["patient", "ORGANISM", 92, 99], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 149, 169], ["ALKP", "GENE_OR_GENE_PRODUCT", 171, 175], ["alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 178, 202], ["ALT", "SIMPLE_CHEMICAL", 204, 207], ["bilirubin", "SIMPLE_CHEMICAL", 213, 222], ["alkaline phosphatase", "PROTEIN", 149, 169], ["ALKP", "PROTEIN", 171, 175], ["alanine aminotransferase", "PROTEIN", 178, 202], ["ALT", "PROTEIN", 204, 207], ["patient", "SPECIES", 92, 99], ["The prednisolone dose", "TREATMENT", 0, 21], ["alkaline phosphatase", "TEST", 149, 169], ["ALKP", "TEST", 171, 175], ["alanine aminotransferase", "TEST", 178, 202], ["ALT", "TEST", 204, 207], ["bilirubin", "TEST", 213, 222]]], ["While all cases had these values assessed at diagnosis and at the first recheck, not all cases had these values measured each time the prednisolone dose was altered.", [["prednisolone", "CHEMICAL", 135, 147], ["prednisolone", "CHEMICAL", 135, 147], ["prednisolone", "SIMPLE_CHEMICAL", 135, 147], ["the prednisolone dose", "TREATMENT", 131, 152]]], ["To account for variation in instruments used to assess biochemical parameters, and corresponding variation in reference ranges, the ALKP, ALT and bilirubin have been presented as multiples of the upper limit of the reference range for the individual machine used.", [["bilirubin", "CHEMICAL", 146, 155], ["bilirubin", "CHEMICAL", 146, 155], ["ALKP", "SIMPLE_CHEMICAL", 132, 136], ["ALT", "SIMPLE_CHEMICAL", 138, 141], ["bilirubin", "SIMPLE_CHEMICAL", 146, 155], ["ALKP", "PROTEIN", 132, 136], ["ALT", "PROTEIN", 138, 141], ["bilirubin", "PROTEIN", 146, 155], ["variation in instruments", "PROBLEM", 15, 39], ["biochemical parameters", "TEST", 55, 77], ["the ALKP", "TEST", 128, 136], ["ALT", "TEST", 138, 141], ["bilirubin", "TEST", 146, 155], ["the individual machine", "TREATMENT", 235, 257], ["upper limit", "OBSERVATION_MODIFIER", 196, 207]]], ["Due to individual patient variation in the way prednisolone was tapered and timing of blood samples, the biochemical values were plotted against the prednisolone dose at the time of sampling rather than against specific time points.", [["blood samples", "ANATOMY", 86, 99], ["prednisolone", "CHEMICAL", 47, 59], ["prednisolone", "CHEMICAL", 149, 161], ["prednisolone", "CHEMICAL", 47, 59], ["prednisolone", "CHEMICAL", 149, 161], ["patient", "ORGANISM", 18, 25], ["prednisolone", "SIMPLE_CHEMICAL", 47, 59], ["blood samples", "ORGANISM_SUBSTANCE", 86, 99], ["prednisolone", "SIMPLE_CHEMICAL", 149, 161], ["patient", "SPECIES", 18, 25], ["individual patient variation", "PROBLEM", 7, 35], ["the way prednisolone", "TREATMENT", 39, 59], ["blood samples", "TEST", 86, 99], ["the biochemical values", "TEST", 101, 123], ["the prednisolone dose", "TREATMENT", 145, 166]]], ["Thus, the values were recorded and plotted graphically against different oral doses of prednisolone, including the values at diagnosis of CH; the values after prednisolone 1-2 mg/ kg/day for 2-4 weeks; 0.5-1 mg/kg/day; 0.5-1 mg/ kg/EOD (every other day); 0.25-0.5 mg/kg/EOD; after cessation of prednisolone treatment (if applicable) and after restarting prednisolone treatment if cessation of medication caused a relapse in clinical signs.", [["oral", "ANATOMY", 73, 77], ["prednisolone", "CHEMICAL", 87, 99], ["CH", "DISEASE", 138, 140], ["prednisolone", "CHEMICAL", 159, 171], ["prednisolone", "CHEMICAL", 294, 306], ["prednisolone", "CHEMICAL", 354, 366], ["prednisolone", "CHEMICAL", 87, 99], ["prednisolone", "CHEMICAL", 159, 171], ["prednisolone", "CHEMICAL", 294, 306], ["prednisolone", "CHEMICAL", 354, 366], ["oral", "ORGANISM_SUBDIVISION", 73, 77], ["prednisolone", "SIMPLE_CHEMICAL", 87, 99], ["prednisolone", "SIMPLE_CHEMICAL", 159, 171], ["prednisolone", "SIMPLE_CHEMICAL", 294, 306], ["prednisolone", "SIMPLE_CHEMICAL", 354, 366], ["the values", "TEST", 6, 16], ["prednisolone", "TREATMENT", 87, 99], ["prednisolone", "TREATMENT", 159, 171], ["prednisolone treatment", "TREATMENT", 294, 316], ["prednisolone treatment", "TREATMENT", 354, 376], ["medication", "TREATMENT", 393, 403], ["a relapse in clinical signs", "PROBLEM", 411, 438]]], ["Additional therapies used included combinations of S-adenosylmethionine, silybin, ursodeoxycholic acid, antibiotics and hepatic diet.Statistical analysisShapiro-Wilk normality testing was performed on the data and identified a lack of normal distribution, typical of small data sets.", [["hepatic", "ANATOMY", 120, 127], ["S-adenosylmethionine", "CHEMICAL", 51, 71], ["silybin", "CHEMICAL", 73, 80], ["ursodeoxycholic acid", "CHEMICAL", 82, 102], ["S-adenosylmethionine", "CHEMICAL", 51, 71], ["silybin", "CHEMICAL", 73, 80], ["ursodeoxycholic acid", "CHEMICAL", 82, 102], ["S-adenosylmethionine", "SIMPLE_CHEMICAL", 51, 71], ["silybin", "SIMPLE_CHEMICAL", 73, 80], ["ursodeoxycholic acid", "SIMPLE_CHEMICAL", 82, 102], ["antibiotics", "SIMPLE_CHEMICAL", 104, 115], ["hepatic", "ORGAN", 120, 127], ["Additional therapies", "TREATMENT", 0, 20], ["S-adenosylmethionine", "TREATMENT", 51, 71], ["silybin", "TREATMENT", 73, 80], ["ursodeoxycholic acid", "TREATMENT", 82, 102], ["antibiotics", "TREATMENT", 104, 115], ["hepatic diet", "TREATMENT", 120, 132], ["Statistical analysis", "TEST", 133, 153], ["the data", "TEST", 201, 209], ["hepatic", "ANATOMY", 120, 127], ["normal", "OBSERVATION", 235, 241], ["distribution", "OBSERVATION_MODIFIER", 242, 254], ["small", "OBSERVATION_MODIFIER", 267, 272]]], ["Therefore, the non-parametric twosided Wilcoxon test was used to demonstrate significant (P<0.05) changes in serum ALKP, ALT and bilirubin following prednisolone therapy.ResultsSixteen cases of suspected ESS CH were evaluated during the study period.", [["serum", "ANATOMY", 109, 114], ["bilirubin", "CHEMICAL", 129, 138], ["prednisolone", "CHEMICAL", 149, 161], ["CH", "DISEASE", 208, 210], ["bilirubin", "CHEMICAL", 129, 138], ["prednisolone", "CHEMICAL", 149, 161], ["serum", "ORGANISM_SUBSTANCE", 109, 114], ["ALKP", "SIMPLE_CHEMICAL", 115, 119], ["ALT", "SIMPLE_CHEMICAL", 121, 124], ["bilirubin", "SIMPLE_CHEMICAL", 129, 138], ["prednisolone", "SIMPLE_CHEMICAL", 149, 161], ["serum ALKP", "PROTEIN", 109, 119], ["ALT", "PROTEIN", 121, 124], ["the non-parametric twosided Wilcoxon test", "TEST", 11, 52], ["serum ALKP", "TEST", 109, 119], ["ALT", "TEST", 121, 124], ["bilirubin", "TEST", 129, 138], ["prednisolone therapy", "TREATMENT", 149, 169], ["suspected ESS CH", "PROBLEM", 194, 210], ["the study", "TEST", 233, 242], ["significant", "OBSERVATION_MODIFIER", 77, 88]]], ["Two cases were excluded because Hepatitis, lobular and interface, lymphocytic and neutrophilic, chronic, severe with mild portal fibrosis.", [["lobular", "ANATOMY", 43, 50], ["lymphocytic", "ANATOMY", 66, 77], ["neutrophilic", "ANATOMY", 82, 94], ["Hepatitis", "DISEASE", 32, 41], ["fibrosis", "DISEASE", 129, 137], ["lobular", "CANCER", 43, 50], ["portal", "MULTI-TISSUE_STRUCTURE", 122, 128], ["Hepatitis, lobular and interface", "PROBLEM", 32, 64], ["lymphocytic", "PROBLEM", 66, 77], ["neutrophilic", "PROBLEM", 82, 94], ["mild portal fibrosis", "PROBLEM", 117, 137], ["lobular", "OBSERVATION", 43, 50], ["interface", "OBSERVATION_MODIFIER", 55, 64], ["lymphocytic", "OBSERVATION_MODIFIER", 66, 77], ["neutrophilic", "OBSERVATION_MODIFIER", 82, 94], ["chronic", "OBSERVATION_MODIFIER", 96, 103], ["severe", "OBSERVATION_MODIFIER", 105, 111], ["mild", "OBSERVATION_MODIFIER", 117, 121], ["portal", "ANATOMY", 122, 128], ["fibrosis", "OBSERVATION", 129, 137]]], ["Grade 1 copper hepatic biopsies were not performed, and two cases were excluded because their histopathology results were not consistent with the previously published WSAVA criteria for CH.", [["hepatic biopsies", "ANATOMY", 15, 31], ["copper", "CHEMICAL", 8, 14], ["CH", "DISEASE", 186, 188], ["copper", "CHEMICAL", 8, 14], ["hepatic biopsies", "CANCER", 15, 31], ["Grade 1 copper hepatic biopsies", "PROBLEM", 0, 31], ["hepatic", "ANATOMY", 15, 22], ["biopsies", "OBSERVATION", 23, 31]]], ["All cases had been diagnosed following evaluation of wedge liver biopsies taken during laparotomy or laparoscopy.", [["liver", "ANATOMY", 59, 64], ["wedge liver biopsies", "MULTI-TISSUE_STRUCTURE", 53, 73], ["evaluation", "TEST", 39, 49], ["wedge liver biopsies", "TEST", 53, 73], ["laparotomy", "TEST", 87, 97], ["laparoscopy", "TREATMENT", 101, 112], ["liver", "ANATOMY", 59, 64], ["biopsies", "OBSERVATION", 65, 73], ["laparotomy", "OBSERVATION", 87, 97], ["laparoscopy", "OBSERVATION", 101, 112]]], ["Within these cases, one dog was being treated with levothyroxine for hypothyroidism at the time of recruitment, and one case was subsequently diagnosed with protein-losing nephropathy eight months after initially presenting for hepatic disease, and its urine protein creatinine ratio improved following treatment with standard doses of benazepril (0.5 mg/kg SID PO).", [["hepatic", "ANATOMY", 228, 235], ["urine", "ANATOMY", 253, 258], ["levothyroxine", "CHEMICAL", 51, 64], ["hypothyroidism", "DISEASE", 69, 83], ["nephropathy", "DISEASE", 172, 183], ["hepatic disease", "DISEASE", 228, 243], ["creatinine", "CHEMICAL", 267, 277], ["benazepril", "CHEMICAL", 336, 346], ["levothyroxine", "CHEMICAL", 51, 64], ["creatinine", "CHEMICAL", 267, 277], ["benazepril", "CHEMICAL", 336, 346], ["dog", "ORGANISM", 24, 27], ["levothyroxine", "SIMPLE_CHEMICAL", 51, 64], ["hepatic", "ORGAN", 228, 235], ["urine", "ORGANISM_SUBSTANCE", 253, 258], ["creatinine", "SIMPLE_CHEMICAL", 267, 277], ["benazepril", "SIMPLE_CHEMICAL", 336, 346], ["dog", "SPECIES", 24, 27], ["levothyroxine", "TREATMENT", 51, 64], ["hypothyroidism", "PROBLEM", 69, 83], ["protein-losing nephropathy", "PROBLEM", 157, 183], ["hepatic disease", "PROBLEM", 228, 243], ["its urine protein creatinine ratio", "TEST", 249, 283], ["benazepril", "TREATMENT", 336, 346], ["recruitment", "OBSERVATION", 99, 110], ["hepatic", "ANATOMY", 228, 235], ["disease", "OBSERVATION", 236, 243]]], ["Four of the 12 cases showed no clinical signs of CH at diagnosis but were investigated after routine blood sampling for an unrelated reason detected elevations of liver enzymes.", [["blood", "ANATOMY", 101, 106], ["liver", "ANATOMY", 163, 168], ["CH", "DISEASE", 49, 51], ["blood", "ORGANISM_SUBSTANCE", 101, 106], ["liver", "ORGAN", 163, 168], ["liver enzymes", "PROTEIN", 163, 176], ["clinical signs of CH", "PROBLEM", 31, 51], ["routine blood sampling", "TEST", 93, 115], ["elevations of liver enzymes", "PROBLEM", 149, 176], ["no", "UNCERTAINTY", 28, 30], ["liver", "ANATOMY", 163, 168]]], ["Seven of the 12 cases had bile culture performed and no bacteria were cultured; however, the remaining five patients did not have this evaluated.", [["bile culture", "ANATOMY", 26, 38], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["bile culture", "TEST", 26, 38], ["bacteria", "PROBLEM", 56, 64], ["bile", "ANATOMY", 26, 30]]], ["Table 1 summarises the histopathological diagnosis for each of the 12 ESS cases included in the study.", [["the study", "TEST", 92, 101]]], ["None of the 12 ESS displayed significant qualitative copper accumulation (table 1) and therefore quantitative copper analysis was not performed in these cases.", [["copper", "CHEMICAL", 53, 59], ["copper", "CHEMICAL", 110, 116], ["copper", "CHEMICAL", 53, 59], ["copper", "CHEMICAL", 110, 116], ["copper", "SIMPLE_CHEMICAL", 53, 59], ["copper", "SIMPLE_CHEMICAL", 110, 116], ["significant qualitative copper accumulation", "PROBLEM", 29, 72], ["quantitative copper analysis", "TEST", 97, 125], ["significant", "OBSERVATION_MODIFIER", 29, 40]]], ["Furthermore, there was no histopathological evidence of significant biliary tract inflammation in any of the evaluated samples from the 12 cases.", [["biliary tract", "ANATOMY", 68, 81], ["samples", "ANATOMY", 119, 126], ["biliary tract inflammation", "DISEASE", 68, 94], ["biliary tract", "PATHOLOGICAL_FORMATION", 68, 81], ["significant biliary tract inflammation", "PROBLEM", 56, 94], ["no histopathological evidence of", "UNCERTAINTY", 23, 55], ["significant", "OBSERVATION_MODIFIER", 56, 67], ["biliary tract", "ANATOMY", 68, 81], ["inflammation", "OBSERVATION", 82, 94]]], ["The mean prednisolone starting dosage was 1.1 mg/kg/day (range: 1.0-2.0 mg/kg/day).", [["prednisolone", "CHEMICAL", 9, 21], ["prednisolone", "CHEMICAL", 9, 21], ["prednisolone", "SIMPLE_CHEMICAL", 9, 21], ["The mean prednisolone starting dosage", "TREATMENT", 0, 37]]], ["Symptomatic patients showed a subjective improvement clinically within four weeks according to the owners.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["Table 2 reports the clinical abnormalities reported for each case, both at enrolment and at the first recheck appointment, as well as additional treatments provided to each patient at the time of diagnosis.", [["patient", "ORGANISM", 173, 180], ["patient", "SPECIES", 173, 180], ["the clinical abnormalities", "PROBLEM", 16, 42], ["additional treatments", "TREATMENT", 134, 155]]], ["Two out of the 12 cases were euthanased due to CH-related signs while receiving prednisolone, with survival times of 122 and 741 days from diagnosis.", [["CH", "DISEASE", 47, 49], ["prednisolone", "CHEMICAL", 80, 92], ["prednisolone", "CHEMICAL", 80, 92], ["prednisolone", "SIMPLE_CHEMICAL", 80, 92], ["CH", "PROBLEM", 47, 49], ["prednisolone", "TREATMENT", 80, 92]]], ["Clinical signs that prompted euthanasia for these two patients included hepatic encephalopathy, melaena, jaundice and lethargy.", [["hepatic", "ANATOMY", 72, 79], ["hepatic encephalopathy", "DISEASE", 72, 94], ["melaena", "DISEASE", 96, 103], ["jaundice", "DISEASE", 105, 113], ["lethargy", "DISEASE", 118, 126], ["patients", "ORGANISM", 54, 62], ["hepatic", "ORGAN", 72, 79], ["patients", "SPECIES", 54, 62], ["Clinical signs", "TEST", 0, 14], ["hepatic encephalopathy", "PROBLEM", 72, 94], ["melaena", "PROBLEM", 96, 103], ["jaundice", "PROBLEM", 105, 113], ["lethargy", "PROBLEM", 118, 126], ["hepatic", "ANATOMY", 72, 79], ["encephalopathy", "OBSERVATION", 80, 94], ["melaena", "OBSERVATION", 96, 103], ["jaundice", "OBSERVATION", 105, 113]]], ["The remaining 10 patients are alive and clinically well at the time of manuscript submission, with seven patients still receiving a mean dosage of 0.4 mg/kg prednisolone EOD (range: 0.25 mg/kg/EOD-1 mg/kg/day).", [["prednisolone", "CHEMICAL", 157, 169], ["prednisolone", "CHEMICAL", 157, 169], ["patients", "ORGANISM", 17, 25], ["patients", "ORGANISM", 105, 113], ["prednisolone", "SIMPLE_CHEMICAL", 157, 169], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 105, 113], ["a mean dosage", "TREATMENT", 130, 143], ["prednisolone EOD", "TREATMENT", 157, 173]]], ["Three patients stopped prednisolone therapy without a concurrent elevation in liver parameters, while three cases stopped and needed to be restarted on prednisolone due to recurrence of CH-related signs or an elevation in liver parameters.", [["liver", "ANATOMY", 78, 83], ["liver", "ANATOMY", 222, 227], ["prednisolone", "CHEMICAL", 23, 35], ["prednisolone", "CHEMICAL", 152, 164], ["CH", "DISEASE", 186, 188], ["prednisolone", "CHEMICAL", 23, 35], ["prednisolone", "CHEMICAL", 152, 164], ["patients", "ORGANISM", 6, 14], ["prednisolone", "SIMPLE_CHEMICAL", 23, 35], ["liver", "ORGAN", 78, 83], ["prednisolone", "SIMPLE_CHEMICAL", 152, 164], ["liver", "ORGAN", 222, 227], ["patients", "SPECIES", 6, 14], ["prednisolone therapy", "TREATMENT", 23, 43], ["a concurrent elevation in liver parameters", "PROBLEM", 52, 94], ["prednisolone", "TREATMENT", 152, 164], ["CH", "PROBLEM", 186, 188], ["related signs", "PROBLEM", 189, 202], ["an elevation in liver parameters", "PROBLEM", 206, 238], ["elevation", "OBSERVATION", 65, 74], ["liver", "ANATOMY", 78, 83], ["elevation", "OBSERVATION", 209, 218], ["liver", "ANATOMY", 222, 227]]], ["At the time of submission, four patients are currently in the process of having their prednisolone dose reduced with the aim to stop and monitor for recurrence of clinical signs.", [["prednisolone", "CHEMICAL", 86, 98], ["prednisolone", "CHEMICAL", 86, 98], ["patients", "ORGANISM", 32, 40], ["prednisolone", "SIMPLE_CHEMICAL", 86, 98], ["patients", "SPECIES", 32, 40], ["their prednisolone dose", "TREATMENT", 80, 103], ["clinical signs", "PROBLEM", 163, 177]]], ["Table 3 presents the median values for ALKP, ALT and bilirubin at diagnosis of CH, as well as the values at the patients' first recheck 2-4 weeks after starting prednisolone.", [["bilirubin", "CHEMICAL", 53, 62], ["prednisolone", "CHEMICAL", 161, 173], ["bilirubin", "CHEMICAL", 53, 62], ["prednisolone", "CHEMICAL", 161, 173], ["ALKP", "SIMPLE_CHEMICAL", 39, 43], ["ALT", "SIMPLE_CHEMICAL", 45, 48], ["bilirubin", "SIMPLE_CHEMICAL", 53, 62], ["patients", "ORGANISM", 112, 120], ["prednisolone", "SIMPLE_CHEMICAL", 161, 173], ["ALKP", "PROTEIN", 39, 43], ["ALT", "PROTEIN", 45, 48], ["patients", "SPECIES", 112, 120], ["the median values", "TEST", 17, 34], ["ALKP", "TEST", 39, 43], ["ALT", "TEST", 45, 48], ["bilirubin", "TEST", 53, 62], ["prednisolone", "TREATMENT", 161, 173]]], ["Two-sided Wilcoxon test demonstrated a significant reduction in ALKP, ALT and bilirubin at the first recheck following prednisolone treatment with P values 0.0010, 0.002 and 0.0156, respectively.", [["bilirubin", "CHEMICAL", 78, 87], ["prednisolone", "CHEMICAL", 119, 131], ["bilirubin", "CHEMICAL", 78, 87], ["prednisolone", "CHEMICAL", 119, 131], ["ALKP", "SIMPLE_CHEMICAL", 64, 68], ["ALT", "SIMPLE_CHEMICAL", 70, 73], ["bilirubin", "SIMPLE_CHEMICAL", 78, 87], ["prednisolone", "SIMPLE_CHEMICAL", 119, 131], ["ALKP", "PROTEIN", 64, 68], ["ALT", "PROTEIN", 70, 73], ["Two-sided Wilcoxon test", "TEST", 0, 23], ["a significant reduction", "PROBLEM", 37, 60], ["ALKP", "TEST", 64, 68], ["ALT", "TEST", 70, 73], ["bilirubin", "TEST", 78, 87], ["prednisolone treatment", "TREATMENT", 119, 141], ["P values", "TEST", 147, 155], ["sided", "ANATOMY_MODIFIER", 4, 9], ["significant", "OBSERVATION_MODIFIER", 39, 50], ["reduction", "OBSERVATION_MODIFIER", 51, 60]]], ["Due to variability in the length of time patients remained on the tapering doses of prednisolone, the authors elected not to assess for significant changes between the remaining prednisolone doses.", [["prednisolone", "CHEMICAL", 84, 96], ["prednisolone", "CHEMICAL", 178, 190], ["prednisolone", "CHEMICAL", 84, 96], ["prednisolone", "CHEMICAL", 178, 190], ["patients", "ORGANISM", 41, 49], ["prednisolone", "SIMPLE_CHEMICAL", 84, 96], ["prednisolone", "SIMPLE_CHEMICAL", 178, 190], ["patients", "SPECIES", 41, 49], ["prednisolone", "TREATMENT", 84, 96], ["significant changes", "PROBLEM", 136, 155], ["the remaining prednisolone doses", "TREATMENT", 164, 196], ["variability", "OBSERVATION_MODIFIER", 7, 18], ["length", "OBSERVATION_MODIFIER", 26, 32]]], ["Figures 1 and 2 depict the serum values for ALKP and ALT, respectively, from the 12 ESS cases in this study.", [["serum", "ANATOMY", 27, 32], ["serum", "ORGANISM_SUBSTANCE", 27, 32], ["ALKP", "GENE_OR_GENE_PRODUCT", 44, 48], ["ALT", "SIMPLE_CHEMICAL", 53, 56], ["ALKP", "PROTEIN", 44, 48], ["ALT", "PROTEIN", 53, 56], ["Figures", "TEST", 0, 7], ["the serum values", "TEST", 23, 39], ["ALKP", "TEST", 44, 48], ["ALT", "TEST", 53, 56], ["this study", "TEST", 97, 107]]], ["In all dogs, there were elevations in ALKP and ALT before prednisolone treatment, but following initiation of prednisolone therapy all values significantly reduced for all patients.", [["prednisolone", "CHEMICAL", 58, 70], ["prednisolone", "CHEMICAL", 110, 122], ["prednisolone", "CHEMICAL", 58, 70], ["prednisolone", "CHEMICAL", 110, 122], ["dogs", "ORGANISM", 7, 11], ["ALKP", "SIMPLE_CHEMICAL", 38, 42], ["ALT", "SIMPLE_CHEMICAL", 47, 50], ["prednisolone", "SIMPLE_CHEMICAL", 58, 70], ["prednisolone", "SIMPLE_CHEMICAL", 110, 122], ["patients", "ORGANISM", 172, 180], ["dogs", "SPECIES", 7, 11], ["patients", "SPECIES", 172, 180], ["elevations in ALKP", "PROBLEM", 24, 42], ["ALT", "TREATMENT", 47, 50], ["prednisolone treatment", "TREATMENT", 58, 80], ["prednisolone therapy", "TREATMENT", 110, 130], ["elevations", "OBSERVATION_MODIFIER", 24, 34]]], ["However, in the 11 patients that had oral prednisolone reduced to 0.25-0.5 mg/kg/EOD or stopped entirely, seven (64 per cent) documented an increase in either or both ALKP and ALT.", [["oral", "ANATOMY", 37, 41], ["prednisolone", "CHEMICAL", 42, 54], ["prednisolone", "CHEMICAL", 42, 54], ["patients", "ORGANISM", 19, 27], ["oral", "ORGANISM_SUBDIVISION", 37, 41], ["prednisolone", "SIMPLE_CHEMICAL", 42, 54], ["ALKP", "SIMPLE_CHEMICAL", 167, 171], ["ALT", "SIMPLE_CHEMICAL", 176, 179], ["ALT", "PROTEIN", 176, 179], ["patients", "SPECIES", 19, 27], ["oral prednisolone", "TREATMENT", 37, 54], ["ALT", "TEST", 176, 179], ["increase", "OBSERVATION_MODIFIER", 140, 148]]], ["In the three cases that had ALKP measurements following restarting prednisolone after cessation of treatment, the ALKP values were subjectively decreased (figure 1), and the same was found for measured ALT (figure 2).", [["prednisolone", "CHEMICAL", 67, 79], ["prednisolone", "CHEMICAL", 67, 79], ["prednisolone", "SIMPLE_CHEMICAL", 67, 79], ["ALT", "SIMPLE_CHEMICAL", 202, 205], ["ALT", "PROTEIN", 202, 205], ["prednisolone", "TREATMENT", 67, 79], ["treatment", "TREATMENT", 99, 108], ["the ALKP values", "TEST", 110, 125], ["ALT", "TEST", 202, 205]]], ["In 5 of the 12 ESS cases, the measured serum ALKP never returned to within the reference range.", [["serum", "ANATOMY", 39, 44], ["serum", "ORGANISM_SUBSTANCE", 39, 44], ["ALKP", "GENE_OR_GENE_PRODUCT", 45, 49], ["serum ALKP", "PROTEIN", 39, 49], ["the measured serum ALKP", "TEST", 26, 49]]], ["Furthermore, we found that 9 of the 12 cases documented serum ALT that did not return to within the reference range, despite resolution of clinical signs.", [["serum", "ANATOMY", 56, 61], ["serum", "ORGANISM_SUBSTANCE", 56, 61], ["ALT", "SIMPLE_CHEMICAL", 62, 65], ["serum ALT", "PROTEIN", 56, 65], ["serum ALT", "TEST", 56, 65], ["clinical signs", "TEST", 139, 153]]], ["Figure 3 presents the values of serum bilirubin in the nine ESS that had these values measured.", [["serum", "ANATOMY", 32, 37], ["bilirubin", "CHEMICAL", 38, 47], ["bilirubin", "CHEMICAL", 38, 47], ["serum", "ORGANISM_SUBSTANCE", 32, 37], ["bilirubin", "SIMPLE_CHEMICAL", 38, 47], ["serum bilirubin", "PROTEIN", 32, 47], ["serum bilirubin", "TEST", 32, 47], ["these values", "TEST", 73, 85]]], ["The initial Figure 1 Serum (ALKP) as a multiple of the upper limit of the reference range in 12 ESS with CH, at diagnosis (before prednisolone treatment), first recheck (2-4 weeks after starting 1-2 mg/kg/day prednisolone) and at tapering doses of prednisolone.", [["prednisolone", "CHEMICAL", 130, 142], ["prednisolone", "CHEMICAL", 209, 221], ["prednisolone", "CHEMICAL", 248, 260], ["prednisolone", "CHEMICAL", 130, 142], ["prednisolone", "CHEMICAL", 209, 221], ["prednisolone", "CHEMICAL", 248, 260], ["Serum", "ORGANISM_SUBSTANCE", 21, 26], ["ALKP", "GENE_OR_GENE_PRODUCT", 28, 32], ["prednisolone", "SIMPLE_CHEMICAL", 130, 142], ["prednisolone", "SIMPLE_CHEMICAL", 209, 221], ["prednisolone", "SIMPLE_CHEMICAL", 248, 260], ["The initial Figure", "TEST", 0, 18], ["Serum (ALKP", "TEST", 21, 32], ["prednisolone treatment", "TREATMENT", 130, 152], ["prednisolone", "TREATMENT", 209, 221], ["prednisolone", "TREATMENT", 248, 260], ["upper limit", "OBSERVATION_MODIFIER", 55, 66]]], ["A significant difference was identified between the values at diagnosis and first recheck; however, due to variability of dosing, the authors did not assess statistical differences between the remaining prednisolone doses.", [["prednisolone", "CHEMICAL", 203, 215], ["prednisolone", "CHEMICAL", 203, 215], ["prednisolone", "SIMPLE_CHEMICAL", 203, 215], ["the remaining prednisolone doses", "TREATMENT", 189, 221], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["difference", "OBSERVATION", 14, 24]]], ["Each coloured shape represents an individual patient.", [["patient", "ORGANISM", 45, 52], ["patient", "SPECIES", 45, 52], ["coloured", "OBSERVATION_MODIFIER", 5, 13], ["shape", "OBSERVATION_MODIFIER", 14, 19], ["individual", "OBSERVATION_MODIFIER", 34, 44]]], ["ALKP, alkaline phosphatase; CH, chronic hepatitis; EOD, Every Other Day; ESS, English springer spaniels.Resultsvalues are elevated before prednisolone treatment in six patients, and there is a significant reduction in these values following initiation of prednisolone.", [["chronic hepatitis", "DISEASE", 32, 49], ["prednisolone", "CHEMICAL", 138, 150], ["prednisolone", "CHEMICAL", 255, 267], ["prednisolone", "CHEMICAL", 138, 150], ["prednisolone", "CHEMICAL", 255, 267], ["ALKP", "SIMPLE_CHEMICAL", 0, 4], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 6, 26], ["prednisolone", "SIMPLE_CHEMICAL", 138, 150], ["patients", "ORGANISM", 168, 176], ["prednisolone", "SIMPLE_CHEMICAL", 255, 267], ["ALKP", "PROTEIN", 0, 4], ["alkaline phosphatase", "PROTEIN", 6, 26], ["patients", "SPECIES", 168, 176], ["ALKP", "TEST", 0, 4], ["alkaline phosphatase", "TEST", 6, 26], ["chronic hepatitis", "PROBLEM", 32, 49], ["elevated", "PROBLEM", 122, 130], ["prednisolone treatment", "TREATMENT", 138, 160], ["a significant reduction in these values", "PROBLEM", 191, 230], ["prednisolone", "TREATMENT", 255, 267], ["alkaline phosphatase", "OBSERVATION_MODIFIER", 6, 26], ["chronic", "OBSERVATION_MODIFIER", 32, 39], ["hepatitis", "OBSERVATION", 40, 49], ["elevated", "OBSERVATION_MODIFIER", 122, 130], ["significant", "OBSERVATION_MODIFIER", 193, 204], ["reduction", "OBSERVATION_MODIFIER", 205, 214]]], ["Five of the six patients with elevated serum bilirubin showed a return to normal range, and the one patient whose elevated bilirubin did not return to normal is still early in the treatment course and has shown a substantial decrease which is approaching the reference interval.DiscussionThis study documents that some ESS with histologically confirmed idiopathic CH show clinical and clinicopathological improvement to prednisolone 1-2 mg/kg/day, in addition to standard supportive treatments.", [["serum", "ANATOMY", 39, 44], ["bilirubin", "CHEMICAL", 45, 54], ["bilirubin", "CHEMICAL", 123, 132], ["idiopathic CH", "DISEASE", 353, 366], ["prednisolone", "CHEMICAL", 420, 432], ["bilirubin", "CHEMICAL", 45, 54], ["bilirubin", "CHEMICAL", 123, 132], ["prednisolone", "CHEMICAL", 420, 432], ["patients", "ORGANISM", 16, 24], ["serum", "ORGANISM_SUBSTANCE", 39, 44], ["bilirubin", "GENE_OR_GENE_PRODUCT", 45, 54], ["patient", "ORGANISM", 100, 107], ["bilirubin", "GENE_OR_GENE_PRODUCT", 123, 132], ["prednisolone", "SIMPLE_CHEMICAL", 420, 432], ["serum bilirubin", "PROTEIN", 39, 54], ["patients", "SPECIES", 16, 24], ["patient", "SPECIES", 100, 107], ["elevated serum bilirubin", "PROBLEM", 30, 54], ["elevated bilirubin", "PROBLEM", 114, 132], ["a substantial decrease", "PROBLEM", 211, 233], ["This study", "TEST", 288, 298], ["idiopathic CH", "PROBLEM", 353, 366], ["prednisolone", "TREATMENT", 420, 432], ["standard supportive treatments", "TREATMENT", 463, 493], ["normal range", "OBSERVATION_MODIFIER", 74, 86], ["normal", "OBSERVATION", 151, 157], ["substantial", "OBSERVATION_MODIFIER", 213, 224], ["decrease", "OBSERVATION_MODIFIER", 225, 233], ["idiopathic", "OBSERVATION", 353, 363]]], ["The median time since diagnosis in our current study was 1715 days (range: 672-2105 days) and although we cannot make direct comparisons, it does appear that the ESS in our study had an improved survival compared with the previously documented median survival time of 189 days (range: 1-1211 days).", [["the ESS", "TEST", 158, 165], ["our study", "TEST", 169, 178]]], ["22 Unfortunately, we do not have a direct control population for comparison; however, given the aggressive nature of ESS CH, and the previously published benefits of prednisolone for canine CH, 25Figure 2Serum (ALT) as a multiple of the upper limit of the reference range in 12 ESS with CH, at diagnosis (before prednisolone treatment), first recheck (2-4 weeks after starting 1-2 mg/kg/day prednisolone) and at tapering doses of prednisolone.", [["CH", "DISEASE", 121, 123], ["prednisolone", "CHEMICAL", 166, 178], ["25Figure 2Serum", "CHEMICAL", 194, 209], ["CH", "DISEASE", 287, 289], ["prednisolone", "CHEMICAL", 312, 324], ["prednisolone", "CHEMICAL", 391, 403], ["prednisolone", "CHEMICAL", 430, 442], ["prednisolone", "CHEMICAL", 166, 178], ["25Figure 2Serum", "CHEMICAL", 194, 209], ["prednisolone", "CHEMICAL", 312, 324], ["prednisolone", "CHEMICAL", 391, 403], ["prednisolone", "CHEMICAL", 430, 442], ["prednisolone", "SIMPLE_CHEMICAL", 166, 178], ["canine", "ORGANISM", 183, 189], ["25Figure 2Serum", "SIMPLE_CHEMICAL", 194, 209], ["ALT", "SIMPLE_CHEMICAL", 211, 214], ["prednisolone", "SIMPLE_CHEMICAL", 312, 324], ["prednisolone", "SIMPLE_CHEMICAL", 391, 403], ["prednisolone", "SIMPLE_CHEMICAL", 430, 442], ["canine", "SPECIES", 183, 189], ["prednisolone", "TREATMENT", 166, 178], ["canine CH", "TREATMENT", 183, 192], ["ALT", "TEST", 211, 214], ["prednisolone treatment", "TREATMENT", 312, 334], ["prednisolone", "TREATMENT", 391, 403], ["prednisolone", "TREATMENT", 430, 442], ["upper limit", "OBSERVATION_MODIFIER", 237, 248]]], ["A significant difference was identified between the values at diagnosis and first recheck; however, due to variability of dosing, the authors did not assess statistical differences between the remaining prednisolone doses.", [["prednisolone", "CHEMICAL", 203, 215], ["prednisolone", "CHEMICAL", 203, 215], ["prednisolone", "SIMPLE_CHEMICAL", 203, 215], ["the remaining prednisolone doses", "TREATMENT", 189, 221], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["difference", "OBSERVATION", 14, 24]]], ["Each coloured shape represents an individual patient.", [["patient", "ORGANISM", 45, 52], ["patient", "SPECIES", 45, 52], ["coloured", "OBSERVATION_MODIFIER", 5, 13], ["shape", "OBSERVATION_MODIFIER", 14, 19], ["individual", "OBSERVATION_MODIFIER", 34, 44]]], ["ALT, alanine aminotransferase; CH, chronic hepatitis; EOD, Every Other Day; ESS, English springer spaniels.Figure 3Serum (bilirubin) as a multiple of the upper limit of the reference range in nine ESS with CH, at diagnosis (before prednisolone treatment), first recheck (2-4 weeks after starting 1-2 mg/kg/day prednisolone) and at tapering doses of prednisolone.", [["alanine", "CHEMICAL", 5, 12], ["chronic hepatitis", "DISEASE", 35, 52], ["bilirubin", "CHEMICAL", 122, 131], ["prednisolone", "CHEMICAL", 231, 243], ["prednisolone", "CHEMICAL", 310, 322], ["prednisolone", "CHEMICAL", 349, 361], ["alanine", "CHEMICAL", 5, 12], ["bilirubin", "CHEMICAL", 122, 131], ["prednisolone", "CHEMICAL", 231, 243], ["prednisolone", "CHEMICAL", 310, 322], ["prednisolone", "CHEMICAL", 349, 361], ["ALT", "SIMPLE_CHEMICAL", 0, 3], ["alanine", "AMINO_ACID", 5, 12], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 13, 29], ["3Serum", "SIMPLE_CHEMICAL", 114, 120], ["bilirubin", "SIMPLE_CHEMICAL", 122, 131], ["prednisolone", "SIMPLE_CHEMICAL", 231, 243], ["prednisolone", "SIMPLE_CHEMICAL", 310, 322], ["prednisolone", "SIMPLE_CHEMICAL", 349, 361], ["ALT", "PROTEIN", 0, 3], ["ALT", "TEST", 0, 3], ["alanine aminotransferase", "TEST", 5, 29], ["chronic hepatitis", "PROBLEM", 35, 52], ["Figure 3Serum (bilirubin", "TEST", 107, 131], ["prednisolone treatment", "TREATMENT", 231, 253], ["prednisolone", "TREATMENT", 310, 322], ["prednisolone", "TREATMENT", 349, 361], ["chronic", "OBSERVATION_MODIFIER", 35, 42], ["hepatitis", "OBSERVATION", 43, 52], ["upper limit", "OBSERVATION_MODIFIER", 154, 165]]], ["A significant difference was identified between the values at diagnosis and first recheck; however, due to variability of dosing, the authors did not assess statistical differences between the remaining prednisolone doses.", [["prednisolone", "CHEMICAL", 203, 215], ["prednisolone", "CHEMICAL", 203, 215], ["prednisolone", "SIMPLE_CHEMICAL", 203, 215], ["the remaining prednisolone doses", "TREATMENT", 189, 221], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["difference", "OBSERVATION", 14, 24]]], ["Each coloured shape represents an individual patient.", [["patient", "ORGANISM", 45, 52], ["patient", "SPECIES", 45, 52], ["coloured", "OBSERVATION_MODIFIER", 5, 13], ["shape", "OBSERVATION_MODIFIER", 14, 19], ["individual", "OBSERVATION_MODIFIER", 34, 44]]], ["CH, chronic hepatitis; EOD, Every Other Day; ESS, English springer spaniels.Figure 3could benefit them.", [["chronic hepatitis", "DISEASE", 4, 21], ["chronic hepatitis", "PROBLEM", 4, 21], ["chronic", "OBSERVATION_MODIFIER", 4, 11], ["hepatitis", "OBSERVATION", 12, 21]]], ["As a result, we must acknowledge that the supportive treatments provided to the patients may have contributed to our results.", [["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["the supportive treatments", "TREATMENT", 38, 63]]], ["Furthermore, our results suggest that serial measurements of alkaline phosphatase (ALKP), alanine aminotransferase (ALT) and serum bilirubin are useful for monitoring the patient's response to prednisolone therapy, and the increase in some dogs when prednisolone therapy was stopped further supports their use.", [["serum", "ANATOMY", 125, 130], ["alanine", "CHEMICAL", 90, 97], ["bilirubin", "CHEMICAL", 131, 140], ["prednisolone", "CHEMICAL", 193, 205], ["prednisolone", "CHEMICAL", 250, 262], ["alanine", "CHEMICAL", 90, 97], ["bilirubin", "CHEMICAL", 131, 140], ["prednisolone", "CHEMICAL", 193, 205], ["prednisolone", "CHEMICAL", 250, 262], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 61, 81], ["ALKP", "GENE_OR_GENE_PRODUCT", 83, 87], ["alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 90, 114], ["ALT", "SIMPLE_CHEMICAL", 116, 119], ["serum", "ORGANISM_SUBSTANCE", 125, 130], ["bilirubin", "SIMPLE_CHEMICAL", 131, 140], ["patient", "ORGANISM", 171, 178], ["prednisolone", "SIMPLE_CHEMICAL", 193, 205], ["dogs", "ORGANISM", 240, 244], ["prednisolone", "SIMPLE_CHEMICAL", 250, 262], ["alkaline phosphatase", "PROTEIN", 61, 81], ["ALKP", "PROTEIN", 83, 87], ["alanine aminotransferase", "PROTEIN", 90, 114], ["ALT", "PROTEIN", 116, 119], ["patient", "SPECIES", 171, 178], ["serial measurements of alkaline phosphatase", "TEST", 38, 81], ["ALKP", "TEST", 83, 87], ["alanine aminotransferase", "TEST", 90, 114], ["ALT", "TEST", 116, 119], ["serum bilirubin", "TEST", 125, 140], ["prednisolone therapy", "TREATMENT", 193, 213], ["some dogs", "TREATMENT", 235, 244], ["prednisolone therapy", "TREATMENT", 250, 270], ["increase", "OBSERVATION_MODIFIER", 223, 231]]], ["This is the first study providing evidence for the use of prednisolone in some ESS with CH and indeed the first study documenting corticosteroid response in a single rather than multiple breeds.", [["prednisolone", "CHEMICAL", 58, 70], ["CH", "DISEASE", 88, 90], ["prednisolone", "CHEMICAL", 58, 70], ["prednisolone", "SIMPLE_CHEMICAL", 58, 70], ["the first study", "TEST", 8, 23], ["prednisolone", "TREATMENT", 58, 70], ["the first study", "TEST", 102, 117], ["corticosteroid response", "PROBLEM", 130, 153]]], ["26 This positive response was convincing in spite of the absence of a control population without treatment.", [["treatment", "TREATMENT", 97, 106]]], ["These were different dogs from those described in the previous study 22 and offers additional support for a female predisposition with 9 of the 12 cases being female.", [["dogs", "ORGANISM", 21, 25], ["dogs", "SPECIES", 21, 25], ["the previous study", "TEST", 50, 68], ["additional support", "TREATMENT", 83, 101], ["different", "OBSERVATION_MODIFIER", 11, 20], ["dogs", "OBSERVATION", 21, 25]]], ["Interestingly, two previous studies 1 22 identified a young to middle-aged onset of disease in ESS (median age at diagnosis of five years and five years seven months, respectively) which is similar to the median age at diagnosis in our current study of five years.", [["two previous studies", "TEST", 15, 35], ["disease in ESS", "PROBLEM", 84, 98], ["middle", "ANATOMY_MODIFIER", 63, 69], ["disease", "OBSERVATION", 84, 91]]], ["This is younger than the overall median age of eight years in a study of 551 dogs of varying breeds with CH in the UK 1 .", [["CH", "DISEASE", 105, 107], ["dogs", "ORGANISM", 77, 81], ["dogs", "SPECIES", 77, 81], ["a study", "TEST", 62, 69]]], ["Histologically, the liver tissue from ESS CH cases shows a predominant lymphoplasmacytic inflammation with interface hepatitis, variable fibrosis that can extend between portal triads and hepatocellular apoptosis and necrosis.", [["liver tissue", "ANATOMY", 20, 32], ["portal triads", "ANATOMY", 170, 183], ["hepatocellular", "ANATOMY", 188, 202], ["inflammation", "DISEASE", 89, 101], ["hepatitis", "DISEASE", 117, 126], ["fibrosis", "DISEASE", 137, 145], ["necrosis", "DISEASE", 217, 225], ["liver tissue", "TISSUE", 20, 32], ["lymphoplasmacytic inflammation", "PATHOLOGICAL_FORMATION", 71, 101], ["portal triads", "MULTI-TISSUE_STRUCTURE", 170, 183], ["hepatocellular", "CANCER", 188, 202], ["the liver tissue", "TEST", 16, 32], ["ESS CH cases", "TEST", 38, 50], ["a predominant lymphoplasmacytic inflammation", "PROBLEM", 57, 101], ["interface hepatitis", "PROBLEM", 107, 126], ["variable fibrosis", "PROBLEM", 128, 145], ["hepatocellular apoptosis", "PROBLEM", 188, 212], ["necrosis", "PROBLEM", 217, 225], ["liver", "ANATOMY", 20, 25], ["predominant", "OBSERVATION_MODIFIER", 59, 70], ["lymphoplasmacytic", "OBSERVATION_MODIFIER", 71, 88], ["inflammation", "OBSERVATION", 89, 101], ["interface hepatitis", "OBSERVATION", 107, 126], ["variable", "OBSERVATION_MODIFIER", 128, 136], ["fibrosis", "OBSERVATION", 137, 145], ["portal triads", "ANATOMY", 170, 183], ["hepatocellular apoptosis", "OBSERVATION", 188, 212], ["necrosis", "OBSERVATION", 217, 225]]], ["While it would have been interesting to assess liver histopathology following treatment with prednisolone, this was not evaluated in the current study.", [["liver", "ANATOMY", 47, 52], ["prednisolone", "CHEMICAL", 93, 105], ["prednisolone", "CHEMICAL", 93, 105], ["liver", "ORGAN", 47, 52], ["prednisolone", "SIMPLE_CHEMICAL", 93, 105], ["prednisolone", "TREATMENT", 93, 105], ["the current study", "TEST", 133, 150], ["liver", "ANATOMY", 47, 52]]], ["Table 1 summarises the histopathological diagnosis for each of our 12 ESS cases and the features identified are remarkably similar to those expected with human autoimmune hepatitis (AIH).", [["autoimmune hepatitis", "DISEASE", 160, 180], ["AIH", "DISEASE", 182, 185], ["human", "ORGANISM", 154, 159], ["human", "SPECIES", 154, 159], ["human", "SPECIES", 154, 159], ["human autoimmune hepatitis", "PROBLEM", 154, 180], ["autoimmune hepatitis", "OBSERVATION", 160, 180]]], ["28 Hepatic histopathology alone is not considered diagnostic for AIH in people, but instead further validation is required with response to immunosuppressive drugs and positive detection of various serum autoantibodies including non-organ-specific and organ-specific autoantibodies such as antinuclear, smooth muscle, liver cytosol type-I and liver-kidney-microsomal type-I antibodies.", [["Hepatic", "ANATOMY", 3, 10], ["serum", "ANATOMY", 198, 203], ["non-organ", "ANATOMY", 229, 238], ["organ", "ANATOMY", 252, 257], ["smooth muscle", "ANATOMY", 303, 316], ["liver cytosol", "ANATOMY", 318, 331], ["liver", "ANATOMY", 343, 348], ["kidney", "ANATOMY", 349, 355], ["AIH", "DISEASE", 65, 68], ["people", "ORGANISM", 72, 78], ["serum", "ORGANISM_SUBSTANCE", 198, 203], ["organ", "ORGAN", 252, 257], ["smooth muscle", "TISSUE", 303, 316], ["liver", "ORGAN", 318, 323], ["type-I", "GENE_OR_GENE_PRODUCT", 332, 338], ["liver", "ORGAN", 343, 348], ["kidney", "ORGAN", 349, 355], ["type-I antibodies", "GENE_OR_GENE_PRODUCT", 367, 384], ["serum autoantibodies", "PROTEIN", 198, 218], ["autoantibodies", "PROTEIN", 267, 281], ["antinuclear, smooth muscle, liver cytosol type-I and liver-kidney-microsomal type-I antibodies", "PROTEIN", 290, 384], ["people", "SPECIES", 72, 78], ["Hepatic histopathology", "TEST", 3, 25], ["AIH", "PROBLEM", 65, 68], ["further validation", "TEST", 92, 110], ["immunosuppressive drugs", "TREATMENT", 140, 163], ["various serum autoantibodies", "PROBLEM", 190, 218], ["non-organ", "TEST", 229, 238], ["specific autoantibodies", "PROBLEM", 258, 281], ["antinuclear", "TEST", 290, 301], ["Hepatic", "ANATOMY", 3, 10], ["histopathology", "OBSERVATION", 11, 25], ["not considered", "UNCERTAINTY", 35, 49], ["smooth muscle", "ANATOMY", 303, 316], ["liver", "ANATOMY", 318, 323], ["liver", "ANATOMY", 343, 348], ["kidney", "ANATOMY", 349, 355]]], ["29 Human leucocyte antigen alleles which confer an increased risk for developing AIH have been found in affected individuals.", [["AIH", "DISEASE", 81, 84], ["Human leucocyte antigen", "GENE_OR_GENE_PRODUCT", 3, 26], ["AIH", "CANCER", 81, 84], ["Human leucocyte antigen alleles", "DNA", 3, 34], ["Human", "SPECIES", 3, 8], ["Human leucocyte antigen alleles", "TEST", 3, 34], ["developing AIH", "PROBLEM", 70, 84], ["affected individuals", "PROBLEM", 104, 124], ["increased", "OBSERVATION_MODIFIER", 51, 60], ["AIH", "OBSERVATION", 81, 84]]], ["30 These alleles have also been shown to influence progression of the disease, which is interesting in light of the previously documented association between dog leucocyte antigen and CH in the ESS.", [["dog leucocyte antigen", "GENE_OR_GENE_PRODUCT", 158, 179], ["dog leucocyte antigen", "PROTEIN", 158, 179], ["the disease", "PROBLEM", 66, 77], ["dog leucocyte antigen", "TEST", 158, 179], ["progression", "OBSERVATION_MODIFIER", 51, 62], ["disease", "OBSERVATION", 70, 77], ["ESS", "OBSERVATION", 194, 197]]], ["31 Regarding assessment of hepatic copper, none of the 12 cases were reported to have significant copper accumulation following qualitative copper grading, but it is possible that variation between the pathologists resulted in a degree of interobserver variation.", [["hepatic", "ANATOMY", 27, 34], ["copper", "CHEMICAL", 35, 41], ["copper", "CHEMICAL", 98, 104], ["copper", "CHEMICAL", 140, 146], ["copper", "CHEMICAL", 35, 41], ["copper", "CHEMICAL", 98, 104], ["copper", "CHEMICAL", 140, 146], ["hepatic", "ORGAN", 27, 34], ["copper", "SIMPLE_CHEMICAL", 35, 41], ["copper", "SIMPLE_CHEMICAL", 98, 104], ["assessment of hepatic copper", "TEST", 13, 41], ["significant copper accumulation", "PROBLEM", 86, 117], ["qualitative copper grading", "TEST", 128, 154], ["hepatic", "ANATOMY", 27, 34], ["significant", "OBSERVATION_MODIFIER", 86, 97], ["copper accumulation", "OBSERVATION", 98, 117], ["interobserver variation", "OBSERVATION", 239, 262]]], ["However, all pathologists were board-certified and as such are very likely to have made the authors aware if they had concerns regarding the qualitative copper assessment of the histopathology specimens.", [["specimens", "ANATOMY", 193, 202], ["copper", "CHEMICAL", 153, 159], ["histopathology specimens", "CANCER", 178, 202], ["the qualitative copper assessment", "TEST", 137, 170], ["the histopathology specimens", "TEST", 174, 202]]], ["An unexpected finding in this study was that 4 of the 12 cases were perceived to be asymptomatic at the time of diagnosis, in contrast to a previous case series suggesting that the disease is usually aggressive and rapidly fatal.", [["this study", "TEST", 25, 35], ["a previous case series", "TEST", 138, 160], ["the disease", "PROBLEM", 177, 188], ["disease", "OBSERVATION", 181, 188], ["aggressive", "OBSERVATION_MODIFIER", 200, 210]]], ["22 These patients may have been identified early in the course of their disease and it is possible they will have become clinically unwell in the future if the disease had not been investigated.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["their disease", "PROBLEM", 66, 79], ["clinically unwell", "PROBLEM", 121, 138], ["the disease", "PROBLEM", 156, 167], ["disease", "OBSERVATION", 160, 167]]], ["Human AIH has an asymptomatic presentation in 25 per cent-34 per cent cases, 32 with 26 per cent-70 per cent of these patients going on to develop clinical signs within 32 months of diagnosis.", [["AIH", "DISEASE", 6, 9], ["Human", "ORGANISM", 0, 5], ["AIH", "CANCER", 6, 9], ["patients", "ORGANISM", 118, 126], ["Human", "SPECIES", 0, 5], ["patients", "SPECIES", 118, 126], ["Human", "SPECIES", 0, 5]]], ["The number of asymptomatic cases in our current study is not too dissimilar from that reported in human literature which could suggest some similarities between human AIH and ESS CH.", [["AIH", "DISEASE", 167, 170], ["CH", "DISEASE", 179, 181], ["human", "ORGANISM", 98, 103], ["human", "ORGANISM", 161, 166], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 161, 166], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 161, 166], ["our current study", "TEST", 36, 53], ["asymptomatic", "OBSERVATION_MODIFIER", 14, 26], ["cases", "OBSERVATION", 27, 32], ["AIH", "OBSERVATION", 167, 170]]], ["It is impossible to know in either people or dogs how long a patient may be asymptomatic before clinical presentation because patients without symptoms are not routinely blood tested.", [["blood", "ANATOMY", 170, 175], ["people", "ORGANISM", 35, 41], ["dogs", "ORGANISM", 45, 49], ["patient", "ORGANISM", 61, 68], ["patients", "ORGANISM", 126, 134], ["blood", "ORGANISM_SUBSTANCE", 170, 175], ["people", "SPECIES", 35, 41], ["dogs", "SPECIES", 45, 49], ["patient", "SPECIES", 61, 68], ["patients", "SPECIES", 126, 134], ["asymptomatic", "PROBLEM", 76, 88], ["symptoms", "PROBLEM", 143, 151]]], ["An equally unexpected finding was the significant reduction in ALKP in patients despite prednisolone therapy.", [["ALKP", "DISEASE", 63, 67], ["prednisolone", "CHEMICAL", 88, 100], ["prednisolone", "CHEMICAL", 88, 100], ["ALKP", "SIMPLE_CHEMICAL", 63, 67], ["patients", "ORGANISM", 71, 79], ["prednisolone", "SIMPLE_CHEMICAL", 88, 100], ["patients", "SPECIES", 71, 79], ["the significant reduction in ALKP", "PROBLEM", 34, 67], ["prednisolone therapy", "TREATMENT", 88, 108], ["significant", "OBSERVATION_MODIFIER", 38, 49], ["reduction", "OBSERVATION_MODIFIER", 50, 59], ["prednisolone therapy", "OBSERVATION", 88, 108]]], ["It is known that corticosteroids induce ALKP activity in dogs, and therefore it is common for patients treated with prednisolone to experience increased serum concentrations of the enzyme.", [["serum", "ANATOMY", 153, 158], ["prednisolone", "CHEMICAL", 116, 128], ["corticosteroids", "CHEMICAL", 17, 32], ["prednisolone", "CHEMICAL", 116, 128], ["corticosteroids", "SIMPLE_CHEMICAL", 17, 32], ["ALKP", "GENE_OR_GENE_PRODUCT", 40, 44], ["dogs", "ORGANISM", 57, 61], ["patients", "ORGANISM", 94, 102], ["prednisolone", "SIMPLE_CHEMICAL", 116, 128], ["serum", "ORGANISM_SUBSTANCE", 153, 158], ["ALKP", "PROTEIN", 40, 44], ["enzyme", "PROTEIN", 181, 187], ["dogs", "SPECIES", 57, 61], ["patients", "SPECIES", 94, 102], ["corticosteroids", "TREATMENT", 17, 32], ["ALKP activity in dogs", "PROBLEM", 40, 61], ["prednisolone", "TREATMENT", 116, 128], ["increased serum concentrations", "PROBLEM", 143, 173], ["the enzyme", "TEST", 177, 187]]], ["33 The significant reduction in serum ALKP seen in our cohort following initiation of prednisolone treatment suggests that, in these cases, the initial enzyme elevation before corticosteroid administration was primarily disease induced.", [["serum", "ANATOMY", 32, 37], ["prednisolone", "CHEMICAL", 86, 98], ["prednisolone", "CHEMICAL", 86, 98], ["serum", "ORGANISM_SUBSTANCE", 32, 37], ["ALKP", "GENE_OR_GENE_PRODUCT", 38, 42], ["prednisolone", "SIMPLE_CHEMICAL", 86, 98], ["corticosteroid", "SIMPLE_CHEMICAL", 176, 190], ["serum ALKP", "PROTEIN", 32, 42], ["The significant reduction in serum ALKP", "PROBLEM", 3, 42], ["prednisolone treatment", "TREATMENT", 86, 108], ["the initial enzyme elevation", "PROBLEM", 140, 168], ["corticosteroid administration", "TREATMENT", 176, 205], ["significant", "OBSERVATION_MODIFIER", 7, 18], ["reduction", "OBSERVATION_MODIFIER", 19, 28], ["serum ALKP", "OBSERVATION_MODIFIER", 32, 42]]], ["Therefore, controlling the disease with prednisolone appeared to result in a corresponding, significant reduction in hepatocellular damage and cholestasis.", [["hepatocellular", "ANATOMY", 117, 131], ["prednisolone", "CHEMICAL", 40, 52], ["hepatocellular damage", "DISEASE", 117, 138], ["cholestasis", "DISEASE", 143, 154], ["prednisolone", "CHEMICAL", 40, 52], ["prednisolone", "SIMPLE_CHEMICAL", 40, 52], ["hepatocellular", "CANCER", 117, 131], ["the disease", "PROBLEM", 23, 34], ["prednisolone", "TREATMENT", 40, 52], ["significant reduction in hepatocellular damage", "PROBLEM", 92, 138], ["cholestasis", "PROBLEM", 143, 154], ["disease", "OBSERVATION", 27, 34], ["significant", "OBSERVATION_MODIFIER", 92, 103], ["reduction", "OBSERVATION_MODIFIER", 104, 113], ["hepatocellular damage", "OBSERVATION", 117, 138], ["cholestasis", "OBSERVATION", 143, 154]]], ["The continued mild elevations in ALKP on treatment are consistent with steroid induction of enzymes supported by the fact that bilirubin became normal in six cases.Figure 3We recognise there are limitations to this investigation.", [["ALKP", "CHEMICAL", 33, 37], ["steroid", "CHEMICAL", 71, 78], ["bilirubin", "CHEMICAL", 127, 136], ["steroid", "CHEMICAL", 71, 78], ["bilirubin", "CHEMICAL", 127, 136], ["ALKP", "SIMPLE_CHEMICAL", 33, 37], ["steroid", "SIMPLE_CHEMICAL", 71, 78], ["bilirubin", "SIMPLE_CHEMICAL", 127, 136], ["enzymes", "PROTEIN", 92, 99], ["The continued mild elevations in ALKP", "PROBLEM", 0, 37], ["treatment", "TREATMENT", 41, 50], ["steroid induction of enzymes", "TREATMENT", 71, 99], ["bilirubin", "TEST", 127, 136], ["this investigation", "TEST", 210, 228], ["mild", "OBSERVATION_MODIFIER", 14, 18], ["elevations", "OBSERVATION_MODIFIER", 19, 29], ["consistent with", "UNCERTAINTY", 55, 70]]], ["Due to the clinical nature of this cohort study, with individual patients being managed by different veterinarians, there was some variability in the way prednisolone was tapered and timing of blood samples.", [["blood samples", "ANATOMY", 193, 206], ["prednisolone", "CHEMICAL", 154, 166], ["prednisolone", "CHEMICAL", 154, 166], ["patients", "ORGANISM", 65, 73], ["prednisolone", "SIMPLE_CHEMICAL", 154, 166], ["blood samples", "ORGANISM_SUBSTANCE", 193, 206], ["patients", "SPECIES", 65, 73], ["this cohort study", "TEST", 30, 47], ["the way prednisolone", "TREATMENT", 146, 166], ["blood samples", "TEST", 193, 206], ["variability", "OBSERVATION_MODIFIER", 131, 142]]], ["Therefore, the authors did not plot the measured serum values of ALT, ALKP and bilirubin against time from initiation of treatment, but instead the values were plotted against different doses of prednisolone.", [["serum", "ANATOMY", 49, 54], ["bilirubin", "CHEMICAL", 79, 88], ["prednisolone", "CHEMICAL", 195, 207], ["bilirubin", "CHEMICAL", 79, 88], ["prednisolone", "CHEMICAL", 195, 207], ["serum", "ORGANISM_SUBSTANCE", 49, 54], ["ALT", "SIMPLE_CHEMICAL", 65, 68], ["ALKP", "SIMPLE_CHEMICAL", 70, 74], ["bilirubin", "SIMPLE_CHEMICAL", 79, 88], ["prednisolone", "SIMPLE_CHEMICAL", 195, 207], ["ALT", "PROTEIN", 65, 68], ["serum values", "TEST", 49, 61], ["ALT", "TEST", 65, 68], ["ALKP", "TEST", 70, 74], ["bilirubin", "TEST", 79, 88], ["treatment", "TREATMENT", 121, 130], ["the values", "TEST", 144, 154], ["prednisolone", "TREATMENT", 195, 207]]], ["Furthermore, all cases received additional supportive medications for CH which varied between patients and could have influenced results.", [["CH", "DISEASE", 70, 72], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["additional supportive medications", "TREATMENT", 32, 65]]], ["However, this variability is inherently difficult to overcome when dealing with patients in clinical practice and also made it challenging to accurately standardise a clinical scoring system.", [["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88]]], ["It is also important to note that cases were enrolled at different times which resulted in patients being at different stages of their disease with some having fully recovered while others having more recently been diagnosed and started on medication at the time of manuscript submission.ConclusionThis study documents that some ESS with histologically confirmed idiopathic CH show clinical and clinicopathological improvement to prednisolone 1-2 mg/kg/day, in addition to standard supportive dietary and medical management.", [["idiopathic CH", "DISEASE", 363, 376], ["prednisolone", "CHEMICAL", 430, 442], ["prednisolone", "CHEMICAL", 430, 442], ["patients", "ORGANISM", 91, 99], ["prednisolone", "SIMPLE_CHEMICAL", 430, 442], ["patients", "SPECIES", 91, 99], ["their disease", "PROBLEM", 129, 142], ["medication", "TREATMENT", 240, 250], ["This study", "TEST", 298, 308], ["some ESS", "TEST", 324, 332], ["idiopathic CH", "PROBLEM", 363, 376], ["prednisolone", "TREATMENT", 430, 442], ["medical management", "TREATMENT", 505, 523], ["idiopathic", "OBSERVATION", 363, 373]]], ["Further studies are indicated to investigate potential serum markers of autoimmunity and the use of other immunosuppressive treatments in affected dogs.", [["serum", "ANATOMY", 55, 60], ["autoimmunity", "DISEASE", 72, 84], ["serum", "ORGANISM_SUBSTANCE", 55, 60], ["dogs", "ORGANISM", 147, 151], ["dogs", "SPECIES", 147, 151], ["Further studies", "TEST", 0, 15], ["serum markers", "TEST", 55, 68], ["autoimmunity", "PROBLEM", 72, 84], ["other immunosuppressive treatments", "TREATMENT", 100, 134], ["affected dogs", "PROBLEM", 138, 151]]]], "357cf79289853edb47c22d83148c140eb6d87197": [["INTRODUCTIONAcute upper respiratory infection (AURI) is one of the most widespread infections among humans.", [["upper respiratory infection", "DISEASE", 18, 45], ["AURI", "DISEASE", 47, 51], ["infections", "DISEASE", 83, 93], ["humans", "ORGANISM", 100, 106], ["humans", "SPECIES", 100, 106], ["humans", "SPECIES", 100, 106], ["INTRODUCTIONAcute upper respiratory infection", "PROBLEM", 0, 45], ["upper", "ANATOMY_MODIFIER", 18, 23], ["respiratory", "ANATOMY", 24, 35], ["infection", "OBSERVATION", 36, 45], ["widespread", "OBSERVATION_MODIFIER", 72, 82], ["infections", "OBSERVATION", 83, 93]]], ["Respiratory viruses are a common cause of AURI, which is responsible for approximately 200 million cases of pneumonia worldwide annually (He et al.,2017; Sande, Njunge, Ngoi, Mutunga, & Pollard,2019) .", [["Respiratory viruses", "DISEASE", 0, 19], ["AURI", "DISEASE", 42, 46], ["pneumonia", "DISEASE", 108, 117], ["AURI", "CANCER", 42, 46], ["Respiratory viruses", "SPECIES", 0, 19], ["Respiratory viruses", "PROBLEM", 0, 19], ["AURI", "PROBLEM", 42, 46], ["pneumonia", "PROBLEM", 108, 117], ["Sande", "TEST", 154, 159], ["viruses", "OBSERVATION", 12, 19], ["pneumonia", "OBSERVATION", 108, 117]]], ["The common cold is the most widespread AURI caused by a virus (Ludwig et al.,2013) ; other viruses that cause AURI include influenza A, measles, rubella, etc. AURIs are a significant public health problem and a source of increased socioeconomic burden worldwide, as evident by the serious global public health crises caused by multiple AURI pandemics during the course of J o u r n a l P r e -p r o o f human history.", [["AURI", "DISEASE", 39, 43], ["AURI", "DISEASE", 110, 114], ["influenza A", "DISEASE", 123, 134], ["measles, rubella", "DISEASE", 136, 152], ["AURIs", "DISEASE", 159, 164], ["AURI", "CANCER", 39, 43], ["influenza A", "ORGANISM", 123, 134], ["human", "ORGANISM", 403, 408], ["human", "SPECIES", 403, 408], ["human", "SPECIES", 403, 408], ["a virus", "PROBLEM", 54, 61], ["other viruses", "PROBLEM", 85, 98], ["AURI", "PROBLEM", 110, 114], ["influenza A", "PROBLEM", 123, 134], ["measles", "PROBLEM", 136, 143], ["rubella", "PROBLEM", 145, 152], ["AURIs", "PROBLEM", 159, 164], ["a significant public health problem", "PROBLEM", 169, 204], ["increased socioeconomic burden", "PROBLEM", 221, 251], ["the serious global public health crises", "PROBLEM", 277, 316], ["multiple AURI pandemics", "PROBLEM", 327, 350], ["common cold", "ANATOMY", 4, 15], ["influenza", "OBSERVATION", 123, 132], ["significant", "OBSERVATION_MODIFIER", 171, 182], ["increased", "OBSERVATION_MODIFIER", 221, 230], ["socioeconomic", "OBSERVATION_MODIFIER", 231, 244], ["burden", "OBSERVATION", 245, 251]]], ["One hundred two years ago, the first wave of the Spanish influenza (Spanish flu) pandemic occurred in the spring and summer of 1918.", [["influenza", "DISEASE", 57, 66], ["Spanish flu) pandemic", "DISEASE", 68, 89], ["the Spanish influenza", "PROBLEM", 45, 66], ["pandemic", "PROBLEM", 81, 89]]], ["Thereafter, a serious epidemic occurred from September through December, spreading widely from France across the globe, thus causing the second pandemic wave.", [["a serious epidemic", "PROBLEM", 12, 30], ["the second pandemic wave", "PROBLEM", 133, 157], ["serious", "OBSERVATION_MODIFIER", 14, 21], ["globe", "ANATOMY", 113, 118]]], ["The following year, the Spanish flu spread from Eurasia to Oceania, New Zealand, and Australia, constituting the third wave (Crosby,1989) .", [["New", "OBSERVATION_MODIFIER", 68, 71]]], ["During the Spanish flu pandemic, approximately 600 million people were infected (the total world population at the time was 2 billion people) (Lamb,2001) .", [["flu pandemic", "DISEASE", 19, 31], ["people", "ORGANISM", 59, 65], ["people", "ORGANISM", 134, 140], ["people", "SPECIES", 59, 65], ["people", "SPECIES", 134, 140]]], ["The morbidity rate was 20% to 40%; the death toll approximately 20 to 50 million; and the mortality rate was 2.5% to 5%, far exceeding the number of deaths that occurred during the First World War (Taubenberger & Morens,2006) .INTRODUCTIONAnother AURI pandemic was severe acute respiratory syndrome (SARS), which occurred in Guangdong, China, in 2002 .", [["death", "DISEASE", 39, 44], ["deaths", "DISEASE", 149, 155], ["acute respiratory syndrome", "DISEASE", 272, 298], ["SARS", "DISEASE", 300, 304], ["The morbidity rate", "TEST", 0, 18], ["the mortality rate", "TEST", 86, 104], ["severe acute respiratory syndrome", "PROBLEM", 265, 298], ["SARS", "PROBLEM", 300, 304], ["severe", "OBSERVATION_MODIFIER", 265, 271], ["acute", "OBSERVATION_MODIFIER", 272, 277], ["respiratory syndrome", "OBSERVATION", 278, 298]]], ["It first spread to Southeast Asia and then across the globe (China,2003) .", [["globe", "ANATOMY", 54, 59]]], ["The SARS pandemic was not eliminated until mid-2003.", [["SARS", "DISEASE", 4, 8], ["The SARS pandemic", "PROBLEM", 0, 17]]], ["According to statistics released by the World Health Organization (WHO) in July 2003, there were 8,098 cases of SARS worldwide, involving 32 countries and regions.", [["SARS", "DISEASE", 112, 116], ["SARS", "PROBLEM", 112, 116]]], ["The global death toll due to SARS was 774, with a case fatality rate of nearly 11% (Department Of Communicable Disease, WHO,2004) .", [["death", "DISEASE", 11, 16], ["SARS", "DISEASE", 29, 33], ["SARS", "PROBLEM", 29, 33], ["a case fatality rate", "TEST", 48, 68], ["global", "OBSERVATION_MODIFIER", 4, 10], ["death", "OBSERVATION", 11, 16]]], ["SARS also caused the collapse of patient care services in health care systems due to staff shortages.", [["SARS", "DISEASE", 0, 4], ["patient", "ORGANISM", 33, 40], ["patient", "SPECIES", 33, 40], ["collapse", "OBSERVATION", 21, 29]]], ["Since medical and nursing staff were infected with SARS, hospital intensive care units (ICUs) could not be run safely, forcing emergency departments to close down (Caulford,2004; Ahmad,2003; Parry,2003) .", [["SARS", "DISEASE", 51, 55]]], ["This was followed by the Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak that occurred in Saudi Arabia J o u r n a l P r e -p r o o f in July 2012.", [["respiratory syndrome coronavirus", "DISEASE", 37, 69], ["MERS-CoV) outbreak", "DISEASE", 71, 89], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 25, 69], ["MERS-CoV", "ORGANISM", 71, 79], ["Middle East respiratory syndrome coronavirus", "SPECIES", 25, 69], ["MERS-CoV", "SPECIES", 71, 79], ["the Middle East respiratory syndrome coronavirus", "PROBLEM", 21, 69], ["Middle", "ANATOMY_MODIFIER", 25, 31], ["respiratory syndrome", "OBSERVATION", 37, 57]]], ["The global death toll due to MERS was 858, with a case fatality rate of 34.4%, which was even higher than that for SARS (WHO MERS-CoV Research Group,2013; Assiri et al.,2013) .", [["death", "DISEASE", 11, 16], ["MERS", "DISEASE", 29, 33], ["SARS", "DISEASE", 115, 119], ["a case fatality rate", "TEST", 48, 68], ["global", "OBSERVATION_MODIFIER", 4, 10], ["death", "OBSERVATION", 11, 16]]], ["Since AURIs are a serious threat to the health of the world's population and are a large significant obstacle to achieve the goal of building healthy cities via the WHO Healthy Cities Project (TSOUROS,1995) , strengthening preventive and control measures for AURI diseases is vital to reducing the global socioeconomic burden and improving human health globally, paving the way towards building healthy and smart cities.THEORYThe transmission of AURIs in humans is generally believed to occur in three ways: 1) inhalation of liquid droplets containing the virus; 2) close contact with infected persons;THEORYand 3) contact with surfaces contaminated with respiratory viruses.", [["AURIs", "DISEASE", 6, 11], ["AURI diseases", "DISEASE", 259, 272], ["AURIs", "DISEASE", 446, 451], ["respiratory viruses", "DISEASE", 655, 674], ["human", "ORGANISM", 340, 345], ["AURIs", "GENE_OR_GENE_PRODUCT", 446, 451], ["humans", "ORGANISM", 455, 461], ["human", "SPECIES", 340, 345], ["humans", "SPECIES", 455, 461], ["persons", "SPECIES", 594, 601], ["human", "SPECIES", 340, 345], ["humans", "SPECIES", 455, 461], ["AURIs", "PROBLEM", 6, 11], ["strengthening preventive and control measures", "TREATMENT", 209, 254], ["AURI diseases", "PROBLEM", 259, 272], ["the global socioeconomic burden", "PROBLEM", 294, 325], ["AURIs", "PROBLEM", 446, 451], ["inhalation of liquid droplets", "TREATMENT", 511, 540], ["respiratory viruses", "PROBLEM", 655, 674], ["AURIs", "OBSERVATION", 6, 11], ["serious", "OBSERVATION_MODIFIER", 18, 25], ["large", "OBSERVATION_MODIFIER", 83, 88], ["significant", "OBSERVATION_MODIFIER", 89, 100], ["obstacle", "OBSERVATION", 101, 109], ["AURIs", "OBSERVATION", 446, 451], ["respiratory viruses", "OBSERVATION", 655, 674]]], ["Moreover, aerosol transmission has been known to play an important role within enclosed spaces.", [["aerosol transmission", "TREATMENT", 10, 30]]], ["Many traditional AURIs, such as influenza and tuberculosis, as well as many emerging infectious diseases are spread by the airborne route.", [["influenza and tuberculosis", "DISEASE", 32, 58], ["infectious diseases", "DISEASE", 85, 104], ["Many traditional AURIs", "PROBLEM", 0, 22], ["influenza", "PROBLEM", 32, 41], ["tuberculosis", "PROBLEM", 46, 58], ["many emerging infectious diseases", "PROBLEM", 71, 104], ["AURIs", "OBSERVATION", 17, 22], ["tuberculosis", "OBSERVATION", 46, 58], ["infectious", "OBSERVATION", 85, 95]]], ["A retrospective cohort study conducted in Hong Kong in 2003 suggested that aerosol transmission may have been an important transmission route during the SARS epidemic (Yu et al.,2004) .", [["SARS", "DISEASE", 153, 157], ["A retrospective cohort study", "TEST", 0, 28], ["aerosol transmission", "TREATMENT", 75, 95]]], ["Other studies reported that MERS-CoV infection may have been airborne (, , o, Zhang, Ma, & Zhou,2020; Ergenekon, Mustafa, & Vedat,2014) .", [["infection", "DISEASE", 37, 46], ["MERS-CoV", "ORGANISM", 28, 36], ["MERS-CoV", "SPECIES", 28, 36], ["Other studies", "TEST", 0, 13], ["CoV infection", "PROBLEM", 33, 46], ["infection", "OBSERVATION", 37, 46]]], ["Since the coronavirus disease 2019 J o u r n a l P r e -p r o o f pandemic has spread rapidly, aerosol transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has come into focus.", [["coronavirus disease", "DISEASE", 10, 29], ["acute respiratory syndrome coronavirus", "DISEASE", 126, 164], ["coronavirus", "ORGANISM", 10, 21], ["coronavirus", "SPECIES", 10, 21], ["severe acute respiratory syndrome coronavirus", "SPECIES", 119, 164], ["SARS-CoV-2", "SPECIES", 168, 178], ["the coronavirus disease", "PROBLEM", 6, 29], ["pandemic", "PROBLEM", 66, 74], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 119, 164], ["coronavirus disease", "OBSERVATION", 10, 29], ["severe", "OBSERVATION_MODIFIER", 119, 125], ["acute", "OBSERVATION_MODIFIER", 126, 131], ["respiratory syndrome", "OBSERVATION", 132, 152]]], ["WHO health officials stated that there is still insufficient evidence that SARS-CoV-2 is transmitted through the air, except in certain medical settings such as during intubation.", [["SARS", "DISEASE", 75, 79], ["SARS-CoV-2", "ORGANISM", 75, 85], ["SARS", "PROBLEM", 75, 79], ["intubation", "TREATMENT", 168, 178], ["air", "OBSERVATION", 113, 116]]], ["To date, some studies have reported the presence of SARS-CoV-2 particles in the air in isolation rooms from hospitals treating COVID-19 patients (Yuanfang J,2020; Guo, Wang, Zhang, Li, & Chen,2020; Joshua L. Santarpia, 2020; Liu, 2020) , but other similar studies in Singapore and Hong Kong have failed to detect SARS-CoV-2 particles in the air (Cheng, 2020; Ong, 2020) .", [["SARS", "DISEASE", 52, 56], ["SARS", "DISEASE", 313, 317], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144], ["SARS-CoV", "SPECIES", 313, 321], ["some studies", "TEST", 9, 21], ["SARS", "PROBLEM", 52, 56], ["CoV", "TEST", 57, 60], ["SARS", "TEST", 313, 317], ["air", "ANATOMY", 80, 83], ["air", "ANATOMY", 341, 344]]], ["Additional retrospective studies conducted as the SARS-CoV-2 epidemic progressed demonstrated that airborne transmission was one of the most likely mechanisms explaining the spatial pattern of infections.", [["SARS", "DISEASE", 50, 54], ["infections", "DISEASE", 193, 203], ["SARS-CoV-2", "ORGANISM", 50, 60], ["Additional retrospective studies", "TEST", 0, 32], ["the SARS", "TEST", 46, 54], ["CoV", "TEST", 55, 58], ["airborne transmission", "PROBLEM", 99, 120], ["infections", "PROBLEM", 193, 203], ["infections", "OBSERVATION", 193, 203]]], ["This contention has been highlighted in an open letter signed by 239 scientists from 32 countries that was featured in the Journal of Clinical Infectious Diseases on July 6.", [["Infectious Diseases", "DISEASE", 143, 162], ["Infectious", "OBSERVATION", 143, 153]]], ["Three days later, the WHO published a scientific brief on the web and said that the transmission of SARS-CoV-2 by the aerosol route has not been demonstrated, and much more research is needed.", [["SARS", "DISEASE", 100, 104], ["SARS-CoV-2", "ORGANISM", 100, 110], ["SARS", "PROBLEM", 100, 104], ["CoV", "TEST", 105, 108], ["the aerosol route", "TREATMENT", 114, 131]]], ["Therefore, it is crucial to find more evidence to confirm whether SARS-CoV-2 is transmitted through the air.THEORYAlthough all patients in the previous studies had tested positive for SARS-CoV-2 and had COVID-19, little attention has been paid to the follow-up of recovered patients.", [["SARS", "DISEASE", 66, 70], ["SARS", "DISEASE", 184, 188], ["SARS-CoV-2", "ORGANISM", 66, 76], ["patients", "ORGANISM", 127, 135], ["patients", "ORGANISM", 274, 282], ["patients", "SPECIES", 127, 135], ["patients", "SPECIES", 274, 282], ["SARS-CoV", "SPECIES", 184, 192], ["SARS", "PROBLEM", 66, 70], ["the previous studies", "TEST", 139, 159], ["SARS", "PROBLEM", 184, 188], ["CoV", "TEST", 189, 192], ["COVID", "TEST", 203, 208], ["air", "OBSERVATION", 104, 107]]], ["There have been some reported cases of patients who recovered from COVID-19 but tested positive again a few days later, even though they were quarantined after being discharge, and the re-detectable positive (RP) rate was 14.5% (Lan et al.,2020) .", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["COVID", "TEST", 67, 72], ["RP) rate", "TEST", 209, 217]]], ["The reason for this J o u r n a l P r e -p r o o f observation remains unclear, and it is uncertain whether RP patients could cause new infections after being discharged.", [["infections", "DISEASE", 136, 146], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["new infections", "PROBLEM", 132, 146], ["new", "OBSERVATION_MODIFIER", 132, 135], ["infections", "OBSERVATION", 136, 146]]], ["However, even though the pandemic has been largely controlled in several countries such as China and South Korea, RP patients may increase the risk of infection in cities because there are a growing number of patients who tested negative and were then discharged.", [["infection", "DISEASE", 151, 160], ["patients", "ORGANISM", 117, 125], ["patients", "ORGANISM", 209, 217], ["patients", "SPECIES", 117, 125], ["patients", "SPECIES", 209, 217], ["infection", "PROBLEM", 151, 160], ["largely", "OBSERVATION_MODIFIER", 43, 50], ["controlled", "OBSERVATION_MODIFIER", 51, 61], ["infection", "OBSERVATION", 151, 160]]], ["In addition, there is no environmental evidence confirming whether recovered patients are still shedding SARS-CoV-2 particles; therefore, urgent investigations are needed because it could be one of the reasons for the observed RP patients.", [["SARS", "DISEASE", 105, 109], ["patients", "ORGANISM", 77, 85], ["patients", "ORGANISM", 230, 238], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 230, 238], ["still shedding SARS", "PROBLEM", 90, 109], ["urgent investigations", "TEST", 138, 159], ["no environmental evidence confirming", "UNCERTAINTY", 22, 58]]], ["Therefore, our study aims to 1) determine whether SARS-CoV-2 particles are present in the indoor air, with an objective to test the hypothesis of airborne transmission of SARS-CoV-2, and 2) determine whether recovered patients are still shedding SARS-CoV-2 particles, thus providing much-needed environmental evidence for the management of COVID-19 patients during the recovery period.Study designGuizhou Province is located in Southwest China.", [["SARS", "DISEASE", 50, 54], ["SARS", "DISEASE", 171, 175], ["SARS", "DISEASE", 246, 250], ["patients", "ORGANISM", 218, 226], ["patients", "ORGANISM", 349, 357], ["patients", "SPECIES", 218, 226], ["patients", "SPECIES", 349, 357], ["SARS-CoV", "SPECIES", 171, 179], ["our study", "TEST", 11, 20], ["SARS", "PROBLEM", 50, 54], ["CoV", "TEST", 55, 58], ["SARS", "PROBLEM", 171, 175], ["CoV", "TEST", 176, 179], ["still shedding SARS", "PROBLEM", 231, 250], ["COVID", "TEST", 340, 345]]], ["The first COVID-19 patient was reported on January 22, 2020, and the last patient was reported on March 16, 2020 ( changing gloves between units that are not removed before exiting the unit, limiting entry and exit into the ICU by staff, and outfitting all units with negative pressure equipment.", [["patient", "ORGANISM", 19, 26], ["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 19, 26], ["patient", "SPECIES", 74, 81], ["negative pressure equipment", "TREATMENT", 268, 295]]], ["The ICU was routinely cleaned three times daily at 7:00, 12:00, and 17:00.Study designRoutine cleaning included sweeping the floor, wiping the tables with 1,000 mg/L chlorine-containing disinfectant, clearing rubbish, and sterilizing the indoor air for 30 min using an ozone disinfection machine.", [["chlorine", "CHEMICAL", 166, 174], ["ozone", "CHEMICAL", 269, 274], ["chlorine", "CHEMICAL", 166, 174], ["ozone", "CHEMICAL", 269, 274], ["chlorine", "SIMPLE_CHEMICAL", 166, 174], ["L chlorine", "TREATMENT", 164, 174], ["disinfectant", "TREATMENT", 186, 198], ["an ozone disinfection machine", "TREATMENT", 266, 295]]], ["Additionally, the surfaces of all objects were wiped using 75% medicinal alcohol when staff were free.Study designThe sampling was performed on March 11, 2020 at 19:00, two hours after the completion of routine cleaning, when only one ready-for-discharge patient was isolated and under observation in the ICU at Jiangjunshan Hospital.", [["alcohol", "CHEMICAL", 73, 80], ["alcohol", "CHEMICAL", 73, 80], ["alcohol", "SIMPLE_CHEMICAL", 73, 80], ["patient", "ORGANISM", 255, 262], ["patient", "SPECIES", 255, 262], ["The sampling", "TEST", 114, 126], ["routine cleaning", "TREATMENT", 203, 219], ["surfaces", "OBSERVATION_MODIFIER", 18, 26]]], ["Two types of samples were taken as shown in Fig. 2 : surface samples were taken from locations A, B, C, D, and E, and high-volume air samples were taken from locations F and G.Air samplesHigh-volume air samples were collected using a WA 400 Portable viral aerosol sampler (Dingblue Tech, Inc., http://www.dingbluetech.cn/) at 400 L/min for 15 mins (23\u00b11\u00b0C, -15 Pa, RH 45%), while the patient was present and was not wearing a mask.", [["samples", "ANATOMY", 13, 20], ["surface samples", "ANATOMY", 53, 68], ["samples", "CANCER", 13, 20], ["B", "CELL", 98, 99], ["C", "SIMPLE_CHEMICAL", 101, 102], ["D", "SIMPLE_CHEMICAL", 104, 105], ["E", "SIMPLE_CHEMICAL", 111, 112], ["patient", "ORGANISM", 384, 391], ["patient", "SPECIES", 384, 391], ["samples", "TEST", 13, 20], ["surface samples", "TEST", 53, 68], ["A, B, C, D, and E", "TEST", 95, 112], ["high-volume air samples", "PROBLEM", 118, 141], ["G.Air samples", "TEST", 174, 187], ["RH", "TEST", 365, 367], ["a mask", "TREATMENT", 424, 430]]], ["Air was pumped across an air collection tube and collected into a sterile tube containing 3 mL of viral transport media.", [["tube", "TISSUE", 40, 44], ["tube", "TISSUE", 74, 78], ["Air", "TREATMENT", 0, 3], ["an air collection tube", "TREATMENT", 22, 44], ["a sterile tube", "TREATMENT", 64, 78], ["viral transport media", "TREATMENT", 98, 119], ["air collection", "OBSERVATION", 25, 39], ["tube", "OBSERVATION", 40, 44], ["tube", "OBSERVATION", 74, 78], ["transport media", "OBSERVATION", 104, 119]]], ["Each air collection tube was collected independently to avoid cross-contamination.", [["tube", "TISSUE", 20, 24], ["Each air collection tube", "TREATMENT", 0, 24], ["cross-contamination", "PROBLEM", 62, 81], ["air", "OBSERVATION", 5, 8], ["collection tube", "OBSERVATION", 9, 24]]], ["According to the code for indoor environmental pollution control J o u r n a l P r e -p r o o f of civil building engineering GB50325-2010 (2013 (China, 2013) published by the Ministry of Housing and Urban-Rural Development of the People's Republic of China and the number and density of patients in the ICU at Jiangjunshan Hospital, the two sampling points (F and G) were designed as 1) 0.5 m away from the patient's bedside in the isolation room and 2) in the middle of the staff PPE dressing room.", [["patients", "ORGANISM", 288, 296], ["patient", "ORGANISM", 408, 415], ["People", "SPECIES", 231, 237], ["patients", "SPECIES", 288, 296], ["patient", "SPECIES", 408, 415], ["density", "OBSERVATION_MODIFIER", 277, 284], ["middle", "ANATOMY_MODIFIER", 462, 468]]], ["The sampling height for both locations was 1.5 m.", [["The sampling height", "TEST", 0, 19]]], ["Sampling points were chosen to avoid medical equipment, walls, doors, aisles, and air conditioning vents to prevent obstruction and interference.Surface samplesTo evaluate the efficacy of routine cleaning, we used sterile synthetic fibre swabs with plastic shafts to collect surface environmental samples.", [["samples", "ANATOMY", 153, 160], ["surface", "ANATOMY", 275, 282], ["samples", "ANATOMY", 297, 304], ["obstruction", "DISEASE", 116, 127], ["Sampling points", "TEST", 0, 15], ["air conditioning vents", "TREATMENT", 82, 104], ["obstruction and interference", "PROBLEM", 116, 144], ["Surface samples", "TEST", 145, 160], ["routine cleaning", "TREATMENT", 188, 204], ["sterile synthetic fibre swabs", "TREATMENT", 214, 243], ["plastic shafts", "TREATMENT", 249, 263], ["surface environmental samples", "TEST", 275, 304], ["air conditioning", "OBSERVATION", 82, 98], ["obstruction", "OBSERVATION", 116, 127]]], ["Swabs were premoistened with viral transport media and wiped over the surface of the object for a few seconds and then placed immediately into sterile tubes containing 3 mL of viral transport media.Surface samplesEach swab was collected independently to avoid cross-contamination.Sample analysisAll samples were stored at 4\u00b0C and shipped to the testing laboratory in ice packs within four hours of sampling to test for SARS-CoV-2.", [["Swabs", "ANATOMY", 0, 5], ["surface", "ANATOMY", 70, 77], ["samples", "ANATOMY", 206, 213], ["swab", "ANATOMY", 218, 222], ["samples", "ANATOMY", 299, 306], ["SARS", "DISEASE", 419, 423], ["SARS-CoV", "SPECIES", 419, 427], ["Swabs", "TEST", 0, 5], ["viral transport media", "TREATMENT", 29, 50], ["sterile tubes", "TREATMENT", 143, 156], ["viral transport media", "TREATMENT", 176, 197], ["Surface samples", "TEST", 198, 213], ["Each swab", "TEST", 213, 222], ["cross-contamination", "PROBLEM", 260, 279], ["Sample analysis", "TEST", 280, 295], ["All samples", "TEST", 295, 306], ["ice packs", "TREATMENT", 367, 376], ["sampling to test", "TEST", 398, 414], ["SARS", "TEST", 419, 423], ["CoV", "TEST", 424, 427], ["tubes", "OBSERVATION", 151, 156]]], ["Quantitative analysis of the SARS-CoV-2 ribonucleic acid (RNA) genome was carried out by quantitative real-time polymerase chain reaction (qRT-PCR) according to the Otherwise, the sample was considered to be negative if both targets had no apparent logarithmic phase or if the Ct value was \u226540 or indeterminate.", [["ribonucleic acid", "CHEMICAL", 40, 56], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 29, 39], ["SARS-CoV-2 ribonucleic acid (RNA) genome", "DNA", 29, 69], ["SARS-CoV", "SPECIES", 29, 37], ["Quantitative analysis", "TEST", 0, 21], ["the SARS", "TEST", 25, 33], ["CoV", "TEST", 34, 37], ["2 ribonucleic acid (RNA) genome", "PROBLEM", 38, 69], ["the sample", "TEST", 176, 186], ["the Ct value", "TEST", 273, 285], ["indeterminate", "OBSERVATION_MODIFIER", 297, 310]]], ["In this study, an \"intense positive\" constituted a positive result from both the ORF1ab gene and the N gene of SARS-CoV-2.", [["SARS", "DISEASE", 111, 115], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 81, 87], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 111, 121], ["ORF1ab gene", "DNA", 81, 92], ["N gene", "DNA", 101, 107], ["SARS-CoV-2", "DNA", 111, 121], ["SARS-CoV", "SPECIES", 111, 119], ["this study", "TEST", 3, 13], ["the ORF1ab gene", "TREATMENT", 77, 92]]], ["In addition, tests were repeated when a sample tested positive.", [["tests", "TEST", 13, 18], ["a sample", "TEST", 38, 46]]], ["The sample was confirmed to be positive when the second test was also positive.Patient detailsAssessment of the patient epidemiological history revealed that the patient, a 64-yearold female, returned to Guizhou from Wuhan, China, on January 12, 2020, and developed symptoms, including low fewer and cough, on February 11, 2020.", [["sample", "ANATOMY", 4, 10], ["cough", "DISEASE", 300, 305], ["patient", "ORGANISM", 112, 119], ["patient", "ORGANISM", 162, 169], ["female", "ORGANISM", 184, 190], ["Patient", "SPECIES", 79, 86], ["patient", "SPECIES", 112, 119], ["patient", "SPECIES", 162, 169], ["The sample", "TEST", 0, 10], ["the second test", "TEST", 45, 60], ["symptoms", "PROBLEM", 266, 274], ["low fewer and cough", "PROBLEM", 286, 305], ["low fewer", "OBSERVATION_MODIFIER", 286, 295], ["cough", "OBSERVATION", 300, 305]]], ["On February 12, 2020, she was hospitalized after SARS-CoV-2 infection was confirmed at Jiangjunshan Hospital.Patient detailsThe first post-admission chest computed tomography (CT) imaging showed that the J o u r n a l P r e -p r o o f patient had 1) lobular patchy hyperdense shadows in both lungs, 2) emphysema, 3) cardiomegaly, and 4) aortic sclerosis.", [["lobular", "ANATOMY", 250, 257], ["lungs", "ANATOMY", 292, 297], ["emphysema", "ANATOMY", 302, 311], ["aortic", "ANATOMY", 337, 343], ["SARS-CoV-2 infection", "DISEASE", 49, 69], ["emphysema", "DISEASE", 302, 311], ["cardiomegaly", "DISEASE", 316, 328], ["aortic sclerosis", "DISEASE", 337, 353], ["SARS-CoV-2", "ORGANISM", 49, 59], ["patient", "ORGANISM", 235, 242], ["lobular patchy", "PATHOLOGICAL_FORMATION", 250, 264], ["lungs", "ORGAN", 292, 297], ["aortic", "ORGAN", 337, 343], ["Patient", "SPECIES", 109, 116], ["patient", "SPECIES", 235, 242], ["SARS", "PROBLEM", 49, 53], ["CoV-2 infection", "PROBLEM", 54, 69], ["The first post-admission chest computed tomography", "TEST", 124, 174], ["CT) imaging", "TEST", 176, 187], ["lobular patchy hyperdense shadows in both lungs", "PROBLEM", 250, 297], ["emphysema", "PROBLEM", 302, 311], ["cardiomegaly", "PROBLEM", 316, 328], ["4) aortic sclerosis", "PROBLEM", 334, 353], ["infection", "OBSERVATION", 60, 69], ["chest", "ANATOMY", 149, 154], ["lobular", "OBSERVATION_MODIFIER", 250, 257], ["patchy", "OBSERVATION_MODIFIER", 258, 264], ["hyperdense", "OBSERVATION_MODIFIER", 265, 275], ["shadows", "OBSERVATION", 276, 283], ["both", "ANATOMY_MODIFIER", 287, 291], ["lungs", "ANATOMY", 292, 297], ["emphysema", "OBSERVATION", 302, 311], ["cardiomegaly", "OBSERVATION", 316, 328], ["aortic", "ANATOMY", 337, 343], ["sclerosis", "OBSERVATION", 344, 353]]], ["A routine blood test revealed the following counts:Patient detailstotal white blood cells, 7.", [["blood", "ANATOMY", 10, 15], ["detailstotal white blood cells", "ANATOMY", 59, 89], ["blood", "ORGANISM_SUBSTANCE", 10, 15], ["white blood cells", "CELL", 72, 89], ["detailstotal white blood cells", "CELL_TYPE", 59, 89], ["Patient", "SPECIES", 51, 58], ["A routine blood test", "TEST", 0, 20], ["Patient detailstotal white blood cells", "TEST", 51, 89]]], ["4\u00d7109/L; neutrophils, 77.2%; and lymphocytes, 13.4%.", [["neutrophils", "ANATOMY", 9, 20], ["lymphocytes", "ANATOMY", 33, 44], ["neutrophils", "CELL", 9, 20], ["lymphocytes", "CELL", 33, 44], ["neutrophils", "CELL_TYPE", 9, 20], ["lymphocytes", "CELL_TYPE", 33, 44], ["neutrophils", "TEST", 9, 20], ["lymphocytes", "TEST", 33, 44], ["lymphocytes", "ANATOMY", 33, 44]]], ["On February 19, 2020, the patient was transferred to the ICU due to deterioration in her condition.", [["patient", "ORGANISM", 26, 33], ["patient", "SPECIES", 26, 33], ["deterioration in her condition", "PROBLEM", 68, 98], ["deterioration", "OBSERVATION", 68, 81]]], ["After treatment, her condition improved, and she tested negative twice for SARS-CoV-2 on March 8 and 9, 2020.", [["SARS", "DISEASE", 75, 79], ["treatment", "TREATMENT", 6, 15], ["SARS", "PROBLEM", 75, 79], ["CoV", "TEST", 80, 83]]], ["She then continued to be isolated and under observation for an additional 14 days (Fig. 3) .RESULTSA total of seven samples were taken, and the positive test rate for SARS-CoV-2 was 14.29% (1/7).", [["samples", "ANATOMY", 116, 123], ["SARS", "DISEASE", 167, 171], ["samples", "CANCER", 116, 123], ["SARS-CoV-2", "ORGANISM", 167, 177], ["SARS-CoV", "SPECIES", 167, 175], ["seven samples", "TEST", 110, 123], ["the positive test rate", "TEST", 140, 162], ["SARS", "TEST", 167, 171], ["CoV", "TEST", 172, 175]]], ["In this study, all samples taken from surface and air environments from the staff PPE dressing room tested negative, but the air sample from the isolation room was intensely positive, as shown in Table 1 .DISCUSSIONIn this study, we found that SARS-CoV-2 particles were present in the air of an isolation room in the ICU.", [["samples", "ANATOMY", 19, 26], ["surface", "ANATOMY", 38, 45], ["SARS", "DISEASE", 244, 248], ["this study", "TEST", 3, 13], ["all samples", "TEST", 15, 26], ["the staff PPE dressing room", "TEST", 72, 99], ["the air sample", "TEST", 121, 135], ["this study", "TEST", 218, 228], ["SARS", "PROBLEM", 244, 248], ["CoV", "TEST", 249, 252], ["air environments", "OBSERVATION", 50, 66], ["air", "ANATOMY", 285, 288]]], ["The findings agreed with those reported by other studies that found that SARS-CoV-2 was present in indoor air (Yuanfang J,2020;Guo, Wang, Zhang, Li, & Chen,2020;Joshua L. Santarpia, 2020; Liu, 2020) .", [["SARS", "DISEASE", 73, 77], ["SARS-CoV-2", "ORGANISM", 73, 83], ["other studies", "TEST", 43, 56], ["SARS", "PROBLEM", 73, 77], ["CoV", "TEST", 78, 81]]], ["This result is an underlying piece of evidence supporting the hypothesis of airborne transmission of SARS-CoV-2.", [["SARS", "DISEASE", 101, 105], ["SARS-CoV-2", "ORGANISM", 101, 111], ["SARS-CoV", "SPECIES", 101, 109]]], ["Moreover, our findings constituted the first piece of environmental evidence that patients who tested negative for SARS-CoV-2 may still be shedding the virus.", [["SARS", "DISEASE", 115, 119], ["patients", "ORGANISM", 82, 90], ["SARS-CoV-2", "ORGANISM", 115, 125], ["patients", "SPECIES", 82, 90], ["SARS-CoV", "SPECIES", 115, 123], ["SARS", "PROBLEM", 115, 119], ["CoV", "TEST", 120, 123], ["shedding the virus", "PROBLEM", 139, 157], ["virus", "OBSERVATION", 152, 157]]], ["Since reported median estimates of the half-life of SARS-CoV-2 in aerosols range from approximately 1.1 to 1.2 hours (95% confidence intervals of 0.64 to 2.64) (van Doremalen et al.,2020), our J o u r n a l P r e -p r o o f samples were taken 48 hours after the patient had tested negative for SARS-CoV-2 and two hours after the last disinfection operation at Jiangjunshan Hospital.", [["SARS", "DISEASE", 52, 56], ["SARS", "DISEASE", 294, 298], ["patient", "ORGANISM", 262, 269], ["patient", "SPECIES", 262, 269], ["SARS", "PROBLEM", 52, 56], ["CoV", "TEST", 57, 60], ["a l P r e -p r o o f samples", "TEST", 203, 231], ["SARS", "PROBLEM", 294, 298], ["the last disinfection operation", "TREATMENT", 325, 356]]], ["It may be inferred that the aerial presence of SARS-CoV-2 in our study was not a result of retention.", [["SARS", "DISEASE", 47, 51], ["SARS-CoV", "SPECIES", 47, 55], ["SARS", "PROBLEM", 47, 51], ["our study", "TEST", 61, 70], ["retention", "PROBLEM", 91, 100], ["SARS", "OBSERVATION", 47, 51], ["retention", "OBSERVATION", 91, 100]]], ["It is known that recovered patients who are still discharging the virus may have an increased risk of RP.", [["RP", "DISEASE", 102, 104], ["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["the virus", "PROBLEM", 62, 71], ["an increased risk of RP", "PROBLEM", 81, 104], ["increased", "OBSERVATION_MODIFIER", 84, 93], ["RP", "OBSERVATION", 102, 104]]], ["Although the reason for RP remains unclear, potential major factors include virology, immunology, and sampling methodologies.", [["RP", "PROBLEM", 24, 26], ["sampling methodologies", "TEST", 102, 124]]], ["A recent pathological research report found that SARS-CoV-2 could remain in the lung tissue of a ready-for-discharge patient (Yao,2020) , and we believe this study also supported the current virologic understanding of RP occurrence among COVID-19 patients, i.e., the false negatives caused by faulty sampling methodologies, viral residues in the patient's body, intermittent viral release in the patient's body (Xing Y-H,2020), and viral distribution (W\u00f6lfel R,2020; Xia, Tong, Liu, Shen, & Guo,2020) .", [["lung tissue", "ANATOMY", 80, 91], ["RP", "ANATOMY", 218, 220], ["body", "ANATOMY", 356, 360], ["body", "ANATOMY", 406, 410], ["SARS", "DISEASE", 49, 53], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 49, 59], ["lung tissue", "TISSUE", 80, 91], ["patient", "ORGANISM", 117, 124], ["patients", "ORGANISM", 247, 255], ["patient", "ORGANISM", 346, 353], ["body", "ORGANISM_SUBDIVISION", 356, 360], ["patient", "ORGANISM", 396, 403], ["body", "ORGANISM_SUBDIVISION", 406, 410], ["patient", "SPECIES", 117, 124], ["patients", "SPECIES", 247, 255], ["patient", "SPECIES", 346, 353], ["patient", "SPECIES", 396, 403], ["SARS-CoV", "SPECIES", 49, 57], ["SARS", "PROBLEM", 49, 53], ["this study", "TEST", 153, 163], ["the false negatives", "PROBLEM", 263, 282], ["faulty sampling methodologies", "PROBLEM", 293, 322], ["viral residues in the patient's body", "PROBLEM", 324, 360], ["intermittent viral release", "PROBLEM", 362, 388], ["lung", "ANATOMY", 80, 84], ["viral residues", "OBSERVATION", 324, 338], ["viral release", "OBSERVATION", 375, 388], ["viral distribution", "OBSERVATION", 432, 450]]], ["Negative nasopharyngeal swab tests may result in disregarding the above factors.", [["nasopharyngeal swab", "ANATOMY", 9, 28], ["nasopharyngeal swab tests", "TEST", 9, 34], ["nasopharyngeal", "ANATOMY", 9, 23], ["swab", "OBSERVATION", 24, 28]]], ["Another study reported that supplementing negative results with an anal swab test at discharge failed to reduce RP occurrence in COVID-19 patients (Liao, Jianghong An Xuejiao, et al., 2020) .", [["anal swab", "ANATOMY", 67, 76], ["anal swab", "MULTI-TISSUE_STRUCTURE", 67, 76], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["Another study", "TEST", 0, 13], ["an anal swab test", "TEST", 64, 81], ["RP occurrence", "PROBLEM", 112, 125], ["COVID", "TEST", 129, 134], ["anal", "ANATOMY", 67, 71]]], ["This study also analysed the differences in anti-SARS-CoV-2 IgG and IgM antibody levels in both RP and non-RP patients at the time of discharge but did not find any significant differences.DISCUSSIONAccording to the guidelines for the diagnosis and treatment of pneumonia caused by SARS-CoV-2 (sixth edition) published by the National Health Commission of the People's Republic of China (China b,2020) , the discharge criteria for recovered patients included a return to normal temperature for more than three days, a significant improvement in respiratory symptoms, a significant absorption of pulmonary lesions on chest CT Unlike other studies, SARS-CoV-2 was not detected on object surfaces in our study (Cheng et al.,2020b; Guo, Wang, Zhang, Li, & Chen,2020 ;Joshua L. Santarpia,2020; Liu,2020; Ong et al.) , which may be due to differences in routine cleaning operations that could lead to different levels of SARS-CoV-2 in the environment; for J o u r n a l P r e -p r o o f example, the frequency of disinfection at Jiangjunshan Hospital was higher than that reported in other locations (Guo, Wang, Zhang, Li, & Chen,2020; Liu,2020; Ong et al.) .DISCUSSIONAdditionally, the number and density of patients in the ICU at Jiangjunshan Hospital were much lower than those at other hospitals, indicating a markedly reduced risk of SARS-CoV-2 contamination in the environment.", [["RP", "ANATOMY", 96, 98], ["respiratory", "ANATOMY", 545, 556], ["pulmonary lesions", "ANATOMY", 595, 612], ["pneumonia", "DISEASE", 262, 271], ["SARS", "DISEASE", 282, 286], ["pulmonary lesions", "DISEASE", 595, 612], ["SARS", "DISEASE", 647, 651], ["SARS", "DISEASE", 915, 919], ["SARS", "DISEASE", 1333, 1337], ["anti-SARS-CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 44, 63], ["IgM antibody", "GENE_OR_GENE_PRODUCT", 68, 80], ["patients", "ORGANISM", 110, 118], ["SARS-CoV-2", "ORGANISM", 282, 292], ["patients", "ORGANISM", 441, 449], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 595, 612], ["patients", "ORGANISM", 1203, 1211], ["anti-SARS-CoV-2 IgG", "PROTEIN", 44, 63], ["IgM antibody", "PROTEIN", 68, 80], ["patients", "SPECIES", 110, 118], ["patients", "SPECIES", 441, 449], ["patients", "SPECIES", 1203, 1211], ["SARS-CoV", "SPECIES", 282, 290], ["This study", "TEST", 0, 10], ["anti-SARS", "TEST", 44, 53], ["CoV", "TEST", 54, 57], ["IgG", "TEST", 60, 63], ["IgM antibody levels", "TEST", 68, 87], ["treatment", "TREATMENT", 249, 258], ["pneumonia", "PROBLEM", 262, 271], ["SARS", "PROBLEM", 282, 286], ["respiratory symptoms", "PROBLEM", 545, 565], ["pulmonary lesions", "PROBLEM", 595, 612], ["chest CT", "TEST", 616, 624], ["other studies", "TEST", 632, 645], ["SARS", "TEST", 647, 651], ["our study", "TEST", 697, 706], ["routine cleaning operations", "TREATMENT", 848, 875], ["SARS", "PROBLEM", 915, 919], ["disinfection", "PROBLEM", 1007, 1019], ["SARS", "PROBLEM", 1333, 1337], ["CoV", "PROBLEM", 1338, 1341], ["pneumonia", "OBSERVATION", 262, 271], ["significant", "OBSERVATION_MODIFIER", 518, 529], ["improvement", "OBSERVATION_MODIFIER", 530, 541], ["respiratory symptoms", "OBSERVATION", 545, 565], ["pulmonary", "ANATOMY", 595, 604], ["lesions", "OBSERVATION", 605, 612], ["chest", "ANATOMY", 616, 621], ["disinfection", "OBSERVATION", 1007, 1019], ["density", "OBSERVATION_MODIFIER", 1192, 1199], ["markedly", "OBSERVATION_MODIFIER", 1308, 1316], ["reduced", "OBSERVATION_MODIFIER", 1317, 1324], ["SARS", "OBSERVATION", 1333, 1337]]], ["Moreover, many studies have shown that factors such as temperature and humidity can affect the spread of the virus in enclosed indoor environments (Feng, Bi, Zhang, Cai, & Huang,2020; Zhang et al.,2019) .DISCUSSIONSome studies reported that the rate in which SARS-CoV-2 spread was accelerated in cold and dry conditions (Casanova, Jeon, Rutal, , Weber, & Sobsey,2010; Chin, Chu, Perera, Hui, & Poon,2020) .", [["SARS", "DISEASE", 259, 263], ["many studies", "TEST", 10, 22], ["temperature and humidity", "PROBLEM", 55, 79], ["the rate", "TEST", 241, 249], ["CoV", "TEST", 264, 267]]], ["Within an infected person, respiratory droplets with high humidity are produced under high humidity conditions by the atomization of human secretions containing the virus as they pass the air passage through out lung during coughing and sneezing.", [["respiratory droplets", "ANATOMY", 27, 47], ["secretions", "ANATOMY", 139, 149], ["lung", "ANATOMY", 212, 216], ["coughing", "DISEASE", 224, 232], ["sneezing", "DISEASE", 237, 245], ["human", "ORGANISM", 133, 138], ["secretions", "ORGANISM_SUBDIVISION", 139, 149], ["lung", "ORGAN", 212, 216], ["person", "SPECIES", 19, 25], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 133, 138], ["respiratory droplets", "PROBLEM", 27, 47], ["high humidity", "TREATMENT", 53, 66], ["high humidity conditions", "TREATMENT", 86, 110], ["human secretions", "PROBLEM", 133, 149], ["the virus", "PROBLEM", 161, 170], ["coughing", "PROBLEM", 224, 232], ["sneezing", "PROBLEM", 237, 245], ["infected", "OBSERVATION", 10, 18], ["respiratory droplets", "OBSERVATION", 27, 47], ["high humidity", "OBSERVATION", 53, 66], ["air passage", "OBSERVATION", 188, 199], ["lung", "ANATOMY", 212, 216], ["coughing", "OBSERVATION", 224, 232], ["sneezing", "OBSERVATION", 237, 245]]], ["These droplets undergo size reduction due to the drying of water content if the surrounding air humidity and temperature are very low.", [["water", "SIMPLE_CHEMICAL", 59, 64], ["size reduction", "TREATMENT", 23, 37], ["the drying of water content", "PROBLEM", 45, 72], ["the surrounding air humidity", "TEST", 76, 104], ["very low", "PROBLEM", 125, 133], ["size", "OBSERVATION_MODIFIER", 23, 27], ["reduction", "OBSERVATION", 28, 37], ["air humidity", "OBSERVATION", 92, 104]]], ["In contrast, the size of the droplet is not reduced if the surrounding air humidity and temperature are high (Chen, Liu, Lin, & Chen,2015; Liu, Wei, Li, & Ooi,2017; Wu, Zhang, & Zhang,2016) .", [["the surrounding air humidity", "TEST", 55, 83], ["size", "OBSERVATION_MODIFIER", 17, 21], ["droplet", "OBSERVATION", 29, 36], ["not", "UNCERTAINTY", 40, 43], ["reduced", "OBSERVATION_MODIFIER", 44, 51], ["air humidity", "OBSERVATION", 71, 83], ["high", "OBSERVATION_MODIFIER", 104, 108]]], ["At the same time, the virus could become diluted with the surrounding water content in the air and become less active.", [["water", "SIMPLE_CHEMICAL", 70, 75], ["the virus", "PROBLEM", 18, 27], ["virus", "OBSERVATION", 22, 27], ["water content", "OBSERVATION", 70, 83], ["air", "ANATOMY", 91, 94], ["less", "OBSERVATION_MODIFIER", 106, 110], ["active", "OBSERVATION_MODIFIER", 111, 117]]], ["Therefore, a humid environment may be beneficial for maintaining droplet size and reducing viral activity and may therefore play a larger role than the temperature of the indoor environment where a SARS-CoV-2-infected patient is located.DISCUSSIONIn our study, the relative humidity in the ICU at Jiangjunshan Hospital was 45%, which may imply that the droplets shed by the ready-for-discharge patient may undergo size J o u r n a l P r e -p r o o f reduction due to the surrounding air conditions being dry.", [["droplet", "ANATOMY", 65, 72], ["SARS", "DISEASE", 198, 202], ["SARS-CoV-2", "ORGANISM", 198, 208], ["patient", "ORGANISM", 218, 225], ["patient", "ORGANISM", 394, 401], ["patient", "SPECIES", 218, 225], ["patient", "SPECIES", 394, 401], ["a humid environment", "TREATMENT", 11, 30], ["a SARS", "TEST", 196, 202], ["our study", "TEST", 250, 259], ["a l P r e -p r o o f reduction", "TREATMENT", 429, 459], ["the surrounding air conditions", "PROBLEM", 467, 497], ["viral activity", "OBSERVATION", 91, 105], ["infected", "OBSERVATION", 209, 217], ["air conditions", "OBSERVATION", 483, 497], ["dry", "OBSERVATION", 504, 507]]], ["As the expiratory droplet size of the SARS-CoV-2 distribution had a peak size between 0.25 and 1.0 \u03bcm (Liu,2020) , viruses with aerodynamic diameters smaller than 0.5 \u03bcm can remain suspended in the air instead of quickly settling onto the surfaces of objects, and exhaled droplet nuclei can be transmitted between occupants via the airborne route (Ai, Huang, & Melikov,2019) .DISCUSSIONAdditionally, although our sampling was performed two hours after the last routine cleaning, the frequency of disinfection of object surfaces was higher than that of the air in the ICU at Jiangjunshan Hospital, which may have resulted in the air samples but not the object surfaces testing positive for SARS-CoV-2.", [["air samples", "ANATOMY", 628, 639], ["SARS", "DISEASE", 38, 42], ["SARS", "DISEASE", 689, 693], ["SARS-CoV", "SPECIES", 689, 697], ["the expiratory droplet size", "TEST", 3, 30], ["the SARS", "TEST", 34, 42], ["a peak size", "TEST", 66, 77], ["viruses", "PROBLEM", 115, 122], ["aerodynamic diameters", "TEST", 128, 149], ["the last routine cleaning", "TREATMENT", 452, 477], ["disinfection of object surfaces", "TREATMENT", 496, 527], ["the air samples", "TEST", 624, 639], ["the object surfaces testing", "TEST", 648, 675], ["SARS", "PROBLEM", 689, 693], ["CoV", "TEST", 694, 697], ["size", "OBSERVATION_MODIFIER", 26, 30], ["SARS", "OBSERVATION", 38, 42], ["peak", "OBSERVATION_MODIFIER", 68, 72], ["size", "OBSERVATION_MODIFIER", 73, 77], ["aerodynamic", "OBSERVATION_MODIFIER", 128, 139], ["diameters", "OBSERVATION_MODIFIER", 140, 149], ["smaller", "OBSERVATION_MODIFIER", 150, 157], ["air", "OBSERVATION", 198, 201], ["exhaled", "OBSERVATION", 264, 271], ["droplet nuclei", "OBSERVATION", 272, 286], ["air", "OBSERVATION", 556, 559], ["air samples", "OBSERVATION", 628, 639]]], ["To solve the problem of the longterm presence of SARS-CoV-2 viral aerosols in enclosed environments and reduce the risk of SARS-CoV-2 infection, we believe that it is necessary to increase the frequency of indoor air disinfection and to keep the relative humidity of the indoor environment at a high level to maintain droplet size, thereby reducing viral activity.DISCUSSIONOur study has several limitations.", [["SARS", "DISEASE", 49, 53], ["SARS-CoV-2 infection", "DISEASE", 123, 143], ["SARS-CoV-2", "ORGANISM", 123, 133], ["SARS-CoV-2", "SPECIES", 123, 133], ["SARS", "PROBLEM", 49, 53], ["CoV-2 viral aerosols", "TREATMENT", 54, 74], ["SARS", "PROBLEM", 123, 127], ["CoV-2 infection", "PROBLEM", 128, 143], ["indoor air disinfection", "TREATMENT", 206, 229], ["DISCUSSIONOur study", "TEST", 364, 383], ["droplet size", "OBSERVATION", 318, 330], ["viral activity", "OBSERVATION", 349, 363]]], ["First, viral cultures were not performed to demonstrate its viability.", [["viral cultures", "TEST", 7, 21]]], ["Second, the sample size was small due to the low incidence of COVID-19 in Guizhou Province.", [["COVID-19", "CHEMICAL", 62, 70], ["the sample size", "TEST", 8, 23], ["COVID", "TEST", 62, 67], ["size", "OBSERVATION_MODIFIER", 19, 23], ["small", "OBSERVATION_MODIFIER", 28, 33], ["low incidence", "OBSERVATION_MODIFIER", 45, 58]]], ["Moreover, due to the lack of consumables (air collection tubes), our research began during the late stage of the epidemic in Guizhou, and we were unable to continue performing air sample tests.", [["air collection tubes", "TREATMENT", 42, 62], ["air sample tests", "TEST", 176, 192], ["epidemic", "OBSERVATION_MODIFIER", 113, 121]]], ["The concentration of airborne SARS-CoV-2 was not quantified.", [["airborne SARS", "TEST", 21, 34]]], ["The aerodynamic size distribution of SARS-CoV-2 aerosols was not evaluated.", [["SARS", "DISEASE", 37, 41], ["SARS", "PROBLEM", 37, 41], ["aerodynamic", "OBSERVATION_MODIFIER", 4, 15], ["size", "OBSERVATION_MODIFIER", 16, 20], ["distribution", "OBSERVATION_MODIFIER", 21, 33], ["SARS", "OBSERVATION", 37, 41]]], ["Additional studies are needed to confirm our observations.CONCLUSIONSOur findings revealed the presence of SARS-CoV-2 in the indoor air of the ICU and indicate that the virus may be shed via aerosol for days, even after a patient has tested negative.", [["SARS", "DISEASE", 107, 111], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 107, 117], ["patient", "ORGANISM", 222, 229], ["patient", "SPECIES", 222, 229], ["SARS-CoV", "SPECIES", 107, 115], ["Additional studies", "TEST", 0, 18], ["SARS", "PROBLEM", 107, 111], ["CoV", "TEST", 112, 115], ["the virus", "PROBLEM", 165, 174], ["virus", "OBSERVATION", 169, 174]]], ["This finding may be one of the reasons for the observation of RP patients.", [["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["RP patients", "TREATMENT", 62, 73], ["may be", "UNCERTAINTY", 13, 19]]], ["This finding provides valuable empirical information and environmental evidence for the effective management of COVID-19 patients during the convalescent period.", [["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["COVID", "TEST", 112, 117]]], ["We suggest that it is necessary to extend the detection time for COVID-19 patients at the time of discharge and to continually monitor the air surrounding recovered COVID-19 patients for the presence of SARS-CoV-2.", [["SARS", "DISEASE", 203, 207], ["patients", "ORGANISM", 74, 82], ["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 74, 82], ["patients", "SPECIES", 174, 182], ["SARS-CoV", "SPECIES", 203, 211], ["COVID", "TEST", 65, 70], ["SARS", "PROBLEM", 203, 207]]], ["Additionally, the frequency of indoor air disinfection needs to be increased, and the indoor relative humidity should be kept at a high level.CONCLUSIONSOur findings can be used to improve both routine cleaning during the outbreak and clinical and disease management guidelines for discharged COVID-19 patients.CONCLUSIONSSince ICUs are required to maintain negative pressure, close off the isolation ward, and isolate patients in the wards for days at a stretch, it is not possible to use traditional architectural design measures to reduce airborne virus concentrations such as adequate and effective ventilation and ultraviolet germicidal lamps.", [["patients", "ORGANISM", 302, 310], ["patients", "ORGANISM", 419, 427], ["patients", "SPECIES", 302, 310], ["patients", "SPECIES", 419, 427], ["indoor air disinfection", "TREATMENT", 31, 54], ["both routine cleaning", "TREATMENT", 189, 210], ["clinical and disease management", "TREATMENT", 235, 266], ["traditional architectural design measures", "TREATMENT", 490, 531], ["airborne virus concentrations", "TREATMENT", 542, 571], ["effective ventilation", "TREATMENT", 593, 614], ["ultraviolet germicidal lamps", "TREATMENT", 619, 647], ["air disinfection", "OBSERVATION", 38, 54], ["pressure", "OBSERVATION_MODIFIER", 367, 375]]], ["Additionally, it is difficult to limit the number and density of patients in ICUs and avoid overcrowding during emergency situations like the early stage of the epidemic in Wuhan.", [["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["density", "OBSERVATION_MODIFIER", 54, 61], ["epidemic", "OBSERVATION_MODIFIER", 161, 169]]], ["Therefore, to enhance the isolation and care facilities for infectious diseases, smart designs for health and quarantine facilities and ICUs are receiving more attention.", [["infectious diseases", "DISEASE", 60, 79], ["infectious diseases", "PROBLEM", 60, 79]]], ["Attention should be given to the physical elements and environments of buildings that had been designed to reduce the risk of infectious diseases such as Yersinia pestis, tuberculosis, typhoid, polio, and flu during historical epidemics prior to the development of medicines (Megahed & Ghoneim,2020) .", [["infectious diseases", "DISEASE", 126, 145], ["Yersinia pestis", "DISEASE", 154, 169], ["tuberculosis", "DISEASE", 171, 183], ["typhoid", "DISEASE", 185, 192], ["polio", "DISEASE", 194, 199], ["flu", "DISEASE", 205, 208], ["Yersinia pestis", "ORGANISM", 154, 169], ["Yersinia pestis", "SPECIES", 154, 169], ["Yersinia pestis", "SPECIES", 154, 169], ["infectious diseases", "PROBLEM", 126, 145], ["Yersinia pestis", "PROBLEM", 154, 169], ["tuberculosis", "PROBLEM", 171, 183], ["typhoid", "PROBLEM", 185, 192], ["polio", "PROBLEM", 194, 199], ["flu", "PROBLEM", 205, 208], ["historical epidemics", "PROBLEM", 216, 236], ["medicines", "TREATMENT", 265, 274], ["infectious", "OBSERVATION", 126, 136]]], ["In late 2014, a total of 56 hospitals in the United States of America were designated as specially designed, high-level isolation units (HLIUs) equipped with an advanced infrastructure, advanced laboratory capabilities, and well-trained staff by state governments and federal public health authorities to care for patients with highly hazardous communicable diseases (HHCDs) (Herstein et al.,2018) .", [["hazardous communicable diseases", "DISEASE", 335, 366], ["HHCDs", "DISEASE", 368, 373], ["patients", "ORGANISM", 314, 322], ["patients", "SPECIES", 314, 322], ["high-level isolation units", "TREATMENT", 109, 135], ["highly hazardous communicable diseases", "PROBLEM", 328, 366]]], ["To improve the ability to prevent, treat, and manage viral respiratory infections and prevent future crises similar to COVID-19, we suggest that the following points be considered when designing smart buildings and hospitals in the future: 1) development of new air disinfection equipment with better disinfection efficiency and observable sustained effects; 2) strengthening of the cooperation and communication between scientists belonging to different fields such as environmental engineering, architecture, clinical medicine, and public health to design smarter and more effective ICUs that conform to health and isolation standards; 3) integration of information communication technology with hospital operations; and 4) implementation of the concept of the Internet of Things within smart hospitals in smart cities (Silva, Khan, & Han,2018) .Declaration of interestsThe authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.", [["respiratory", "ANATOMY", 59, 70], ["viral respiratory infections", "DISEASE", 53, 81], ["viral respiratory infections", "PROBLEM", 53, 81], ["future crises", "PROBLEM", 94, 107], ["COVID", "TEST", 119, 124], ["new air disinfection equipment", "TREATMENT", 258, 288], ["hospital operations", "TREATMENT", 698, 717], ["new", "OBSERVATION_MODIFIER", 258, 261], ["air disinfection", "OBSERVATION", 262, 278]]]], "40e22da9b80c58635cb6675194f4cb7b937a044c": [["Coronaviruses are classified into four genera, with bat coronaviruses known as the gene source of Alphacoronavirus and Betacoronavirus, and avian coronaviruses as the gene source of Gammacoronavirus and Deltacoronavirus [1, 2] .", [["avian coronaviruses", "DISEASE", 140, 159], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["bat coronaviruses", "ORGANISM", 52, 69], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 98, 114], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 119, 134], ["avian coronaviruses", "ORGANISM", 140, 159], ["avian coronaviruses", "SPECIES", 140, 159], ["bat coronaviruses", "SPECIES", 52, 69], ["Coronaviruses", "PROBLEM", 0, 13], ["bat coronaviruses", "PROBLEM", 52, 69], ["Alphacoronavirus", "PROBLEM", 98, 114], ["Betacoronavirus", "PROBLEM", 119, 134], ["avian coronaviruses", "PROBLEM", 140, 159], ["Gammacoronavirus", "PROBLEM", 182, 198]]], ["However, lineage A Betacoronavirus is unique among the genus in originating in rodents instead of bats [3] .", [["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 19, 34], ["lineage", "OBSERVATION_MODIFIER", 9, 16], ["genus", "OBSERVATION_MODIFIER", 55, 60]]], ["Lineage A Betacoronavirus comprises several coronavirus species, including murine coronavirus, human coronavirus HKU1, Chinese Rattus coronavirus HKU24, rabbit coronavirus HKU14 and Betacoronavirus 1 [3] [4] [5] .", [["murine coronavirus", "DISEASE", 75, 93], ["coronavirus", "ORGANISM", 44, 55], ["murine coronavirus", "ORGANISM", 75, 93], ["human", "ORGANISM", 95, 100], ["coronavirus HKU1", "ORGANISM", 101, 117], ["Chinese Rattus coronavirus", "ORGANISM", 119, 145], ["HKU24", "ORGANISM", 146, 151], ["rabbit coronavirus", "ORGANISM", 153, 171], ["HKU14", "ORGANISM", 172, 177], ["murine", "SPECIES", 75, 81], ["coronavirus", "SPECIES", 82, 93], ["human", "SPECIES", 95, 100], ["coronavirus", "SPECIES", 101, 112], ["Rattus coronavirus", "SPECIES", 127, 145], ["rabbit", "SPECIES", 153, 159], ["coronavirus", "SPECIES", 160, 171], ["murine coronavirus", "SPECIES", 75, 93], ["human coronavirus", "SPECIES", 95, 112], ["Chinese Rattus coronavirus", "SPECIES", 119, 145], ["rabbit coronavirus", "SPECIES", 153, 171], ["several coronavirus species", "PROBLEM", 36, 63], ["murine coronavirus", "PROBLEM", 75, 93], ["human coronavirus", "TEST", 95, 112], ["HKU1", "TEST", 113, 117], ["Chinese Rattus coronavirus", "TEST", 119, 145], ["rabbit coronavirus HKU14", "TEST", 153, 177], ["Betacoronavirus", "TEST", 182, 197], ["coronavirus species", "OBSERVATION", 44, 63], ["murine coronavirus", "OBSERVATION", 75, 93]]], ["Betacoronavirus 1 is best known for its tendency for recombination and interspecies transmission among various mammalian species [3, 6, 7] .", [["Betacoronavirus 1", "GENE_OR_GENE_PRODUCT", 0, 17], ["Betacoronavirus", "TREATMENT", 0, 15], ["its tendency", "PROBLEM", 36, 48]]], ["In particular, human coronavirus OC43 (HCoV OC43) likely originated from a relatively recent zoonotic transmission event, with the most recent common ancestor of HCoV OC43 and bovine coronavirus (BCoV) dating to around 1890 [8] .", [["bovine coronavirus", "DISEASE", 176, 194], ["human", "ORGANISM", 15, 20], ["coronavirus OC43", "ORGANISM", 21, 37], ["HCoV OC43", "ORGANISM", 39, 48], ["HCoV OC43", "ORGANISM", 162, 171], ["bovine coronavirus", "ORGANISM", 176, 194], ["BCoV", "CANCER", 196, 200], ["human", "SPECIES", 15, 20], ["coronavirus", "SPECIES", 21, 32], ["bovine", "SPECIES", 176, 182], ["coronavirus", "SPECIES", 183, 194], ["human coronavirus OC43", "SPECIES", 15, 37], ["HCoV", "SPECIES", 39, 43], ["HCoV", "SPECIES", 162, 166], ["bovine coronavirus", "SPECIES", 176, 194], ["BCoV", "SPECIES", 196, 200], ["human coronavirus OC43 (HCoV OC43", "PROBLEM", 15, 48], ["bovine coronavirus", "PROBLEM", 176, 194], ["zoonotic", "OBSERVATION_MODIFIER", 93, 101], ["bovine coronavirus", "OBSERVATION", 176, 194]]], ["Besides cattle, BCoV-like viruses have been detected in various ungulates, including water buffalo calves with gastroenteritis in Italy [9, 10] .", [["gastroenteritis", "DISEASE", 111, 126], ["cattle", "ORGANISM", 8, 14], ["BCoV-like viruses", "ORGANISM", 16, 33], ["calves", "ORGANISM", 99, 105], ["cattle", "SPECIES", 8, 14], ["calves", "SPECIES", 99, 105], ["cattle", "SPECIES", 8, 14], ["buffalo", "SPECIES", 91, 98], ["BCoV", "TEST", 16, 20], ["viruses", "PROBLEM", 26, 33], ["gastroenteritis", "PROBLEM", 111, 126], ["viruses", "OBSERVATION", 26, 33], ["ungulates", "OBSERVATION_MODIFIER", 64, 73], ["gastroenteritis", "OBSERVATION", 111, 126]]], ["However, only partial gene sequences, the longest one being~9.6 kb spanning ORF1b to nucleocapsid (N), were obtained from the buffalo viruses [9, 10] .", [["ORF1b", "GENE_OR_GENE_PRODUCT", 76, 81], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 85, 101], ["buffalo", "ORGANISM", 126, 133], ["partial gene sequences", "DNA", 14, 36], ["ORF1b", "DNA", 76, 81], ["buffalo viruses", "SPECIES", 126, 141], ["partial gene sequences", "TEST", 14, 36]]]], "PMC7119615": [["IntroductionRabies viruses are in the order Mononegavirales (enveloped negative strand RNA viruses with unsegmented genomes), family Rhabdoviridae, and belong to the Lyssavirus genus.", [["IntroductionRabies viruses", "ORGANISM", 0, 26], ["Mononegavirales", "GENE_OR_GENE_PRODUCT", 44, 59], ["Rhabdoviridae", "GENE_OR_GENE_PRODUCT", 133, 146], ["Lyssavirus genus", "ORGANISM", 166, 182], ["unsegmented genomes", "DNA", 104, 123], ["IntroductionRabies viruses", "PROBLEM", 0, 26], ["Rhabdoviridae", "TREATMENT", 133, 146], ["viruses", "OBSERVATION", 19, 26]]], ["Based on the nucleotide sequence and deduced percentage of amino acid similarity in the nucleoprotein (N), the Lyssavirus genus is divided into six established genotypes (Bourhy et al., 1992, Bourhy et al., 1993).", [["nucleotide", "CHEMICAL", 13, 23], ["amino acid", "CHEMICAL", 59, 69], ["nucleotide", "CHEMICAL", 13, 23], ["amino acid", "CHEMICAL", 59, 69], ["amino acid", "AMINO_ACID", 59, 69], ["the nucleotide sequence", "TEST", 9, 32], ["amino acid similarity", "PROBLEM", 59, 80], ["the Lyssavirus genus", "TREATMENT", 107, 127], ["amino acid", "OBSERVATION", 59, 69]]], ["The genus is composed of classical rabies virus (genotype 1) and the rabies-related viruses: Lagos Bat virus (genotype 2), Mokola virus (genotype 3), Duvenhage virus (genotype 4), and European Bat Lyssaviruses (EBL) 1 and 2 (genotypes 5 and 6, respectively) (Familusi et al., 1972, Crick et al., 1982, Foggin, 1983, King and Crick, 1988, Bourhy et al., 1993).", [["rabies virus", "DISEASE", 35, 47], ["classical", "ORGANISM", 25, 34], ["rabies virus", "ORGANISM", 35, 47], ["rabies-related viruses", "ORGANISM", 69, 91], ["Lagos Bat virus", "ORGANISM", 93, 108], ["genotype 2", "ORGANISM", 110, 120], ["Mokola virus", "ORGANISM", 123, 135], ["genotype 3", "ORGANISM", 137, 147], ["Duvenhage virus", "ORGANISM", 150, 165], ["rabies virus", "SPECIES", 35, 47], ["Bat virus", "SPECIES", 99, 108], ["Mokola virus", "SPECIES", 123, 135], ["Duvenhage virus", "SPECIES", 150, 165], ["rabies virus", "SPECIES", 35, 47], ["Lagos Bat virus", "SPECIES", 93, 108], ["Mokola virus", "SPECIES", 123, 135], ["Duvenhage virus", "SPECIES", 150, 165], ["European Bat Lyssaviruses", "SPECIES", 184, 209], ["classical rabies virus", "PROBLEM", 25, 47], ["the rabies-related viruses", "PROBLEM", 65, 91], ["Lagos Bat virus", "PROBLEM", 93, 108], ["genotype", "TEST", 110, 118], ["Mokola virus (genotype", "TREATMENT", 123, 145], ["Duvenhage virus (genotype", "TREATMENT", 150, 175], ["European Bat Lyssaviruses (EBL)", "TREATMENT", 184, 215], ["genus", "ANATOMY", 4, 9]]], ["The more recent Australian Bat Lyssavirus, first reported in 1996 (Fraser et al., 1996), has been classified as a separate and distinct genotype (genotype 7) within the Lyssavirus genus (Gould et al., 1998) (Fig. 1).IntroductionAll mammals are susceptible to rabies, but the major hosts are wild and domestic canines and felines, viverrids, mustelids, racoons and Microchiroptera (insectivorous and haematophagous bats).", [["felines", "ANATOMY", 321, 328], ["mustelids", "ANATOMY", 341, 350], ["rabies", "DISEASE", 259, 265], ["rabies", "ORGANISM", 259, 265], ["canines", "ORGAN", 309, 316], ["haematophagous bats", "ORGANISM", 399, 418], ["rabies", "SPECIES", 259, 265], ["rabies", "PROBLEM", 259, 265], ["viverrids", "TREATMENT", 330, 339], ["mustelids", "TREATMENT", 341, 350]]], ["All genotypes, with the exception of genotype 2, are known to cause human disease.", [["human", "ORGANISM", 68, 73], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73], ["All genotypes", "PROBLEM", 0, 13], ["genotype 2", "PROBLEM", 37, 47], ["human disease", "PROBLEM", 68, 81]]], ["The illness caused by the rabies-related viruses is virtually indistinguishable from classical rabies (Smith et al., 1992).", [["illness", "DISEASE", 4, 11], ["rabies", "DISEASE", 26, 32], ["rabies", "DISEASE", 95, 101], ["rabies", "ORGANISM", 26, 32], ["The illness", "PROBLEM", 0, 11], ["the rabies-related viruses", "PROBLEM", 22, 48], ["illness", "OBSERVATION", 4, 11]]], ["Classical rabies viruses have a world-wide distribution except for a few island nations such as Great Britain, Ireland, New Zealand and Hawaii, the continents of Australia and Antarctica and an increasing number of Western European countries.", [["rabies viruses", "DISEASE", 10, 24], ["rabies viruses", "ORGANISM", 10, 24], ["rabies viruses", "SPECIES", 10, 24], ["Classical rabies viruses", "PROBLEM", 0, 24], ["few", "OBSERVATION_MODIFIER", 69, 72], ["Great", "OBSERVATION_MODIFIER", 96, 101], ["New", "OBSERVATION_MODIFIER", 120, 123], ["Zealand", "OBSERVATION_MODIFIER", 124, 131], ["increasing", "OBSERVATION_MODIFIER", 194, 204]]], ["The Lagos Bat, Mokola and Duvenhage viruses of genotypes 2\u20134 are mainly restricted in distribution to the African Continent.", [["Duvenhage viruses", "ORGANISM", 26, 43], ["Mokola and Duvenhage viruses of genotypes", "TREATMENT", 15, 56]]], ["However, a genotype 2 isolate has been isolated recently from an imported fruit bat in France (Aubert, 1999).IntroductionThe bat viruses of genotypes 5 and 6 have only been isolated in Europe.", [["bat viruses", "ORGANISM", 125, 136], ["genotypes 5", "ORGANISM", 140, 151], ["a genotype 2 isolate", "PROBLEM", 9, 29], ["The bat viruses of genotypes", "TREATMENT", 121, 149], ["fruit bat", "OBSERVATION", 74, 83]]], ["European bat Lyssavirus 1 (EBL1) isolates are found primarily in Eptesicus bats, whilst EBL2 isolates have only been identified in Myotis bats (Brass, 1994).", [["European bat Lyssavirus 1", "ORGANISM", 0, 25], ["EBL1", "GENE_OR_GENE_PRODUCT", 27, 31], ["Eptesicus bats", "ORGANISM", 65, 79], ["EBL2", "GENE_OR_GENE_PRODUCT", 88, 92], ["Myotis bats", "ORGANISM", 131, 142], ["European bat Lyssavirus 1", "SPECIES", 0, 25], ["Eptesicus bats", "SPECIES", 65, 79], ["Myotis bats", "SPECIES", 131, 142], ["European bat Lyssavirus", "TEST", 0, 23], ["isolates", "TEST", 33, 41], ["Eptesicus bats", "OBSERVATION", 65, 79], ["Myotis bats", "OBSERVATION", 131, 142]]], ["The EBLs have been further classified into the phylogenetic lineages EBL1a, EBL1b, EBL2a and EBL2b (Amengual et al., 1997).IntroductionThe accepted diagnostic standard for rabies detection, the fluorescent antibody test (FAT), detects virus antigen in brain smears using fluorescently-labelled anti-rabies antibodies (Dean and Abelseth, 1973).", [["brain", "ANATOMY", 252, 257], ["EBLs", "CANCER", 4, 8], ["EBL1a", "GENE_OR_GENE_PRODUCT", 69, 74], ["EBL1b", "GENE_OR_GENE_PRODUCT", 76, 81], ["EBL2a", "GENE_OR_GENE_PRODUCT", 83, 88], ["EBL2b", "GENE_OR_GENE_PRODUCT", 93, 98], ["rabies", "ORGANISM", 172, 178], ["brain", "ORGAN", 252, 257], ["fluorescently", "SIMPLE_CHEMICAL", 271, 284], ["anti-rabies antibodies", "SIMPLE_CHEMICAL", 294, 316], ["EBLs", "PROTEIN", 4, 8], ["EBL1a", "DNA", 69, 74], ["EBL1b", "DNA", 76, 81], ["EBL2a", "DNA", 83, 88], ["EBL2b", "DNA", 93, 98], ["FAT", "PROTEIN", 221, 224], ["virus antigen", "PROTEIN", 235, 248], ["anti-rabies antibodies", "PROTEIN", 294, 316], ["rabies", "SPECIES", 172, 178], ["The EBLs", "TEST", 0, 8], ["EBL1b", "TEST", 76, 81], ["EBL2a", "TEST", 83, 88], ["rabies detection", "TEST", 172, 188], ["the fluorescent antibody test", "TEST", 190, 219], ["virus antigen", "TEST", 235, 248], ["brain smears", "TEST", 252, 264], ["fluorescently", "TEST", 271, 284], ["brain", "ANATOMY", 252, 257]]], ["The sensitivity of this detection method is good with classical rabies isolates, but may be reduced with isolates from the rabies-related viruses (Perrin et al., 1992).", [["rabies", "DISEASE", 123, 129], ["rabies", "ORGANISM", 64, 70], ["rabies", "ORGANISM", 123, 129], ["rabies", "SPECIES", 64, 70], ["this detection method", "TEST", 19, 40], ["classical rabies isolates", "PROBLEM", 54, 79], ["isolates", "PROBLEM", 105, 113]]], ["In addition, FAT cannot be used to distinguish between the genotypes.IntroductionPCR-based assays have the added advantage over the standard diagnostic assays that they produce a product that can be further analysed by sequencing.", [["FAT", "GENE_OR_GENE_PRODUCT", 13, 16], ["FAT", "PROTEIN", 13, 16], ["IntroductionPCR", "TEST", 69, 84]]], ["The resultant data can then be used for phylogenetic analyses that enable a highly accurate characterisation of virus isolates.", [["phylogenetic analyses", "TEST", 40, 61], ["virus isolates", "PROBLEM", 112, 126]]], ["A hemi-nested reverse transcriptase PCR (hnRT-PCR) assay that uses a cocktail of primers capable of detecting the six established genotypes of rabies and rabies-related viruses has been described (Heaton et al., 1997).", [["rabies", "DISEASE", 143, 149], ["rabies-related viruses", "DISEASE", 154, 176], ["rabies", "ORGANISM", 143, 149], ["rabies", "ORGANISM", 154, 160], ["hemi-nested reverse transcriptase PCR", "DNA", 2, 39], ["rabies", "SPECIES", 143, 149], ["A hemi-nested reverse transcriptase PCR", "TEST", 0, 39], ["hnRT", "TEST", 41, 45], ["a cocktail of primers", "TREATMENT", 67, 88], ["rabies", "PROBLEM", 143, 149], ["rabies-related viruses", "PROBLEM", 154, 176]]], ["The hnRT-PCR offers a higher level of sensitivity than the FAT for normal and decomposed tissues (Heaton et al., 1997), but it does not distinguish between the genotypes.", [["tissues", "ANATOMY", 89, 96], ["FAT", "GENE_OR_GENE_PRODUCT", 59, 62], ["tissues", "TISSUE", 89, 96], ["hnRT-PCR", "DNA", 4, 12], ["FAT", "PROTEIN", 59, 62], ["The hnRT-PCR", "TEST", 0, 12]]], ["However, the resultant N-terminal 405 bp sequence data is sufficient to distinguish between the various genotypes (Fig. 1).", [["N", "CHEMICAL", 23, 24], ["N-terminal 405 bp sequence", "DNA", 23, 49], ["terminal 405 bp sequence data", "TEST", 25, 54]]], ["More recently, an assay using PCR-ELISA was described which could amplify and distinguish genotype 1, 5 and 6 viruses (Black et al., 2000).IntroductionA technique that gives rise to phylogenetic data much more rapidly than sequencing involves the use of TaqMan\u2122 probes.", [["TaqMan\u2122 probes", "DNA", 254, 268], ["an assay", "TEST", 15, 23], ["PCR", "TEST", 30, 33], ["ELISA", "TEST", 34, 39], ["genotype", "TEST", 90, 98], ["IntroductionA technique", "TREATMENT", 139, 162], ["phylogenetic data", "TEST", 182, 199], ["TaqMan\u2122 probes", "TREATMENT", 254, 268]]], ["A result confirming the genetic lineage of an isolate can be achieved using TaqMan\u2122 probes within a few minutes of completing a standard PCR or reverse transcriptase-polymerase chain reaction (RT-PCR) cycle.", [["TaqMan\u2122 probes", "DNA", 76, 90], ["reverse transcriptase", "PROTEIN", 144, 165], ["TaqMan\u2122 probes", "TREATMENT", 76, 90], ["a standard PCR", "TEST", 126, 140], ["reverse transcriptase-polymerase chain reaction", "TREATMENT", 144, 191]]], ["A closed tube system can be used for the PCR and to measure the fluorescence emitted by the TaqMan\u2122 probes, resulting in minimal post-PCR manipulation and therefore, a reduction in potential cross contamination.", [["tube", "TISSUE", 9, 13], ["TaqMan\u2122 probes", "DNA", 92, 106], ["A closed tube system", "TREATMENT", 0, 20], ["the PCR", "TEST", 37, 44], ["the fluorescence", "TEST", 60, 76], ["the TaqMan\u2122 probes", "TEST", 88, 106], ["minimal post-PCR manipulation", "TREATMENT", 121, 150], ["a reduction", "TREATMENT", 166, 177], ["potential cross contamination", "PROBLEM", 181, 210], ["closed", "OBSERVATION_MODIFIER", 2, 8], ["tube", "OBSERVATION", 9, 13], ["minimal", "OBSERVATION_MODIFIER", 121, 128], ["reduction", "OBSERVATION_MODIFIER", 168, 177], ["cross contamination", "OBSERVATION", 191, 210]]], ["Since its development, TaqMan\u2122 has found many applications in research, viral and bacteriological diagnostics and epidemiological studies (Chen et al., 1997, Sharma et al., 1999, McGoldrick et al., 1998, Kimura et al., 1999, Laue et al., 1999).IntroductionUsing the sequence data from a number of isolates from each of the rabies and rabies-related virus genotypes, TaqMan\u2122 probes were designed to distinguish the six established genotypes of rabies and rabies-related viruses.", [["TaqMan\u2122", "CHEMICAL", 23, 30], ["rabies", "DISEASE", 323, 329], ["rabies", "DISEASE", 334, 340], ["rabies", "DISEASE", 443, 449], ["rabies", "DISEASE", 454, 460], ["rabies", "ORGANISM", 323, 329], ["rabies-related virus", "ORGANISM", 334, 354], ["rabies", "ORGANISM", 443, 449], ["rabies-related viruses", "ORGANISM", 454, 476], ["rabies", "SPECIES", 323, 329], ["rabies", "SPECIES", 443, 449], ["bacteriological diagnostics", "TEST", 82, 109], ["epidemiological studies", "TEST", 114, 137], ["the sequence data", "TEST", 262, 279], ["the rabies", "TEST", 319, 329], ["related virus genotypes", "PROBLEM", 341, 364], ["TaqMan\u2122 probes", "TREATMENT", 366, 380], ["rabies", "PROBLEM", 443, 449], ["related viruses", "PROBLEM", 461, 476]]], ["Due to the genetic diversity of genotype 1 isolates, a combination of three probes was found to be necessary to detect all of the classical isolates tested.", [["genotype 1 isolates", "TREATMENT", 32, 51]]], ["The remaining five genotypes required only a single probe each.", [["a single probe each", "TREATMENT", 43, 62]]], ["Using these probes rapid identification and classification of suspect rabies virus isolates can be made within a few hours and provide additionally useful epidemiological data in general research.Cells and viruses ::: MethodsVirus isolates (n=106) from the six established genotypes of rabies and rabies-related viruses and one Australian bat Lyssavirus isolate were selected for this study.", [["Cells", "ANATOMY", 196, 201], ["rabies and rabies", "DISEASE", 286, 303], ["rabies virus", "ORGANISM", 70, 82], ["Cells", "CELL", 196, 201], ["MethodsVirus isolates", "ORGANISM", 218, 239], ["rabies", "ORGANISM", 286, 292], ["rabies", "ORGANISM", 297, 303], ["rabies virus", "SPECIES", 70, 82], ["rabies", "SPECIES", 286, 292], ["these probes rapid identification", "TEST", 6, 39], ["rabies virus isolates", "PROBLEM", 70, 91], ["viruses", "TEST", 206, 213], ["MethodsVirus isolates", "TEST", 218, 239], ["rabies", "PROBLEM", 286, 292], ["rabies-related viruses", "PROBLEM", 297, 319], ["Australian bat Lyssavirus isolate", "TREATMENT", 328, 361], ["this study", "TEST", 380, 390]]], ["The rabies virus isolates were propagated and passaged in mice or wherever possible in BHK-21 cells as described (King, 1996, Heaton et al., 1997, Black et al., 2000).", [["BHK-21 cells", "ANATOMY", 87, 99], ["rabies virus", "ORGANISM", 4, 16], ["mice", "ORGANISM", 58, 62], ["BHK-21 cells", "CELL", 87, 99], ["BHK-21 cells", "CELL_LINE", 87, 99], ["mice", "SPECIES", 58, 62], ["rabies virus", "SPECIES", 4, 16], ["mice", "SPECIES", 58, 62], ["BHK-21", "SPECIES", 87, 93], ["The rabies virus isolates", "PROBLEM", 0, 25]]], ["The first 405 bases of the N gene had previously been sequenced to confirm the genotype of the strain.", [["N gene", "DNA", 27, 33], ["the strain", "PROBLEM", 91, 101]]], ["The RNA from eighteen other non-rabies viruses important in the veterinary field was also tested to assess the specificity of the primers and probes.", [["non-rabies viruses", "ORGANISM", 28, 46], ["The RNA from eighteen other non-rabies viruses", "PROBLEM", 0, 46], ["viruses", "OBSERVATION", 39, 46]]], ["These were, Classical Swine Fever Virus, Border Disease Virus, Bovine Viral Diarrhoea Viruses types 1 and 2, Porcine Epidemic Diarrhoea Virus, Porcine Respiratory Coronavirus, Porcine Reproductive & Respiratory Syndrome Virus, Bromo Mosaic Virus, Newcastle Disease Virus, Avian Paramyxovirus, Feline Calicivirus, Feline Infectious Peritonitis Virus, Feline Coronavirus, Feline Herpes Virus, Feline Poxvirus, Feline Immunodeficiency, Virus Feline Leukaemia Virus and Feline Spumavirus.RNA extraction and cDNA synthesis ::: MethodsTotal RNA was extracted directly from rabies-infected BHK-21 monolayers or infected mouse brain tissue using TRIzol\u00ae (Gibco BRL) according to manufacturer's instructions.", [["BHK-21 monolayers", "ANATOMY", 583, 600], ["brain tissue", "ANATOMY", 619, 631], ["Swine Fever", "DISEASE", 22, 33], ["Border Disease Virus", "DISEASE", 41, 61], ["Viral Diarrhoea Viruses", "DISEASE", 70, 93], ["Epidemic Diarrhoea Virus", "DISEASE", 117, 141], ["Porcine Respiratory Coronavirus", "DISEASE", 143, 174], ["Porcine Reproductive & Respiratory Syndrome Virus", "DISEASE", 176, 225], ["Bromo Mosaic Virus", "DISEASE", 227, 245], ["Newcastle Disease Virus", "DISEASE", 247, 270], ["Avian Paramyxovirus", "DISEASE", 272, 291], ["Feline Calicivirus", "DISEASE", 293, 311], ["Feline", "DISEASE", 313, 319], ["Infectious Peritonitis Virus", "DISEASE", 320, 348], ["Feline Coronavirus", "DISEASE", 350, 368], ["Feline Herpes Virus", "DISEASE", 370, 389], ["Feline Poxvirus", "DISEASE", 391, 406], ["Feline Immunodeficiency", "DISEASE", 408, 431], ["Feline Leukaemia Virus", "DISEASE", 439, 461], ["Feline Spumavirus", "DISEASE", 466, 483], ["Swine Fever Virus", "ORGANISM", 22, 39], ["Border Disease Virus", "ORGANISM", 41, 61], ["Bovine Viral Diarrhoea Viruses", "ORGANISM", 63, 93], ["Porcine", "ORGANISM", 109, 116], ["Epidemic Diarrhoea Virus", "ORGANISM", 117, 141], ["Porcine Respiratory Coronavirus", "ORGANISM", 143, 174], ["Porcine Reproductive & Respiratory Syndrome Virus", "ORGANISM", 176, 225], ["Bromo Mosaic Virus", "ORGANISM", 227, 245], ["Newcastle Disease Virus", "ORGANISM", 247, 270], ["Avian Paramyxovirus", "ORGANISM", 272, 291], ["Feline Calicivirus", "ORGANISM", 293, 311], ["Feline Infectious Peritonitis Virus", "ORGANISM", 313, 348], ["Feline Coronavirus", "ORGANISM", 350, 368], ["Feline Herpes Virus", "ORGANISM", 370, 389], ["Feline Poxvirus", "ORGANISM", 391, 406], ["Feline Immunodeficiency", "ORGANISM", 408, 431], ["Virus Feline Leukaemia Virus", "ORGANISM", 433, 461], ["Feline", "ORGANISM", 466, 472], ["Spumavirus", "ORGANISM", 473, 483], ["rabies", "ORGANISM", 567, 573], ["BHK-21 monolayers", "CELL", 583, 600], ["mouse", "ORGANISM", 613, 618], ["brain tissue", "TISSUE", 619, 631], ["MethodsTotal RNA", "RNA", 522, 538], ["Swine Fever Virus", "SPECIES", 22, 39], ["Bovine", "SPECIES", 63, 69], ["Porcine", "SPECIES", 109, 116], ["Porcine", "SPECIES", 143, 150], ["Porcine", "SPECIES", 176, 183], ["Avian", "SPECIES", 272, 277], ["Feline", "SPECIES", 293, 299], ["Feline", "SPECIES", 350, 356], ["Feline Herpes Virus", "SPECIES", 370, 389], ["Feline", "SPECIES", 391, 397], ["Feline", "SPECIES", 408, 414], ["Feline", "SPECIES", 439, 445], ["Feline", "SPECIES", 466, 472], ["mouse", "SPECIES", 613, 618], ["Swine Fever Virus", "SPECIES", 22, 39], ["Border Disease Virus", "SPECIES", 41, 61], ["Bovine Viral Diarrhoea Viruses types 1", "SPECIES", 63, 101], ["Porcine Epidemic Diarrhoea Virus", "SPECIES", 109, 141], ["Porcine Respiratory Coronavirus, Porcine Reproductive & Respiratory Syndrome Virus", "SPECIES", 143, 225], ["Bromo Mosaic Virus", "SPECIES", 227, 245], ["Newcastle Disease Virus", "SPECIES", 247, 270], ["Feline Infectious Peritonitis Virus", "SPECIES", 313, 348], ["Feline Herpes Virus", "SPECIES", 370, 389], ["rabies", "SPECIES", 567, 573], ["BHK-21", "SPECIES", 583, 589], ["mouse", "SPECIES", 613, 618], ["Classical Swine Fever Virus", "PROBLEM", 12, 39], ["Border Disease Virus", "PROBLEM", 41, 61], ["Bovine Viral Diarrhoea Viruses types", "PROBLEM", 63, 99], ["Porcine Epidemic Diarrhoea Virus", "PROBLEM", 109, 141], ["Porcine Respiratory Coronavirus", "PROBLEM", 143, 174], ["Porcine Reproductive & Respiratory Syndrome Virus", "PROBLEM", 176, 225], ["Bromo Mosaic Virus", "PROBLEM", 227, 245], ["Newcastle Disease Virus", "PROBLEM", 247, 270], ["Avian Paramyxovirus", "TREATMENT", 272, 291], ["Feline Calicivirus", "PROBLEM", 293, 311], ["Feline Infectious Peritonitis Virus", "PROBLEM", 313, 348], ["Feline Coronavirus", "PROBLEM", 350, 368], ["Feline Herpes Virus", "PROBLEM", 370, 389], ["Feline Poxvirus", "TREATMENT", 391, 406], ["Feline Immunodeficiency", "PROBLEM", 408, 431], ["Virus Feline Leukaemia Virus", "TREATMENT", 433, 461], ["Feline Spumavirus", "TREATMENT", 466, 483], ["RNA extraction", "TREATMENT", 484, 498], ["MethodsTotal RNA", "PROBLEM", 522, 538], ["infected BHK", "PROBLEM", 574, 586], ["infected mouse brain tissue", "PROBLEM", 604, 631], ["TRIzol\u00ae (Gibco BRL", "TREATMENT", 638, 656], ["Viral", "OBSERVATION_MODIFIER", 70, 75], ["Diarrhoea Viruses", "OBSERVATION", 76, 93], ["Diarrhoea Virus", "OBSERVATION", 126, 141], ["Respiratory Coronavirus", "OBSERVATION", 151, 174], ["Respiratory Syndrome", "OBSERVATION", 199, 219], ["Bromo Mosaic Virus", "OBSERVATION", 227, 245], ["Feline Calicivirus", "OBSERVATION", 293, 311], ["Infectious", "OBSERVATION_MODIFIER", 320, 330], ["Peritonitis", "OBSERVATION", 331, 342], ["Feline Coronavirus", "OBSERVATION", 350, 368], ["Feline Immunodeficiency", "OBSERVATION", 408, 431], ["Leukaemia Virus", "OBSERVATION", 446, 461], ["21 monolayers", "OBSERVATION_MODIFIER", 587, 600], ["infected mouse brain tissue", "OBSERVATION", 604, 631]]], ["Complementary DNA was produced using the RNA extracted from each of the infected cultures or mouse brains and the messenger sense RT primer JW12 as described (Heaton et al., 1997).Primers and TaqMan\u2122 probes ::: MethodsThe primer sets for PCR amplification were based on those of Heaton et al. (1997) although a new messenger sense primer BB6 was found to be more efficient than JW12 for PCR amplification.", [["cultures", "ANATOMY", 81, 89], ["brains", "ANATOMY", 99, 105], ["DNA", "CELLULAR_COMPONENT", 14, 17], ["cultures", "CELL", 81, 89], ["mouse", "ORGANISM", 93, 98], ["brains", "ORGAN", 99, 105], ["BB6", "GENE_OR_GENE_PRODUCT", 338, 341], ["messenger sense RT primer JW12", "DNA", 114, 144], ["TaqMan\u2122 probes", "DNA", 192, 206], ["primer BB6", "DNA", 331, 341], ["JW12", "DNA", 378, 382], ["mouse", "SPECIES", 93, 98], ["mouse", "SPECIES", 93, 98], ["Complementary DNA", "PROBLEM", 0, 17], ["the RNA", "PROBLEM", 37, 44], ["the infected cultures", "TEST", 68, 89], ["mouse brains", "PROBLEM", 93, 105], ["Methods", "TREATMENT", 211, 218], ["PCR amplification", "TEST", 238, 255], ["a new messenger sense primer BB6", "TEST", 309, 341], ["PCR amplification", "TEST", 387, 404], ["infected", "OBSERVATION", 72, 80]]], ["The TaqMan\u2122 probes were designed by eye using multiple alignments (MegAlign, Dnastar) following the recommended criteria (Applied Biosystems, UK).", [["eye", "ANATOMY", 36, 39], ["eye", "ORGAN", 36, 39], ["TaqMan\u2122 probes", "DNA", 4, 18], ["The TaqMan\u2122 probes", "TEST", 0, 18]]], ["They were based on regions of high homology that were specific to each genotype and were synthesised by Applied Biosystems.", [["high homology", "PROBLEM", 30, 43]]], ["A list of primers and probes is given in Table 2.TaqMan\u2122 reaction ::: MethodsThe cDNAs were amplified using the specific primer set BB6 (messenger sense) and a cocktail of JW6(DPL)/JW6(M)/JW6(E) (genomic sense) (Table 2).", [["BB6", "GENE_OR_GENE_PRODUCT", 132, 135], ["cDNAs", "DNA", 81, 86], ["primer set BB6", "DNA", 121, 135], ["JW6", "DNA", 172, 175], ["JW6", "DNA", 188, 191], ["primers and probes", "TREATMENT", 10, 28], ["Methods", "TREATMENT", 70, 77], ["a cocktail", "TEST", 158, 168]]], ["For each probe the conditions were optimised with relation to Mg2+ concentration and annealing temperature.", [["Mg2", "CHEMICAL", 62, 65], ["Mg2+", "CHEMICAL", 62, 66], ["Mg2+", "SIMPLE_CHEMICAL", 62, 66], ["Mg2", "PROTEIN", 62, 65], ["Mg2+ concentration", "TREATMENT", 62, 80], ["annealing temperature", "PROBLEM", 85, 106]]], ["Amplification of 5 \u03bcl of the cDNA template was performed in a final volume of 50 \u03bcl of 1\u00d7 PCR buffer containing 4.0\u20136.0 mM magnesium chloride (Applied Biosystems) (Mg2+ concentration for each probe given in Table 2), 200 \u03bcM each dNTP, 5.0 pmol of primer BB6, 7.5 pmol of each primer JW6(DPL), JW6(M) and JW6(E), 0.5 U of AmpliTaq GOLD (Applied Biosystems) and 5 pmol of the probes for genotypes 2\u20136 or 2.5 pmol of each of the three genotype 1 probes to be used in combination.", [["magnesium chloride", "CHEMICAL", 123, 141], ["Mg2", "CHEMICAL", 164, 167], ["dNTP", "CHEMICAL", 229, 233], ["magnesium chloride", "CHEMICAL", 123, 141], ["dNTP", "CHEMICAL", 229, 233], ["magnesium chloride", "SIMPLE_CHEMICAL", 123, 141], ["Mg2+", "SIMPLE_CHEMICAL", 164, 168], ["cDNA template", "DNA", 29, 42], ["the cDNA template", "TREATMENT", 25, 42], ["PCR buffer", "TEST", 90, 100], ["mM magnesium chloride (Applied Biosystems)", "TREATMENT", 120, 162], ["Mg2+ concentration", "TREATMENT", 164, 182], ["dNTP", "TEST", 229, 233], ["primer BB6", "TEST", 247, 257], ["AmpliTaq GOLD (Applied Biosystems", "TREATMENT", 321, 354], ["the probes", "TEST", 370, 380], ["genotypes", "TEST", 385, 394], ["the three genotype 1 probes", "TREATMENT", 422, 449]]], ["The amplification was carried out in 0.2 ml TaqMan\u2122 optical tubes on an Applied Biosystems Thermal Cycler 2400.", [["The amplification", "TREATMENT", 0, 17], ["TaqMan\u2122 optical tubes", "TREATMENT", 44, 65], ["an Applied Biosystems Thermal Cycler", "TREATMENT", 69, 105]]], ["The cycling conditions were as described (Black et al., 2000) with the exception of annealing temperatures (Table 2).Fluorescence monitoring ::: MethodsFluorescence monitoring was performed according to the Manufacturer's directions (Perkin\u2013Elmer, 1994).", [["Fluorescence monitoring", "TEST", 117, 140], ["MethodsFluorescence monitoring", "TEST", 145, 175]]], ["On completion of the PCR the samples were analysed in the closed PCR tubes using a Applied Biosystems LS50B luminescence spectrometer to quantify the fluorescence emitted by the TaqMan\u2122 probes.", [["samples", "ANATOMY", 29, 36], ["TaqMan\u2122 probes", "DNA", 178, 192], ["the PCR", "TEST", 17, 24], ["the closed PCR tubes", "TREATMENT", 54, 74], ["a Applied Biosystems LS50B luminescence spectrometer", "TREATMENT", 81, 133], ["PCR tubes", "OBSERVATION", 65, 74]]], ["The tubes were scanned at 518 nm (FAM) and then 582 nm (TAMRA), with an excitation wavelength of 488 nm.", [["tubes", "ANATOMY", 4, 9], ["tubes", "TISSUE", 4, 9], ["The tubes", "TREATMENT", 0, 9], ["an excitation wavelength", "TEST", 69, 93], ["tubes", "OBSERVATION", 4, 9], ["488 nm", "OBSERVATION", 97, 103]]], ["Data acquisition and analyses were carried out using the Fluorescence Data Manager (Applied Biosystems) and microsoft excel Spreadsheets.", [["Data acquisition", "TEST", 0, 16], ["analyses", "TEST", 21, 29], ["microsoft excel Spreadsheets", "TREATMENT", 108, 136]]], ["The increase in sample fluorescence was compared with the fluorescence of no template controls in triplicate.", [["sample", "ANATOMY", 16, 22], ["The increase in sample fluorescence", "PROBLEM", 0, 35], ["the fluorescence", "TEST", 54, 70], ["increase", "OBSERVATION_MODIFIER", 4, 12]]], ["The magnitude of the generated signal (\u0394RQ) represents the difference between the sample RQ (RQ+) and the mean value attained for the no template controls RQ (RQ\u2212), where RQ is the emission intensity of the reporter divided by the emission intensity of the quencher.", [["the sample RQ", "TEST", 78, 91], ["the mean value", "TEST", 102, 116], ["magnitude", "OBSERVATION_MODIFIER", 4, 13]]], ["In this equation, the quencher acts as an internal standard to normalise fluctuations in fluorescent intensity due to non-specific effects such as concentration changes due to volume fluctuations.", [["the quencher acts", "TREATMENT", 18, 35], ["fluorescent intensity", "TEST", 89, 110], ["non-specific effects", "PROBLEM", 118, 138], ["concentration changes", "PROBLEM", 147, 168], ["volume fluctuations", "PROBLEM", 176, 195], ["volume fluctuations", "OBSERVATION", 176, 195]]], ["Any other fluctuations not due to PCR-related nuclease digestion are normalised by taking the RQ+ value for a tube that contains all the components including template and subtracting the RQ\u2212 value for the no template control tubes.", [["tube", "TISSUE", 110, 114], ["Any other fluctuations", "PROBLEM", 0, 22], ["PCR", "TEST", 34, 37], ["nuclease digestion", "PROBLEM", 46, 64], ["a tube", "TREATMENT", 108, 114], ["template", "TREATMENT", 158, 166], ["template control tubes", "TREATMENT", 208, 230], ["tube", "OBSERVATION", 110, 114], ["tubes", "OBSERVATION", 225, 230]]], ["This final \u0394RQ value reliably indicates the magnitude of the signal generated by the given set of PCR conditions.", [["\u0394RQ", "DNA", 11, 14], ["This final \u0394RQ value", "TEST", 0, 20], ["PCR conditions", "TEST", 98, 112]]], ["A final calculation, defined as the threshold \u0394RQ, was carried out to obtain a numerical cut-off value above which a given \u0394RQ should represent a positive result.", [["\u0394RQ", "PROTEIN", 123, 126], ["A final calculation", "TEST", 0, 19], ["positive", "OBSERVATION", 146, 154]]], ["This value is calculated at a 99% confidence interval using the standard deviation (S.D.) obtained from the three no template controls (Perkin\u2013Elmer, 1994).", [["This value", "TEST", 0, 10]]], ["For the purposes of this assay a higher threshold \u0394RQ (1.0) than that calculated using this method (usually <0.5) was adopted.Fluorescence monitoring ::: MethodsA confirmatory test for successful PCR amplification was carried out by ethidium bromide stained agarose gel electrophoresis during the development of the assay.TaqMan\u2122 assay optimisation ::: ResultsUsing 1.5 mM magnesium at an annealing temperature of 51 \u00b0C, the RT-PCR gave clear well-defined bands on agarose gels.", [["ethidium bromide", "CHEMICAL", 233, 249], ["magnesium", "CHEMICAL", 373, 382], ["ethidium bromide", "CHEMICAL", 233, 249], ["magnesium", "CHEMICAL", 373, 382], ["ethidium bromide", "SIMPLE_CHEMICAL", 233, 249], ["agarose", "SIMPLE_CHEMICAL", 258, 265], ["magnesium", "SIMPLE_CHEMICAL", 373, 382], ["agarose", "SIMPLE_CHEMICAL", 465, 472], ["this assay", "TEST", 20, 30], ["this method", "TEST", 87, 98], ["Fluorescence monitoring", "TEST", 126, 149], ["MethodsA confirmatory test", "TEST", 154, 180], ["successful PCR amplification", "TEST", 185, 213], ["ethidium bromide", "TREATMENT", 233, 249], ["agarose gel electrophoresis", "TEST", 258, 285], ["the assay", "TEST", 312, 321], ["mM magnesium", "TEST", 370, 382], ["an annealing temperature", "TEST", 386, 410], ["\u00b0C", "TEST", 417, 419], ["the RT-PCR", "TEST", 421, 431], ["agarose gels", "TREATMENT", 465, 477]]], ["However, these conditions produced poor \u0394RQ readings in the TaqMan\u2122 assay.", [["\u0394RQ", "DNA", 40, 43], ["the TaqMan\u2122 assay", "TEST", 56, 73]]], ["The RT-PCR was therefore, re-optimised for each TaqMan\u2122 probe with respect to magnesium concentration and annealing temperature to obtain the highest intensity of reporter fluorescence whilst maintaining the highest specificity possible.", [["magnesium", "CHEMICAL", 78, 87], ["magnesium", "CHEMICAL", 78, 87], ["magnesium", "SIMPLE_CHEMICAL", 78, 87], ["TaqMan\u2122 probe", "DNA", 48, 61], ["The RT-PCR", "TEST", 0, 10], ["each TaqMan\u2122 probe", "TREATMENT", 43, 61], ["magnesium concentration", "TREATMENT", 78, 101], ["annealing temperature", "TEST", 106, 127], ["reporter fluorescence", "TEST", 163, 184]]], ["Agarose gel electrophoretic analyses of the RT-PCR products in the TaqMan\u2122 assays gave weaker specific and often secondary non-specific bands, but were useful for confirming negative TaqMan\u2122 results during assay development.", [["Agarose", "SIMPLE_CHEMICAL", 0, 7], ["RT-PCR products", "DNA", 44, 59], ["Agarose gel electrophoretic analyses", "TEST", 0, 36], ["the RT", "TEST", 40, 46], ["PCR products", "TREATMENT", 47, 59], ["the TaqMan\u2122 assays", "TEST", 63, 81], ["secondary non-specific bands", "PROBLEM", 113, 141]]], ["None of the eighteen non-rabies viruses tested gave any bands when examined by agarose gel electrophoresis.Discrimination of the rabies and rabies-related viruses ::: ResultsThe \u0394RQ values for each of the genotypes are summarised in Fig. 2.", [["rabies", "DISEASE", 129, 135], ["rabies", "DISEASE", 140, 146], ["agarose", "SIMPLE_CHEMICAL", 79, 86], ["rabies", "ORGANISM", 129, 135], ["rabies", "ORGANISM", 140, 146], ["\u0394RQ", "PROTEIN", 178, 181], ["rabies", "SPECIES", 129, 135], ["the eighteen non-rabies viruses", "PROBLEM", 8, 39], ["any bands", "PROBLEM", 52, 61], ["agarose gel electrophoresis", "TEST", 79, 106], ["The \u0394RQ values", "TEST", 174, 188]]], ["Fig. 2a\u2013f displays the individual values returned for each isolate.", [["2a\u2013f", "DNA", 5, 9], ["the individual values", "TEST", 19, 40]]], ["The three genotype 1 probes (TQM1a, TQM1b and TQM1c) used in combination detected all of the genotype 1 isolates and none of the isolates from the other genotypes or viruses tested (Fig. 2a).", [["genotype 1 probes", "DNA", 10, 27], ["TQM1a", "DNA", 29, 34], ["TQM1b", "DNA", 36, 41], ["TQM1c", "DNA", 46, 51], ["The three genotype 1 probes", "TREATMENT", 0, 27], ["TQM1a", "TEST", 29, 34], ["TQM1b and TQM1c)", "TREATMENT", 36, 52], ["the isolates", "TEST", 125, 137], ["viruses", "PROBLEM", 166, 173], ["viruses", "OBSERVATION", 166, 173]]], ["Similarly, the probes used individually to detect genotypes 3\u20136 (TQM3, TQM4, TQM5 and TQM6, respectively) specifically detected all isolates from their respective genotype panels and none of the other genotypes or viruses tested (Fig. 2c\u2013f).", [["genotypes 3\u20136", "DNA", 50, 63], ["TQM3", "DNA", 65, 69], ["TQM4", "DNA", 71, 75], ["TQM5", "DNA", 77, 81], ["TQM6", "DNA", 86, 90], ["the probes", "TEST", 11, 21], ["genotypes", "TEST", 50, 59], ["TQM3", "TEST", 65, 69], ["TQM4", "TEST", 71, 75], ["their respective genotype panels", "TEST", 146, 178], ["viruses", "OBSERVATION", 214, 221]]], ["The probe used to detect the genotype 2 isolates also detected four of the genotype 3 isolates (Fig. 2b).", [["The probe", "TREATMENT", 0, 9], ["the genotype 2 isolates", "TREATMENT", 25, 48]]], ["Fortunately, the genotype 3 probe detected only genotype 3 isolates (Fig. 2c).", [["genotype 3 probe", "DNA", 17, 33]]], ["Thus, if an isolate tested positive with both the genotype 2 and genotype 3 probes it was classed as genotype 3.", [["genotype 2 and genotype 3 probes", "DNA", 50, 82], ["an isolate", "TEST", 9, 19]]], ["Isolates detected with the genotype 3 probe only, were classed as genotype 3.", [["genotype 3 probe", "DNA", 27, 43], ["Isolates", "TEST", 0, 8], ["the genotype 3 probe", "TREATMENT", 23, 43]]], ["Similarly, isolates detected with the genotype 2 probe only, were classed as genotype 2.Discrimination of the rabies and rabies-related viruses ::: ResultsThe genotype 3 isolates that gave positive results with the TQM2 probe were RV174\u2013RV177.", [["rabies", "DISEASE", 110, 116], ["rabies", "DISEASE", 121, 127], ["RV174\u2013RV177", "CHEMICAL", 231, 242], ["rabies", "ORGANISM", 110, 116], ["rabies", "ORGANISM", 121, 127], ["genotype 2 probe", "DNA", 38, 54], ["TQM2 probe", "DNA", 215, 225], ["rabies", "SPECIES", 110, 116], ["the genotype 2 probe", "TREATMENT", 34, 54], ["the TQM2 probe", "TEST", 211, 225]]], ["All four viruses were isolated from cats in Zimbabwe and have identical sequences in the 405 bp 5\u2032 region of the nucleoprotein gene (unpublished data).", [["cats", "ORGANISM", 36, 40], ["405 bp 5\u2032 region", "DNA", 89, 105], ["nucleoprotein gene", "DNA", 113, 131], ["cats", "SPECIES", 36, 40], ["All four viruses", "PROBLEM", 0, 16], ["bp", "TEST", 93, 95], ["four", "OBSERVATION_MODIFIER", 4, 8], ["viruses", "OBSERVATION", 9, 16]]], ["Using the RT-PCR primers developed by Heaton et al. (1997) as well as the RT-PCR primers used in the development of this TaqMan\u2122 assay these four isolates gave two bands on agarose gel electrophoresis.", [["agarose", "SIMPLE_CHEMICAL", 173, 180], ["RT-PCR primers", "DNA", 10, 24], ["RT-PCR primers", "DNA", 74, 88], ["TaqMan\u2122", "DNA", 121, 128], ["the RT-PCR primers", "TREATMENT", 6, 24], ["the RT-PCR primers", "TREATMENT", 70, 88], ["this TaqMan\u2122 assay", "TEST", 116, 134], ["agarose gel electrophoresis", "TREATMENT", 173, 200]]], ["With respect to the TQM2 probe region, RV174\u2013RV177 have four base differences, whilst the remaining genotype 3 isolates contain five base differences from the probe.", [["RV174\u2013RV177", "GENE_OR_GENE_PRODUCT", 39, 50], ["TQM2 probe region", "DNA", 20, 37], ["RV174\u2013RV177", "DNA", 39, 50], ["four base differences", "PROBLEM", 56, 77], ["the remaining genotype 3 isolates", "PROBLEM", 86, 119], ["base", "OBSERVATION_MODIFIER", 61, 65], ["differences", "OBSERVATION_MODIFIER", 66, 77], ["five", "OBSERVATION_MODIFIER", 128, 132], ["base", "OBSERVATION_MODIFIER", 133, 137], ["differences", "OBSERVATION_MODIFIER", 138, 149]]], ["The maximum number of base differences between the TQM2 probe and the genotype 2 isolates is three for RV1, RV41 and RV767.", [["TQM2 probe", "DNA", 51, 61], ["the TQM2 probe", "TREATMENT", 47, 61], ["RV1", "TEST", 103, 106], ["RV41", "TEST", 108, 112], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18], ["base", "OBSERVATION_MODIFIER", 22, 26], ["differences", "OBSERVATION_MODIFIER", 27, 38]]], ["These latter isolates gave relatively low \u0394RQ results (2.43, 1.08 and 1.46, respectively) compared with the remaining isolates, which were all identical to the probe and, with the exception of RV2 (2.04), gave results in the range 7.07\u20137.87.", [["RV2", "TEST", 193, 196]]], ["The \u0394RQ results with TQM2 for the genotype 3 isolates (RV174\u2013RV177) were in the range 1.12\u20132.07.", [["TQM2", "DNA", 21, 25], ["TQM2", "TEST", 21, 25], ["the genotype", "TEST", 30, 42]]], ["Examination of the remainder of the available sequence data for these isolates as well as sequencing of DNA from the second band on the agarose gels failed to reveal any further areas of possible homology to the probe.Discrimination of the rabies and rabies-related viruses ::: ResultsPossible patterns in the \u0394RQ values were sought to determine if the number of differences between the target sequence and probe within a genotype was reflected in the \u0394RQ value.", [["rabies", "DISEASE", 240, 246], ["rabies", "DISEASE", 251, 257], ["DNA", "CELLULAR_COMPONENT", 104, 107], ["rabies", "ORGANISM", 240, 246], ["rabies", "ORGANISM", 251, 257], ["\u0394RQ", "DNA", 310, 313], ["rabies", "SPECIES", 240, 246], ["Examination", "TEST", 0, 11], ["the available sequence data", "TEST", 32, 59], ["these isolates", "TREATMENT", 64, 78], ["sequencing of DNA", "TEST", 90, 107], ["the agarose gels", "TEST", 132, 148], ["the \u0394RQ values", "TEST", 306, 320], ["the target sequence", "TEST", 383, 402], ["a genotype", "TEST", 420, 430]]], ["All the genotype 1 isolates had from 0 to 4 differences between the TQM1 probes and target sequence but there was no apparent pattern between the number of differences and \u0394RQ.", [["TQM1", "GENE_OR_GENE_PRODUCT", 68, 72], ["TQM1 probes", "DNA", 68, 79], ["\u0394RQ", "DNA", 172, 175], ["the TQM1 probes", "TEST", 64, 79], ["target sequence", "TEST", 84, 99], ["no apparent", "UNCERTAINTY", 114, 125]]], ["All of the other genotypes had at least five differences between the target sequence and TQM1 probes.", [["target sequence", "DNA", 69, 84], ["TQM1 probes", "DNA", 89, 100], ["the target sequence", "TEST", 65, 84]]], ["All of the genotype 3 isolates had no or one base difference to the TQM3 probe and again no pattern was seen between the differences and \u0394RQ.", [["TQM3 probe", "DNA", 68, 78], ["\u0394RQ", "DNA", 137, 140]]], ["Of the other genotypes, the closest to this probe was 5+ differences with the genotype 2 isolates and 7+ differences with the remaining genotypes.", [["the genotype 2 isolates", "TEST", 74, 97]]], ["All the genotype 4 isolates were identical to the TQM4 probe, which had six or more base differences to the other genotypes.", [["TQM4 probe", "DNA", 50, 60]]], ["All the genotype 5 and 6 isolates had no or one base difference to their respective probes and again no patterns were seen between the differences and \u0394RQ.", [["\u0394RQ", "DNA", 151, 154]]], ["The TQM5 probe had 7+ base differences and the TQM6 probe had 6+ base differences to the other genotypes.", [["TQM5", "GENE_OR_GENE_PRODUCT", 4, 8], ["TQM5 probe", "DNA", 4, 14], ["TQM6 probe", "DNA", 47, 57], ["The TQM5 probe", "TEST", 0, 14], ["7+ base differences", "PROBLEM", 19, 38], ["the TQM6 probe", "TEST", 43, 57], ["base", "OBSERVATION_MODIFIER", 22, 26], ["differences", "OBSERVATION_MODIFIER", 27, 38]]], ["The only probe that seemed to show any pattern was the TQM2 probe as mentioned above, where differences in \u0394RQ reflected the complementarity of probe to target sequences for all but one of the genotype 2 isolates.", [["TQM2 probe", "DNA", 55, 65], ["\u0394RQ", "DNA", 107, 110]]], ["It appears that the lower discriminatory limit of probe detection is four base differences between probe and target sequence.", [["target sequence", "DNA", 109, 124], ["probe and target sequence", "TEST", 99, 124], ["lower", "OBSERVATION_MODIFIER", 20, 25], ["discriminatory", "OBSERVATION_MODIFIER", 26, 40], ["base", "OBSERVATION_MODIFIER", 74, 78]]], ["This was seen with the genotype 1 probes and is the most likely explanation for the detection of the genotype 3 isolates RV174\u2013177 by the TQM2 probe.", [["RV174\u2013177", "CHEMICAL", 121, 130], ["genotype 1 probes", "DNA", 23, 40], ["TQM2 probe", "DNA", 138, 148], ["most likely explanation", "UNCERTAINTY", 52, 75]]], ["No isolates with more than four base differences to the probe were falsely detected.Discrimination of the rabies and rabies-related viruses ::: ResultsThe genotype 7 isolate was tested with these probes and was negative with all of them.", [["rabies", "DISEASE", 106, 112], ["rabies", "DISEASE", 117, 123], ["rabies", "ORGANISM", 106, 112], ["rabies", "ORGANISM", 117, 123], ["rabies", "SPECIES", 106, 112], ["isolates", "PROBLEM", 3, 11], ["The genotype 7 isolate", "TEST", 151, 173], ["these probes", "TEST", 190, 202], ["isolates", "OBSERVATION", 3, 11], ["more", "OBSERVATION_MODIFIER", 17, 21], ["base", "OBSERVATION_MODIFIER", 32, 36], ["differences", "OBSERVATION_MODIFIER", 37, 48]]], ["A genotype 7 probe was not designed as only one isolate was available for testing.DiscussionDespite the availability of an effective vaccine, rabies is still a significant problem in many parts of the world.", [["rabies", "DISEASE", 142, 148], ["genotype 7 probe", "DNA", 2, 18], ["rabies", "SPECIES", 142, 148], ["A genotype 7 probe", "TREATMENT", 0, 18], ["testing", "TEST", 74, 81], ["an effective vaccine", "TREATMENT", 120, 140], ["significant", "OBSERVATION_MODIFIER", 160, 171], ["problem", "OBSERVATION", 172, 179]]], ["A rapid test that could distinguish between the rabies genotypes would be very advantageous for both epidemiological studies, for example in Africa and Europe where more than one genotype co-exist, and as a diagnostic test in the case of an outbreak.", [["rabies", "ORGANISM", 48, 54], ["rabies", "SPECIES", 48, 54], ["A rapid test", "TEST", 0, 12], ["the rabies genotypes", "PROBLEM", 44, 64], ["both epidemiological studies", "TEST", 96, 124], ["a diagnostic test", "TEST", 205, 222], ["outbreak", "OBSERVATION", 241, 249]]], ["In the UK the most likely genotypes that could enter this country from mainland Europe are classical rabies and the EBLs.", [["rabies", "DISEASE", 101, 107], ["UK", "GENE_OR_GENE_PRODUCT", 7, 9], ["most likely", "UNCERTAINTY", 14, 25]]], ["At present genotype differentiation relies on RT-PCR and subsequent sequencing or monoclonal antibody typing.", [["monoclonal antibody", "PROTEIN", 82, 101], ["RT-PCR", "TEST", 46, 52], ["subsequent sequencing", "TEST", 57, 78], ["monoclonal antibody typing", "TEST", 82, 108]]], ["Rapid genotyping of any strain found in the UK would be particularly important, as the outcome may dictate the control measures implemented.", [["UK", "GENE_OR_GENE_PRODUCT", 44, 46], ["any strain", "PROBLEM", 20, 30], ["the control measures", "TREATMENT", 107, 127]]], ["Classical rabies has the potential to establish within indigenous terrestrial animal populations and hence may require the implementation of extensive control measures, whereas, the EBLs are likely to be limited to spread among the UK bat population and could prove difficult to control.DiscussionThis report describes the development and application of eight TaqMan\u2122 probes to differentiate between six genotypes of rabies and rabies-related viruses.", [["rabies", "DISEASE", 10, 16], ["rabies", "DISEASE", 417, 423], ["rabies", "DISEASE", 428, 434], ["rabies", "ORGANISM", 10, 16], ["rabies", "ORGANISM", 417, 423], ["rabies-related viruses", "ORGANISM", 428, 450], ["TaqMan\u2122 probes", "DNA", 360, 374], ["rabies", "SPECIES", 10, 16], ["rabies", "SPECIES", 417, 423], ["extensive control measures", "TREATMENT", 141, 167], ["the EBLs", "TEST", 178, 186], ["eight TaqMan\u2122 probes", "TREATMENT", 354, 374], ["six genotypes of rabies and rabies-related viruses", "PROBLEM", 400, 450]]], ["Using this method a definitive result can be acquired within a few minutes of completion of a standard RT-PCR cycle.", [["a standard RT-PCR cycle", "TREATMENT", 92, 115]]], ["Monoclonal antibody analysis usually necessitates the growth of virus in cell culture, which may be impossible or result in a delay of several days with decomposed material.", [["cell culture", "ANATOMY", 73, 85], ["cell culture", "CELL", 73, 85], ["Monoclonal antibody", "PROTEIN", 0, 19], ["Monoclonal antibody analysis", "TEST", 0, 28], ["virus in cell culture", "PROBLEM", 64, 85], ["decomposed material", "PROBLEM", 153, 172]]], ["An additional problem encountered with monoclonal antibody typing is that the results are subject to individual interpretation.", [["monoclonal antibody", "PROTEIN", 39, 58], ["monoclonal antibody typing", "TEST", 39, 65]]], ["Sequence analysis gives a definitive answer and is thus more reliable, but can also take several days to achieve a result unless there is direct access to automated sequencing equipment.", [["Sequence analysis", "TEST", 0, 17], ["automated sequencing equipment", "TREATMENT", 155, 185]]], ["An additional advantage of TaqMan\u2122 is that it is a closed tube system that significantly reduces the risk of cross contamination by PCR products and thus results in increased confidence in the results acquired.DiscussionThe N gene was selected as the target for this assay as it is well conserved and has been intensively used to classify rabies isolates into their respective genotypes (Black et al., 2000, Bourhy et al., 1992, Bourhy et al., 1993, Kissi et al., 1995, Smith et al., 1992).", [["TaqMan\u2122", "SIMPLE_CHEMICAL", 27, 34], ["tube", "TISSUE", 58, 62], ["rabies", "ORGANISM", 339, 345], ["N gene", "DNA", 224, 230], ["rabies", "SPECIES", 339, 345], ["a closed tube system", "TREATMENT", 49, 69], ["cross contamination", "PROBLEM", 109, 128], ["PCR products", "TREATMENT", 132, 144], ["this assay", "TEST", 262, 272], ["closed", "OBSERVATION_MODIFIER", 51, 57], ["tube", "OBSERVATION", 58, 62], ["increased", "OBSERVATION_MODIFIER", 165, 174]]], ["There is a large amount of N gene sequence data available, which, on examination, revealed conserved regions specific to each genotype that could be used to design genotype specific TaqMan\u2122 probes.", [["N gene sequence", "DNA", 27, 42], ["TaqMan\u2122 probes", "DNA", 182, 196], ["N gene sequence data", "TEST", 27, 47], ["examination", "TEST", 69, 80], ["large", "OBSERVATION_MODIFIER", 11, 16], ["amount", "OBSERVATION_MODIFIER", 17, 23]]], ["The classical rabies virus isolates have a greater representation in our archive and due to extensive geographical distribution and host range, demonstrate a much broader genetic diversity than the other genotypes.", [["rabies virus", "ORGANISM", 14, 26], ["rabies virus", "SPECIES", 14, 26], ["The classical rabies virus isolates", "PROBLEM", 0, 35], ["greater", "OBSERVATION_MODIFIER", 43, 50], ["extensive", "OBSERVATION_MODIFIER", 92, 101], ["geographical", "OBSERVATION_MODIFIER", 102, 114], ["host range", "OBSERVATION", 132, 142]]], ["For this reason, three probes were required in combination to detect all of the classical isolates tested.", [["three probes", "TREATMENT", 17, 29]]], ["All three probes cover the same region of the gene, but have one base change from the others in either the fifth or sixth position.", [["All three probes", "TREATMENT", 0, 16], ["three", "OBSERVATION_MODIFIER", 4, 9], ["probes", "OBSERVATION_MODIFIER", 10, 16], ["gene", "OBSERVATION", 46, 50], ["one", "OBSERVATION_MODIFIER", 61, 64], ["base", "OBSERVATION_MODIFIER", 65, 69], ["change", "OBSERVATION", 70, 76]]], ["The remaining five genotypes had sufficient similarities in specific regions to enable the use of a single probe for their discrimination.DiscussionThe TaqMan\u2122 probes were optimised individually with relation to magnesium concentration and annealing temperature to yield the highest intensity of reporter fluorescent intensity without compromising specificity.", [["magnesium", "CHEMICAL", 212, 221], ["magnesium", "CHEMICAL", 212, 221], ["magnesium", "SIMPLE_CHEMICAL", 212, 221], ["TaqMan\u2122 probes", "DNA", 152, 166], ["a single probe", "TREATMENT", 98, 112], ["The TaqMan\u2122 probes", "TREATMENT", 148, 166], ["magnesium concentration", "TREATMENT", 212, 235], ["annealing temperature", "PROBLEM", 240, 261]]], ["Unfortunately, when relative specificities were compared, the probes were found to have different optimum Mg2+ concentrations.", [["Mg2", "CHEMICAL", 106, 109], ["Mg2+", "CHEMICAL", 106, 110], ["Mg2+", "SIMPLE_CHEMICAL", 106, 110], ["Mg2", "PROTEIN", 106, 109]]], ["Using the Universal 2X master mix (Applied Biosystems), which became available more recently it may be possible to standardise the reaction mixes to ease panel preparation.", [["the Universal 2X master mix", "TREATMENT", 6, 33], ["ease panel preparation", "TREATMENT", 149, 171]]], ["Magnesium chloride affects annealing and the melting temperatures of both the TaqMan\u2122 probe and the PCR primers as it help stabilise the hybridisation complexes.", [["Magnesium chloride", "CHEMICAL", 0, 18], ["Magnesium chloride", "CHEMICAL", 0, 18], ["Magnesium chloride", "SIMPLE_CHEMICAL", 0, 18], ["TaqMan\u2122 probe", "DNA", 78, 91], ["PCR primers", "DNA", 100, 111], ["Magnesium chloride", "TREATMENT", 0, 18], ["the melting temperatures", "PROBLEM", 41, 65], ["the TaqMan\u2122 probe", "TREATMENT", 74, 91], ["the PCR primers", "TREATMENT", 96, 111], ["hybridisation complexes", "OBSERVATION", 137, 160]]], ["It is also required for Taq DNA polymerase activity and affects FAM quenching by TAMRA on the probe.", [["FAM", "CHEMICAL", 64, 67], ["TAMRA", "CHEMICAL", 81, 86], ["FAM", "CHEMICAL", 64, 67], ["TAMRA", "CHEMICAL", 81, 86], ["Taq", "GENE_OR_GENE_PRODUCT", 24, 27], ["DNA", "CELLULAR_COMPONENT", 28, 31], ["FAM", "SIMPLE_CHEMICAL", 64, 67], ["TAMRA", "SIMPLE_CHEMICAL", 81, 86], ["Taq DNA polymerase", "PROTEIN", 24, 42], ["Taq DNA polymerase activity", "TREATMENT", 24, 51]]], ["Increasing the magnesium concentration can enhance TAMRA quenching in the intact probe (Livak et al., 1995), which is important for calculation of RQ\u2212, that is, the lower the reporter emissions in RQ\u2212, the greater \u0394RQ will be in the presence of specific template.", [["magnesium", "CHEMICAL", 15, 24], ["TAMRA", "CHEMICAL", 51, 56], ["magnesium", "CHEMICAL", 15, 24], ["TAMRA", "CHEMICAL", 51, 56], ["magnesium", "SIMPLE_CHEMICAL", 15, 24], ["TAMRA", "SIMPLE_CHEMICAL", 51, 56], ["RQ", "GENE_OR_GENE_PRODUCT", 147, 149], ["\u0394RQ", "PROTEIN", 214, 217], ["Increasing the magnesium concentration", "PROBLEM", 0, 38], ["magnesium concentration", "OBSERVATION_MODIFIER", 15, 38]]], ["However, too little or too much magnesium can result in reduced amplification efficiency or amplification of non-target sequences.", [["magnesium", "CHEMICAL", 32, 41], ["magnesium", "CHEMICAL", 32, 41], ["magnesium", "SIMPLE_CHEMICAL", 32, 41], ["non-target sequences", "DNA", 109, 129], ["magnesium", "TREATMENT", 32, 41], ["reduced amplification efficiency", "PROBLEM", 56, 88], ["non-target sequences", "TEST", 109, 129]]], ["The PCR primers were known to produce (Heaton et al., 1997) specific product at a range of temperatures, although this was strongest and cleanest with respect to non-specific products at 51 \u00b0C. The annealing temperature was therefore optimised, again to achieve the best possible \u0394RQ values.", [["\u0394RQ", "SIMPLE_CHEMICAL", 280, 283], ["PCR primers", "DNA", 4, 15], ["\u0394RQ", "PROTEIN", 280, 283], ["The PCR primers", "TEST", 0, 15], ["non-specific products", "TREATMENT", 162, 183], ["The annealing temperature", "TEST", 194, 219]]], ["We observed that when transferring the technology to the newer ABI7200 reader, the \u0394RQ values were much higher than obtained previously using the LS50B and the threshold value required re-evaluation.", [["ABI7200", "DNA", 63, 70], ["\u0394RQ", "DNA", 83, 86], ["LS50B", "DNA", 146, 151], ["the \u0394RQ values", "TEST", 79, 93], ["re-evaluation", "TEST", 185, 198]]], ["Hence, the actual values represented in Fig. 2 may be significantly different when alternative readers are used.DiscussionThe assay appears to be highly specific and reproducible.", [["the actual values", "TEST", 7, 24], ["The assay", "TEST", 122, 131], ["significantly different", "OBSERVATION_MODIFIER", 54, 77]]], ["All the rabies and rabies-related virus RNA samples used in the development of this assay had been amplified previously using the PCR protocol described by Heaton et al. (1997) and the products sequenced partially and genotyped.", [["samples", "ANATOMY", 44, 51], ["rabies", "DISEASE", 8, 14], ["rabies", "DISEASE", 19, 25], ["rabies", "ORGANISM", 8, 14], ["rabies-related virus", "ORGANISM", 19, 39], ["rabies", "SPECIES", 8, 14], ["related virus RNA samples", "PROBLEM", 26, 51], ["this assay", "TEST", 79, 89], ["the PCR protocol", "TREATMENT", 126, 142], ["the products", "TREATMENT", 181, 193]]], ["Due to the large number of available isolates, a representative group of genotype 1 isolates were carefully selected for this covering as wide a range of animal hosts, geographical isolation and sequence variation, as possible.", [["genotype 1 isolates", "PROBLEM", 73, 92], ["geographical isolation", "TREATMENT", 168, 190], ["sequence variation", "TEST", 195, 213], ["large", "OBSERVATION_MODIFIER", 11, 16]]], ["All of the genotype 2\u20136 isolates available in our archive were tested and a selection of unrelated viruses were also tested to ensure the specificity of the assays for rabies and rabies-related viruses.", [["rabies", "DISEASE", 168, 174], ["rabies", "DISEASE", 179, 185], ["rabies", "ORGANISM", 168, 174], ["rabies-related viruses", "ORGANISM", 179, 201], ["rabies", "SPECIES", 168, 174], ["rabies", "SPECIES", 179, 185], ["the genotype 2\u20136 isolates", "TREATMENT", 7, 32], ["unrelated viruses", "PROBLEM", 89, 106], ["the assays", "TEST", 153, 163], ["rabies", "PROBLEM", 168, 174], ["rabies", "PROBLEM", 179, 185], ["related viruses", "PROBLEM", 186, 201]]], ["Seven of the eight probes were used directly to give a definitive result, whilst the remaining probe, that for detecting Lagos Bat isolates had to be used alongside the Mokola probe to determine whether a positive result is a Lagos Bat or Mokola isolate.", [["Mokola probe", "DNA", 169, 181], ["Mokola isolate", "TREATMENT", 239, 253]]], ["Detection by the Mokola probe or both probes indicated a Mokola isolate, while detection with the Lagos Bat probe and not the Mokola probe indicated a Lagos Bat isolate.", [["Mokola probe", "DNA", 17, 29], ["Lagos Bat probe", "DNA", 98, 113], ["Mokola probe", "DNA", 126, 138], ["the Mokola probe", "TREATMENT", 13, 29], ["a Mokola isolate", "TREATMENT", 55, 71], ["the Lagos Bat probe", "TREATMENT", 94, 113], ["a Lagos Bat isolate", "TREATMENT", 149, 168]]], ["For complete confidence, automated sequencing may be used to confirm the genotype of an isolate.", [["automated sequencing", "TEST", 25, 45]]], ["It was not deemed necessary to further discriminate between the EBL1a and b and EBL2a and b subgroups as generic EBL1 and EBL2 probes would be sufficient for the aims of this assay.", [["EBL1a", "GENE_OR_GENE_PRODUCT", 64, 69], ["b", "GENE_OR_GENE_PRODUCT", 74, 75], ["EBL2a", "GENE_OR_GENE_PRODUCT", 80, 85], ["b", "GENE_OR_GENE_PRODUCT", 90, 91], ["EBL1", "GENE_OR_GENE_PRODUCT", 113, 117], ["EBL2", "GENE_OR_GENE_PRODUCT", 122, 126], ["EBL1a and b and EBL2a and b subgroups", "DNA", 64, 101], ["EBL1 and EBL2 probes", "DNA", 113, 133], ["the EBL1a", "TEST", 60, 69], ["generic EBL1", "TEST", 105, 117], ["EBL2 probes", "TREATMENT", 122, 133], ["this assay", "TEST", 170, 180]]], ["In the case of an outbreak, the control measures introduced would be the same whether an \u2018a\u2019 or \u2018b\u2019 subgroup was responsible.DiscussionThe material used during the development of the assay was passaged in either BHK cells or mice to obtain large quantities of RNA permitting uniform validation experiments.", [["BHK cells", "ANATOMY", 212, 221], ["BHK cells", "CELL", 212, 221], ["mice", "ORGANISM", 225, 229], ["BHK cells", "CELL_LINE", 212, 221], ["mice", "SPECIES", 225, 229], ["BHK", "SPECIES", 212, 215], ["mice", "SPECIES", 225, 229], ["the control measures", "TREATMENT", 28, 48], ["the assay", "TEST", 179, 188], ["large quantities of RNA", "PROBLEM", 240, 263], ["outbreak", "OBSERVATION", 18, 26]]], ["The assay has been used successfully on panels of original rabies infected material (data not included).", [["rabies infected", "DISEASE", 59, 74], ["rabies", "ORGANISM", 59, 65], ["rabies", "SPECIES", 59, 65], ["The assay", "TEST", 0, 9], ["original rabies infected material", "PROBLEM", 50, 83]]], ["The sensitivity of the assay with each probe was found to be similar to that reported by Heaton et al. (1997) for the RT-PCR alone, approximately 0.02 TCID50 per ml (data not included).DiscussionThe assay described above is a rapid and sensitive method for distinguishing between the rabies and rabies-related viruses with several advantages over traditional genotyping techniques.", [["rabies", "DISEASE", 284, 290], ["rabies", "DISEASE", 295, 301], ["rabies", "ORGANISM", 284, 290], ["rabies", "ORGANISM", 295, 301], ["rabies", "SPECIES", 284, 290], ["rabies", "SPECIES", 295, 301], ["the assay", "TEST", 19, 28], ["the RT-PCR", "TREATMENT", 114, 124], ["The assay", "TEST", 195, 204], ["the rabies and rabies-related viruses", "PROBLEM", 280, 317], ["traditional genotyping techniques", "TREATMENT", 347, 380]]], ["It is more rapid than traditional typing methods and reduces the need for further processing of the RT-PCR product, thereby reducing the risk of cross-contamination.", [["traditional typing methods", "TEST", 22, 48], ["the RT-PCR product", "TREATMENT", 96, 114], ["cross-contamination", "PROBLEM", 145, 164], ["more", "OBSERVATION_MODIFIER", 6, 10], ["rapid", "OBSERVATION_MODIFIER", 11, 16], ["cross-contamination", "OBSERVATION", 145, 164]]], ["It has the potential to be used in both diagnostic and research laboratories in the identification and classification of suspect rabies isolates in the case of a potential outbreak situation, or for generating routine epidemiological information.", [["rabies", "DISEASE", 129, 135], ["rabies", "ORGANISM", 129, 135], ["rabies", "SPECIES", 129, 135], ["rabies isolates", "PROBLEM", 129, 144]]], ["The probes may be used in the development of quantitative real time PCR assays using either the Light Cycler (Roche Applied Science) or ABI7700 (Applied Biosystems) technologies.", [["The probes", "TREATMENT", 0, 10], ["the Light Cycler", "TREATMENT", 92, 108]]]], "PMC7300786": [["SITUATION OF COVID\u201019 IN JAPANCoronavirus disease 2019, also known as COVID\u201019, has rapidly become a worldwide emergency.", [["JAPANCoronavirus disease", "DISEASE", 25, 49], ["JAPANCoronavirus disease", "PROBLEM", 25, 49]]], ["Since mid\u2010January 2020, there have been cases of infected new COVID\u201019 cases in Japan.", [["infected new COVID\u2010", "TREATMENT", 49, 68]]], ["As the COVID\u201019 is pandemic outbreak, the number of patients in Japan exceeded 1,000 on March 21st and 9,299 on April 17th (Data sourced from Japan Ministry of Health, Labour, & Welfare).", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["pandemic outbreak", "PROBLEM", 19, 36]]], ["In order to curb the spread of the epidemic, primary, middle and high school students suspended classes and undergraduate students extended their holidays.", [["middle", "ANATOMY_MODIFIER", 54, 60]]], ["Now, the spread of the new coronavirus is continuing.", [["coronavirus", "DISEASE", 27, 38], ["coronavirus", "ORGANISM", 27, 38], ["the new coronavirus", "PROBLEM", 19, 38], ["spread", "OBSERVATION_MODIFIER", 9, 15], ["new", "OBSERVATION_MODIFIER", 23, 26], ["coronavirus", "OBSERVATION", 27, 38]]], ["The government announced on April 7th that it made emergency statements for seven prefectures (Saitama, Chiba, Tokyo, Kanagawa, Osaka, Hyogo, and Fukuoka) where COVID\u201019 infection is spreading across the region, and it expanded the national emergency declaration on April 16th.", [["infection", "DISEASE", 170, 179], ["infection", "PROBLEM", 170, 179], ["infection", "OBSERVATION", 170, 179]]], ["Facilities and stores that may come into intimate contact, such as recreation facilities, gyms and bars that serve alcohol at night, are closed due to the government's refraining from doing business.", [["alcohol", "CHEMICAL", 115, 122], ["alcohol", "CHEMICAL", 115, 122], ["alcohol", "SIMPLE_CHEMICAL", 115, 122]]], ["Of the medical facilities, hospitals that treat infected people are in a critical situation, as in other countries, because the number of infected people is increasing day by day.", [["people", "ORGANISM", 57, 63], ["people", "ORGANISM", 147, 153], ["people", "SPECIES", 57, 63], ["people", "SPECIES", 147, 153], ["infected", "OBSERVATION", 138, 146], ["increasing", "OBSERVATION_MODIFIER", 157, 167]]], ["The Japanese Society of Infectious Diseases announced that they should change the way of treatment of infectious diseases and announce the \"clinical response to new coronavirus infectious diseases\" to clinical sites involving medical treatment.", [["Infectious Diseases", "DISEASE", 24, 43], ["infectious diseases", "DISEASE", 102, 121], ["coronavirus infectious diseases", "DISEASE", 165, 196], ["coronavirus", "ORGANISM", 165, 176], ["treatment", "TREATMENT", 89, 98], ["infectious diseases", "PROBLEM", 102, 121], ["new coronavirus infectious diseases", "PROBLEM", 161, 196], ["medical treatment", "TREATMENT", 226, 243], ["Infectious", "OBSERVATION", 24, 34], ["infectious", "OBSERVATION", 102, 112]]], ["Japanese Prime Minister, Shinzo Abe emphasized that as far as possible not to go out for reasons that are not necessary or urgent, but will not be blocked, in order to reduce the economic pressure caused by new type COVID\u201019 to the people, the government decided to issue 100,000 yen per person to relieve the stress of new type COVID\u201019 on people's lives.SITUATION OF COVID\u201019 IN JAPANAt present, the age of patients with onset in Japan is widely distributed from children to the elderly, but more than 90% of deaths are over 60 years old.", [["deaths", "DISEASE", 511, 517], ["people", "ORGANISM", 232, 238], ["people", "ORGANISM", 341, 347], ["patients", "ORGANISM", 409, 417], ["children", "ORGANISM", 465, 473], ["people", "SPECIES", 232, 238], ["person", "SPECIES", 288, 294], ["people", "SPECIES", 341, 347], ["patients", "SPECIES", 409, 417], ["children", "SPECIES", 465, 473], ["the economic pressure", "TEST", 175, 196], ["widely", "OBSERVATION_MODIFIER", 441, 447]]], ["China, Italy and United States of America have reported cases of children dying of new type COVID\u201019, so we should pay take it as a big serious (Livingston & Bucher, 2020; Sinha et al., 2020).", [["children", "ORGANISM", 65, 73], ["children", "SPECIES", 65, 73]]], ["In addition, masks have become a necessity for people.", [["people", "ORGANISM", 47, 53], ["people", "SPECIES", 47, 53], ["masks", "TREATMENT", 13, 18]]], ["Not to go out as less as possible, if you have symptoms that are suspected of being infected, you should do your own home isolation or follow the hospital's isolation treatment system.", [["symptoms", "PROBLEM", 47, 55], ["the hospital's isolation treatment system", "TREATMENT", 142, 183]]], ["This is an essential period for Japanese fight against new COVID\u201019.CURRENT STATUS OF JAPANESE PRIVATE DENTAL CLINICSA few clinics and hospitals where infection has happened were already closed, but most clinics that do not be required to be closed, such as internal medicine, ophthalmology, otolaryngology and dermatology, provide most of the usual medical care.", [["infection", "DISEASE", 151, 160], ["infection", "PROBLEM", 151, 160], ["infection", "OBSERVATION", 151, 160]]], ["For the time being, the dental clinics offer the same treatment as usual.", [["the same treatment", "TREATMENT", 45, 63]]], ["What is a little different from usual is that while taking precautions to see patients with suspected COVID\u201019 infection (those who have concentrated contacts with infected person or those who have symptoms).", [["infection", "DISEASE", 111, 120], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["person", "SPECIES", 173, 179], ["symptoms", "PROBLEM", 198, 206], ["little different", "OBSERVATION_MODIFIER", 10, 26], ["infection", "OBSERVATION", 111, 120]]], ["Due to the characteristics of the dental environment, the risk of cross\u2010infection between dentists and patients may be high.", [["cross\u2010infection", "DISEASE", 66, 81], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["cross\u2010infection", "PROBLEM", 66, 81]]], ["In addition, a large amount of droplets and aerosols may be generated during dental treatment, but the standard protective measures in daily clinical work are not enough to prevent the spread of COVID\u201019, especially when the patients are in the incubation period, are unknown of their infected or conceal their infection (Puisieux, Brabletz, & Caramel, 2020).", [["COVID", "DISEASE", 195, 200], ["infection", "DISEASE", 311, 320], ["patients", "ORGANISM", 225, 233], ["patients", "SPECIES", 225, 233], ["a large amount of droplets", "TREATMENT", 13, 39], ["aerosols", "TREATMENT", 44, 52], ["dental treatment", "TREATMENT", 77, 93], ["the standard protective measures", "TREATMENT", 99, 131], ["their infection", "PROBLEM", 305, 320], ["large", "OBSERVATION_MODIFIER", 15, 20], ["amount", "OBSERVATION_MODIFIER", 21, 27], ["droplets", "OBSERVATION", 31, 39], ["infected", "OBSERVATION", 285, 293], ["infection", "OBSERVATION", 311, 320]]], ["To prevent the spread of infection, dentists are trying to prevent infection between patients and between patients and medical staffs.", [["infection", "DISEASE", 25, 34], ["infection", "DISEASE", 67, 76], ["patients", "ORGANISM", 85, 93], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 85, 93], ["patients", "SPECIES", 106, 114], ["infection", "PROBLEM", 25, 34], ["infection", "PROBLEM", 67, 76], ["spread", "OBSERVATION_MODIFIER", 15, 21], ["infection", "OBSERVATION", 25, 34], ["infection", "OBSERVATION", 67, 76]]], ["Medical staffs are engaged in medical care to prevent clusters of infection in the clinic.CURRENT STATUS OF JAPANESE PRIVATE DENTAL CLINICSHere are the infection control methods in a private dental office (Tada Dental Clinic, Hyogo, Japan) refer to the Correspondence guide to new coronavirus infectious disease in medical institution from Japanese Society for Infection Prevention and Control (March 10, 2020, Japanese Society for Infection Prevention and Control);Postpone the non\u2010urgent dental treatment.", [["infection", "DISEASE", 66, 75], ["infection", "DISEASE", 152, 161], ["coronavirus infectious disease", "DISEASE", 281, 311], ["Infection", "DISEASE", 361, 370], ["Infection", "DISEASE", 432, 441], ["coronavirus", "ORGANISM", 281, 292], ["infection", "PROBLEM", 66, 75], ["new coronavirus infectious disease", "PROBLEM", 277, 311], ["Infection Prevention", "TREATMENT", 361, 381], ["Infection Prevention", "TREATMENT", 432, 452], ["the non\u2010urgent dental treatment", "TREATMENT", 475, 506], ["infection", "OBSERVATION", 66, 75]]], ["Reduce the number of outpatient reservations.Disinfecting spaces inside the clinic from the front door to the waiting room, reception, corridor and doors entering the clinic, especially alcohol disinfection of parts that people touch with hands, ventilation and humidification in the room.", [["alcohol", "CHEMICAL", 186, 193], ["alcohol", "CHEMICAL", 186, 193], ["alcohol", "SIMPLE_CHEMICAL", 186, 193], ["people", "ORGANISM", 221, 227], ["people", "SPECIES", 221, 227], ["outpatient reservations", "TREATMENT", 21, 44], ["ventilation", "TREATMENT", 246, 257], ["humidification", "TREATMENT", 262, 276], ["number", "OBSERVATION_MODIFIER", 11, 17]]], ["Use of hypochlorous acid water or stabilized chlorine dioxide in anticipation of an auxiliary effect (effect on COVID\u201019 is undetermined).Reduce the chances of people meeting in the waiting room.", [["hypochlorous acid", "CHEMICAL", 7, 24], ["chlorine dioxide", "CHEMICAL", 45, 61], ["hypochlorous acid", "CHEMICAL", 7, 24], ["chlorine dioxide", "CHEMICAL", 45, 61], ["hypochlorous acid", "SIMPLE_CHEMICAL", 7, 24], ["chlorine dioxide", "SIMPLE_CHEMICAL", 45, 61], ["people", "ORGANISM", 160, 166], ["people", "SPECIES", 160, 166], ["hypochlorous acid water", "TREATMENT", 7, 30], ["stabilized chlorine dioxide", "TREATMENT", 34, 61], ["an auxiliary effect", "PROBLEM", 81, 100]]], ["Keep people apart in the waiting room, keep chairs as far away as possible, shorten the meeting time or wait in your own car.Temperature measurement of every patient.Place alcohol sprays for hand disinfection everywhere, and let the patients sterilize his/her hands every time he touches something.Staffs wear a surgical mask, goggles and gloves as usual.Use of rubber dam and not only intraoral vacuum but also extraoral vacuum.Preparation of protective clothing and caps for the time of serious spread of infection (Masks, disinfectants, goggles, gloves and gauze are hard to come by.)Staff temperature measurement, confirmation of symptoms, disinfection of staff room, not to eat and drink in staff room.Staff training including thorough disinfection of hands before and after removing the mask or goggles and gloves.Staff with daily education and training to prevent infection.Distributing masks and alcohol sprays to staffs.Request for cooperation to prevent infection of family members of staffs.", [["hand", "ANATOMY", 191, 195], ["alcohol", "CHEMICAL", 172, 179], ["infection", "DISEASE", 507, 516], ["infection", "DISEASE", 871, 880], ["alcohol", "CHEMICAL", 904, 911], ["infection", "DISEASE", 964, 973], ["alcohol", "CHEMICAL", 172, 179], ["alcohol", "CHEMICAL", 904, 911], ["people", "ORGANISM", 5, 11], ["patient", "ORGANISM", 158, 165], ["hand", "ORGANISM_SUBDIVISION", 191, 195], ["patients", "ORGANISM", 233, 241], ["people", "SPECIES", 5, 11], ["patient", "SPECIES", 158, 165], ["patients", "SPECIES", 233, 241], ["Temperature measurement", "TEST", 125, 148], ["alcohol sprays", "TREATMENT", 172, 186], ["hand disinfection", "TREATMENT", 191, 208], ["a surgical mask", "TREATMENT", 310, 325], ["goggles and gloves", "TREATMENT", 327, 345], ["rubber dam", "TREATMENT", 362, 372], ["intraoral vacuum", "TREATMENT", 386, 402], ["extraoral vacuum", "TREATMENT", 412, 428], ["protective clothing", "TREATMENT", 444, 463], ["caps", "TREATMENT", 468, 472], ["infection", "PROBLEM", 507, 516], ["goggles", "TREATMENT", 540, 547], ["gloves", "TREATMENT", 549, 555], ["gauze", "TREATMENT", 560, 565], ["Staff temperature measurement", "TEST", 587, 616], ["symptoms", "PROBLEM", 634, 642], ["Staff training", "TREATMENT", 707, 721], ["thorough disinfection of hands", "TREATMENT", 732, 762], ["the mask", "TREATMENT", 789, 797], ["gloves", "TREATMENT", 813, 819], ["daily education", "TREATMENT", 831, 846], ["training", "TREATMENT", 851, 859], ["infection", "PROBLEM", 871, 880], ["infection", "PROBLEM", 964, 973], ["surgical mask", "OBSERVATION", 312, 325], ["rubber dam", "OBSERVATION", 362, 372], ["vacuum", "OBSERVATION", 396, 402], ["extraoral", "ANATOMY", 412, 421], ["vacuum", "OBSERVATION", 422, 428], ["protective clothing", "OBSERVATION", 444, 463], ["infection", "OBSERVATION", 507, 516], ["hands", "ANATOMY", 757, 762], ["infection", "OBSERVATION", 871, 880], ["infection", "OBSERVATION", 964, 973]]]], "89b0a7d066719cd6d1b45eae693a70a4045ccb5b": [["IntroductionSince December of 2019, the SARS-CoV-2 pandemic has impacted millions of lives worldwide.", [["SARS", "DISEASE", 40, 44], ["SARS-CoV-2", "ORGANISM", 40, 50]]], ["As of 23 rd March 2020, more than 340,000 people are reported to be infected, with ~4-5% mortalities (https://coronavirus.jhu.edu/map.html).", [["people", "ORGANISM", 42, 48], ["people", "SPECIES", 42, 48], ["infected", "OBSERVATION", 68, 76]]], ["The SARS-CoV-2 is a single-stranded RNA virus belonging to the Coronaviridae family of zoonotic viruses that infect mammals and birds (Andersen et al., 2020) .", [["SARS", "DISEASE", 4, 8], ["zoonotic viruses", "DISEASE", 87, 103], ["SARS-CoV-2", "ORGANISM", 4, 14], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 63, 76], ["birds", "ORGANISM", 128, 133], ["SARS-CoV-2", "DNA", 4, 14], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8], ["a single-stranded RNA virus", "PROBLEM", 18, 45]]], ["The novel SARS-CoV-2 was first isolated from lung airway epithelial cells of patient with pneumonia .", [["lung airway epithelial cells", "ANATOMY", 45, 73], ["pneumonia", "DISEASE", 90, 99], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 10, 20], ["lung airway epithelial cells", "CELL", 45, 73], ["patient", "ORGANISM", 77, 84], ["SARS-CoV-2", "DNA", 10, 20], ["lung airway epithelial cells", "CELL_TYPE", 45, 73], ["patient", "SPECIES", 77, 84], ["SARS-CoV", "SPECIES", 10, 18], ["The novel SARS", "TEST", 0, 14], ["lung airway epithelial cells", "PROBLEM", 45, 73], ["pneumonia", "PROBLEM", 90, 99], ["lung", "ANATOMY", 45, 49], ["airway epithelial cells", "OBSERVATION", 50, 73], ["pneumonia", "OBSERVATION", 90, 99]]], ["Since then it has been reported that SARS-CoV-2 employ receptor angiotensin converting enzyme 2 (ACE2) for entry into human cells and utilise Transmembrane Serine Protease 2 (TMPRSS2) for Spike (S) Protein priming (Hoffmann et al., 2020) .", [["cells", "ANATOMY", 124, 129], ["angiotensin", "CHEMICAL", 64, 75], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 37, 47], ["angiotensin converting enzyme 2", "GENE_OR_GENE_PRODUCT", 64, 95], ["ACE2", "GENE_OR_GENE_PRODUCT", 97, 101], ["human", "ORGANISM", 118, 123], ["cells", "CELL", 124, 129], ["Transmembrane Serine Protease 2", "GENE_OR_GENE_PRODUCT", 142, 173], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 175, 182], ["receptor angiotensin converting enzyme 2", "PROTEIN", 55, 95], ["ACE2", "PROTEIN", 97, 101], ["human cells", "CELL_TYPE", 118, 129], ["Transmembrane Serine Protease 2", "PROTEIN", 142, 173], ["TMPRSS2", "PROTEIN", 175, 182], ["human", "SPECIES", 118, 123], ["human", "SPECIES", 118, 123], ["SARS", "PROBLEM", 37, 41], ["CoV", "TEST", 42, 45], ["receptor angiotensin", "TREATMENT", 55, 75], ["enzyme", "TEST", 87, 93], ["entry into human cells", "TREATMENT", 107, 129], ["Transmembrane Serine Protease", "TREATMENT", 142, 171], ["Spike", "PROBLEM", 188, 193]]], ["SARS-CoV-2 shares ~80% sequence similarity with SARS-CoV and ~50% with Middle East respiratory syndrome coronavirus (MERS-CoV), all of which cause severe respiratory symptoms (Hoffmann et al., 2020) .IntroductionMoreover, in addition to respiratory disease, SARS and MERS are known to cause liver impairments (Alsaad et al., 2017; Chau et al., 2004; Zhang et al., 2020) .IntroductionImportantly, SARS-CoV-2 RNA was discovered in stool sample of the first US patient, indicating gastrointestinal tract infection (Holshue et al., 2020) .", [["respiratory", "ANATOMY", 154, 165], ["respiratory", "ANATOMY", 237, 248], ["liver", "ANATOMY", 291, 296], ["stool sample", "ANATOMY", 429, 441], ["gastrointestinal tract", "ANATOMY", 478, 500], ["SARS", "DISEASE", 0, 4], ["SARS-CoV", "DISEASE", 48, 56], ["Middle East respiratory syndrome coronavirus", "DISEASE", 71, 115], ["respiratory symptoms", "DISEASE", 154, 174], ["respiratory disease", "DISEASE", 237, 256], ["SARS", "DISEASE", 258, 262], ["liver impairments", "DISEASE", 291, 308], ["gastrointestinal tract infection", "DISEASE", 478, 510], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS-CoV", "ORGANISM", 48, 56], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 71, 115], ["MERS-CoV", "ORGANISM", 117, 125], ["liver", "ORGAN", 291, 296], ["SARS-CoV-2", "ORGANISM", 396, 406], ["patient", "ORGANISM", 458, 465], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 478, 500], ["SARS-CoV-2 RNA", "RNA", 396, 410], ["patient", "SPECIES", 458, 465], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 48, 56], ["Middle East respiratory syndrome coronavirus", "SPECIES", 71, 115], ["MERS-CoV", "SPECIES", 117, 125], ["SARS-CoV", "SPECIES", 396, 404], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["SARS", "TEST", 48, 52], ["CoV", "TEST", 53, 56], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 71, 115], ["severe respiratory symptoms", "PROBLEM", 147, 174], ["respiratory disease", "PROBLEM", 237, 256], ["SARS", "PROBLEM", 258, 262], ["liver impairments", "PROBLEM", 291, 308], ["SARS", "PROBLEM", 396, 400], ["stool sample", "TEST", 429, 441], ["gastrointestinal tract infection", "PROBLEM", 478, 510], ["respiratory syndrome", "OBSERVATION", 83, 103], ["severe", "OBSERVATION_MODIFIER", 147, 153], ["respiratory", "ANATOMY", 154, 165], ["respiratory", "ANATOMY", 237, 248], ["disease", "OBSERVATION", 249, 256], ["liver", "ANATOMY", 291, 296], ["gastrointestinal tract", "ANATOMY", 478, 500], ["infection", "OBSERVATION", 501, 510]]], ["A recent study reported 14-53% cases with higher levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the liver of COVID-19 patients (Huang et al., 2020; Zhang et al., 2020) .", [["liver", "ANATOMY", 134, 139], ["alanine", "CHEMICAL", 59, 66], ["aspartate", "CHEMICAL", 94, 103], ["alanine", "CHEMICAL", 59, 66], ["aspartate", "CHEMICAL", 94, 103], ["alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 59, 83], ["ALT", "SIMPLE_CHEMICAL", 85, 88], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 94, 120], ["AST", "SIMPLE_CHEMICAL", 122, 125], ["liver", "ORGAN", 134, 139], ["patients", "ORGANISM", 152, 160], ["alanine aminotransferase", "PROTEIN", 59, 83], ["ALT", "PROTEIN", 85, 88], ["aspartate aminotransferase", "PROTEIN", 94, 120], ["AST", "PROTEIN", 122, 125], ["patients", "SPECIES", 152, 160], ["A recent study", "TEST", 0, 14], ["alanine aminotransferase", "TEST", 59, 83], ["ALT", "TEST", 85, 88], ["aspartate aminotransferase", "TEST", 94, 120], ["AST", "TEST", 122, 125], ["COVID", "TEST", 143, 148], ["liver", "ANATOMY", 134, 139]]], ["Moreover, these symptoms were elevated in intensive care unit (ICU) patients compared to patients who did not require ICU (Huang et al., 2020) .", [["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 89, 97], ["these symptoms", "PROBLEM", 10, 24]]], ["It remains to be investigated whether SARS-CoV-2 directly infect liver cells.", [["liver cells", "ANATOMY", 65, 76], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 38, 48], ["liver cells", "CELL", 65, 76], ["liver cells", "CELL_TYPE", 65, 76], ["SARS-CoV", "SPECIES", 38, 46], ["SARS", "PROBLEM", 38, 42], ["CoV", "TEST", 43, 46], ["liver", "ANATOMY", 65, 70]]], ["In addition, concerns have been raised on effect of SARS-CoV-2 infection on pre-existing liver condition Mao et al., 2020; Zhang et al., 2020) .", [["liver", "ANATOMY", 89, 94], ["SARS", "DISEASE", 52, 56], ["infection", "DISEASE", 63, 72], ["SARS-CoV-2", "ORGANISM", 52, 62], ["liver", "ORGAN", 89, 94], ["SARS", "PROBLEM", 52, 56], ["CoV", "PROBLEM", 57, 60], ["2 infection", "PROBLEM", 61, 72], ["pre-existing liver condition", "PROBLEM", 76, 104], ["liver", "ANATOMY", 89, 94]]], ["Since SARS-CoV-2 binds to ACE2 and require TMPRSS2 for activation, we surveyed the human liver (from tumor and adjacent normal regions of hepatocellular carcinoma patients) by sc-RNA-seq to identify which cell type co-express these two genes.IntroductionHere we report that ACE2 and TMPRSS2 are co-expressed in only one sub-population in human liver.", [["liver", "ANATOMY", 89, 94], ["tumor", "ANATOMY", 101, 106], ["hepatocellular carcinoma", "ANATOMY", 138, 162], ["cell", "ANATOMY", 205, 209], ["liver", "ANATOMY", 344, 349], ["tumor", "DISEASE", 101, 106], ["hepatocellular carcinoma", "DISEASE", 138, 162], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 6, 16], ["ACE2", "GENE_OR_GENE_PRODUCT", 26, 30], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 43, 50], ["human", "ORGANISM", 83, 88], ["liver", "ORGAN", 89, 94], ["tumor", "CANCER", 101, 106], ["hepatocellular carcinoma", "CANCER", 138, 162], ["patients", "ORGANISM", 163, 171], ["cell type", "CELL", 205, 214], ["ACE2", "GENE_OR_GENE_PRODUCT", 274, 278], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 283, 290], ["human", "ORGANISM", 338, 343], ["liver", "ORGAN", 344, 349], ["ACE2", "PROTEIN", 26, 30], ["TMPRSS2", "PROTEIN", 43, 50], ["ACE2", "PROTEIN", 274, 278], ["TMPRSS2", "PROTEIN", 283, 290], ["human", "SPECIES", 83, 88], ["patients", "SPECIES", 163, 171], ["human", "SPECIES", 338, 343], ["SARS-CoV", "SPECIES", 6, 14], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 338, 343], ["SARS", "PROBLEM", 6, 10], ["ACE2", "TEST", 26, 30], ["TMPRSS2", "TREATMENT", 43, 50], ["tumor", "PROBLEM", 101, 106], ["hepatocellular carcinoma", "PROBLEM", 138, 162], ["ACE2", "TEST", 274, 278], ["TMPRSS2", "TEST", 283, 290], ["liver", "ANATOMY", 89, 94], ["tumor", "OBSERVATION", 101, 106], ["hepatocellular", "ANATOMY", 138, 152], ["carcinoma", "OBSERVATION", 153, 162], ["human", "ANATOMY_MODIFIER", 338, 343], ["liver", "ANATOMY", 344, 349]]], ["Based on expression of cell type specific markers ALB (Albumin), KRT (Keratin), EPCAM and unique expression pattern of TROP2 (TACSTD2) and SOX9 (SRY-box 9), we annotated this population as liver progenitors.", [["cell", "ANATOMY", 23, 27], ["liver progenitors", "ANATOMY", 189, 206], ["cell", "CELL", 23, 27], ["ALB", "GENE_OR_GENE_PRODUCT", 50, 53], ["Albumin", "GENE_OR_GENE_PRODUCT", 55, 62], ["KRT", "GENE_OR_GENE_PRODUCT", 65, 68], ["Keratin", "GENE_OR_GENE_PRODUCT", 70, 77], ["EPCAM", "GENE_OR_GENE_PRODUCT", 80, 85], ["TROP2", "GENE_OR_GENE_PRODUCT", 119, 124], ["TACSTD2", "GENE_OR_GENE_PRODUCT", 126, 133], ["SOX9", "GENE_OR_GENE_PRODUCT", 139, 143], ["SRY-box 9", "GENE_OR_GENE_PRODUCT", 145, 154], ["liver progenitors", "CELL", 189, 206], ["cell type specific markers", "PROTEIN", 23, 49], ["ALB", "PROTEIN", 50, 53], ["Albumin", "PROTEIN", 55, 62], ["KRT", "PROTEIN", 65, 68], ["Keratin", "PROTEIN", 70, 77], ["EPCAM", "PROTEIN", 80, 85], ["TROP2", "PROTEIN", 119, 124], ["TACSTD2", "PROTEIN", 126, 133], ["SOX9", "DNA", 139, 143], ["SRY-box 9", "DNA", 145, 154], ["liver progenitors", "CELL_TYPE", 189, 206], ["ALB (Albumin)", "TREATMENT", 50, 63], ["KRT (Keratin)", "TREATMENT", 65, 78], ["EPCAM", "TREATMENT", 80, 85], ["TROP2 (TACSTD2)", "TREATMENT", 119, 134], ["SOX9 (SRY-box", "TEST", 139, 152], ["liver", "ANATOMY", 189, 194]]], ["Our results suggest SARS-CoV-2 binding receptor ACE2 is only expressed on TROP2 high cholangiocytebiased progenitors while serine protease TMPRSS2 is expressed by TROP2 high and TROP2 int population.", [["TROP2 high cholangiocytebiased progenitors", "ANATOMY", 74, 116], ["serine", "CHEMICAL", 123, 129], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 20, 30], ["ACE2", "GENE_OR_GENE_PRODUCT", 48, 52], ["TROP2", "GENE_OR_GENE_PRODUCT", 74, 79], ["progenitors", "CELL", 105, 116], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 139, 146], ["TROP2", "GENE_OR_GENE_PRODUCT", 163, 168], ["SARS-CoV-2 binding receptor", "PROTEIN", 20, 47], ["ACE2", "PROTEIN", 48, 52], ["TROP2 high cholangiocytebiased progenitors", "CELL_TYPE", 74, 116], ["serine protease", "PROTEIN", 123, 138], ["TMPRSS2", "PROTEIN", 139, 146], ["TROP2 high and TROP2 int population", "CELL_LINE", 163, 198], ["SARS-CoV", "SPECIES", 20, 28], ["SARS", "PROBLEM", 20, 24], ["CoV", "TEST", 25, 28], ["TROP2 high cholangiocytebiased progenitors", "TREATMENT", 74, 116], ["serine protease TMPRSS2", "TEST", 123, 146], ["TROP2", "TEST", 163, 168], ["TROP2 int population", "PROBLEM", 178, 198]]], ["These results indicate that SARS-CoV-2 infection might preferentially infect the TROP2 high cholangiocyte-biased progenitor pool, thereby compromising the regenerative abilities of infected liver and/or contributing to liver pathology.Expression of ACE2 and TMPRSS2 in human liver scRNA-seq atlasWe performed scRNA-seq on human liver tissue obtained from tumor and adjacent normal tissue of hepatocellular carcinoma patients (Sharma et al., in revision) .", [["cholangiocyte", "ANATOMY", 92, 105], ["progenitor pool", "ANATOMY", 113, 128], ["liver", "ANATOMY", 190, 195], ["liver", "ANATOMY", 219, 224], ["liver", "ANATOMY", 275, 280], ["liver tissue", "ANATOMY", 328, 340], ["tumor", "ANATOMY", 355, 360], ["tissue", "ANATOMY", 381, 387], ["hepatocellular carcinoma", "ANATOMY", 391, 415], ["infection", "DISEASE", 39, 48], ["liver pathology", "DISEASE", 219, 234], ["tumor", "DISEASE", 355, 360], ["hepatocellular carcinoma", "DISEASE", 391, 415], ["SARS-CoV-2", "ORGANISM", 28, 38], ["TROP2", "GENE_OR_GENE_PRODUCT", 81, 86], ["cholangiocyte", "CELL", 92, 105], ["progenitor", "CELL", 113, 123], ["liver", "ORGAN", 190, 195], ["liver", "ORGAN", 219, 224], ["ACE2", "GENE_OR_GENE_PRODUCT", 249, 253], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 258, 265], ["human", "ORGANISM", 269, 274], ["liver", "ORGAN", 275, 280], ["scRNA-seq", "GENE_OR_GENE_PRODUCT", 309, 318], ["human", "ORGANISM", 322, 327], ["liver tissue", "TISSUE", 328, 340], ["tumor", "CANCER", 355, 360], ["normal tissue", "TISSUE", 374, 387], ["hepatocellular carcinoma", "CANCER", 391, 415], ["patients", "ORGANISM", 416, 424], ["TROP2 high cholangiocyte-biased progenitor pool", "CELL_TYPE", 81, 128], ["ACE2", "PROTEIN", 249, 253], ["TMPRSS2", "PROTEIN", 258, 265], ["human liver scRNA-seq atlasWe", "DNA", 269, 298], ["scRNA-seq", "DNA", 309, 318], ["human", "SPECIES", 269, 274], ["human", "SPECIES", 322, 327], ["patients", "SPECIES", 416, 424], ["SARS-CoV-2", "SPECIES", 28, 38], ["human", "SPECIES", 269, 274], ["human", "SPECIES", 322, 327], ["SARS", "PROBLEM", 28, 32], ["CoV-2 infection", "PROBLEM", 33, 48], ["infected liver", "PROBLEM", 181, 195], ["liver pathology", "PROBLEM", 219, 234], ["ACE2", "TEST", 249, 253], ["TMPRSS2", "TEST", 258, 265], ["scRNA", "TEST", 281, 286], ["scRNA", "TEST", 309, 314], ["tumor", "PROBLEM", 355, 360], ["hepatocellular carcinoma", "PROBLEM", 391, 415], ["revision", "TREATMENT", 444, 452], ["regenerative", "OBSERVATION_MODIFIER", 155, 167], ["infected", "OBSERVATION", 181, 189], ["liver", "ANATOMY", 190, 195], ["liver", "ANATOMY", 219, 224], ["pathology", "OBSERVATION", 225, 234], ["liver", "ANATOMY", 275, 280], ["liver", "ANATOMY", 328, 333], ["tumor", "OBSERVATION", 355, 360], ["normal tissue", "OBSERVATION_MODIFIER", 374, 387], ["hepatocellular", "ANATOMY", 391, 405], ["carcinoma", "OBSERVATION", 406, 415], ["revision", "OBSERVATION", 444, 452]]], ["In total, we analysed ~74,000 cells and employed Louvain algorithm for clustering of these cells.", [["cells", "ANATOMY", 30, 35], ["cells", "ANATOMY", 91, 96], ["cells", "CELL", 30, 35], ["cells", "CELL", 91, 96], ["74,000 cells", "CELL_LINE", 23, 35], ["Louvain algorithm", "TREATMENT", 49, 66], ["clustering of these cells", "PROBLEM", 71, 96]]], ["We identified 29 clusters based on the expression of cell type specific genes.Expression of ACE2 and TMPRSS2 in human liver scRNA-seq atlasThese clusters were further annotated into hepatocyte, epithelial progenitors, lymphoid and myeloid cells ( Figure 1A ) and observed specific enrichment of EPCAM + and SOX9 + epithelial progenitor cluster in normal liver ( Figure 1B) .", [["cell", "ANATOMY", 53, 57], ["liver", "ANATOMY", 118, 123], ["hepatocyte", "ANATOMY", 182, 192], ["epithelial progenitors", "ANATOMY", 194, 216], ["lymphoid", "ANATOMY", 218, 226], ["myeloid cells", "ANATOMY", 231, 244], ["SOX9 + epithelial progenitor cluster", "ANATOMY", 307, 343], ["liver", "ANATOMY", 354, 359], ["cell", "CELL", 53, 57], ["ACE2", "GENE_OR_GENE_PRODUCT", 92, 96], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 101, 108], ["human", "ORGANISM", 112, 117], ["liver", "ORGAN", 118, 123], ["hepatocyte", "CELL", 182, 192], ["epithelial progenitors", "CELL", 194, 216], ["lymphoid", "CELL", 218, 226], ["myeloid cells", "CELL", 231, 244], ["Figure 1A", "CELL", 247, 256], ["EPCAM", "GENE_OR_GENE_PRODUCT", 295, 300], ["SOX9", "GENE_OR_GENE_PRODUCT", 307, 311], ["liver", "ORGAN", 354, 359], ["cell type specific genes", "DNA", 53, 77], ["ACE2", "PROTEIN", 92, 96], ["TMPRSS2", "PROTEIN", 101, 108], ["human liver scRNA-seq atlas", "DNA", 112, 139], ["hepatocyte, epithelial progenitors", "CELL_TYPE", 182, 216], ["lymphoid and myeloid cells", "CELL_TYPE", 218, 244], ["EPCAM", "PROTEIN", 295, 300], ["SOX9", "PROTEIN", 307, 311], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 112, 117], ["ACE2", "TEST", 92, 96], ["TMPRSS2 in human liver scRNA", "TREATMENT", 101, 129], ["EPCAM", "TEST", 295, 300], ["SOX9", "TEST", 307, 311], ["29 clusters", "OBSERVATION_MODIFIER", 14, 25], ["cell", "OBSERVATION", 53, 57], ["liver", "ANATOMY", 118, 123], ["hepatocyte", "ANATOMY", 182, 192], ["epithelial progenitors", "OBSERVATION", 194, 216], ["lymphoid", "ANATOMY", 218, 226], ["myeloid cells", "OBSERVATION", 231, 244], ["epithelial progenitor cluster", "OBSERVATION", 314, 343], ["normal", "OBSERVATION", 347, 353], ["liver", "ANATOMY", 354, 359]]], ["We identified the specific markers for every cluster ( Figure 1C ) and observed the co-expression of KRT18 and KRT19 in epithelial progenitor cluster.", [["epithelial progenitor", "ANATOMY", 120, 141], ["KRT18", "GENE_OR_GENE_PRODUCT", 101, 106], ["KRT19", "GENE_OR_GENE_PRODUCT", 111, 116], ["epithelial progenitor", "CELL", 120, 141], ["KRT18", "PROTEIN", 101, 106], ["KRT19", "PROTEIN", 111, 116], ["epithelial progenitor cluster", "CELL_TYPE", 120, 149], ["KRT18", "TEST", 101, 106], ["epithelial progenitor cluster", "OBSERVATION", 120, 149]]], ["Next, we investigated which cell types in the human liver co-express SARS-CoV-2 binding receptor ACE2 and the priming enzyme TMPRSS2.", [["cell", "ANATOMY", 28, 32], ["liver", "ANATOMY", 52, 57], ["cell", "CELL", 28, 32], ["human", "ORGANISM", 46, 51], ["liver", "ORGAN", 52, 57], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 69, 79], ["ACE2", "GENE_OR_GENE_PRODUCT", 97, 101], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 125, 132], ["SARS-CoV-2 binding receptor", "PROTEIN", 69, 96], ["ACE2", "PROTEIN", 97, 101], ["priming enzyme", "PROTEIN", 110, 124], ["TMPRSS2", "PROTEIN", 125, 132], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 46, 51], ["SARS", "TEST", 69, 73], ["CoV", "TEST", 74, 77], ["receptor ACE2", "TEST", 88, 101], ["the priming enzyme TMPRSS2", "TEST", 106, 132], ["cell types", "OBSERVATION", 28, 38], ["human", "ANATOMY_MODIFIER", 46, 51], ["liver", "ANATOMY", 52, 57]]], ["Our analysis revealed the specific expression of ACE2 and TMPRSS2 in the epithelial progenitor cluster ( Figure 1D and 1E).", [["epithelial progenitor", "ANATOMY", 73, 94], ["ACE2", "GENE_OR_GENE_PRODUCT", 49, 53], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 58, 65], ["epithelial progenitor", "CELL", 73, 94], ["ACE2", "PROTEIN", 49, 53], ["TMPRSS2", "PROTEIN", 58, 65], ["epithelial progenitor cluster", "CELL_TYPE", 73, 102], ["Our analysis", "TEST", 0, 12], ["ACE2", "TEST", 49, 53], ["TMPRSS2", "TEST", 58, 65], ["epithelial progenitor", "ANATOMY", 73, 94]]], ["This suggests that EPCAM + liver progenitors express machinery for both SARS-CoV-2 entry (ACE2) as well as priming (TMPRSS2) and might be susceptible for viral infection leading to liver dysfunction.TROP2+ liver epithelial progenitors express ACE2 and TMPRSS2A recent scRNA-seq study has suggested the heterogeneity in EPCAM + liver epithelial progenitors (Aizarani et al., 2019) .", [["EPCAM + liver progenitors", "ANATOMY", 19, 44], ["liver", "ANATOMY", 181, 186], ["TROP2+ liver epithelial progenitors", "ANATOMY", 199, 234], ["EPCAM + liver epithelial progenitors", "ANATOMY", 319, 355], ["viral infection", "DISEASE", 154, 169], ["liver dysfunction", "DISEASE", 181, 198], ["EPCAM", "GENE_OR_GENE_PRODUCT", 19, 24], ["liver progenitors", "CELL", 27, 44], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 72, 82], ["ACE2", "GENE_OR_GENE_PRODUCT", 90, 94], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 116, 123], ["liver", "ORGAN", 181, 186], ["TROP2", "GENE_OR_GENE_PRODUCT", 199, 204], ["ACE2", "GENE_OR_GENE_PRODUCT", 243, 247], ["TMPRSS2A", "GENE_OR_GENE_PRODUCT", 252, 260], ["EPCAM + liver epithelial progenitors", "CELL", 319, 355], ["EPCAM", "PROTEIN", 19, 24], ["liver progenitors", "CELL_TYPE", 27, 44], ["ACE2", "PROTEIN", 90, 94], ["TMPRSS2", "PROTEIN", 116, 123], ["TROP2", "PROTEIN", 199, 204], ["liver epithelial progenitors", "CELL_TYPE", 206, 234], ["ACE2", "PROTEIN", 243, 247], ["TMPRSS2A", "PROTEIN", 252, 260], ["EPCAM", "PROTEIN", 319, 324], ["liver epithelial progenitors", "CELL_TYPE", 327, 355], ["EPCAM", "TEST", 19, 24], ["both SARS", "TEST", 67, 76], ["CoV-2 entry (ACE2)", "TREATMENT", 77, 95], ["priming (TMPRSS2)", "TREATMENT", 107, 124], ["viral infection", "PROBLEM", 154, 169], ["liver dysfunction", "PROBLEM", 181, 198], ["TROP2", "TEST", 199, 204], ["ACE2", "TEST", 243, 247], ["TMPRSS2A recent scRNA", "TEST", 252, 273], ["seq study", "TEST", 274, 283], ["the heterogeneity in EPCAM", "PROBLEM", 298, 324], ["liver epithelial progenitors", "PROBLEM", 327, 355], ["EPCAM", "OBSERVATION", 19, 24], ["liver", "ANATOMY", 27, 32], ["infection", "OBSERVATION", 160, 169], ["liver", "ANATOMY", 181, 186], ["dysfunction", "OBSERVATION", 187, 198], ["liver", "ANATOMY", 206, 211], ["epithelial progenitors", "OBSERVATION", 212, 234], ["liver", "ANATOMY", 327, 332], ["epithelial progenitors", "OBSERVATION", 333, 355]]], ["Therefore, we further sub-clustered the epithelial cells (hepatocytes and progenitors) to understand the nature of ACE2 expressing liver progenitors ( Figure 2A ).", [["epithelial cells", "ANATOMY", 40, 56], ["hepatocytes", "ANATOMY", 58, 69], ["progenitors", "ANATOMY", 74, 85], ["liver progenitors", "ANATOMY", 131, 148], ["epithelial cells", "CELL", 40, 56], ["hepatocytes", "CELL", 58, 69], ["progenitors", "CELL", 74, 85], ["ACE2", "GENE_OR_GENE_PRODUCT", 115, 119], ["liver progenitors", "CELL", 131, 148], ["epithelial cells", "CELL_TYPE", 40, 56], ["hepatocytes", "CELL_TYPE", 58, 69], ["progenitors", "CELL_TYPE", 74, 85], ["ACE2", "PROTEIN", 115, 119], ["liver progenitors", "CELL_TYPE", 131, 148], ["epithelial cells", "OBSERVATION", 40, 56], ["liver", "ANATOMY", 131, 136]]], ["Sub-clustering also showed the predominant presence of normal liver cells in the progenitor cluster ( Figure 2B ).", [["liver cells", "ANATOMY", 62, 73], ["progenitor cluster", "ANATOMY", 81, 99], ["liver cells", "CELL", 62, 73], ["progenitor", "CELL", 81, 91], ["normal liver cells", "CELL_TYPE", 55, 73], ["predominant", "OBSERVATION_MODIFIER", 31, 42], ["normal", "OBSERVATION", 55, 61], ["liver", "ANATOMY", 62, 67], ["cells", "OBSERVATION", 68, 73], ["progenitor cluster", "OBSERVATION", 81, 99]]], ["Further we detected the presence of these cells in adjacent normal region from multiple individuals ( Figure 2C ).TROP2+ liver epithelial progenitors express ACE2 and TMPRSS2Interestingly, lower abundance of these cells in human liver is in concordance with the rare stem-like or progenitor population in epithelial tissues.", [["cells", "ANATOMY", 42, 47], ["TROP2+ liver epithelial progenitors", "ANATOMY", 114, 149], ["cells", "ANATOMY", 214, 219], ["liver", "ANATOMY", 229, 234], ["stem-like", "ANATOMY", 267, 276], ["progenitor population", "ANATOMY", 280, 301], ["epithelial tissues", "ANATOMY", 305, 323], ["cells", "CELL", 42, 47], ["TROP2", "GENE_OR_GENE_PRODUCT", 114, 119], ["liver epithelial progenitors", "CELL", 121, 149], ["ACE2", "GENE_OR_GENE_PRODUCT", 158, 162], ["cells", "CELL", 214, 219], ["human", "ORGANISM", 223, 228], ["liver", "ORGAN", 229, 234], ["stem-like", "CELL", 267, 276], ["progenitor population", "CELL", 280, 301], ["epithelial tissues", "TISSUE", 305, 323], ["TROP2", "PROTEIN", 114, 119], ["liver epithelial progenitors", "CELL_TYPE", 121, 149], ["ACE2", "PROTEIN", 158, 162], ["TMPRSS2Interestingly", "PROTEIN", 167, 187], ["stem-like or progenitor population", "CELL_TYPE", 267, 301], ["human", "SPECIES", 223, 228], ["human", "SPECIES", 223, 228], ["these cells", "PROBLEM", 36, 47], ["TROP2", "TEST", 114, 119], ["ACE2", "TEST", 158, 162], ["TMPRSS2Interestingly", "TEST", 167, 187], ["these cells in human liver", "PROBLEM", 208, 234], ["the rare stem", "PROBLEM", 258, 271], ["cells", "OBSERVATION", 42, 47], ["normal", "OBSERVATION", 60, 66], ["region", "ANATOMY_MODIFIER", 67, 73], ["multiple", "OBSERVATION_MODIFIER", 79, 87], ["liver", "ANATOMY", 121, 126], ["epithelial progenitors", "OBSERVATION", 127, 149], ["lower", "OBSERVATION_MODIFIER", 189, 194], ["these cells", "OBSERVATION", 208, 219], ["human", "ANATOMY_MODIFIER", 223, 228], ["liver", "ANATOMY", 229, 234], ["rare", "OBSERVATION_MODIFIER", 262, 266], ["stem", "OBSERVATION", 267, 271], ["progenitor population", "OBSERVATION", 280, 301], ["epithelial tissues", "ANATOMY", 305, 323]]], ["Next, we analysed the expression of hepatocyte, cholangiocyte and bi-potent markers in these clusters.", [["hepatocyte", "ANATOMY", 36, 46], ["cholangiocyte", "ANATOMY", 48, 61], ["hepatocyte", "CELL", 36, 46], ["cholangiocyte", "CELL", 48, 61], ["hepatocyte, cholangiocyte and bi-potent markers", "PROTEIN", 36, 83], ["hepatocyte", "ANATOMY", 36, 46], ["cholangiocyte", "ANATOMY", 48, 61]]], ["The progenitor cluster specifically expressed EPCAM (progenitor marker) as well as KRT19 and CFTR (Cystic fibrosis transmembrane conductance regulator) which are known to be expressed in progenitors with a cholangiocyte fate bias ( Figure 2D ) (Cohn et al., 1993) .", [["progenitor", "ANATOMY", 4, 14], ["progenitor", "ANATOMY", 53, 63], ["progenitors", "ANATOMY", 187, 198], ["cholangiocyte", "ANATOMY", 206, 219], ["fibrosis", "DISEASE", 106, 114], ["progenitor", "CELL", 4, 14], ["EPCAM", "GENE_OR_GENE_PRODUCT", 46, 51], ["progenitor", "CELL", 53, 63], ["KRT19", "GENE_OR_GENE_PRODUCT", 83, 88], ["CFTR", "GENE_OR_GENE_PRODUCT", 93, 97], ["Cystic fibrosis transmembrane conductance regulator", "GENE_OR_GENE_PRODUCT", 99, 150], ["progenitors", "CELL", 187, 198], ["EPCAM", "PROTEIN", 46, 51], ["progenitor marker", "PROTEIN", 53, 70], ["KRT19", "PROTEIN", 83, 88], ["CFTR", "PROTEIN", 93, 97], ["Cystic fibrosis transmembrane conductance regulator", "PROTEIN", 99, 150], ["KRT19", "TEST", 83, 88], ["CFTR (Cystic fibrosis transmembrane conductance regulator", "PROBLEM", 93, 150], ["cholangiocyte", "ANATOMY", 206, 219]]], ["Importantly, we failed to detect expression of hepatocyte fate bias genes, ASGR1 (Asialoglycoprotein receptor 1) and ALB in this cluster.", [["hepatocyte", "ANATOMY", 47, 57], ["hepatocyte", "CELL", 47, 57], ["ASGR1", "GENE_OR_GENE_PRODUCT", 75, 80], ["Asialoglycoprotein receptor 1", "GENE_OR_GENE_PRODUCT", 82, 111], ["ALB", "GENE_OR_GENE_PRODUCT", 117, 120], ["hepatocyte fate bias genes", "DNA", 47, 73], ["ASGR1", "DNA", 75, 80], ["Asialoglycoprotein receptor 1", "PROTEIN", 82, 111], ["ALB", "DNA", 117, 120], ["hepatocyte fate bias genes", "PROBLEM", 47, 73], ["ASGR1 (Asialoglycoprotein receptor", "TREATMENT", 75, 109], ["ALB", "TREATMENT", 117, 120], ["hepatocyte", "ANATOMY", 47, 57]]], ["Since this progenitor cluster demonstrated bias for cholangiocyte fate we further investigated the expression of TROP2 gene.", [["progenitor", "ANATOMY", 11, 21], ["cholangiocyte", "ANATOMY", 52, 65], ["progenitor", "CELL", 11, 21], ["cholangiocyte", "CELL", 52, 65], ["TROP2", "GENE_OR_GENE_PRODUCT", 113, 118], ["TROP2 gene", "DNA", 113, 123], ["TROP2 gene", "TREATMENT", 113, 123]]], ["The TROP2 expression is known to mark the fate of liver epithelial progenitors where lower TROP2 expression is linked with hepatocyte fate and TROP2 high cells with cholangiocyte fate (Aizarani et al., 2019) .Recently, Aizarani et al., demonstrated the progenitor-like properties of TROP2 + cellswhere TROP2 Int cells demonstrated highest organoid forming efficiency followed by TROP2 high cells, while TROP2 low cells failed to generate organoids (Aizarani et al., 2019) .", [["liver epithelial progenitors", "ANATOMY", 50, 78], ["hepatocyte", "ANATOMY", 123, 133], ["TROP2 high cells", "ANATOMY", 143, 159], ["cholangiocyte", "ANATOMY", 165, 178], ["progenitor", "ANATOMY", 253, 263], ["TROP2 + cellswhere TROP2 Int cells", "ANATOMY", 283, 317], ["organoid", "ANATOMY", 339, 347], ["TROP2 high cells", "ANATOMY", 379, 395], ["TROP2 low cells", "ANATOMY", 403, 418], ["organoids", "ANATOMY", 438, 447], ["TROP2", "GENE_OR_GENE_PRODUCT", 4, 9], ["liver epithelial progenitors", "CELL", 50, 78], ["TROP2", "GENE_OR_GENE_PRODUCT", 91, 96], ["hepatocyte", "CELL", 123, 133], ["TROP2 high cells", "CELL", 143, 159], ["cholangiocyte", "CELL", 165, 178], ["progenitor", "CELL", 253, 263], ["TROP2", "GENE_OR_GENE_PRODUCT", 283, 288], ["TROP2 high cells", "CELL", 379, 395], ["cells", "CELL", 413, 418], ["organoids", "CELL", 438, 447], ["TROP2", "PROTEIN", 4, 9], ["liver epithelial progenitors", "CELL_TYPE", 50, 78], ["TROP2", "PROTEIN", 91, 96], ["TROP2 high cells", "CELL_TYPE", 143, 159], ["TROP2", "PROTEIN", 283, 288], ["TROP2 Int cells", "CELL_LINE", 302, 317], ["TROP2 high cells", "CELL_LINE", 379, 395], ["TROP2 low cells", "CELL_LINE", 403, 418], ["lower TROP2 expression", "PROBLEM", 85, 107], ["hepatocyte fate", "TEST", 123, 138], ["TROP2 high cells", "PROBLEM", 143, 159], ["the progenitor", "TEST", 249, 263], ["TROP2", "TEST", 283, 288], ["TROP2 Int cells", "TEST", 302, 317], ["highest organoid forming efficiency", "PROBLEM", 331, 366], ["TROP2 high cells", "PROBLEM", 379, 395], ["TROP2 low cells", "PROBLEM", 403, 418], ["liver", "ANATOMY", 50, 55], ["epithelial", "ANATOMY_MODIFIER", 56, 66], ["lower", "ANATOMY_MODIFIER", 85, 90], ["TROP2 expression", "OBSERVATION", 91, 107], ["high cells", "OBSERVATION", 149, 159], ["cholangiocyte", "ANATOMY", 165, 178], ["highest organoid", "OBSERVATION", 331, 347], ["forming efficiency", "OBSERVATION", 348, 366], ["high cells", "OBSERVATION", 385, 395]]], ["Therefore, we investigated whether any of the epithelial clusters co-expressed ACE2, TMPRSS2, and TROP2.", [["epithelial clusters", "ANATOMY", 46, 65], ["epithelial", "TISSUE", 46, 56], ["ACE2", "GENE_OR_GENE_PRODUCT", 79, 83], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 85, 92], ["TROP2", "GENE_OR_GENE_PRODUCT", 98, 103], ["ACE2", "PROTEIN", 79, 83], ["TMPRSS2", "PROTEIN", 85, 92], ["TROP2", "PROTEIN", 98, 103], ["ACE2", "TEST", 79, 83], ["TMPRSS2", "TEST", 85, 92], ["TROP2", "TEST", 98, 103], ["epithelial", "ANATOMY_MODIFIER", 46, 56]]], ["Notably, we observed that only the EPCAM + progenitor cluster expressed all three genes ( Figure 2E ).", [["EPCAM + progenitor", "ANATOMY", 35, 53], ["EPCAM", "GENE_OR_GENE_PRODUCT", 35, 40], ["EPCAM", "PROTEIN", 35, 40]]], ["Next we sub-divided this cluster into TROP2 low, intermediate and high cells and investigated the expression of ACE2, TMPRSS2 and other cell fate markers.", [["high cells", "ANATOMY", 66, 76], ["cell", "ANATOMY", 136, 140], ["TROP2", "GENE_OR_GENE_PRODUCT", 38, 43], ["cells", "CELL", 71, 76], ["ACE2", "GENE_OR_GENE_PRODUCT", 112, 116], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 118, 125], ["cell", "CELL", 136, 140], ["TROP2 low, intermediate and high cells", "CELL_LINE", 38, 76], ["ACE2", "PROTEIN", 112, 116], ["TMPRSS2", "PROTEIN", 118, 125], ["cell fate markers", "PROTEIN", 136, 153], ["ACE2", "TEST", 112, 116], ["TMPRSS2", "TEST", 118, 125], ["high cells", "OBSERVATION", 66, 76], ["cell fate markers", "OBSERVATION", 136, 153]]], ["Remarkably, we observed that TROP2 high cells expressed the highest levels of ACE2 and TMPRSS2, followed by TROP2 Int and TROP2 low cells ( Figure 2F ).", [["TROP2 high cells", "ANATOMY", 29, 45], ["cells", "ANATOMY", 132, 137], ["TROP2 high cells", "CELL", 29, 45], ["ACE2", "GENE_OR_GENE_PRODUCT", 78, 82], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 87, 94], ["TROP2 Int", "GENE_OR_GENE_PRODUCT", 108, 117], ["TROP2 high cells", "CELL_LINE", 29, 45], ["ACE2", "PROTEIN", 78, 82], ["TMPRSS2", "PROTEIN", 87, 94], ["TROP2 Int", "PROTEIN", 108, 117], ["TROP2 low cells", "CELL_LINE", 122, 137], ["TROP2 high cells", "PROBLEM", 29, 45], ["ACE2", "TEST", 78, 82], ["TMPRSS2", "TEST", 87, 94], ["TROP2", "TEST", 108, 113], ["TROP2 low cells", "PROBLEM", 122, 137]]], ["Our analysis revealed that TROP2 Int (bipotent) cells also express MUC6 and SOX9, whereas TROP2 high (cholangiocyte fate bias) cells express makers such as CFTR, CXCL8, HES1 and KRT19.", [["TROP2 Int (bipotent) cells", "ANATOMY", 27, 53], ["cholangiocyte", "ANATOMY", 102, 115], ["cells", "ANATOMY", 127, 132], ["TROP2 Int", "GENE_OR_GENE_PRODUCT", 27, 36], ["MUC6", "GENE_OR_GENE_PRODUCT", 67, 71], ["SOX9", "GENE_OR_GENE_PRODUCT", 76, 80], ["TROP2", "GENE_OR_GENE_PRODUCT", 90, 95], ["CFTR", "GENE_OR_GENE_PRODUCT", 156, 160], ["CXCL8", "GENE_OR_GENE_PRODUCT", 162, 167], ["HES1", "GENE_OR_GENE_PRODUCT", 169, 173], ["KRT19", "GENE_OR_GENE_PRODUCT", 178, 183], ["TROP2 Int (bipotent) cells", "CELL_LINE", 27, 53], ["MUC6", "PROTEIN", 67, 71], ["SOX9", "PROTEIN", 76, 80], ["TROP2", "PROTEIN", 90, 95], ["CFTR", "PROTEIN", 156, 160], ["CXCL8", "PROTEIN", 162, 167], ["HES1", "PROTEIN", 169, 173], ["KRT19", "PROTEIN", 178, 183], ["Our analysis", "TEST", 0, 12], ["TROP2", "TEST", 27, 32], ["MUC6", "TEST", 67, 71], ["SOX9", "TEST", 76, 80], ["TROP2", "TEST", 90, 95], ["CFTR", "TEST", 156, 160], ["CXCL8", "TEST", 162, 167], ["HES1", "TEST", 169, 173], ["KRT19", "TEST", 178, 183]]], ["Taken together, our results suggest that SARS-CoV-2 can infect TROP2 high cells via ACE2 and TMPRSS2, thereby contributing to liver dysfunction by compromising the ability of the human liver to regenerate cholangiocytes.Recently, Aizarani et al., demonstrated the progenitor-like properties of TROP2 + cellsAdditionally given the recent discussion on possible intrauterine vertical transmission of SARS-CoV-2, we also analysed human fetal liver scRNA-seq atlas at 16 and 21Recently, Aizarani et al., demonstrated the progenitor-like properties of TROP2 + cellsweek EGA.", [["TROP2 high cells", "ANATOMY", 63, 79], ["liver", "ANATOMY", 126, 131], ["liver", "ANATOMY", 185, 190], ["cholangiocytes", "ANATOMY", 205, 219], ["progenitor", "ANATOMY", 264, 274], ["TROP2 + cells", "ANATOMY", 294, 307], ["fetal liver", "ANATOMY", 433, 444], ["progenitor", "ANATOMY", 517, 527], ["TROP2 + cellsweek", "ANATOMY", 547, 564], ["liver dysfunction", "DISEASE", 126, 143], ["SARS", "DISEASE", 398, 402], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 41, 51], ["TROP2 high cells", "CELL", 63, 79], ["ACE2", "GENE_OR_GENE_PRODUCT", 84, 88], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 93, 100], ["liver", "ORGAN", 126, 131], ["human", "ORGANISM", 179, 184], ["liver", "ORGAN", 185, 190], ["cholangiocytes", "CELL", 205, 219], ["progenitor", "CELL", 264, 274], ["TROP2 + cells", "CELL", 294, 307], ["SARS-CoV-2", "ORGANISM", 398, 408], ["human", "ORGANISM", 427, 432], ["fetal", "MULTI-TISSUE_STRUCTURE", 433, 438], ["liver", "ORGAN", 439, 444], ["progenitor", "CELL", 517, 527], ["TROP2", "GENE_OR_GENE_PRODUCT", 547, 552], ["TROP2 high cells", "CELL_TYPE", 63, 79], ["ACE2", "PROTEIN", 84, 88], ["TMPRSS2", "PROTEIN", 93, 100], ["TROP2 + cells", "CELL_LINE", 294, 307], ["TROP2", "PROTEIN", 547, 552], ["human", "SPECIES", 179, 184], ["human", "SPECIES", 427, 432], ["SARS-CoV", "SPECIES", 41, 49], ["human", "SPECIES", 179, 184], ["SARS-CoV", "SPECIES", 398, 406], ["human", "SPECIES", 427, 432], ["SARS", "TEST", 41, 45], ["CoV", "TEST", 46, 49], ["TROP2 high cells", "PROBLEM", 63, 79], ["ACE2", "TEST", 84, 88], ["TMPRSS2", "TEST", 93, 100], ["liver dysfunction", "PROBLEM", 126, 143], ["the progenitor", "PROBLEM", 260, 274], ["TROP2 + cells", "PROBLEM", 294, 307], ["TROP2 + cellsweek EGA", "PROBLEM", 547, 568], ["liver", "ANATOMY", 126, 131], ["dysfunction", "OBSERVATION", 132, 143], ["liver", "ANATOMY", 185, 190], ["liver", "ANATOMY", 439, 444]]], ["Our analysis indicated very low to negligible level of ACE2 and an absence of TMPRSS2 expression in EPCAM+ fetal liver cells ( Figure 3A -D).", [["EPCAM+ fetal liver cells", "ANATOMY", 100, 124], ["ACE2", "GENE_OR_GENE_PRODUCT", 55, 59], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 78, 85], ["EPCAM+ fetal liver cells", "CELL", 100, 124], ["Figure 3A -D", "CELL", 127, 139], ["ACE2", "PROTEIN", 55, 59], ["TMPRSS2", "PROTEIN", 78, 85], ["EPCAM", "PROTEIN", 100, 105], ["fetal liver cells", "CELL_TYPE", 107, 124], ["Our analysis", "TEST", 0, 12], ["very low to negligible level of ACE2", "PROBLEM", 23, 59], ["TMPRSS2 expression", "PROBLEM", 78, 96], ["EPCAM", "TEST", 100, 105], ["fetal liver cells", "PROBLEM", 107, 124], ["TMPRSS2 expression", "OBSERVATION", 78, 96], ["fetal", "ANATOMY_MODIFIER", 107, 112], ["liver", "ANATOMY", 113, 118]]], ["Our limited analysis suggest that fetal liver may not express the machinery required for SARS-CoV-2 infection.DiscussionIn recent reports of SARS-CoV-2 pandemic in human population, the presence of viral mRNA in infected patient's stool suggests a potential GI (gastrointestinal) tract infection in COVID-19 patients.", [["fetal liver", "ANATOMY", 34, 45], ["stool", "ANATOMY", 231, 236], ["GI (gastrointestinal) tract", "ANATOMY", 258, 285], ["infection", "DISEASE", 100, 109], ["SARS-CoV-2 pandemic", "DISEASE", 141, 160], ["GI (gastrointestinal) tract infection", "DISEASE", 258, 295], ["fetal", "ORGAN", 34, 39], ["liver", "ORGAN", 40, 45], ["SARS-CoV-2", "ORGANISM", 89, 99], ["SARS-CoV-2", "ORGANISM", 141, 151], ["human", "ORGANISM", 164, 169], ["patient", "ORGANISM", 221, 228], ["stool", "ORGANISM_SUBSTANCE", 231, 236], ["GI", "ORGANISM_SUBDIVISION", 258, 260], ["gastrointestinal) tract", "PATHOLOGICAL_FORMATION", 262, 285], ["patients", "ORGANISM", 308, 316], ["viral mRNA", "RNA", 198, 208], ["human", "SPECIES", 164, 169], ["patient", "SPECIES", 221, 228], ["patients", "SPECIES", 308, 316], ["SARS-CoV", "SPECIES", 89, 97], ["human", "SPECIES", 164, 169], ["Our limited analysis", "TEST", 0, 20], ["fetal liver", "PROBLEM", 34, 45], ["SARS", "PROBLEM", 89, 93], ["CoV-2 infection", "PROBLEM", 94, 109], ["SARS", "PROBLEM", 141, 145], ["viral mRNA in infected patient's stool", "PROBLEM", 198, 236], ["a potential GI (gastrointestinal) tract infection", "PROBLEM", 246, 295], ["liver", "ANATOMY", 40, 45], ["infection", "OBSERVATION", 100, 109], ["viral mRNA", "OBSERVATION", 198, 208], ["gastrointestinal", "ANATOMY", 262, 278], ["infection", "OBSERVATION", 286, 295]]], ["SARS-CoV-2 can reach the liver either through the general circulation once patient has become viraemic or through transmigration through the GI tract.", [["liver", "ANATOMY", 25, 30], ["GI tract", "ANATOMY", 141, 149], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["liver", "ORGAN", 25, 30], ["patient", "ORGANISM", 75, 82], ["GI tract", "ORGANISM_SUBDIVISION", 141, 149], ["patient", "SPECIES", 75, 82], ["viraemic", "PROBLEM", 94, 102], ["liver", "ANATOMY", 25, 30], ["viraemic", "OBSERVATION", 94, 102], ["GI tract", "ANATOMY", 141, 149]]], ["We surveyed human liver scRNA-seq data to understand the expression pattern of ACE2 and TMPRSS2 gene which are essential for SARS-CoV-2 entry into human cells.", [["liver", "ANATOMY", 18, 23], ["cells", "ANATOMY", 153, 158], ["human", "ORGANISM", 12, 17], ["liver", "ORGAN", 18, 23], ["ACE2", "GENE_OR_GENE_PRODUCT", 79, 83], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 88, 95], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 125, 135], ["human", "ORGANISM", 147, 152], ["cells", "CELL", 153, 158], ["human liver scRNA-seq", "DNA", 12, 33], ["ACE2", "PROTEIN", 79, 83], ["TMPRSS2 gene", "DNA", 88, 100], ["human cells", "CELL_TYPE", 147, 158], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 147, 152], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 147, 152], ["ACE2 and TMPRSS2 gene", "PROBLEM", 79, 100], ["SARS", "PROBLEM", 125, 129], ["CoV", "TEST", 130, 133], ["liver", "ANATOMY", 18, 23]]], ["Our analysis reveals that in human liver only EPCAM + progenitors co-express genes for viral entry (ACE2) and S-protein priming (TMPRSS2).", [["liver", "ANATOMY", 35, 40], ["EPCAM + progenitors", "ANATOMY", 46, 65], ["human", "ORGANISM", 29, 34], ["liver", "ORGAN", 35, 40], ["EPCAM + progenitors", "CELL", 46, 65], ["ACE2", "GENE_OR_GENE_PRODUCT", 100, 104], ["S-protein", "GENE_OR_GENE_PRODUCT", 110, 119], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 129, 136], ["EPCAM + progenitors", "CELL_TYPE", 46, 65], ["ACE2", "PROTEIN", 100, 104], ["TMPRSS2", "DNA", 129, 136], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 29, 34], ["Our analysis", "TEST", 0, 12], ["viral entry", "PROBLEM", 87, 98], ["ACE2", "TEST", 100, 104], ["S-protein priming", "TREATMENT", 110, 127], ["liver", "ANATOMY", 35, 40]]], ["Further analyses revealed the specific expression of ACE2 and TMPRSS2 in TROP2 high cells.", [["TROP2 high cells", "ANATOMY", 73, 89], ["ACE2", "GENE_OR_GENE_PRODUCT", 53, 57], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 62, 69], ["TROP2 high cells", "CELL", 73, 89], ["ACE2", "PROTEIN", 53, 57], ["TMPRSS2", "PROTEIN", 62, 69], ["TROP2 high cells", "CELL_LINE", 73, 89], ["Further analyses", "TEST", 0, 16], ["ACE2", "TEST", 53, 57], ["TMPRSS2 in TROP2 high cells", "PROBLEM", 62, 89], ["high cells", "OBSERVATION", 79, 89]]], ["These results indicate that ACE2 and TMPRSS2 are specifically present in liver progenitors with a cholangiocyte fate bias, suggesting SARS-CoV-2 may be affecting cholangiocyte precursors, thereby potentially impeding the homeostasis of the cholangiocyte pool.", [["liver progenitors", "ANATOMY", 73, 90], ["cholangiocyte", "ANATOMY", 98, 111], ["cholangiocyte precursors", "ANATOMY", 162, 186], ["cholangiocyte", "ANATOMY", 240, 253], ["ACE2", "GENE_OR_GENE_PRODUCT", 28, 32], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 37, 44], ["liver progenitors", "CELL", 73, 90], ["cholangiocyte", "CELL", 98, 111], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 134, 144], ["cholangiocyte precursors", "CELL", 162, 186], ["cholangiocyte", "CANCER", 240, 253], ["ACE2", "PROTEIN", 28, 32], ["TMPRSS2", "PROTEIN", 37, 44], ["liver progenitors", "CELL_TYPE", 73, 90], ["cholangiocyte precursors", "CELL_TYPE", 162, 186], ["ACE2", "TEST", 28, 32], ["TMPRSS2", "TEST", 37, 44], ["a cholangiocyte fate bias", "TEST", 96, 121], ["SARS", "PROBLEM", 134, 138], ["CoV", "TEST", 139, 142], ["cholangiocyte precursors", "PROBLEM", 162, 186], ["liver", "ANATOMY", 73, 78], ["progenitors", "ANATOMY_MODIFIER", 79, 90], ["cholangiocyte", "ANATOMY", 98, 111], ["cholangiocyte", "ANATOMY", 162, 175], ["cholangiocyte", "ANATOMY", 240, 253]]], ["Recent studies have reported the expression of ACE2 in cholangiocytes, however, did not reflect over the heterogeneity of ACE2 + population (Chai et al., 2020) .", [["cholangiocytes", "ANATOMY", 55, 69], ["ACE2", "GENE_OR_GENE_PRODUCT", 47, 51], ["cholangiocytes", "CELL", 55, 69], ["ACE2", "GENE_OR_GENE_PRODUCT", 122, 126], ["ACE2", "PROTEIN", 47, 51], ["cholangiocytes", "CELL_TYPE", 55, 69], ["ACE2", "PROTEIN", 122, 126], ["Recent studies", "TEST", 0, 14], ["ACE2 in cholangiocytes", "PROBLEM", 47, 69], ["cholangiocytes", "ANATOMY", 55, 69]]], ["In this study we explored the heterogeneity of ACE2 + cells and systematically characterised ACE2 and TMPRSS2 co-expression as hallmarks of TROP2 + epithelial progenitors.DiscussionOur study reveals the potential of SARS-CoV-2 to infect TROP2 + progenitor like cells in human liver.", [["ACE2 + cells", "ANATOMY", 47, 59], ["TROP2 + epithelial progenitors", "ANATOMY", 140, 170], ["TROP2 + progenitor like cells", "ANATOMY", 237, 266], ["liver", "ANATOMY", 276, 281], ["ACE2", "GENE_OR_GENE_PRODUCT", 47, 51], ["ACE2", "GENE_OR_GENE_PRODUCT", 93, 97], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 102, 109], ["TROP2", "GENE_OR_GENE_PRODUCT", 140, 145], ["SARS-CoV-2", "ORGANISM", 216, 226], ["TROP2 + progenitor like cells", "CELL", 237, 266], ["human", "ORGANISM", 270, 275], ["liver", "ORGAN", 276, 281], ["ACE2", "PROTEIN", 47, 51], ["ACE2", "PROTEIN", 93, 97], ["TMPRSS2", "PROTEIN", 102, 109], ["TROP2", "PROTEIN", 140, 145], ["epithelial progenitors", "CELL_TYPE", 148, 170], ["TROP2 + progenitor like cells", "CELL_TYPE", 237, 266], ["human", "SPECIES", 270, 275], ["human", "SPECIES", 270, 275], ["this study", "TEST", 3, 13], ["ACE2 + cells", "PROBLEM", 47, 59], ["ACE2", "TEST", 93, 97], ["TMPRSS2 co-expression", "TEST", 102, 123], ["TROP2", "TEST", 140, 145], ["epithelial progenitors", "PROBLEM", 148, 170], ["DiscussionOur study", "TEST", 171, 190], ["SARS", "PROBLEM", 216, 220], ["CoV", "TEST", 221, 224], ["TROP2", "TEST", 237, 242], ["progenitor like cells in human liver", "PROBLEM", 245, 281], ["epithelial progenitors", "OBSERVATION", 148, 170], ["human", "ANATOMY_MODIFIER", 270, 275], ["liver", "ANATOMY", 276, 281]]], ["It is important to note that TROP2 is expressed in multiple epithelial progenitors (Crowell et al., 2019; Okabe et al., 2009; Vallone et al., 2016) .", [["epithelial progenitors", "ANATOMY", 60, 82], ["TROP2", "GENE_OR_GENE_PRODUCT", 29, 34], ["epithelial progenitors", "CELL", 60, 82], ["TROP2", "PROTEIN", 29, 34], ["multiple epithelial progenitors", "CELL_TYPE", 51, 82], ["multiple", "OBSERVATION_MODIFIER", 51, 59], ["epithelial progenitors", "OBSERVATION", 60, 82]]], ["In the future it will be important to survey other GI tract tissues at single-cell level for the expression of ACE2 and TMPRSS2 and their associated transcriptomes.", [["GI tract tissues", "ANATOMY", 51, 67], ["cell", "ANATOMY", 78, 82], ["GI tract tissues", "TISSUE", 51, 67], ["single-cell", "CELL", 71, 82], ["ACE2", "GENE_OR_GENE_PRODUCT", 111, 115], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 120, 127], ["ACE2", "PROTEIN", 111, 115], ["TMPRSS2", "PROTEIN", 120, 127], ["ACE2", "PROBLEM", 111, 115], ["TMPRSS2", "PROBLEM", 120, 127]]], ["Given the GI tract infection and multi-organ failure in COVID-19, it is important to understand whether other progenitor-like cells are also susceptible to SARS-CoV-2 infection.", [["GI tract", "ANATOMY", 10, 18], ["multi-organ", "ANATOMY", 33, 44], ["progenitor-like cells", "ANATOMY", 110, 131], ["GI tract infection", "DISEASE", 10, 28], ["multi-organ failure", "DISEASE", 33, 52], ["infection", "DISEASE", 167, 176], ["GI tract", "ORGANISM_SUBDIVISION", 10, 18], ["COVID-19", "CELL", 56, 64], ["progenitor-like cells", "CELL", 110, 131], ["SARS-CoV-2", "ORGANISM", 156, 166], ["progenitor-like cells", "CELL_TYPE", 110, 131], ["SARS-CoV", "SPECIES", 156, 164], ["the GI tract infection", "PROBLEM", 6, 28], ["multi-organ failure", "PROBLEM", 33, 52], ["COVID", "TEST", 56, 61], ["other progenitor-like cells", "PROBLEM", 104, 131], ["SARS", "PROBLEM", 156, 160], ["CoV-2 infection", "PROBLEM", 161, 176], ["GI tract", "ANATOMY", 10, 18], ["infection", "OBSERVATION", 19, 28], ["multi-organ", "ANATOMY", 33, 44], ["failure", "OBSERVATION", 45, 52], ["infection", "OBSERVATION", 167, 176]]], ["Moreover, TROP2 expression has been associated with amplifying progenitor cells in partial hepatectomy mouse model (Okabe et al., 2009) indicating the important role of TROP2 + cells in liver regeneration.", [["progenitor cells", "ANATOMY", 63, 79], ["TROP2 + cells", "ANATOMY", 169, 182], ["liver", "ANATOMY", 186, 191], ["TROP2", "GENE_OR_GENE_PRODUCT", 10, 15], ["progenitor cells", "CELL", 63, 79], ["mouse", "ORGANISM", 103, 108], ["TROP2 + cells", "CELL", 169, 182], ["liver", "ORGAN", 186, 191], ["TROP2", "PROTEIN", 10, 15], ["amplifying progenitor cells", "CELL_TYPE", 52, 79], ["TROP2", "PROTEIN", 169, 174], ["mouse", "SPECIES", 103, 108], ["mouse", "SPECIES", 103, 108], ["TROP2 expression", "PROBLEM", 10, 26], ["partial hepatectomy mouse model", "TREATMENT", 83, 114], ["TROP2 + cells", "TREATMENT", 169, 182], ["liver regeneration", "PROBLEM", 186, 204], ["progenitor cells", "OBSERVATION", 63, 79], ["partial", "OBSERVATION_MODIFIER", 83, 90], ["hepatectomy", "OBSERVATION", 91, 102], ["liver", "ANATOMY", 186, 191], ["regeneration", "OBSERVATION", 192, 204]]], ["Taken together, our analysis suggests that adult human liver TROP2 + progenitors could be a prime target of SARS-CoV-2 ( Figure 3E ).Figure-4 Heterogeneity of ACE2 and TMPRSS2 expression in liver progenitorsSchematic of TROP2 expression level and cell fate choices in adult human liver progenitor cells.", [["liver TROP2 + progenitors", "ANATOMY", 55, 80], ["liver progenitors", "ANATOMY", 190, 207], ["cell", "ANATOMY", 247, 251], ["liver progenitor cells", "ANATOMY", 280, 302], ["human", "ORGANISM", 49, 54], ["liver TROP2 + progenitors", "CELL", 55, 80], ["SARS-CoV-2", "ORGANISM", 108, 118], ["ACE2", "GENE_OR_GENE_PRODUCT", 159, 163], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 168, 175], ["liver", "ORGAN", 190, 195], ["TROP2", "GENE_OR_GENE_PRODUCT", 220, 225], ["cell", "CELL", 247, 251], ["human", "ORGANISM", 274, 279], ["liver progenitor cells", "CELL", 280, 302], ["adult human liver TROP2 + progenitors", "CELL_TYPE", 43, 80], ["ACE2", "PROTEIN", 159, 163], ["TMPRSS2", "PROTEIN", 168, 175], ["liver progenitors", "CELL_TYPE", 190, 207], ["TROP2", "PROTEIN", 220, 225], ["adult human liver progenitor cells", "CELL_TYPE", 268, 302], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 274, 279], ["human", "SPECIES", 49, 54], ["SARS-CoV", "SPECIES", 108, 116], ["human", "SPECIES", 274, 279], ["our analysis", "TEST", 16, 28], ["SARS", "TEST", 108, 112], ["CoV", "TEST", 113, 116], ["Figure", "TEST", 133, 139], ["ACE2", "PROBLEM", 159, 163], ["TMPRSS2 expression in liver progenitors", "PROBLEM", 168, 207], ["Schematic of TROP2 expression level", "PROBLEM", 207, 242], ["cell fate choices", "TREATMENT", 247, 264], ["liver", "ANATOMY", 55, 60], ["liver", "ANATOMY", 190, 195], ["progenitors", "ANATOMY_MODIFIER", 196, 207], ["TROP2 expression", "OBSERVATION", 220, 236], ["cell fate choices", "OBSERVATION", 247, 264], ["liver", "ANATOMY", 280, 285], ["progenitor cells", "OBSERVATION", 286, 302]]], ["TROP2 high cells express genes exhibiting cholangiocyte fate bias.", [["TROP2 high cells", "ANATOMY", 0, 16], ["cholangiocyte", "ANATOMY", 42, 55], ["TROP2", "GENE_OR_GENE_PRODUCT", 0, 5], ["cells", "CELL", 11, 16], ["cholangiocyte", "CELL", 42, 55], ["TROP2 high cells", "CELL_LINE", 0, 16], ["TROP2 high cells", "TEST", 0, 16], ["cholangiocyte fate bias", "PROBLEM", 42, 65], ["cholangiocyte fate bias", "OBSERVATION", 42, 65]]], ["The TROP2 high cells also express higher level of ACE2 and TMPRESS2 making these cells more susceptible for SARS-CoV-2 infection, indicating implications in COVID-19 associated liver dysfunctions.Tissue acquisitionThe fresh tissue samples were obtained from Singapore General Hospital (SGH) andTissue acquisitionNational University (NUH) with written consent and approval from central institution review board of singhealth (CIRB2012/669/B) for study on liver cancer.", [["TROP2 high cells", "ANATOMY", 4, 20], ["cells", "ANATOMY", 81, 86], ["liver", "ANATOMY", 177, 182], ["Tissue", "ANATOMY", 196, 202], ["tissue samples", "ANATOMY", 224, 238], ["liver cancer", "ANATOMY", 454, 466], ["infection", "DISEASE", 119, 128], ["liver dysfunctions", "DISEASE", 177, 195], ["CIRB2012/669/B", "CHEMICAL", 425, 439], ["liver cancer", "DISEASE", 454, 466], ["TROP2 high cells", "CELL", 4, 20], ["ACE2", "GENE_OR_GENE_PRODUCT", 50, 54], ["TMPRESS2", "GENE_OR_GENE_PRODUCT", 59, 67], ["cells", "CELL", 81, 86], ["SARS-CoV-2", "ORGANISM", 108, 118], ["liver", "ORGAN", 177, 182], ["Tissue", "TISSUE", 196, 202], ["tissue samples", "CANCER", 224, 238], ["liver cancer", "CANCER", 454, 466], ["TROP2 high cells", "CELL_LINE", 4, 20], ["ACE2", "PROTEIN", 50, 54], ["TMPRESS2", "PROTEIN", 59, 67], ["SARS-CoV", "SPECIES", 108, 116], ["The TROP2 high cells", "TEST", 0, 20], ["ACE2", "TEST", 50, 54], ["these cells", "PROBLEM", 75, 86], ["SARS", "PROBLEM", 108, 112], ["CoV-2 infection", "PROBLEM", 113, 128], ["COVID", "TEST", 157, 162], ["liver dysfunctions", "PROBLEM", 177, 195], ["Tissue acquisition", "TEST", 196, 214], ["liver cancer", "PROBLEM", 454, 466], ["high cells", "OBSERVATION", 10, 20], ["infection", "OBSERVATION", 119, 128], ["liver", "ANATOMY", 177, 182], ["dysfunctions", "OBSERVATION", 183, 195], ["liver", "ANATOMY", 454, 459], ["cancer", "OBSERVATION", 460, 466]]], ["The samples were delivered in with MACS Tissue Storage Solution (Miltenyi, Cat#:130-100-008).Human fetal liver samplesThe donation of fetal liver tissues for research was approved by the Centralised trimester (16 and 21 weeks EGA) elective pregnancy terminations carried out for socio-psychological reasons.", [["samples", "ANATOMY", 4, 11], ["fetal liver samples", "ANATOMY", 99, 118], ["fetal liver tissues", "ANATOMY", 134, 153], ["Human", "ORGANISM", 93, 98], ["fetal liver samples", "ORGANISM_SUBSTANCE", 99, 118], ["fetal liver tissues", "TISSUE", 134, 153], ["Human", "SPECIES", 93, 98], ["Human", "SPECIES", 93, 98], ["Human fetal liver samples", "TEST", 93, 118], ["elective pregnancy terminations", "TREATMENT", 231, 262], ["liver", "ANATOMY", 105, 110], ["fetal", "ANATOMY_MODIFIER", 134, 139], ["liver", "ANATOMY", 140, 145]]], ["All fetuses were considered structurally normal on ultrasound examination prior to termination and by gross morphological examination following termination.", [["fetuses", "ANATOMY", 4, 11], ["fetuses", "ORGANISM", 4, 11], ["ultrasound examination", "TEST", 51, 73], ["gross morphological examination", "TEST", 102, 133], ["normal", "OBSERVATION", 41, 47]]], ["In total 2 fetuses of 16 and 21 weeks EGA were used for this study.Tissue processingTissues were transferred immediately using the following procedure.", [["fetuses", "ANATOMY", 11, 18], ["Tissue", "ANATOMY", 67, 73], ["Tissues", "ANATOMY", 84, 91], ["fetuses", "ORGANISM", 11, 18], ["Tissue", "TISSUE", 67, 73], ["Tissues", "CANCER", 84, 91], ["this study", "TEST", 56, 66], ["Tissue processing", "TEST", 67, 84], ["the following procedure", "TREATMENT", 127, 150]]], ["Tissue was transferred to a sterile 10mm 2 tissue culture dish and cut into very small fragments.Tissue processingThe dissociation buffer consisted of 0.43mg/ml of Collagenase IV (Thermofisher, Cat#:Declaration of InterestsNo conflict of interest to declare", [["Tissue", "ANATOMY", 0, 6], ["fragments", "ANATOMY", 87, 96], ["Tissue", "ANATOMY", 97, 103], ["Tissue", "TISSUE", 0, 6], ["Tissue", "TISSUE", 97, 103], ["Collagenase IV", "GENE_OR_GENE_PRODUCT", 164, 178], ["Collagenase IV", "PROTEIN", 164, 178], ["a sterile 10mm 2 tissue culture dish", "TREATMENT", 26, 62], ["very small fragments", "PROBLEM", 76, 96], ["Tissue processing", "TEST", 97, 114], ["The dissociation buffer", "TREATMENT", 114, 137], ["Collagenase IV", "TREATMENT", 164, 178], ["very", "OBSERVATION_MODIFIER", 76, 80], ["small", "OBSERVATION_MODIFIER", 81, 86], ["fragments", "OBSERVATION", 87, 96]]]], "776a2bc2e0eb29fd2cf604d9f9a335fb9ead0528": [["IntroductionFlos Lonicerae, a flower of Lonicera japonica that possessed antibacterial, anti-inflammatory, antiviral, antiendotoxin, blood fat reducing, antipyretic, etc., has been widely used in traditional Chinese medicine to treat exopathogenic wind-heat, epidemic febrile diseases, sores, carbuncles, furuncles and some infection diseases (Wang 2008) , and it has also been employed extensively to prevent and treat some serious viral diseases of human and veterinary, such as SASR coronavirus, H1N1 (Swine) flu virus, and being called the \"bouvardin\" (Jiao 2009 ).IntroductionFlos Lonicerae extract that was extracted from Lonicera japonica has been widely used in Chinese medicine preparations (Shang et al. 2011) , such as Jin Yin Hua San, Jin Yin Hua oral liquid, Shuang-Huang-Lian freeze-dried powders of injection, Shuang-Huang-Lian oral liquid, Yin-Qiao capsule and Yin-Qiao-Jie-Du tablets, etc., which are extensively used for treating acute upper respiratory tract infection caused by virus or bacterial infection in clinical practice.", [["flower", "ANATOMY", 30, 36], ["blood", "ANATOMY", 133, 138], ["carbuncles", "ANATOMY", 293, 303], ["furuncles", "ANATOMY", 305, 314], ["oral", "ANATOMY", 843, 847], ["upper respiratory tract", "ANATOMY", 954, 977], ["Flos Lonicerae", "CHEMICAL", 12, 26], ["febrile diseases", "DISEASE", 268, 284], ["sores", "DISEASE", 286, 291], ["carbuncles", "DISEASE", 293, 303], ["furuncles", "DISEASE", 305, 314], ["infection diseases", "DISEASE", 324, 342], ["viral diseases", "DISEASE", 433, 447], ["SASR coronavirus", "DISEASE", 481, 497], ["H1N1", "DISEASE", 499, 503], ["Swine) flu virus", "DISEASE", 505, 521], ["Flos Lonicerae extract", "CHEMICAL", 581, 603], ["Lonicera japonica", "CHEMICAL", 628, 645], ["upper respiratory tract infection", "DISEASE", 954, 987], ["bacterial infection", "DISEASE", 1007, 1026], ["Flos Lonicerae", "ORGANISM", 12, 26], ["flower", "ORGANISM_SUBDIVISION", 30, 36], ["Lonicera japonica", "ORGANISM", 40, 57], ["antiendotoxin", "SIMPLE_CHEMICAL", 118, 131], ["blood", "ORGANISM_SUBSTANCE", 133, 138], ["fat", "SIMPLE_CHEMICAL", 139, 142], ["human", "ORGANISM", 451, 456], ["SASR coronavirus", "ORGANISM", 481, 497], ["H1N1 (Swine) flu virus", "ORGANISM", 499, 521], ["Flos Lonicerae", "ORGANISM", 581, 595], ["Lonicera japonica", "ORGANISM", 628, 645], ["oral", "ORGANISM_SUBDIVISION", 843, 847], ["Yin-Qiao capsule", "SIMPLE_CHEMICAL", 856, 872], ["upper respiratory", "ORGANISM_SUBDIVISION", 954, 971], ["tract", "ORGANISM_SUBDIVISION", 972, 977], ["Lonicera japonica", "SPECIES", 40, 57], ["human", "SPECIES", 451, 456], ["coronavirus", "SPECIES", 486, 497], ["Swine) flu virus", "SPECIES", 505, 521], ["Lonicera japonica", "SPECIES", 628, 645], ["Lonicera japonica", "SPECIES", 40, 57], ["human", "SPECIES", 451, 456], ["SASR coronavirus", "SPECIES", 481, 497], ["Swine) flu virus", "SPECIES", 505, 521], ["Lonicera japonica", "SPECIES", 628, 645], ["IntroductionFlos Lonicerae", "TREATMENT", 0, 26], ["Lonicera japonica", "TREATMENT", 40, 57], ["antibacterial", "TREATMENT", 73, 86], ["anti-inflammatory", "TREATMENT", 88, 105], ["antiviral", "TREATMENT", 107, 116], ["antiendotoxin", "TREATMENT", 118, 131], ["blood fat reducing", "TREATMENT", 133, 151], ["antipyretic", "TREATMENT", 153, 164], ["traditional Chinese medicine", "TREATMENT", 196, 224], ["epidemic febrile diseases", "PROBLEM", 259, 284], ["sores, carbuncles, furuncles", "PROBLEM", 286, 314], ["some infection diseases", "PROBLEM", 319, 342], ["some serious viral diseases of human", "PROBLEM", 420, 456], ["SASR coronavirus", "PROBLEM", 481, 497], ["H1N1", "PROBLEM", 499, 503], ["flu virus", "PROBLEM", 512, 521], ["IntroductionFlos Lonicerae extract", "TREATMENT", 569, 603], ["Jin Yin Hua oral liquid", "TREATMENT", 747, 770], ["Shuang", "TREATMENT", 772, 778], ["Huang-Lian freeze", "TREATMENT", 779, 796], ["injection", "TREATMENT", 814, 823], ["Shuang", "TREATMENT", 825, 831], ["Huang-Lian oral liquid", "TREATMENT", 832, 854], ["Yin-Qiao capsule", "TREATMENT", 856, 872], ["Yin-Qiao", "TREATMENT", 877, 885], ["Jie-Du tablets", "TREATMENT", 886, 900], ["acute upper respiratory tract infection", "PROBLEM", 948, 987], ["virus", "PROBLEM", 998, 1003], ["bacterial infection", "PROBLEM", 1007, 1026], ["some", "OBSERVATION_MODIFIER", 319, 323], ["infection", "OBSERVATION", 324, 333], ["Hua", "ANATOMY", 755, 758], ["upper", "ANATOMY_MODIFIER", 954, 959], ["respiratory tract", "ANATOMY", 960, 977], ["infection", "OBSERVATION", 978, 987], ["bacterial", "OBSERVATION_MODIFIER", 1007, 1016], ["infection", "OBSERVATION", 1017, 1026]]], ["And oral preparations of Flos Lonicerae extract are usually more accepted for patients than injections owing to their elimination of pain and discomfort, and lower costs to produce oral formulations, but their clinical effect was unsatisfactory compared with that of injections, which becomes one of the most limited points in the development of Chinese medicine preparations.", [["oral", "ANATOMY", 4, 8], ["oral", "ANATOMY", 181, 185], ["Flos Lonicerae extract", "CHEMICAL", 25, 47], ["pain", "DISEASE", 133, 137], ["oral", "ORGANISM_SUBDIVISION", 4, 8], ["patients", "ORGANISM", 78, 86], ["oral", "ORGANISM_SUBDIVISION", 181, 185], ["patients", "SPECIES", 78, 86], ["oral preparations", "TREATMENT", 4, 21], ["Flos Lonicerae extract", "TREATMENT", 25, 47], ["injections", "TREATMENT", 92, 102], ["pain", "PROBLEM", 133, 137], ["discomfort", "PROBLEM", 142, 152], ["oral formulations", "TREATMENT", 181, 198], ["injections", "TREATMENT", 267, 277], ["Chinese medicine preparations", "TREATMENT", 346, 375]]], ["The presumptions that whether the low bioavailability of oral Flos Lonicerae extract resulted in the poor efficacy or whether efficacy could be improved as the absorption of active ingredients Table 1 The preliminary study on MS and MS/MS data of the identified components in rat plasma after oral administration of Flos Lonicerae extracts in negative mode. in Flos Lonicerae extract was enhanced are all yet to be investigated.", [["oral", "ANATOMY", 57, 61], ["plasma", "ANATOMY", 280, 286], ["oral", "ANATOMY", 293, 297], ["extracts", "ANATOMY", 331, 339], ["Flos Lonicerae extract", "CHEMICAL", 62, 84], ["Flos Lonicerae", "CHEMICAL", 316, 330], ["oral", "ORGANISM_SUBDIVISION", 57, 61], ["rat", "ORGANISM", 276, 279], ["plasma", "ORGANISM_SUBSTANCE", 280, 286], ["oral", "ORGANISM_SUBDIVISION", 293, 297], ["extracts", "ORGANISM_SUBSTANCE", 331, 339], ["rat", "SPECIES", 276, 279], ["rat", "SPECIES", 276, 279], ["oral Flos Lonicerae extract", "TREATMENT", 57, 84], ["The preliminary study", "TEST", 201, 222], ["MS", "TEST", 226, 228], ["MS/MS data", "TEST", 233, 243], ["oral administration", "TREATMENT", 293, 312], ["Flos Lonicerae extracts", "TREATMENT", 316, 339], ["Flos Lonicerae extract", "TREATMENT", 361, 383]]], ["As shown in Fig. 2 and Table 1 , we found that only phenolic acids and flavones, not saponins were found in the Flos Lonicerae extract.", [["phenolic acids", "CHEMICAL", 52, 66], ["flavones", "CHEMICAL", 71, 79], ["phenolic acids", "CHEMICAL", 52, 66], ["flavones", "CHEMICAL", 71, 79], ["saponins", "CHEMICAL", 85, 93], ["phenolic acids", "SIMPLE_CHEMICAL", 52, 66], ["flavones", "SIMPLE_CHEMICAL", 71, 79], ["saponins", "SIMPLE_CHEMICAL", 85, 93], ["phenolic acids", "TREATMENT", 52, 66], ["flavones", "TREATMENT", 71, 79], ["saponins", "PROBLEM", 85, 93], ["phenolic acids", "OBSERVATION", 52, 66]]], ["According to the HPLC figureprint profile shown in Fig. 1 (A) and UPLC-MS/MS shown in Fig. 1(B) , we found that the contents of phenolic acids in Flos Lonicerae extract such as neochlorogenic acid, chlorogenic acid, cryptochlorogenic acid, 3,5-dicaffeoylquinic acid or 3,4-dicaffeoylquinic acid were about 16.1, 16.9, 16.6, 18.9 and 37.8 mg/ml, respectively, higher largely than that of other ingredients, but their absolute bioavailability orally was significantly low (unpublished).", [["phenolic acids", "CHEMICAL", 128, 142], ["Flos Lonicerae extract", "CHEMICAL", 146, 168], ["neochlorogenic acid", "CHEMICAL", 177, 196], ["chlorogenic acid", "CHEMICAL", 198, 214], ["cryptochlorogenic acid", "CHEMICAL", 216, 238], ["3,5-dicaffeoylquinic acid", "CHEMICAL", 240, 265], ["3,4-dicaffeoylquinic acid", "CHEMICAL", 269, 294], ["phenolic acids", "CHEMICAL", 128, 142], ["neochlorogenic acid", "CHEMICAL", 177, 196], ["chlorogenic acid", "CHEMICAL", 198, 214], ["cryptochlorogenic acid", "CHEMICAL", 216, 238], ["3,5-dicaffeoylquinic acid", "CHEMICAL", 240, 265], ["3,4-dicaffeoylquinic acid", "CHEMICAL", 269, 294], ["phenolic acids", "SIMPLE_CHEMICAL", 128, 142], ["Flos", "SIMPLE_CHEMICAL", 146, 150], ["neochlorogenic acid", "SIMPLE_CHEMICAL", 177, 196], ["chlorogenic acid", "SIMPLE_CHEMICAL", 198, 214], ["cryptochlorogenic acid", "SIMPLE_CHEMICAL", 216, 238], ["3,5-dicaffeoylquinic acid", "SIMPLE_CHEMICAL", 240, 265], ["3,4-dicaffeoylquinic acid", "SIMPLE_CHEMICAL", 269, 294], ["the HPLC figureprint profile", "TEST", 13, 41], ["UPLC", "TEST", 66, 70], ["MS", "PROBLEM", 74, 76], ["phenolic acids", "TREATMENT", 128, 142], ["Flos Lonicerae extract", "TREATMENT", 146, 168], ["neochlorogenic acid", "TEST", 177, 196], ["chlorogenic acid", "TEST", 198, 214], ["cryptochlorogenic acid", "TEST", 216, 238], ["dicaffeoylquinic acid", "TEST", 244, 265], ["dicaffeoylquinic acid", "TEST", 273, 294], ["phenolic acids", "OBSERVATION", 128, 142]]], ["Besides, the content of flavones such as galuteolin was 0.335 mg/ml, lower than that of phenolic acids such as isochlorogenic, and we also found that about 100% of the apically loaded hyperin, galuteolin, rutin were retained on the apical side from Caco-2 cell transport (unpublished).", [["apical", "ANATOMY", 232, 238], ["Caco-2 cell", "ANATOMY", 249, 260], ["flavones", "CHEMICAL", 24, 32], ["galuteolin", "CHEMICAL", 41, 51], ["phenolic acids", "CHEMICAL", 88, 102], ["hyperin", "CHEMICAL", 184, 191], ["galuteolin", "CHEMICAL", 193, 203], ["rutin", "CHEMICAL", 205, 210], ["flavones", "CHEMICAL", 24, 32], ["galuteolin", "CHEMICAL", 41, 51], ["phenolic acids", "CHEMICAL", 88, 102], ["hyperin", "CHEMICAL", 184, 191], ["galuteolin", "CHEMICAL", 193, 203], ["rutin", "CHEMICAL", 205, 210], ["flavones", "SIMPLE_CHEMICAL", 24, 32], ["galuteolin", "SIMPLE_CHEMICAL", 41, 51], ["phenolic acids", "SIMPLE_CHEMICAL", 88, 102], ["isochlorogenic", "SIMPLE_CHEMICAL", 111, 125], ["hyperin", "SIMPLE_CHEMICAL", 184, 191], ["galuteolin", "SIMPLE_CHEMICAL", 193, 203], ["rutin", "SIMPLE_CHEMICAL", 205, 210], ["Caco-2 cell", "CELL", 249, 260], ["flavones", "TREATMENT", 24, 32], ["galuteolin", "TREATMENT", 41, 51], ["phenolic acids", "TREATMENT", 88, 102], ["the apically loaded hyperin, galuteolin", "PROBLEM", 164, 203], ["Caco-2 cell transport", "TREATMENT", 249, 270], ["apical", "ANATOMY_MODIFIER", 232, 238]]], ["Conceptually, all compounds in the pharmaceutical product that are bioavailable in the systemic circulation can be considered as relevant active markers for pharmacological effects.", [["pharmacological effects", "PROBLEM", 157, 180], ["all", "OBSERVATION_MODIFIER", 14, 17], ["compounds", "OBSERVATION_MODIFIER", 18, 27]]], ["Therefore, the properties above of main ingredients in Flos Lonicerae extract led us to postulate that low bioavailability of phenolic acids in Flos Lonicerae extract might result in low efficacy of clinical therapy.IntroductionIn our previous study, we found that phenolic acids instead of flavones in Flos Lonicerae extract were survived good positive correlation between dose and effects of antibacterial, antioxidant and antiviral via pharmacokinetic/pharmacodynamic (PK/PD) model combined with PLS (partial least squares), and the antibacterial, antioxidant and antiviral activities were improved as the contents of phenolic acids in Flos Lonicerae extract were enhanced, and showing obvious correlation between dose of phenolic acids and pharmacological effects.", [["Flos Lonicerae extract", "CHEMICAL", 55, 77], ["phenolic acids", "CHEMICAL", 126, 140], ["Flos Lonicerae extract", "CHEMICAL", 144, 166], ["phenolic acids", "CHEMICAL", 265, 279], ["flavones", "CHEMICAL", 291, 299], ["Flos Lonicerae extract", "CHEMICAL", 303, 325], ["phenolic acids", "CHEMICAL", 621, 635], ["Flos Lonicerae extract", "CHEMICAL", 639, 661], ["phenolic acids", "CHEMICAL", 725, 739], ["phenolic acids", "CHEMICAL", 126, 140], ["phenolic acids", "CHEMICAL", 265, 279], ["flavones", "CHEMICAL", 291, 299], ["phenolic acids", "CHEMICAL", 621, 635], ["phenolic acids", "CHEMICAL", 725, 739], ["Flos", "SIMPLE_CHEMICAL", 55, 59], ["phenolic acids", "SIMPLE_CHEMICAL", 126, 140], ["Flos", "SIMPLE_CHEMICAL", 144, 148], ["phenolic acids", "SIMPLE_CHEMICAL", 265, 279], ["flavones", "SIMPLE_CHEMICAL", 291, 299], ["Flos Lonicerae", "ORGANISM", 303, 317], ["phenolic acids", "SIMPLE_CHEMICAL", 621, 635], ["Flos", "SIMPLE_CHEMICAL", 639, 643], ["phenolic acids", "SIMPLE_CHEMICAL", 725, 739], ["Flos Lonicerae extract", "TREATMENT", 55, 77], ["phenolic acids", "TREATMENT", 126, 140], ["Flos Lonicerae extract", "TREATMENT", 144, 166], ["clinical therapy", "TREATMENT", 199, 215], ["our previous study", "TEST", 231, 249], ["phenolic acids", "TREATMENT", 265, 279], ["flavones", "TREATMENT", 291, 299], ["Flos Lonicerae extract", "TREATMENT", 303, 325], ["antibacterial", "TREATMENT", 394, 407], ["antioxidant", "TREATMENT", 409, 420], ["antiviral via pharmacokinetic/pharmacodynamic (PK/PD) model", "TREATMENT", 425, 484], ["PLS (partial least squares", "TREATMENT", 499, 525], ["the antibacterial", "TREATMENT", 532, 549], ["antioxidant", "TREATMENT", 551, 562], ["antiviral activities", "TREATMENT", 567, 587], ["phenolic acids", "TEST", 621, 635], ["phenolic acids", "TREATMENT", 725, 739], ["pharmacological effects", "TREATMENT", 744, 767], ["low efficacy", "OBSERVATION_MODIFIER", 183, 195], ["phenolic acids", "OBSERVATION", 265, 279], ["phenolic acids", "OBSERVATION", 621, 635]]], ["Besides, it was found that those phenolic acids especially isochrogenic acids in Flos Lonicerae extract were the main bioactive components for antioxidant, antiviral and antibacterial effect by \"Spectrum-activity relationship\" and \"Knock-out/Knock-in\" methods (Wang 2010; Zhang 2011) .", [["phenolic acids", "CHEMICAL", 33, 47], ["isochrogenic acids", "CHEMICAL", 59, 77], ["Flos Lonicerae extract", "CHEMICAL", 81, 103], ["phenolic acids", "CHEMICAL", 33, 47], ["isochrogenic acids", "CHEMICAL", 59, 77], ["phenolic acids", "SIMPLE_CHEMICAL", 33, 47], ["isochrogenic acids", "SIMPLE_CHEMICAL", 59, 77], ["Flos", "SIMPLE_CHEMICAL", 81, 85], ["those phenolic acids", "TREATMENT", 27, 47], ["isochrogenic acids", "TREATMENT", 59, 77], ["Flos Lonicerae extract", "TREATMENT", 81, 103], ["antioxidant", "TREATMENT", 143, 154], ["antiviral and antibacterial effect", "TREATMENT", 156, 190], ["main", "OBSERVATION_MODIFIER", 113, 117], ["bioactive components", "OBSERVATION", 118, 138]]], ["Therefore, how to improve the bioavailabilities of phenolic aicds would be related to pharmacological efficacy improvement of Flos Lonicerae extract directly.IntroductionAccording to our previous study, the intestinal absorption mechanism of phenolic acids was passive diffusion, and involved paracellular route transport mainly governed by the tight junctions (TJs) (Konishi and Kobayashi 2004) , and the modulation of the TJs by absorption enhancers would enhance the paracellular drug transport (Salama et al. 2006) .IntroductionIt was reported that absorption enhancers including surfactants, bile salts and chelating agents, etc. was one of the most promising methods to improve the bioavailability of poorly absorbable drugs orally (Uchiyama et al. 1999) .", [["intestinal", "ANATOMY", 207, 217], ["paracellular", "ANATOMY", 293, 305], ["tight junctions", "ANATOMY", 345, 360], ["TJs", "ANATOMY", 362, 365], ["TJs", "ANATOMY", 424, 427], ["paracellular", "ANATOMY", 470, 482], ["phenolic aicds", "CHEMICAL", 51, 65], ["Flos Lonicerae extract", "CHEMICAL", 126, 148], ["phenolic acids", "CHEMICAL", 242, 256], ["bile salts", "CHEMICAL", 597, 607], ["phenolic acids", "CHEMICAL", 242, 256], ["bile salts", "CHEMICAL", 597, 607], ["phenolic aicds", "SIMPLE_CHEMICAL", 51, 65], ["Flos", "SIMPLE_CHEMICAL", 126, 130], ["intestinal", "ORGAN", 207, 217], ["phenolic acids", "SIMPLE_CHEMICAL", 242, 256], ["paracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 293, 305], ["tight junctions", "CELLULAR_COMPONENT", 345, 360], ["TJs", "CELLULAR_COMPONENT", 362, 365], ["TJs", "GENE_OR_GENE_PRODUCT", 424, 427], ["paracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 470, 482], ["surfactants", "SIMPLE_CHEMICAL", 584, 595], ["bile salts", "SIMPLE_CHEMICAL", 597, 607], ["chelating agents", "SIMPLE_CHEMICAL", 612, 628], ["TJs", "CELL_TYPE", 424, 427], ["absorption enhancers", "DNA", 431, 451], ["phenolic aicds", "PROBLEM", 51, 65], ["Flos Lonicerae extract", "TREATMENT", 126, 148], ["our previous study", "TEST", 183, 201], ["phenolic acids", "PROBLEM", 242, 256], ["passive diffusion", "PROBLEM", 261, 278], ["paracellular route transport", "TREATMENT", 293, 321], ["absorption enhancers", "TREATMENT", 553, 573], ["surfactants", "TREATMENT", 584, 595], ["bile salts", "TREATMENT", 597, 607], ["chelating agents", "TREATMENT", 612, 628], ["poorly absorbable drugs", "TREATMENT", 707, 730], ["phenolic aicds", "OBSERVATION", 51, 65], ["intestinal", "ANATOMY", 207, 217], ["phenolic acids", "OBSERVATION", 242, 256], ["paracellular", "ANATOMY_MODIFIER", 293, 305], ["bile", "ANATOMY", 597, 601]]], ["Recently, it was demonstrated that nitric oxide (NO) donors and polyamines were also effective for improving the intestinal absorption of poorly absorbable drugs the MeOH soluble portion of Flos Lonicerae extract was filtered through a 0.45 m membrane filter and the resulting filtrate was subjected for HPLC analysis.", [["intestinal", "ANATOMY", 113, 123], ["membrane", "ANATOMY", 243, 251], ["nitric oxide", "CHEMICAL", 35, 47], ["NO", "CHEMICAL", 49, 51], ["polyamines", "CHEMICAL", 64, 74], ["Flos Lonicerae extract", "CHEMICAL", 190, 212], ["nitric oxide", "CHEMICAL", 35, 47], ["NO", "CHEMICAL", 49, 51], ["polyamines", "CHEMICAL", 64, 74], ["MeOH", "CHEMICAL", 166, 170], ["nitric oxide", "SIMPLE_CHEMICAL", 35, 47], ["NO", "SIMPLE_CHEMICAL", 49, 51], ["polyamines", "SIMPLE_CHEMICAL", 64, 74], ["intestinal", "ORGAN", 113, 123], ["MeOH", "SIMPLE_CHEMICAL", 166, 170], ["Flos", "SIMPLE_CHEMICAL", 190, 194], ["nitric oxide", "TREATMENT", 35, 47], ["donors", "TREATMENT", 53, 59], ["polyamines", "TREATMENT", 64, 74], ["poorly absorbable drugs", "TREATMENT", 138, 161], ["the MeOH soluble portion of Flos Lonicerae extract", "TREATMENT", 162, 212], ["a 0.45 m membrane filter", "TREATMENT", 234, 258], ["the resulting filtrate", "PROBLEM", 263, 285], ["HPLC analysis", "TEST", 304, 317], ["intestinal", "ANATOMY", 113, 123], ["filtrate", "OBSERVATION", 277, 285]]], ["The analyses were performed using a Waters 2695 Alliance HPLC system (Waters Corp., Milford, MA, USA), consisting of a quaternary pump solvent management system, an on-line degasser, and an autosampler.", [["The analyses", "TEST", 0, 12], ["a quaternary pump solvent management system", "TREATMENT", 117, 160], ["an on-line degasser", "TREATMENT", 162, 181], ["an autosampler", "TREATMENT", 187, 201]]], ["The raw data were detected by 2998 PDA, acquired, and processed with Empower TM software.", [["The raw data", "TEST", 0, 12]]], ["A Hypersil ODS C18 column (250 \u00d7 4.6 mm, 5 m) (Thermo Scientific, Waltham, MA, USA) was applied for all analyses.", [["A Hypersil ODS C18 column", "TEST", 0, 25], ["C18 column", "OBSERVATION_MODIFIER", 15, 25]]], ["The mobile phase was composed of A (acetonitrile) and solvent B (0.4% aqueous phosphoric acid, V/V) with a linear gradient elution: 0-20 min, 10-14% A; 20-50 min, 14-30% A; 50-55 min, 30-10% A; 55-60 min, 10% A. The mobile phase flow rate was 1 ml min \u22121 , the column temperature was controlled at 30 \u2022 C and sample injection volume was 10 l.", [["sample", "ANATOMY", 309, 315], ["solvent B", "CHEMICAL", 54, 63], ["phosphoric acid", "CHEMICAL", 78, 93], ["acetonitrile", "CHEMICAL", 36, 48], ["phosphoric acid", "CHEMICAL", 78, 93], ["A", "SIMPLE_CHEMICAL", 33, 34], ["acetonitrile", "SIMPLE_CHEMICAL", 36, 48], ["solvent B", "SIMPLE_CHEMICAL", 54, 63], ["aqueous phosphoric acid", "SIMPLE_CHEMICAL", 70, 93], ["A (acetonitrile)", "TREATMENT", 33, 49], ["solvent B", "TREATMENT", 54, 63], ["aqueous phosphoric acid", "TEST", 70, 93], ["a linear gradient elution", "TREATMENT", 105, 130], ["The mobile phase flow rate", "TEST", 212, 238], ["the column temperature", "TEST", 257, 279], ["sample injection volume", "TEST", 309, 332], ["mobile phase", "OBSERVATION_MODIFIER", 4, 16]]], ["(B) UPLC-MS/MS profile of Flos Lonicerae extract to determination phenolic acids simultaneous (unpublished).", [["Flos Lonicerae extract", "CHEMICAL", 26, 48], ["phenolic acids", "CHEMICAL", 66, 80], ["phenolic acids", "CHEMICAL", 66, 80], ["Flos", "SIMPLE_CHEMICAL", 26, 30], ["phenolic acids", "SIMPLE_CHEMICAL", 66, 80], ["UPLC", "TEST", 4, 8], ["MS", "PROBLEM", 9, 11], ["MS profile", "PROBLEM", 12, 22], ["Flos Lonicerae extract", "TREATMENT", 26, 48], ["phenolic acids", "TEST", 66, 80]]], ["However, some absorption enhancers can cause damage and irritate the intestinal mucosal membranes.", [["intestinal mucosal membranes", "ANATOMY", 69, 97], ["intestinal mucosal membranes", "MULTI-TISSUE_STRUCTURE", 69, 97], ["absorption enhancers", "DNA", 14, 34], ["some absorption enhancers", "PROBLEM", 9, 34], ["damage and irritate the intestinal mucosal membranes", "PROBLEM", 45, 97], ["intestinal mucosal", "ANATOMY", 69, 87], ["membranes", "OBSERVATION", 88, 97]]], ["Indeed, there existed almost linear relationship between the effectiveness of various absorption enhancers and their membrane toxicity reported by Yamamoto et al. (1996) .", [["membrane", "ANATOMY", 117, 125], ["toxicity", "DISEASE", 126, 134], ["membrane", "CELLULAR_COMPONENT", 117, 125], ["absorption enhancers", "DNA", 86, 106], ["various absorption enhancers", "PROBLEM", 78, 106], ["their membrane toxicity", "PROBLEM", 111, 134], ["linear", "OBSERVATION_MODIFIER", 29, 35], ["absorption enhancers", "OBSERVATION", 86, 106]]], ["Therefore, the absorption enhancers based on tight junctions with high effectiveness and low mucosal toxicity need to be investigated.IntroductionChitosan, a natural polymer obtained by alkaline deacetylation of chitin, is non-toxic, biocompatible, and biodegradable.", [["tight junctions", "ANATOMY", 45, 60], ["mucosal", "ANATOMY", 93, 100], ["toxicity", "DISEASE", 101, 109], ["IntroductionChitosan", "CHEMICAL", 134, 154], ["chitin", "CHEMICAL", 212, 218], ["mucosal", "MULTI-TISSUE_STRUCTURE", 93, 100], ["IntroductionChitosan", "SIMPLE_CHEMICAL", 134, 154], ["alkaline", "SIMPLE_CHEMICAL", 186, 194], ["chitin", "SIMPLE_CHEMICAL", 212, 218], ["absorption enhancers", "DNA", 15, 35], ["the absorption enhancers", "TREATMENT", 11, 35], ["high effectiveness", "PROBLEM", 66, 84], ["low mucosal toxicity", "PROBLEM", 89, 109], ["IntroductionChitosan", "TREATMENT", 134, 154], ["a natural polymer", "TREATMENT", 156, 173], ["alkaline deacetylation of chitin", "TREATMENT", 186, 218], ["non-toxic", "OBSERVATION_MODIFIER", 223, 232], ["biocompatible", "OBSERVATION_MODIFIER", 234, 247]]], ["The ability of chitosan to enhance gastrointestinal (GI) drug absorption has been of special interest (Gao et al. 2008 ).", [["gastrointestinal", "ANATOMY", 35, 51], ["chitosan", "CHEMICAL", 15, 23], ["chitosan", "SIMPLE_CHEMICAL", 15, 23], ["gastrointestinal", "ORGAN", 35, 51], ["chitosan", "TREATMENT", 15, 23], ["gastrointestinal (GI) drug absorption", "TREATMENT", 35, 72], ["gastrointestinal", "ANATOMY", 35, 51]]], ["Illum et al. (1994) proposed that the mechanism of absorption enhancement was a combination of mucoadhesion and a loosening effect on the tension of the tight junctions through ionic interactions with negatively charged groups of glycocalix.", [["tight junctions", "ANATOMY", 153, 168], ["tight junctions", "CELLULAR_COMPONENT", 153, 168], ["glycocalix", "SIMPLE_CHEMICAL", 230, 240], ["absorption enhancement", "PROBLEM", 51, 73], ["mucoadhesion", "PROBLEM", 95, 107], ["a loosening effect", "PROBLEM", 112, 130], ["glycocalix", "TREATMENT", 230, 240], ["absorption enhancement", "OBSERVATION", 51, 73], ["mucoadhesion", "OBSERVATION", 95, 107], ["loosening effect", "OBSERVATION", 114, 130], ["tension", "OBSERVATION_MODIFIER", 138, 145], ["tight junctions", "OBSERVATION", 153, 168]]], ["However, the polymer was only soluble in an acidic environment in which the pH was less or if the order of the pK a value of chitosan (5.5-6.5), which restricted its application to the absorption enhancer seriously.", [["chitosan", "CHEMICAL", 125, 133], ["chitosan", "SIMPLE_CHEMICAL", 125, 133], ["the pH", "TEST", 72, 78], ["chitosan", "TEST", 125, 133]]], ["For example, the reduction of TEER of Caco-2 cell monolayers was found after the apical incubation with chitosan hydrochloride and chitosan glutamate at a pH of 6.20, but no decrease of TEER, which is a good measurement of the tightness of the junctions between the cells, was observed at a pH of 7.40.", [["Caco-2 cell monolayers", "ANATOMY", 38, 60], ["apical", "ANATOMY", 81, 87], ["cells", "ANATOMY", 266, 271], ["chitosan hydrochloride", "CHEMICAL", 104, 126], ["chitosan", "CHEMICAL", 131, 139], ["glutamate", "CHEMICAL", 140, 149], ["hydrochloride", "CHEMICAL", 113, 126], ["glutamate", "CHEMICAL", 140, 149], ["Caco-2 cell monolayers", "CELL", 38, 60], ["chitosan hydrochloride", "SIMPLE_CHEMICAL", 104, 126], ["chitosan glutamate", "SIMPLE_CHEMICAL", 131, 149], ["cells", "CELL", 266, 271], ["Caco-2 cell monolayers", "CELL_LINE", 38, 60], ["Caco-2 cell monolayers", "TREATMENT", 38, 60], ["the apical incubation", "TREATMENT", 77, 98], ["chitosan hydrochloride", "TREATMENT", 104, 126], ["chitosan glutamate", "TREATMENT", 131, 149], ["a pH", "TEST", 153, 157], ["decrease of TEER", "PROBLEM", 174, 190], ["a pH", "TEST", 289, 293], ["reduction", "OBSERVATION_MODIFIER", 17, 26], ["2 cell monolayers", "OBSERVATION", 43, 60], ["apical", "ANATOMY_MODIFIER", 81, 87], ["no", "UNCERTAINTY", 171, 173], ["decrease", "OBSERVATION_MODIFIER", 174, 182], ["good", "OBSERVATION_MODIFIER", 203, 207], ["tightness", "OBSERVATION", 227, 236], ["cells", "ANATOMY", 266, 271]]], ["At this pH, both chitosan salts (hydrochloride, glutamate) did not form clear solutions.", [["chitosan salts", "CHEMICAL", 17, 31], ["hydrochloride", "CHEMICAL", 33, 46], ["glutamate", "CHEMICAL", 48, 57], ["hydrochloride", "CHEMICAL", 33, 46], ["glutamate", "CHEMICAL", 48, 57], ["chitosan salts", "SIMPLE_CHEMICAL", 17, 31], ["hydrochloride", "SIMPLE_CHEMICAL", 33, 46], ["glutamate", "SIMPLE_CHEMICAL", 48, 57], ["both chitosan salts (hydrochloride, glutamate)", "TREATMENT", 12, 58]]], ["In agreement with the results of the TEER experiments, no increase in the transport of the hydrophilic model compound [14C]-mannitol was found at a pH of 7.40 after incubation with these chitosan salts (Jonker et al. 2002) .", [["[14C]-mannitol", "CHEMICAL", 118, 132], ["chitosan salts", "CHEMICAL", 187, 201], ["[14C]-mannitol", "CHEMICAL", 118, 132], ["[14C]-mannitol", "SIMPLE_CHEMICAL", 118, 132], ["chitosan salts", "SIMPLE_CHEMICAL", 187, 201], ["the TEER experiments", "TEST", 33, 53], ["mannitol", "TREATMENT", 124, 132], ["a pH", "TEST", 146, 150], ["these chitosan salts", "TREATMENT", 181, 201], ["increase", "OBSERVATION_MODIFIER", 58, 66]]], ["Therefore, the potential use of chitosans, as absorption enhancer in the more basic environments of intestine, was limited.IntroductionChitosan derivatives have been suggested as promising excipients for absorption enhancement of GI drug in cases in which additional physicochemical properties in the polymer structure were desirable.", [["intestine", "ANATOMY", 100, 109], ["chitosans", "CHEMICAL", 32, 41], ["Chitosan", "CHEMICAL", 135, 143], ["chitosans", "CHEMICAL", 32, 41], ["chitosans", "SIMPLE_CHEMICAL", 32, 41], ["intestine", "ORGAN", 100, 109], ["Chitosan derivatives", "SIMPLE_CHEMICAL", 135, 155], ["GI", "ORGANISM_SUBDIVISION", 230, 232], ["chitosans", "TREATMENT", 32, 41], ["absorption enhancer", "TREATMENT", 46, 65], ["IntroductionChitosan derivatives", "TREATMENT", 123, 155], ["absorption enhancement", "PROBLEM", 204, 226], ["GI drug", "TREATMENT", 230, 237], ["intestine", "ANATOMY", 100, 109], ["GI", "ANATOMY", 230, 232]]], ["Chito-oligosaccharide (COS) shown in Fig. 3 , a new type of chitosan molecular, had remarkable solubility in water at physiological pH due to its low molecular weight, and we found that the contents of d-glucosamine, chitosan dimer, chitosan trimer, chitosan tetramer, chitosan pentamer and chitosan hexamer were 0.", [["Chito-oligosaccharide", "CHEMICAL", 0, 21], ["chitosan", "CHEMICAL", 60, 68], ["d-glucosamine", "CHEMICAL", 202, 215], ["chitosan", "CHEMICAL", 217, 225], ["chitosan", "CHEMICAL", 233, 241], ["chitosan tetramer", "CHEMICAL", 250, 267], ["chitosan pentamer", "CHEMICAL", 269, 286], ["chitosan", "CHEMICAL", 291, 299], ["d-glucosamine", "CHEMICAL", 202, 215], ["Chito-oligosaccharide", "SIMPLE_CHEMICAL", 0, 21], ["chitosan", "SIMPLE_CHEMICAL", 60, 68], ["water", "SIMPLE_CHEMICAL", 109, 114], ["d-glucosamine", "SIMPLE_CHEMICAL", 202, 215], ["chitosan dimer", "SIMPLE_CHEMICAL", 217, 231], ["chitosan trimer", "SIMPLE_CHEMICAL", 233, 248], ["chitosan tetramer", "SIMPLE_CHEMICAL", 250, 267], ["chitosan pentamer", "SIMPLE_CHEMICAL", 269, 286], ["chitosan hexamer", "SIMPLE_CHEMICAL", 291, 307], ["Chito", "TEST", 0, 5], ["a new type of chitosan molecular", "PROBLEM", 46, 78], ["its low molecular weight", "PROBLEM", 142, 166], ["d-glucosamine, chitosan dimer", "TREATMENT", 202, 231], ["chitosan trimer", "TREATMENT", 233, 248], ["chitosan tetramer", "TREATMENT", 250, 267], ["chitosan pentamer and chitosan hexamer", "TREATMENT", 269, 307], ["new", "OBSERVATION_MODIFIER", 48, 51], ["chitosan molecular", "OBSERVATION", 60, 78], ["remarkable", "OBSERVATION_MODIFIER", 84, 94], ["solubility", "OBSERVATION_MODIFIER", 95, 105]]], ["Gao et al. (2008) reported the effect of chitosan oligomers on the intestinal absorption of hydrophilic macromolecular drugs, such as fluorescein isothiocyanate-labeled dextrans (FD4), and found that the bioavailability of FD4 could be all increased by about 2 times by chitosan dimer (0.5%, W/V), 1.5 times by chitosan trimer (0.5%, W/V) and 2.4 times by chitosan hexamer (0.5%, W/V) from jejunum.", [["intestinal", "ANATOMY", 67, 77], ["macromolecular", "ANATOMY", 104, 118], ["jejunum", "ANATOMY", 390, 397], ["chitosan", "CHEMICAL", 41, 49], ["fluorescein isothiocyanate", "CHEMICAL", 134, 160], ["FD4", "CHEMICAL", 223, 226], ["chitosan", "CHEMICAL", 270, 278], ["chitosan", "CHEMICAL", 311, 319], ["chitosan hexamer", "CHEMICAL", 356, 372], ["fluorescein isothiocyanate", "CHEMICAL", 134, 160], ["chitosan oligomers", "SIMPLE_CHEMICAL", 41, 59], ["intestinal", "ORGAN", 67, 77], ["fluorescein isothiocyanate-labeled dextrans", "SIMPLE_CHEMICAL", 134, 177], ["FD4", "SIMPLE_CHEMICAL", 179, 182], ["FD4", "SIMPLE_CHEMICAL", 223, 226], ["chitosan dimer", "SIMPLE_CHEMICAL", 270, 284], ["chitosan trimer", "SIMPLE_CHEMICAL", 311, 326], ["chitosan hexamer", "SIMPLE_CHEMICAL", 356, 372], ["jejunum", "MULTI-TISSUE_STRUCTURE", 390, 397], ["chitosan oligomers", "TREATMENT", 41, 59], ["hydrophilic macromolecular drugs", "TREATMENT", 92, 124], ["fluorescein isothiocyanate", "TREATMENT", 134, 160], ["the bioavailability of FD4", "PROBLEM", 200, 226], ["chitosan trimer", "TREATMENT", 311, 326], ["W/V)", "TREATMENT", 334, 338], ["intestinal", "ANATOMY", 67, 77], ["macromolecular drugs", "OBSERVATION", 104, 124], ["increased", "OBSERVATION_MODIFIER", 240, 249], ["jejunum", "ANATOMY", 390, 397]]], ["Besides, a moderate increase in the colonic absorption of FD4 was observed in the presence of chitosan pentamer (0.5%, W/V) and dimer (0.5%, W/V) from in situ loop method in rats.IntroductionTherefore, the current study arms to demonstrate the effect of COS on the intestinal absorption of phenolic acids in Flos Lonicerae extract using in vitro, in situ and in vivo models.MaterialsFlos Lonicerae extract was purchased from Jiangyin Tianjiang Pharmaceutics Co, Ltd.", [["colonic", "ANATOMY", 36, 43], ["intestinal", "ANATOMY", 265, 275], ["FD4", "CHEMICAL", 58, 61], ["chitosan pentamer", "CHEMICAL", 94, 111], ["COS", "CHEMICAL", 254, 257], ["phenolic acids", "CHEMICAL", 290, 304], ["Flos Lonicerae extract", "CHEMICAL", 308, 330], ["Flos Lonicerae extract", "CHEMICAL", 383, 405], ["phenolic acids", "CHEMICAL", 290, 304], ["colonic", "MULTI-TISSUE_STRUCTURE", 36, 43], ["FD4", "SIMPLE_CHEMICAL", 58, 61], ["chitosan pentamer", "SIMPLE_CHEMICAL", 94, 111], ["rats", "ORGANISM", 174, 178], ["COS", "SIMPLE_CHEMICAL", 254, 257], ["intestinal", "ORGAN", 265, 275], ["phenolic acids", "SIMPLE_CHEMICAL", 290, 304], ["rats", "SPECIES", 174, 178], ["a moderate increase", "PROBLEM", 9, 28], ["the colonic absorption of FD4", "PROBLEM", 32, 61], ["chitosan pentamer", "TEST", 94, 111], ["dimer", "TEST", 128, 133], ["the current study arms", "TEST", 202, 224], ["phenolic acids", "TREATMENT", 290, 304], ["Flos Lonicerae extract", "TREATMENT", 308, 330], ["MaterialsFlos Lonicerae extract", "TREATMENT", 374, 405], ["moderate", "OBSERVATION_MODIFIER", 11, 19], ["increase", "OBSERVATION_MODIFIER", 20, 28], ["colonic", "ANATOMY", 36, 43], ["absorption", "OBSERVATION_MODIFIER", 44, 54], ["chitosan pentamer", "OBSERVATION", 94, 111], ["situ loop", "OBSERVATION", 154, 163], ["intestinal", "ANATOMY", 265, 275], ["phenolic acids", "OBSERVATION", 290, 304]]], ["To assure the homogeneity of the formulation and to prepare consistent hatched, the HPLC figureprint profile Fig. 1(A) of the Flos Lonicerae extract was analyzed, and the chromatographic analysis was carried out under the previous study (Chinese Pharmacopoeia Commission 2010; Chen et al. 2007; Chen, 2007; Wagner et al. 2011) .", [["the formulation", "TREATMENT", 29, 44], ["the HPLC", "TEST", 80, 88], ["the Flos Lonicerae extract", "TREATMENT", 122, 148], ["the chromatographic analysis", "TEST", 167, 195]]], ["A reliable UHPLC-Orbitrap MS system was established for detecting the prototype compounds in Flos Lonicerae extract and dosed plasma with or without COS, respectively (Fig. 2) .", [["plasma", "ANATOMY", 126, 132], ["Flos Lonicerae extract", "CHEMICAL", 93, 115], ["plasma", "ORGANISM_SUBSTANCE", 126, 132], ["A reliable UHPLC", "TEST", 0, 16], ["Orbitrap MS system", "TEST", 17, 35], ["the prototype compounds", "PROBLEM", 66, 89], ["Flos Lonicerae extract", "TREATMENT", 93, 115]]], ["All voucher specimens were deposited in our laboratory for future reference.", [["specimens", "ANATOMY", 12, 21], ["All voucher specimens", "TEST", 0, 21]]], ["Chlorogenic acid, galuteolin and tinidazole (using as internal standard, IS) were purchased from National Institute for the Control of Pharmaceutical and Biological Products.", [["Chlorogenic acid", "CHEMICAL", 0, 16], ["galuteolin", "CHEMICAL", 18, 28], ["tinidazole", "CHEMICAL", 33, 43], ["Chlorogenic acid", "CHEMICAL", 0, 16], ["galuteolin", "CHEMICAL", 18, 28], ["tinidazole", "CHEMICAL", 33, 43], ["Chlorogenic acid", "SIMPLE_CHEMICAL", 0, 16], ["galuteolin", "SIMPLE_CHEMICAL", 18, 28], ["tinidazole", "SIMPLE_CHEMICAL", 33, 43], ["Chlorogenic acid", "TREATMENT", 0, 16], ["galuteolin", "TREATMENT", 18, 28], ["tinidazole", "TREATMENT", 33, 43], ["Pharmaceutical and Biological Products", "TREATMENT", 135, 173]]], ["Neochlorogenic acid, cryptochlorogenic acid, 3,4-dicaffeoylquinic acid and 3,5-dicaffeoylquinic acid (98% pure) was purchased from Sichuan Weikeqi Bio-tech Co., Ltd.", [["Neochlorogenic acid", "CHEMICAL", 0, 19], ["cryptochlorogenic acid", "CHEMICAL", 21, 43], ["3,4-dicaffeoylquinic acid", "CHEMICAL", 45, 70], ["3,5-dicaffeoylquinic acid", "CHEMICAL", 75, 100], ["Neochlorogenic acid", "CHEMICAL", 0, 19], ["cryptochlorogenic acid", "CHEMICAL", 21, 43], ["3,4-dicaffeoylquinic acid", "CHEMICAL", 45, 70], ["3,5-dicaffeoylquinic acid", "CHEMICAL", 75, 100], ["Neochlorogenic acid", "SIMPLE_CHEMICAL", 0, 19], ["cryptochlorogenic acid", "SIMPLE_CHEMICAL", 21, 43], ["3,4-dicaffeoylquinic acid", "SIMPLE_CHEMICAL", 45, 70], ["3,5-dicaffeoylquinic acid", "SIMPLE_CHEMICAL", 75, 100], ["Neochlorogenic acid", "TEST", 0, 19], ["cryptochlorogenic acid", "TEST", 21, 43], ["dicaffeoylquinic acid", "TREATMENT", 49, 70], ["dicaffeoylquinic acid", "TREATMENT", 79, 100]]], ["Heparin Sodium Injection was purchased from Changzhou Qianhong Bio-pharma Co., Ltd.", [["Heparin Sodium", "CHEMICAL", 0, 14], ["Sodium", "CHEMICAL", 8, 14], ["Heparin Sodium", "SIMPLE_CHEMICAL", 0, 14], ["Heparin Sodium Injection", "TREATMENT", 0, 24]]], ["Methanol and acetonitrile (HPLC grade) were purchased from Merck (Merck, Germany), and water was purified Fig. 3 .", [["Methanol", "CHEMICAL", 0, 8], ["acetonitrile", "CHEMICAL", 13, 25], ["Methanol", "CHEMICAL", 0, 8], ["acetonitrile", "CHEMICAL", 13, 25], ["Methanol", "SIMPLE_CHEMICAL", 0, 8], ["acetonitrile", "SIMPLE_CHEMICAL", 13, 25], ["Methanol", "TREATMENT", 0, 8], ["acetonitrile", "TREATMENT", 13, 25]]], ["The production and composition of chito-oligosacharide.", [["chito-oligosacharide", "CHEMICAL", 34, 54], ["chito-oligosacharide", "CHEMICAL", 34, 54], ["chito-oligosacharide", "SIMPLE_CHEMICAL", 34, 54], ["chito-oligosacharide", "TREATMENT", 34, 54]]], ["The analyses were performed using ultra-high performance liquid chromatography with Thermo Scientific Orbitrap mass spectrometry systems (UHPLC-Orbitrap MS).", [["The analyses", "TEST", 0, 12], ["ultra-high performance liquid chromatography", "TEST", 34, 78], ["UHPLC", "TEST", 138, 143]]], ["And all mass spectra were acquired in the positive ion mode, within the mass range 100-2000 m/z.", [["all mass spectra", "TEST", 4, 20], ["mass", "OBSERVATION", 8, 12], ["ion mode", "OBSERVATION_MODIFIER", 51, 59], ["mass", "ANATOMY", 72, 76]]], ["Separation was achieved using Welch ultimate XB-NH2 (100 \u00d7 2.1 mm, 3 m).", [["NH2", "CHEMICAL", 48, 51], ["XB-NH2", "SIMPLE_CHEMICAL", 45, 51], ["NH2", "PROTEIN", 48, 51]]], ["The injection volume used was 5 l.", [["The injection volume", "TREATMENT", 0, 20]]], ["The mobile phase was composed of A (acetonitrile) and solvent B (0.3% aqueous ammonia, V/V) with a linear gradient elution: 0-2 min, 75-40% A; 2-5 min, 40-40% A; 5-8 min, 40-75% A, and held for 2 min, at a flow rate of 400 l/min, resulting chromatographic full-width-at-half-maximum (FWHM) of 3-5 s.", [["solvent B", "CHEMICAL", 54, 63], ["ammonia", "CHEMICAL", 78, 85], ["acetonitrile", "CHEMICAL", 36, 48], ["ammonia", "CHEMICAL", 78, 85], ["A", "SIMPLE_CHEMICAL", 33, 34], ["acetonitrile", "SIMPLE_CHEMICAL", 36, 48], ["solvent B", "SIMPLE_CHEMICAL", 54, 63], ["ammonia", "SIMPLE_CHEMICAL", 78, 85], ["A (acetonitrile)", "TREATMENT", 33, 49], ["solvent B", "TREATMENT", 54, 63], ["aqueous ammonia", "TEST", 70, 85], ["a linear gradient elution", "TEST", 97, 122], ["a flow rate", "TEST", 204, 215], ["width", "TEST", 261, 266], ["mobile phase", "OBSERVATION_MODIFIER", 4, 16]]], ["Analytical data were collected at resolution from 30,000 and scanning rate 1-12 scans/s. by a Milli-Q water purification system (Millipore, Bedford, MA, USA).", [["Analytical data", "TEST", 0, 15], ["scanning rate", "TEST", 61, 74], ["scans", "TEST", 80, 85], ["a Milli", "TEST", 92, 99]]], ["All other chemicals and reagents were of analytical grade.MaterialsDulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), 0.05% trypsin-EDTA, penicillin-streptomycin and non-essential amino acids were obtained from GibcoBRI, Life and Technologies, USA.", [["fetal bovine serum", "ANATOMY", 110, 128], ["FBS", "ANATOMY", 130, 133], ["trypsin-EDTA", "CHEMICAL", 142, 154], ["penicillin", "CHEMICAL", 156, 166], ["streptomycin", "CHEMICAL", 167, 179], ["amino acids", "CHEMICAL", 198, 209], ["EDTA", "CHEMICAL", 150, 154], ["penicillin", "CHEMICAL", 156, 166], ["streptomycin", "CHEMICAL", 167, 179], ["amino acids", "CHEMICAL", 198, 209], ["bovine", "ORGANISM", 116, 122], ["serum", "ORGANISM_SUBSTANCE", 123, 128], ["FBS", "ORGANISM_SUBSTANCE", 130, 133], ["trypsin-EDTA", "SIMPLE_CHEMICAL", 142, 154], ["penicillin-streptomycin", "SIMPLE_CHEMICAL", 156, 179], ["non-essential amino acids", "SIMPLE_CHEMICAL", 184, 209], ["bovine", "SPECIES", 116, 122], ["bovine", "SPECIES", 116, 122], ["Materials", "TEST", 58, 67], ["Eagle's medium (DMEM", "TEST", 87, 107], ["fetal bovine serum", "TEST", 110, 128], ["FBS", "TEST", 130, 133], ["trypsin", "TEST", 142, 149], ["EDTA", "TREATMENT", 150, 154], ["penicillin", "TREATMENT", 156, 166], ["streptomycin", "TREATMENT", 167, 179], ["non-essential amino acids", "TREATMENT", 184, 209]]], ["Collagen type I, sodium pyruvate, MTT (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide) and trypsin TPCK (Tosylamide Phenylethyl Chloromethyl Ketontreated Trypsin) were purchased from Sigma Chemical Co. The human colorectal cancer cell lines (Caco-2, HCT116) were bought from cell bank (Chinese Academy of Sciences).", [["colorectal cancer cell lines", "ANATOMY", 228, 256], ["Caco-2", "ANATOMY", 258, 264], ["HCT116", "ANATOMY", 266, 272], ["cell", "ANATOMY", 291, 295], ["sodium pyruvate", "CHEMICAL", 17, 32], ["MTT", "CHEMICAL", 34, 37], ["3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide", "CHEMICAL", 39, 101], ["TPCK", "CHEMICAL", 115, 119], ["Tosylamide Phenylethyl Chloromethyl Ketontreated Trypsin", "CHEMICAL", 121, 177], ["colorectal cancer", "DISEASE", 228, 245], ["sodium pyruvate", "CHEMICAL", 17, 32], ["MTT", "CHEMICAL", 34, 37], ["3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide", "CHEMICAL", 39, 101], ["TPCK", "CHEMICAL", 115, 119], ["Tosylamide Phenylethyl Chloromethyl", "CHEMICAL", 121, 156], ["Co", "CHEMICAL", 214, 216], ["Collagen type I", "GENE_OR_GENE_PRODUCT", 0, 15], ["sodium pyruvate", "SIMPLE_CHEMICAL", 17, 32], ["MTT", "SIMPLE_CHEMICAL", 34, 37], ["3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide", "SIMPLE_CHEMICAL", 39, 101], ["trypsin TPCK", "SIMPLE_CHEMICAL", 107, 119], ["Tosylamide Phenylethyl Chloromethyl Ketontreated Trypsin", "SIMPLE_CHEMICAL", 121, 177], ["human", "ORGANISM", 222, 227], ["colorectal cancer cell lines", "CELL", 228, 256], ["Caco-2", "CELL", 258, 264], ["HCT116", "CELL", 266, 272], ["cell", "CELL", 291, 295], ["human colorectal cancer cell lines", "CELL_LINE", 222, 256], ["Caco-2", "CELL_LINE", 258, 264], ["HCT116", "CELL_LINE", 266, 272], ["human", "SPECIES", 222, 227], ["human", "SPECIES", 222, 227], ["sodium pyruvate", "TREATMENT", 17, 32], ["MTT", "TEST", 34, 37], ["dimethylthiazole", "TREATMENT", 46, 62], ["diphenyl tetrazolium bromide", "TREATMENT", 73, 101], ["trypsin TPCK", "TREATMENT", 107, 119], ["Tosylamide Phenylethyl Chloromethyl Ketontreated Trypsin", "TREATMENT", 121, 177], ["The human colorectal cancer cell lines", "TREATMENT", 218, 256], ["Caco", "TEST", 258, 262], ["colorectal cancer", "OBSERVATION", 228, 245], ["cell lines", "OBSERVATION", 246, 256]]], ["Madin-Darby canine kidney cell lines (MDCK cell, KG067) were purchased from Keygen biotech Co., Ltd.", [["kidney cell lines", "ANATOMY", 19, 36], ["MDCK cell", "ANATOMY", 38, 47], ["KG067", "ANATOMY", 49, 54], ["Madin-Darby canine kidney cell lines", "CELL", 0, 36], ["MDCK cell", "CELL", 38, 47], ["KG067", "CELL", 49, 54], ["Ltd", "GENE_OR_GENE_PRODUCT", 96, 99], ["Madin-Darby canine kidney cell lines", "CELL_LINE", 0, 36], ["MDCK cell", "CELL_LINE", 38, 47], ["KG067", "CELL_LINE", 49, 54], ["canine", "SPECIES", 12, 18], ["Madin", "TREATMENT", 0, 5], ["Darby canine kidney cell lines", "TREATMENT", 6, 36], ["kidney", "ANATOMY", 19, 25], ["cell lines", "OBSERVATION", 26, 36]]], ["The influenza virus strain, A/PR8/34 (H1N1) was purchased from Chinese Academy of Preventive Medicine.MaterialsMale Sprague-Dawley (SD) rats (\u223c250 g) were supplied by the Experimental Animal Center of Nanjing University of Chinese Medicine (Certificate No.SCXK2008-0033).", [["influenza virus", "DISEASE", 4, 19], ["SCXK2008-0033", "CHEMICAL", 256, 269], ["SCXK2008-0033", "CHEMICAL", 256, 269], ["influenza virus", "ORGANISM", 4, 19], ["A/PR8/34 (H1N1", "ORGANISM", 28, 42], ["Sprague-Dawley (SD) rats", "ORGANISM", 116, 140], ["influenza virus", "SPECIES", 4, 19], ["rats", "SPECIES", 136, 140], ["A/PR8/34 (H1N1)", "SPECIES", 28, 43], ["The influenza virus strain", "PROBLEM", 0, 26], ["A/PR8", "TREATMENT", 28, 33], ["Preventive Medicine", "TREATMENT", 82, 101], ["influenza virus", "OBSERVATION", 4, 19]]], ["The experimental procedures were in compliance with the animal ethics committee of the Nanjing University of Chinese Medicine.MethodsEffect of COS on the intestinal absorption of chlorogenic acid, neochlorogenic acid, cryptochlorogenic acid, 3,4-dicaffeoylquinic acid and 3,5-dicaffeoylquinic acid in Flos LoniceraeIn vitro Caco-2 cell monolayer modelCaco-2 cells were cultured in high glucose DMEM with 10% fetal bovine serum, 1% nonessential amino acids.", [["intestinal", "ANATOMY", 154, 164], ["Caco-2 cell monolayer", "ANATOMY", 324, 345], ["Caco-2 cells", "ANATOMY", 351, 363], ["fetal bovine serum", "ANATOMY", 408, 426], ["COS", "CHEMICAL", 143, 146], ["chlorogenic acid", "CHEMICAL", 179, 195], ["neochlorogenic acid", "CHEMICAL", 197, 216], ["cryptochlorogenic acid", "CHEMICAL", 218, 240], ["3,4-dicaffeoylquinic acid", "CHEMICAL", 242, 267], ["3,5-dicaffeoylquinic acid", "CHEMICAL", 272, 297], ["glucose", "CHEMICAL", 386, 393], ["amino acids", "CHEMICAL", 444, 455], ["chlorogenic acid", "CHEMICAL", 179, 195], ["neochlorogenic acid", "CHEMICAL", 197, 216], ["cryptochlorogenic acid", "CHEMICAL", 218, 240], ["3,4-dicaffeoylquinic acid", "CHEMICAL", 242, 267], ["3,5-dicaffeoylquinic acid", "CHEMICAL", 272, 297], ["glucose", "CHEMICAL", 386, 393], ["amino acids", "CHEMICAL", 444, 455], ["COS", "SIMPLE_CHEMICAL", 143, 146], ["intestinal", "ORGAN", 154, 164], ["chlorogenic acid", "SIMPLE_CHEMICAL", 179, 195], ["neochlorogenic acid", "SIMPLE_CHEMICAL", 197, 216], ["cryptochlorogenic acid", "SIMPLE_CHEMICAL", 218, 240], ["3,4-dicaffeoylquinic acid", "SIMPLE_CHEMICAL", 242, 267], ["3,5-dicaffeoylquinic acid", "SIMPLE_CHEMICAL", 272, 297], ["Caco-2 cell monolayer", "CELL", 324, 345], ["Caco-2 cells", "CELL", 351, 363], ["glucose", "SIMPLE_CHEMICAL", 386, 393], ["bovine", "ORGANISM", 414, 420], ["serum", "ORGANISM_SUBSTANCE", 421, 426], ["amino acids", "AMINO_ACID", 444, 455], ["Flos LoniceraeIn vitro Caco-2 cell monolayer model", "CELL_LINE", 301, 351], ["Caco-2 cells", "CELL_LINE", 351, 363], ["bovine", "SPECIES", 414, 420], ["bovine", "SPECIES", 414, 420], ["The experimental procedures", "TREATMENT", 0, 27], ["Chinese Medicine", "TREATMENT", 109, 125], ["chlorogenic acid", "TEST", 179, 195], ["neochlorogenic acid", "TEST", 197, 216], ["cryptochlorogenic acid", "TEST", 218, 240], ["dicaffeoylquinic acid", "TREATMENT", 246, 267], ["dicaffeoylquinic acid", "TREATMENT", 276, 297], ["Flos LoniceraeIn", "TREATMENT", 301, 317], ["vitro Caco-2 cell monolayer model", "TREATMENT", 318, 351], ["Caco", "TEST", 351, 355], ["fetal bovine serum", "TEST", 408, 426], ["nonessential amino acids", "TEST", 431, 455], ["intestinal", "ANATOMY", 154, 164]]], ["Cells were cultured in a humidified atmosphere of 5% CO 2 at 37 \u2022 C. After reaching 80% confluens, Caco-2 cells were harvested with 0.05% trypsin-EDTA solution and seeded on top of CC inserts in 6-well plates, which has a surface area of 4.2 cm 2 , at a density of 1.0 \u00d7 10 5 cells/cm 2 .", [["Cells", "ANATOMY", 0, 5], ["Caco-2 cells", "ANATOMY", 99, 111], ["surface area", "ANATOMY", 222, 234], ["cells", "ANATOMY", 276, 281], ["trypsin-EDTA", "CHEMICAL", 138, 150], ["CC", "CHEMICAL", 181, 183], ["CO 2", "CHEMICAL", 53, 57], ["EDTA", "CHEMICAL", 146, 150], ["Cells", "CELL", 0, 5], ["Caco-2 cells", "CELL", 99, 111], ["trypsin-", "SIMPLE_CHEMICAL", 138, 146], ["EDTA", "SIMPLE_CHEMICAL", 146, 150], ["Caco-2 cells", "CELL_LINE", 99, 111], ["a humidified atmosphere", "TREATMENT", 23, 46], ["Caco-2 cells", "TREATMENT", 99, 111], ["0.05% trypsin-EDTA solution", "TREATMENT", 132, 159], ["a surface area", "TEST", 220, 234], ["surface", "OBSERVATION_MODIFIER", 222, 229], ["area", "OBSERVATION_MODIFIER", 230, 234], ["4.2 cm", "OBSERVATION_MODIFIER", 238, 244], ["density", "OBSERVATION", 254, 261]]], ["The protocols for cell culture in Transwell inserts were similar to those described previously (Zhou et al. 2012a,b) .In vitro Caco-2 cell monolayer modelCell culture experiments were described previously (Zhou et al. 2012a,b) .", [["cell", "ANATOMY", 18, 22], ["Caco-2 cell monolayer", "ANATOMY", 127, 148], ["Cell", "ANATOMY", 154, 158], ["cell", "CELL", 18, 22], ["Caco-2 cell monolayer", "CELL", 127, 148], ["Cell", "CELL", 154, 158], ["Caco-2 cell monolayer model", "CELL_LINE", 127, 154], ["The protocols", "TREATMENT", 0, 13], ["cell culture", "TEST", 18, 30], ["Transwell inserts", "TREATMENT", 34, 51], ["vitro Caco-2 cell monolayer model", "TREATMENT", 121, 154], ["Cell culture experiments", "TEST", 154, 178]]], ["Briefly, after culture medium was aspirated, the cell monolayers were washed three times with blank HBSS.", [["cell monolayers", "ANATOMY", 49, 64], ["cell monolayers", "CELL", 49, 64], ["culture medium", "TEST", 15, 29], ["the cell monolayers", "TEST", 45, 64], ["blank HBSS", "TEST", 94, 104], ["cell monolayers", "OBSERVATION", 49, 64]]], ["The transepithelial electrical resistance (TEER) values of cell monolayers were measured, which were more than 250 cm 2 .", [["transepithelial", "ANATOMY", 4, 19], ["cell monolayers", "ANATOMY", 59, 74], ["cell monolayers", "CELL", 59, 74], ["The transepithelial electrical resistance", "TEST", 0, 41], ["cell monolayers", "TEST", 59, 74], ["transepithelial", "OBSERVATION", 4, 19], ["electrical resistance", "OBSERVATION", 20, 41], ["cell monolayers", "OBSERVATION", 59, 74]]], ["The monolayers were incubated with the blank HBSS for 1 h with 37 \u2022 C. Thereafter the incubation medium was aspirated.", [["monolayers", "ANATOMY", 4, 14], ["monolayers", "CELL", 4, 14], ["the blank HBSS", "TREATMENT", 35, 49], ["the incubation medium", "TREATMENT", 82, 103]]], ["Afterwards, a solution containing the compound was loaded onto the apical side.", [["apical", "ANATOMY", 67, 73], ["a solution containing the compound", "TREATMENT", 12, 46], ["apical", "ANATOMY_MODIFIER", 67, 73]]], ["Donor samples (400 l) (Apical side) and receiver samples (400 l) (Basolateral side) were taken at different times (typically 1 h), followed by the addition of 400 l drug donor solution to the donor side (AP) and 400 l of blank buffer to the receiver side (BL).", [["Donor samples", "ANATOMY", 0, 13], ["samples", "ANATOMY", 49, 56], ["Donor samples", "TEST", 0, 13], ["receiver samples", "TEST", 40, 56], ["400 l drug donor solution", "TREATMENT", 159, 184], ["blank buffer", "TREATMENT", 221, 233]]], ["The samples were taken at 0, 1, 2, 3 and 4 h after incubation.", [["samples", "ANATOMY", 4, 11], ["The samples", "TEST", 0, 11]]], ["At the end of the transport experiment, integrity of the monolayer was monitored by TEER value.Rat in situ single pass intestinal perfusion studyRat in situ single pass intestinal perfusion model was set at previously described by us (Zhou et al. 2012a,b; Du et al. 2009 ).", [["monolayer", "ANATOMY", 57, 66], ["intestinal", "ANATOMY", 119, 129], ["intestinal", "ANATOMY", 169, 179], ["monolayer", "CELL", 57, 66], ["intestinal", "ORGAN", 119, 129], ["intestinal", "ORGAN", 169, 179], ["Rat", "SPECIES", 95, 98], ["Rat", "SPECIES", 145, 148], ["intestinal perfusion study", "TEST", 119, 145], ["intestinal", "ANATOMY", 119, 129], ["situ", "OBSERVATION_MODIFIER", 152, 156], ["intestinal", "ANATOMY", 169, 179], ["perfusion model", "OBSERVATION", 180, 195]]], ["Briefly, SD rats (body weight: 250-300 g) were fasted overnight with free access to water.", [["body", "ANATOMY", 18, 22], ["SD rats", "ORGANISM", 9, 16], ["body", "ORGANISM_SUBDIVISION", 18, 22], ["rats", "SPECIES", 12, 16], ["body weight", "TEST", 18, 29]]], ["The rats were anesthetized with 20% urethane solution (6 mg/kg).", [["urethane", "CHEMICAL", 36, 44], ["urethane", "CHEMICAL", 36, 44], ["rats", "ORGANISM", 4, 8], ["urethane", "SIMPLE_CHEMICAL", 36, 44], ["rats", "SPECIES", 4, 8], ["20% urethane solution", "TREATMENT", 32, 53]]], ["A midline abdominal incision was made and the small intestine was exposed.", [["abdominal", "ANATOMY", 10, 19], ["small intestine", "ANATOMY", 46, 61], ["abdominal", "ORGANISM_SUBDIVISION", 10, 19], ["small intestine", "ORGAN", 46, 61], ["A midline abdominal incision", "TREATMENT", 0, 28], ["midline", "ANATOMY_MODIFIER", 2, 9], ["abdominal", "ANATOMY", 10, 19], ["incision", "OBSERVATION", 20, 28], ["small", "OBSERVATION_MODIFIER", 46, 51], ["intestine", "ANATOMY", 52, 61], ["exposed", "OBSERVATION", 66, 73]]], ["The bile duct was ligated in order to avoid bile secretion into the perfusate.", [["bile duct", "ANATOMY", 4, 13], ["bile", "ANATOMY", 44, 48], ["bile duct", "MULTI-TISSUE_STRUCTURE", 4, 13], ["bile", "MULTI-TISSUE_STRUCTURE", 44, 48], ["perfusate", "ORGANISM_SUBSTANCE", 68, 77], ["bile secretion into the perfusate", "PROBLEM", 44, 77], ["bile duct", "ANATOMY", 4, 13], ["ligated", "OBSERVATION", 18, 25], ["bile", "ANATOMY", 44, 48], ["perfusate", "OBSERVATION_MODIFIER", 68, 77]]], ["For the regional absorption of drugs, three intestinal sections were isolated and cannulated (all were 10 cm long): duodenum, jejunum and ileum.", [["intestinal sections", "ANATOMY", 44, 63], ["duodenum", "ANATOMY", 116, 124], ["jejunum", "ANATOMY", 126, 133], ["ileum", "ANATOMY", 138, 143], ["intestinal sections", "MULTI-TISSUE_STRUCTURE", 44, 63], ["duodenum", "MULTI-TISSUE_STRUCTURE", 116, 124], ["jejunum", "MULTI-TISSUE_STRUCTURE", 126, 133], ["ileum", "MULTI-TISSUE_STRUCTURE", 138, 143], ["the regional absorption of drugs", "PROBLEM", 4, 36], ["three intestinal sections", "TREATMENT", 38, 63], ["intestinal", "ANATOMY", 44, 54], ["duodenum", "ANATOMY", 116, 124], ["jejunum", "ANATOMY", 126, 133], ["ileum", "ANATOMY", 138, 143]]], ["Each segment was rinsed with normal saline at 37 \u2022 C for 20 min until the washing appeared clear.", [["saline", "SIMPLE_CHEMICAL", 36, 42], ["normal saline", "TREATMENT", 29, 42], ["normal saline", "OBSERVATION", 29, 42], ["clear", "OBSERVATION", 91, 96]]], ["After that, the perfusion solution of drugs as solvent was connected to the each segment and perfusing through each part of the three intestine sections.", [["intestine sections", "ANATOMY", 134, 152], ["intestine sections", "MULTI-TISSUE_STRUCTURE", 134, 152], ["the perfusion solution of drugs", "TREATMENT", 12, 43], ["solvent", "TREATMENT", 47, 54], ["intestine", "ANATOMY", 134, 143]]], ["At the beginning of 30 min, the circulation rate was 0.2 ml min \u22121 controlled by a peristaltic pump to pre-balance, then, perfusate samples were collected.", [["perfusate samples", "ANATOMY", 122, 139], ["the circulation rate", "TEST", 28, 48], ["a peristaltic pump", "TREATMENT", 81, 99], ["perfusate samples", "TEST", 122, 139]]], ["Solutions containing 20 M for chlorogenic acid, neochlorogenic acid and cryptochlorogenic acid, 15 M for 3,5-dicaffeoylquinic acid and 30 M for 3,4-dicaffeoylquinic acid were perfused through the intestinal lumen to investigate the permeabilities of the two studied compounds in the rats in situ intestinal perfusion model.", [["intestinal lumen", "ANATOMY", 196, 212], ["intestinal", "ANATOMY", 296, 306], ["chlorogenic acid", "CHEMICAL", 30, 46], ["neochlorogenic acid", "CHEMICAL", 48, 67], ["cryptochlorogenic acid", "CHEMICAL", 72, 94], ["3,5-dicaffeoylquinic acid", "CHEMICAL", 105, 130], ["3,4-dicaffeoylquinic acid", "CHEMICAL", 144, 169], ["chlorogenic acid", "CHEMICAL", 30, 46], ["neochlorogenic acid", "CHEMICAL", 48, 67], ["cryptochlorogenic acid", "CHEMICAL", 72, 94], ["3,5-dicaffeoylquinic acid", "CHEMICAL", 105, 130], ["3,4-dicaffeoylquinic acid", "CHEMICAL", 144, 169], ["chlorogenic acid", "SIMPLE_CHEMICAL", 30, 46], ["neochlorogenic acid", "SIMPLE_CHEMICAL", 48, 67], ["cryptochlorogenic acid", "SIMPLE_CHEMICAL", 72, 94], ["3,5-dicaffeoylquinic acid", "SIMPLE_CHEMICAL", 105, 130], ["3,4-dicaffeoylquinic acid", "SIMPLE_CHEMICAL", 144, 169], ["intestinal lumen", "MULTI-TISSUE_STRUCTURE", 196, 212], ["rats", "ORGANISM", 283, 287], ["intestinal", "ORGAN", 296, 306], ["rats", "SPECIES", 283, 287], ["chlorogenic acid", "TEST", 30, 46], ["neochlorogenic acid", "TREATMENT", 48, 67], ["cryptochlorogenic acid", "TEST", 72, 94], ["3,5-dicaffeoylquinic acid", "TREATMENT", 105, 130], ["3,4-dicaffeoylquinic acid", "TREATMENT", 144, 169], ["the intestinal lumen", "TREATMENT", 192, 212], ["intestinal lumen", "ANATOMY", 196, 212], ["intestinal", "ANATOMY", 296, 306], ["perfusion model", "OBSERVATION", 307, 322]]], ["In addition, 20 M for chlorogenic acid, neochlorogenic acid and cryptochlorogenic acid, 15 M for 3,5-dicaffeoylquinic acid and 30 M for 3,4-dicaffeoylquinic acid with the addition of COS were also perfused through the intestinal lumen to investigate the effect of chitosan derivatives on the permeabilities of the two studied compounds.", [["intestinal lumen", "ANATOMY", 218, 234], ["chlorogenic acid", "CHEMICAL", 22, 38], ["neochlorogenic acid", "CHEMICAL", 40, 59], ["cryptochlorogenic acid", "CHEMICAL", 64, 86], ["3,5-dicaffeoylquinic acid", "CHEMICAL", 97, 122], ["3,4-dicaffeoylquinic acid", "CHEMICAL", 136, 161], ["chitosan", "CHEMICAL", 264, 272], ["chlorogenic acid", "CHEMICAL", 22, 38], ["neochlorogenic acid", "CHEMICAL", 40, 59], ["cryptochlorogenic acid", "CHEMICAL", 64, 86], ["3,5-dicaffeoylquinic acid", "CHEMICAL", 97, 122], ["3,4-dicaffeoylquinic acid", "CHEMICAL", 136, 161], ["chlorogenic acid", "SIMPLE_CHEMICAL", 22, 38], ["neochlorogenic acid", "SIMPLE_CHEMICAL", 40, 59], ["cryptochlorogenic acid", "SIMPLE_CHEMICAL", 64, 86], ["3,5-dicaffeoylquinic acid", "SIMPLE_CHEMICAL", 97, 122], ["3,4-dicaffeoylquinic acid", "SIMPLE_CHEMICAL", 136, 161], ["COS", "SIMPLE_CHEMICAL", 183, 186], ["intestinal lumen", "MULTI-TISSUE_STRUCTURE", 218, 234], ["chitosan derivatives", "SIMPLE_CHEMICAL", 264, 284], ["chlorogenic acid", "TEST", 22, 38], ["neochlorogenic acid", "TREATMENT", 40, 59], ["cryptochlorogenic acid", "TREATMENT", 64, 86], ["3,5-dicaffeoylquinic acid", "TREATMENT", 97, 122], ["3,4-dicaffeoylquinic acid", "TREATMENT", 136, 161], ["COS", "TREATMENT", 183, 186], ["the intestinal lumen", "TREATMENT", 214, 234], ["chitosan derivatives", "TREATMENT", 264, 284], ["intestinal lumen", "ANATOMY", 218, 234]]], ["The perfusate samples were collected at 30-60, 60-90, 90-120 and 120-150 min, and stored at \u221280 \u2022 C refrigerator until analysis.Rat in vivo pharmacokinetics studyProduct Flos Lonicerae extracts was dissolved in saline with or without COS to give the concentration of 60% (v/v) immediately prior to drug administration.", [["perfusate samples", "ANATOMY", 4, 21], ["extracts", "ANATOMY", 185, 193], ["perfusate samples", "ORGANISM_SUBSTANCE", 4, 21], ["extracts", "ORGANISM_SUBSTANCE", 185, 193], ["saline", "SIMPLE_CHEMICAL", 211, 217], ["Rat", "SPECIES", 128, 131], ["The perfusate samples", "TEST", 0, 21], ["analysis", "TEST", 119, 127], ["vivo pharmacokinetics study", "TEST", 135, 162], ["Product Flos Lonicerae extracts", "TREATMENT", 162, 193], ["saline", "TREATMENT", 211, 217], ["COS", "TREATMENT", 234, 237], ["drug administration", "TREATMENT", 298, 317], ["Flos Lonicerae", "OBSERVATION", 170, 184]]], ["The contents of neochlorogenic acid, chlorogenic acid, cryptochlorogenic acid, 3,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid and COS were determined to be 16.1, 16.9, 16.6, 18.9, 37.8 and 6.25 mg/ml of extracts, respectively.Rat in vivo pharmacokinetics studyMale SD rats (\u223c250 g) were kept in an environmentally controlled breeding room (temperature: 20 \u00b1 2 \u2022 C, relative humidity: 60 \u00b1 5%) for 1 week.", [["extracts", "ANATOMY", 209, 217], ["neochlorogenic acid", "CHEMICAL", 16, 35], ["chlorogenic acid", "CHEMICAL", 37, 53], ["cryptochlorogenic acid", "CHEMICAL", 55, 77], ["3,5-dicaffeoylquinic acid", "CHEMICAL", 79, 104], ["3,4-dicaffeoylquinic acid", "CHEMICAL", 106, 131], ["COS", "CHEMICAL", 136, 139], ["neochlorogenic acid", "CHEMICAL", 16, 35], ["chlorogenic acid", "CHEMICAL", 37, 53], ["cryptochlorogenic acid", "CHEMICAL", 55, 77], ["3,5-dicaffeoylquinic acid", "CHEMICAL", 79, 104], ["3,4-dicaffeoylquinic acid", "CHEMICAL", 106, 131], ["neochlorogenic acid", "SIMPLE_CHEMICAL", 16, 35], ["chlorogenic acid", "SIMPLE_CHEMICAL", 37, 53], ["cryptochlorogenic acid", "SIMPLE_CHEMICAL", 55, 77], ["3,5-dicaffeoylquinic acid", "SIMPLE_CHEMICAL", 79, 104], ["3,4-dicaffeoylquinic acid", "SIMPLE_CHEMICAL", 106, 131], ["COS", "SIMPLE_CHEMICAL", 136, 139], ["extracts", "ORGANISM_SUBSTANCE", 209, 217], ["Male SD rats", "ORGANISM", 266, 278], ["Rat", "SPECIES", 232, 235], ["rats", "SPECIES", 274, 278], ["neochlorogenic acid", "TEST", 16, 35], ["chlorogenic acid", "TEST", 37, 53], ["cryptochlorogenic acid", "TEST", 55, 77], ["dicaffeoylquinic acid", "TEST", 83, 104], ["dicaffeoylquinic acid", "TEST", 110, 131], ["COS", "TEST", 136, 139], ["vivo pharmacokinetics study", "TEST", 239, 266], ["temperature", "TEST", 346, 357]]], ["The animals were fasted for 12 h prior to drug administration of Product Flos Lonicerae extracts with or without COS prepared with a dose of 10 ml/kg.", [["extracts", "ANATOMY", 88, 96], ["animals", "ORGANISM", 4, 11], ["drug administration", "TREATMENT", 42, 61], ["Product Flos Lonicerae extracts", "TREATMENT", 65, 96]]], ["After dosing for 0, 5, 10, 15, 20, 30, 40, 55, 70, 100, 160, 250, 480 min, blood was collected from the pre-intubated catheter and put into tubes with heparin sodium injection (10 l) and ascorbic acid (2 g) at predetermined time points.", [["blood", "ANATOMY", 75, 80], ["tubes", "ANATOMY", 140, 145], ["heparin sodium", "CHEMICAL", 151, 165], ["ascorbic acid", "CHEMICAL", 187, 200], ["sodium", "CHEMICAL", 159, 165], ["ascorbic acid", "CHEMICAL", 187, 200], ["blood", "ORGANISM_SUBSTANCE", 75, 80], ["heparin sodium", "SIMPLE_CHEMICAL", 151, 165], ["ascorbic acid", "SIMPLE_CHEMICAL", 187, 200], ["blood", "TEST", 75, 80], ["the pre-intubated catheter", "TREATMENT", 100, 126], ["heparin sodium injection", "TREATMENT", 151, 175], ["ascorbic acid", "TREATMENT", 187, 200]]], ["Subsequently, plasma was prepared by centrifugation at 1816 \u00d7 g for 7 min and stored at \u221280 \u2022 C for further analysis.Sample preparations and analysisSample treatment and UPLC-MS/MS analysis for samples collected from in vitro, in situ and in vivo models, respectively were described previously (unpublished).Effect of Flos Lonicerae with or without COS on influenza virusMDCK cells were grown in DMEM as described previously (Mehrbod et al. 2009 ), supplemented with 10% FBS and 1% Pen/Strep at 37 \u2022 C in a humidified incubator.", [["plasma", "ANATOMY", 14, 20], ["samples", "ANATOMY", 194, 201], ["MDCK cells", "ANATOMY", 371, 381], ["Flos Lonicerae", "CHEMICAL", 318, 332], ["COS", "CHEMICAL", 349, 352], ["plasma", "ORGANISM_SUBSTANCE", 14, 20], ["Flos Lonicerae", "ORGANISM", 318, 332], ["MDCK cells", "CELL", 371, 381], ["FBS", "ORGANISM_SUBSTANCE", 471, 474], ["influenza virusMDCK cells", "CELL_LINE", 356, 381], ["influenza virusMDCK", "SPECIES", 356, 375], ["influenza virus", "SPECIES", 356, 371], ["further analysis", "TEST", 100, 116], ["Sample preparations", "TREATMENT", 117, 136], ["analysisSample treatment", "TREATMENT", 141, 165], ["UPLC", "TEST", 170, 174], ["MS", "TEST", 175, 177], ["MS analysis", "TEST", 178, 189], ["samples", "TEST", 194, 201], ["Flos Lonicerae", "TREATMENT", 318, 332], ["COS", "PROBLEM", 349, 352], ["influenza virusMDCK cells", "PROBLEM", 356, 381], ["Strep", "PROBLEM", 486, 491], ["a humidified incubator", "TREATMENT", 505, 527], ["Flos Lonicerae", "OBSERVATION", 318, 332]]], ["The media was changed two to three times per week.", [["The media", "TREATMENT", 0, 9]]], ["The influenza virus was propagated in MDCK cells in the presence of 1 g/ml of Trypsin TPCK to create the working stock.", [["MDCK cells", "ANATOMY", 38, 48], ["TPCK", "CHEMICAL", 86, 90], ["influenza virus", "ORGANISM", 4, 19], ["MDCK cells", "CELL", 38, 48], ["Trypsin TPCK", "SIMPLE_CHEMICAL", 78, 90], ["MDCK cells", "CELL_LINE", 38, 48], ["influenza virus", "SPECIES", 4, 19], ["The influenza virus", "PROBLEM", 0, 19], ["Trypsin TPCK", "TREATMENT", 78, 90], ["influenza virus", "OBSERVATION", 4, 19]]], ["During antiviral evaluations, media supplemented with FBS was sucked out and the cell washed with PBS and then it was treated as needed.", [["FBS", "ANATOMY", 54, 57], ["cell", "ANATOMY", 81, 85], ["FBS", "ORGANISM_SUBSTANCE", 54, 57], ["cell", "CELL", 81, 85], ["antiviral evaluations", "TEST", 7, 28], ["media", "TREATMENT", 30, 35], ["FBS", "TREATMENT", 54, 57], ["PBS", "TREATMENT", 98, 101]]], ["The media supplemented with Trypsin TPCK was added.Effect of Flos Lonicerae with or without COS on influenza virusSerum after administration orally into Flos Lonicerae extracts with or without COS at the dosages of 25 mg/kg was added to the MDCK cells after the propagation with influenza virus.", [["extracts", "ANATOMY", 168, 176], ["MDCK cells", "ANATOMY", 241, 251], ["Trypsin TPCK", "CHEMICAL", 28, 40], ["Flos Lonicerae", "CHEMICAL", 61, 75], ["COS", "CHEMICAL", 92, 95], ["influenza virusSerum", "DISEASE", 99, 119], ["COS", "CHEMICAL", 193, 196], ["influenza virus", "DISEASE", 279, 294], ["TPCK", "CHEMICAL", 36, 40], ["Trypsin TPCK", "SIMPLE_CHEMICAL", 28, 40], ["influenza virusSerum", "ORGANISM", 99, 119], ["MDCK cells", "CELL", 241, 251], ["influenza virus", "ORGANISM", 279, 294], ["MDCK cells", "CELL_LINE", 241, 251], ["influenza virus", "SPECIES", 279, 294], ["The media", "TREATMENT", 0, 9], ["Trypsin TPCK", "TREATMENT", 28, 40], ["Flos Lonicerae", "TREATMENT", 61, 75], ["COS", "PROBLEM", 92, 95], ["influenza virusSerum", "TREATMENT", 99, 119], ["Flos Lonicerae extracts", "TREATMENT", 153, 176], ["the MDCK cells", "TREATMENT", 237, 251], ["influenza virus", "PROBLEM", 279, 294], ["Flos Lonicerae", "OBSERVATION", 61, 75], ["influenza virus", "OBSERVATION", 279, 294]]], ["The cells were incubated at 37 \u2022 C for 48 h before viability testing by measuring the conversion of MTT as described by us (Zhou et al., 2012a) .CalculationFor Caco-2 monolayer model, the apparent permeability coefficient (P app ) was calculated as P app = [(dQ/dt)]/[A \u00d7 C], dQ/dt (g/S) was the flux rate, A was the effective surface area of the cell monolayer (4.2 cm 2 ), and C 0 (g/ml) was the initial drug concentration in the donor chamber.", [["cells", "ANATOMY", 4, 9], ["surface area", "ANATOMY", 327, 339], ["cell monolayer", "ANATOMY", 347, 361], ["MTT", "CHEMICAL", 100, 103], ["cells", "CELL", 4, 9], ["MTT", "SIMPLE_CHEMICAL", 100, 103], ["Caco-2 monolayer", "CELL", 160, 176], ["[A \u00d7 C", "SIMPLE_CHEMICAL", 267, 273], ["cell monolayer", "CELL", 347, 361], ["viability testing", "TEST", 51, 68], ["Calculation", "TEST", 145, 156], ["Caco-2 monolayer model", "TREATMENT", 160, 182], ["P app", "TEST", 249, 254], ["dQ/dt)", "TEST", 259, 265], ["A \u00d7 C", "TEST", 268, 273], ["dQ", "TEST", 276, 278], ["dt", "TEST", 279, 281], ["g/S", "TEST", 283, 286], ["the flux rate", "TEST", 292, 305], ["the cell monolayer", "TEST", 343, 361], ["C", "TEST", 379, 380], ["effective", "OBSERVATION_MODIFIER", 317, 326], ["surface", "OBSERVATION_MODIFIER", 327, 334], ["cell monolayer", "OBSERVATION", 347, 361], ["drug concentration", "OBSERVATION", 406, 424], ["donor chamber", "OBSERVATION", 432, 445]]], ["For rat single-pass intestinal perfusion in situ model, the concentration of perfusion fluid was calculated as C out(corrected) = C out PR in /PR out and the effective permeability coefficient (P eff ) was calculated as P eff = Qln[C in /C out(corrected) ]/2 rL.", [["intestinal", "ANATOMY", 20, 30], ["rat", "ORGANISM", 4, 7], ["intestinal", "ORGAN", 20, 30], ["PR", "PROTEIN", 136, 138], ["PR", "PROTEIN", 143, 145], ["rat", "SPECIES", 4, 7], ["rat", "SPECIES", 4, 7], ["perfusion fluid", "TEST", 77, 92], ["PR in /PR", "TREATMENT", 136, 145], ["the effective permeability coefficient (P eff )", "TREATMENT", 154, 201], ["P eff", "TEST", 220, 225], ["C in /C out", "TEST", 232, 243], ["intestinal", "ANATOMY", 20, 30], ["perfusion", "OBSERVATION", 31, 40]]], ["C out(corrected) was effluent drug concentration with correction; C out was effluent drug concentration without correction; C in was influent drug concentration; PR in was influent phenol red concentration; PR out were effluent phenol red concentration; Q was perfusate flow rate; r was radius of intestinal segment and l was intestinal segment length.", [["intestinal", "ANATOMY", 297, 307], ["intestinal", "ANATOMY", 326, 336], ["phenol", "CHEMICAL", 181, 187], ["phenol", "CHEMICAL", 228, 234], ["phenol red", "CHEMICAL", 181, 191], ["phenol red", "CHEMICAL", 228, 238], ["phenol", "SIMPLE_CHEMICAL", 181, 187], ["phenol", "SIMPLE_CHEMICAL", 228, 234], ["intestinal segment", "MULTI-TISSUE_STRUCTURE", 297, 315], ["intestinal segment", "MULTI-TISSUE_STRUCTURE", 326, 344], ["PR", "PROTEIN", 162, 164], ["PR", "PROTEIN", 207, 209], ["effluent drug concentration", "TREATMENT", 21, 48], ["effluent drug concentration", "TREATMENT", 76, 103], ["influent drug concentration", "TREATMENT", 133, 160], ["PR", "TREATMENT", 162, 164], ["influent phenol red concentration", "TREATMENT", 172, 205], ["PR", "TEST", 207, 209], ["effluent phenol red concentration", "TREATMENT", 219, 252], ["perfusate flow rate", "TEST", 260, 279], ["radius", "ANATOMY_MODIFIER", 287, 293], ["intestinal", "ANATOMY", 297, 307], ["segment", "ANATOMY_MODIFIER", 308, 315], ["l", "ANATOMY_MODIFIER", 320, 321], ["intestinal", "ANATOMY", 326, 336], ["segment", "ANATOMY_MODIFIER", 337, 344], ["length", "OBSERVATION_MODIFIER", 345, 351]]], ["InhibitionPharmacokinetic analysisThe peak concentrations (C max ) and the time to reach the peak concentrations (T max ) were determined directly from the plasma concentration-time profiles.", [["plasma", "ANATOMY", 156, 162], ["plasma", "ORGANISM_SUBSTANCE", 156, 162], ["InhibitionPharmacokinetic analysis", "TEST", 0, 34], ["The peak concentrations", "TEST", 34, 57], ["the peak concentrations", "TEST", 89, 112], ["the plasma concentration", "TEST", 152, 176]]], ["The area under the curve (AUC) was calculated by the trapezoidal method from time zero to the final sampling.", [["the final sampling", "TEST", 90, 108], ["curve", "OBSERVATION_MODIFIER", 19, 24]]], ["The absorption enhancement ratios of drugs with or without enhancers were calculated as Absorption enhancement ratio = AUC with enhancer /AUC control(without enhancer).Statistical analysisStatistical significance in the P app , P eff values, pharmacokinetic parameters and inhibition rate index obtained from various treatment groups was estimated by the analysis of variance (Student t-test) or one-way ANOVA.", [["enhancers", "DNA", 59, 68], ["The absorption enhancement ratios of drugs", "PROBLEM", 0, 42], ["Absorption enhancement ratio", "TEST", 88, 116], ["AUC", "TEST", 119, 122], ["enhancer /AUC control", "TREATMENT", 128, 149], ["the P app", "TEST", 216, 225], ["P eff values", "TEST", 228, 240], ["pharmacokinetic parameters", "TEST", 242, 268], ["inhibition rate index", "TEST", 273, 294], ["various treatment groups", "TREATMENT", 309, 333], ["Student t-test", "TEST", 377, 391]]], ["A p value of less than 0.05 was considered to be significantly different.", [["A p value", "TEST", 0, 9]]], ["All data were expressed as mean \u00b1 SD.ResultsEffect of COS on the P app -value of phenolic acids in the apical-to-basolateral (AP-BL) direction in vitro Caco-2 monolayer model As shown in Fig. 4 , COS at the low, medium and high concentrations caused a significant, concentration-dependent increase in the P app -value for neochlorogenic acid, chlorogenic acid, cryptochlorogenic acid, 3,5-dicaffeoylquinic acid and 3,4-dicaffeoylquinic acid compared to the control group (p < 0.05).", [["apical", "ANATOMY", 103, 109], ["basolateral", "ANATOMY", 113, 124], ["Caco-2 monolayer", "ANATOMY", 152, 168], ["phenolic acids", "CHEMICAL", 81, 95], ["neochlorogenic acid", "CHEMICAL", 322, 341], ["chlorogenic acid", "CHEMICAL", 343, 359], ["cryptochlorogenic acid", "CHEMICAL", 361, 383], ["3,5-dicaffeoylquinic acid", "CHEMICAL", 385, 410], ["3,4-dicaffeoylquinic acid", "CHEMICAL", 415, 440], ["phenolic acids", "CHEMICAL", 81, 95], ["neochlorogenic acid", "CHEMICAL", 322, 341], ["chlorogenic acid", "CHEMICAL", 343, 359], ["cryptochlorogenic acid", "CHEMICAL", 361, 383], ["3,5-dicaffeoylquinic acid", "CHEMICAL", 385, 410], ["3,4-dicaffeoylquinic acid", "CHEMICAL", 415, 440], ["phenolic acids", "SIMPLE_CHEMICAL", 81, 95], ["basolateral", "MULTI-TISSUE_STRUCTURE", 113, 124], ["Caco-2 monolayer", "CELL", 152, 168], ["neochlorogenic acid", "SIMPLE_CHEMICAL", 322, 341], ["chlorogenic acid", "SIMPLE_CHEMICAL", 343, 359], ["cryptochlorogenic acid", "SIMPLE_CHEMICAL", 361, 383], ["3,5-dicaffeoylquinic acid", "SIMPLE_CHEMICAL", 385, 410], ["3,4-dicaffeoylquinic acid", "SIMPLE_CHEMICAL", 415, 440], ["Caco-2 monolayer model", "CELL_LINE", 152, 174], ["the P app", "TEST", 61, 70], ["phenolic acids", "TEST", 81, 95], ["vitro Caco", "TREATMENT", 146, 156], ["dependent increase", "PROBLEM", 279, 297], ["the P app", "TEST", 301, 310], ["neochlorogenic acid", "TEST", 322, 341], ["chlorogenic acid", "TEST", 343, 359], ["cryptochlorogenic acid", "TEST", 361, 383], ["dicaffeoylquinic acid", "TREATMENT", 389, 410], ["dicaffeoylquinic acid", "TREATMENT", 419, 440], ["phenolic acids", "OBSERVATION", 81, 95], ["apical", "ANATOMY_MODIFIER", 103, 109], ["basolateral", "ANATOMY_MODIFIER", 113, 124], ["significant", "OBSERVATION_MODIFIER", 252, 263], ["dependent", "OBSERVATION_MODIFIER", 279, 288], ["increase", "OBSERVATION_MODIFIER", 289, 297]]], ["The highest P app -value for neochlorogenic acid, chlorogenic acid, cryptochlorogenic acid, 3,5-dicaffeoylquinic acid and 3,4-dicaffeoylquinic acid was increased to 5700% (9.11 \u00b1 0.43) \u00d7 10 \u22126 cm/s, 9800% (18.97 \u00b1 3.35) \u00d7 10 \u22126 cm/s, 12,800% (14.10 \u00b1 1.4) \u00d7 10 \u22126 cm/s, 3900% (13.90 \u00b1 0.10) \u00d7 10 \u22126 cm/s and 9800% (13.00 \u00b1 0.30) \u00d7 10 \u22126 cm/s with addition of 0.1% (w/v) of COS.Effect of COS on the bioavailability of phenolic acids in situ single pass intestinal perfusion modelAs shown in Fig. 5 , COS led to dose-dependent P eff -values of neochlorogenic acid, chlorogenic acid, cryptochlorogenic acid in duodenum and ileum, but in jejunum COS at low dose yielded maximum absorption, and the P eff -values of 3,5-dicaffeoylquinic acid in duodenum and ileum showed dose-dependent manner, but in jejunum COS at moderate concentration reached maximum absorption.", [["intestinal", "ANATOMY", 452, 462], ["duodenum", "ANATOMY", 607, 615], ["ileum", "ANATOMY", 620, 625], ["jejunum", "ANATOMY", 634, 641], ["duodenum", "ANATOMY", 740, 748], ["ileum", "ANATOMY", 753, 758], ["jejunum", "ANATOMY", 796, 803], ["neochlorogenic acid", "CHEMICAL", 29, 48], ["chlorogenic acid", "CHEMICAL", 50, 66], ["cryptochlorogenic acid", "CHEMICAL", 68, 90], ["3,5-dicaffeoylquinic acid", "CHEMICAL", 92, 117], ["3,4-dicaffeoylquinic acid", "CHEMICAL", 122, 147], ["COS", "CHEMICAL", 387, 390], ["phenolic acids", "CHEMICAL", 417, 431], ["neochlorogenic acid", "CHEMICAL", 542, 561], ["chlorogenic acid", "CHEMICAL", 563, 579], ["cryptochlorogenic acid", "CHEMICAL", 581, 603], ["COS", "CHEMICAL", 642, 645], ["3,5-dicaffeoylquinic acid", "CHEMICAL", 711, 736], ["COS", "CHEMICAL", 804, 807], ["neochlorogenic acid", "CHEMICAL", 29, 48], ["chlorogenic acid", "CHEMICAL", 50, 66], ["cryptochlorogenic acid", "CHEMICAL", 68, 90], ["3,5-dicaffeoylquinic acid", "CHEMICAL", 92, 117], ["3,4-dicaffeoylquinic acid", "CHEMICAL", 122, 147], ["phenolic acids", "CHEMICAL", 417, 431], ["neochlorogenic acid", "CHEMICAL", 542, 561], ["chlorogenic acid", "CHEMICAL", 563, 579], ["cryptochlorogenic acid", "CHEMICAL", 581, 603], ["3,5-dicaffeoylquinic acid", "CHEMICAL", 711, 736], ["neochlorogenic acid", "SIMPLE_CHEMICAL", 29, 48], ["chlorogenic acid", "SIMPLE_CHEMICAL", 50, 66], ["cryptochlorogenic acid", "SIMPLE_CHEMICAL", 68, 90], ["3,5-dicaffeoylquinic acid", "SIMPLE_CHEMICAL", 92, 117], ["3,4-dicaffeoylquinic acid", "SIMPLE_CHEMICAL", 122, 147], ["phenolic acids", "SIMPLE_CHEMICAL", 417, 431], ["intestinal", "ORGAN", 452, 462], ["neochlorogenic acid", "SIMPLE_CHEMICAL", 542, 561], ["chlorogenic acid", "SIMPLE_CHEMICAL", 563, 579], ["cryptochlorogenic acid", "SIMPLE_CHEMICAL", 581, 603], ["duodenum", "MULTI-TISSUE_STRUCTURE", 607, 615], ["ileum", "ORGAN", 620, 625], ["jejunum", "ORGAN", 634, 641], ["3,5-dicaffeoylquinic acid", "SIMPLE_CHEMICAL", 711, 736], ["duodenum", "MULTI-TISSUE_STRUCTURE", 740, 748], ["ileum", "ORGAN", 753, 758], ["jejunum", "ORGAN", 796, 803], ["neochlorogenic acid", "TEST", 29, 48], ["chlorogenic acid", "TEST", 50, 66], ["cryptochlorogenic acid", "TEST", 68, 90], ["dicaffeoylquinic acid", "TEST", 96, 117], ["dicaffeoylquinic acid", "TEST", 126, 147], ["cm/s", "TEST", 264, 268], ["cm/s", "TEST", 299, 303], ["cm/s", "TEST", 337, 341], ["COS", "PROBLEM", 373, 376], ["phenolic acids", "TREATMENT", 417, 431], ["neochlorogenic acid", "TEST", 542, 561], ["chlorogenic acid", "TEST", 563, 579], ["cryptochlorogenic acid in duodenum and ileum", "PROBLEM", 581, 625], ["maximum absorption", "TEST", 666, 684], ["the P eff -values", "TEST", 690, 707], ["phenolic acids", "OBSERVATION", 417, 431], ["intestinal", "ANATOMY", 452, 462], ["perfusion model", "OBSERVATION", 463, 478], ["duodenum", "ANATOMY", 607, 615], ["ileum", "ANATOMY", 620, 625], ["jejunum", "ANATOMY", 634, 641], ["duodenum", "ANATOMY", 740, 748], ["ileum", "ANATOMY", 753, 758], ["jejunum", "ANATOMY", 796, 803]]], ["Besides, COS gave P eff -values of 3,4-dicaffeoylquinic acid in a dose-dependent manner in duodenum and jejunum, but at moderate dose made 3,4-dicaffeoylquinic acid was absorbed maximally in ileum.", [["duodenum", "ANATOMY", 91, 99], ["jejunum", "ANATOMY", 104, 111], ["ileum", "ANATOMY", 191, 196], ["3,4-dicaffeoylquinic acid", "CHEMICAL", 35, 60], ["3,4-dicaffeoylquinic acid", "CHEMICAL", 139, 164], ["3,4-dicaffeoylquinic acid", "CHEMICAL", 35, 60], ["3,4-dicaffeoylquinic acid", "CHEMICAL", 139, 164], ["3,4-dicaffeoylquinic acid", "SIMPLE_CHEMICAL", 35, 60], ["duodenum", "MULTI-TISSUE_STRUCTURE", 91, 99], ["jejunum", "ORGAN", 104, 111], ["3,4-dicaffeoylquinic acid", "SIMPLE_CHEMICAL", 139, 164], ["ileum", "MULTI-TISSUE_STRUCTURE", 191, 196], ["P eff -values", "TEST", 18, 31], ["dicaffeoylquinic acid", "TREATMENT", 39, 60], ["dicaffeoylquinic acid", "TREATMENT", 143, 164], ["duodenum", "ANATOMY", 91, 99], ["jejunum", "ANATOMY", 104, 111], ["ileum", "ANATOMY", 191, 196]]], ["The results indicated that the intestinal absorption of phenolic acids can be enhanced by COS.", [["intestinal", "ANATOMY", 31, 41], ["phenolic acids", "CHEMICAL", 56, 70], ["phenolic acids", "CHEMICAL", 56, 70], ["intestinal", "ORGAN", 31, 41], ["phenolic acids", "SIMPLE_CHEMICAL", 56, 70], ["the intestinal absorption of phenolic acids", "PROBLEM", 27, 70], ["intestinal", "ANATOMY", 31, 41], ["phenolic acids", "OBSERVATION", 56, 70]]], ["Meanwhile, the absorption enhancing effect of phenolic acids might be saturable in different intestine sites.Effect of COS on the bioavailability of phenolic acids in vivo pharmacokinetics studyAs shown in Fig. 6 192% (27,442 .00 \u00b1 2691.25) ng min/ml, 170% (26,936.00 \u00b1 3834.91) ng min/ml and 177% (26,052.00 \u00b1 2140.68) ng min/ml, respectively with the addition of COS at the dosage of 25 mg/kg, although we found that in the previous study that COS at the dosage of 25 mg/kg could result in the maximum enhancing absorption for polyphenol components like chlorogenic acid (unpublished).", [["intestine sites", "ANATOMY", 93, 108], ["phenolic acids", "CHEMICAL", 46, 60], ["COS", "CHEMICAL", 119, 122], ["phenolic acids", "CHEMICAL", 149, 163], ["COS", "CHEMICAL", 365, 368], ["COS", "CHEMICAL", 446, 449], ["polyphenol", "CHEMICAL", 529, 539], ["chlorogenic acid", "CHEMICAL", 556, 572], ["phenolic acids", "CHEMICAL", 46, 60], ["phenolic acids", "CHEMICAL", 149, 163], ["polyphenol", "CHEMICAL", 529, 539], ["chlorogenic acid", "CHEMICAL", 556, 572], ["phenolic acids", "SIMPLE_CHEMICAL", 46, 60], ["intestine sites", "MULTI-TISSUE_STRUCTURE", 93, 108], ["phenolic acids", "SIMPLE_CHEMICAL", 149, 163], ["polyphenol", "SIMPLE_CHEMICAL", 529, 539], ["chlorogenic acid", "SIMPLE_CHEMICAL", 556, 572], ["phenolic acids", "TREATMENT", 46, 60], ["phenolic acids", "TREATMENT", 149, 163], ["vivo pharmacokinetics study", "TEST", 167, 194], ["COS", "TREATMENT", 365, 368], ["the previous study", "TEST", 422, 440], ["the maximum enhancing absorption", "PROBLEM", 492, 524], ["polyphenol components", "TREATMENT", 529, 550], ["chlorogenic acid", "TEST", 556, 572], ["enhancing", "OBSERVATION_MODIFIER", 26, 35], ["phenolic acids", "OBSERVATION", 46, 60], ["intestine", "ANATOMY", 93, 102], ["chlorogenic acid", "OBSERVATION", 556, 572]]], ["Therefore, these findings indicated that 25 mg/kg COS would be the promising enhancer for improving the bioavailability of phenolic acids in Flos Lonicerae extract in rats.Effect of Flos Lonicerae extract with or without COS on influenza virusAs shown in Fig. 7(A) , the antiviral model was built successfully, and the inhibition rate of COS group was no significant compared with that of PBS group, although there was a remarkable increase in inhibition rate value after administrating orally 20 mg/kg ribavirin as a positive control.", [["COS", "CHEMICAL", 50, 53], ["phenolic acids", "CHEMICAL", 123, 137], ["Flos Lonicerae extract", "CHEMICAL", 141, 163], ["Flos Lonicerae extract", "CHEMICAL", 182, 204], ["COS", "CHEMICAL", 221, 224], ["influenza virusAs", "DISEASE", 228, 245], ["ribavirin", "CHEMICAL", 503, 512], ["phenolic acids", "CHEMICAL", 123, 137], ["ribavirin", "CHEMICAL", 503, 512], ["COS", "SIMPLE_CHEMICAL", 50, 53], ["phenolic acids", "SIMPLE_CHEMICAL", 123, 137], ["Flos", "SIMPLE_CHEMICAL", 141, 145], ["rats", "ORGANISM", 167, 171], ["COS", "CELL", 338, 341], ["ribavirin", "SIMPLE_CHEMICAL", 503, 512], ["rats", "SPECIES", 167, 171], ["phenolic acids", "TREATMENT", 123, 137], ["Flos Lonicerae extract", "TREATMENT", 182, 204], ["COS", "PROBLEM", 221, 224], ["influenza virusAs", "PROBLEM", 228, 245], ["the antiviral model", "TREATMENT", 267, 286], ["the inhibition rate", "TEST", 315, 334], ["a remarkable increase in inhibition rate value", "PROBLEM", 419, 465], ["ribavirin", "TREATMENT", 503, 512], ["a positive control", "TREATMENT", 516, 534], ["phenolic acids", "OBSERVATION", 123, 137], ["Flos Lonicerae", "OBSERVATION", 182, 196], ["remarkable", "OBSERVATION_MODIFIER", 421, 431], ["increase", "OBSERVATION_MODIFIER", 432, 440]]], ["However, the difference of antiviral activity between Flos Lonicerae extract with or without COS was significant from Fig. 7(B) .", [["Flos Lonicerae extract", "CHEMICAL", 54, 76], ["Flos Lonicerae", "ORGANISM", 54, 68], ["antiviral activity", "TREATMENT", 27, 45], ["Flos Lonicerae extract", "TREATMENT", 54, 76], ["antiviral activity", "OBSERVATION", 27, 45]]], ["The inhibition rate of Flos Lonicerae extract with COS at dosage of 25 mg/kg was higher than that of without COS, which indicated that the pharmacological effects such as antiviral effect of Flos Lonicerae extract could be significantly improved by addition of COS.", [["Flos Lonicerae extract", "CHEMICAL", 23, 45], ["COS", "CHEMICAL", 51, 54], ["Flos Lonicerae extract", "CHEMICAL", 191, 213], ["Flos Lonicerae", "SIMPLE_CHEMICAL", 23, 37], ["COS", "SIMPLE_CHEMICAL", 51, 54], ["Flos", "SIMPLE_CHEMICAL", 191, 195], ["The inhibition rate of Flos Lonicerae extract", "TREATMENT", 0, 45], ["COS at dosage", "TREATMENT", 51, 64], ["the pharmacological effects", "PROBLEM", 135, 162], ["antiviral effect of Flos Lonicerae extract", "TREATMENT", 171, 213]]], ["Plasma concentration-time profiles of phenolic acids in Flos Lonicerae extract (equivalent to 96.6 mg/kg for neochlorogenic acid, 101.4 mg/kg for chlorogenic acid, 99.6 mg.kg for cryptochlorogenic acid, 113.4 mg/kg for 3,5-dicaffeoylquinic acid and 226.8 mg/kg for 3,4-dicaffeoylquinic acid) with COS after administration to the rat gastrointestine by in vivo pharmacokinetics study.", [["gastrointestine", "ANATOMY", 333, 348], ["phenolic acids", "CHEMICAL", 38, 52], ["Flos Lonicerae extract", "CHEMICAL", 56, 78], ["neochlorogenic acid", "CHEMICAL", 109, 128], ["chlorogenic acid", "CHEMICAL", 146, 162], ["cryptochlorogenic acid", "CHEMICAL", 179, 201], ["3,5-dicaffeoylquinic acid", "CHEMICAL", 219, 244], ["3,4-dicaffeoylquinic acid", "CHEMICAL", 265, 290], ["COS", "CHEMICAL", 297, 300], ["phenolic acids", "CHEMICAL", 38, 52], ["neochlorogenic acid", "CHEMICAL", 109, 128], ["chlorogenic acid", "CHEMICAL", 146, 162], ["cryptochlorogenic acid", "CHEMICAL", 179, 201], ["3,5-dicaffeoylquinic acid", "CHEMICAL", 219, 244], ["3,4-dicaffeoylquinic acid", "CHEMICAL", 265, 290], ["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["phenolic acids", "SIMPLE_CHEMICAL", 38, 52], ["neochlorogenic acid", "SIMPLE_CHEMICAL", 109, 128], ["chlorogenic acid", "SIMPLE_CHEMICAL", 146, 162], ["cryptochlorogenic acid", "SIMPLE_CHEMICAL", 179, 201], ["3,5-dicaffeoylquinic acid", "SIMPLE_CHEMICAL", 219, 244], ["3,4-dicaffeoylquinic acid", "SIMPLE_CHEMICAL", 265, 290], ["rat", "ORGANISM", 329, 332], ["gastrointestine", "CELL", 333, 348], ["rat", "SPECIES", 329, 332], ["rat", "SPECIES", 329, 332], ["Plasma concentration", "TEST", 0, 20], ["phenolic acids", "TREATMENT", 38, 52], ["Flos Lonicerae extract", "TREATMENT", 56, 78], ["neochlorogenic acid", "TREATMENT", 109, 128], ["chlorogenic acid", "TEST", 146, 162], ["cryptochlorogenic acid", "TREATMENT", 179, 201], ["dicaffeoylquinic acid", "TREATMENT", 223, 244], ["dicaffeoylquinic acid", "TREATMENT", 269, 290], ["vivo pharmacokinetics study", "TEST", 355, 382], ["phenolic acids", "OBSERVATION", 38, 52]]], ["Results are expressed as the mean \u00b1 S.D. of 3-5 experiments.DiscussionsIn the present study, we found from Fig. 2 and Table 1 that 24 peaks were detected in dosed plasma with or without COS but not in control plasma by comparing the chemical profiles of dosed plasma with control plasma in negative ion mode.", [["plasma", "ANATOMY", 163, 169], ["plasma", "ANATOMY", 209, 215], ["plasma", "ANATOMY", 260, 266], ["plasma", "ANATOMY", 280, 286], ["plasma", "ORGANISM_SUBSTANCE", 163, 169], ["plasma", "ORGANISM_SUBSTANCE", 209, 215], ["plasma", "ORGANISM_SUBSTANCE", 260, 266], ["plasma", "ORGANISM_SUBSTANCE", 280, 286], ["the present study", "TEST", 74, 91], ["COS", "TREATMENT", 186, 189]]], ["Among these peaks, phenolic acids and flavonoids aglycone containing 12 peaks also appeared in the MS spectra of Flos Lonicerae extract, indicating that these components may be absorbed into the rat plasma in the original form.", [["plasma", "ANATOMY", 199, 205], ["phenolic acids", "CHEMICAL", 19, 33], ["flavonoids aglycone", "CHEMICAL", 38, 57], ["Flos Lonicerae extract", "CHEMICAL", 113, 135], ["phenolic acids", "CHEMICAL", 19, 33], ["flavonoids", "CHEMICAL", 38, 48], ["phenolic acids", "SIMPLE_CHEMICAL", 19, 33], ["flavonoids aglycone", "SIMPLE_CHEMICAL", 38, 57], ["rat", "ORGANISM", 195, 198], ["plasma", "ORGANISM_SUBSTANCE", 199, 205], ["rat plasma", "CELL_TYPE", 195, 205], ["rat", "SPECIES", 195, 198], ["rat", "SPECIES", 195, 198], ["phenolic acids", "TREATMENT", 19, 33], ["flavonoids aglycone", "TREATMENT", 38, 57], ["Flos Lonicerae extract", "TREATMENT", 113, 135], ["peaks", "OBSERVATION_MODIFIER", 12, 17], ["phenolic acids", "OBSERVATION", 19, 33], ["flavonoids aglycone", "OBSERVATION", 38, 57], ["Flos Lonicerae", "OBSERVATION", 113, 127]]], ["The result was consistent with the previous report that flavonoids glucoside like galuteolin, luteolin-7-o-\u2424-d-glucopyranoside, luteolin-7-o-\u2424-d-galactoside, hyperin, Table 2 Pharmacokinetic parameter of chlorogenic acid, neochlorogenic acid, cryptochlorogenic acid, 3,4-dicaffeoylquinic acid and 3,5-dicaffeoylquinic acid in rats after oral administration of Flos Lonicerae extracts with or without the addition of COS (mean \u00b1 S.D., n = 5).Cmax (ng/ml)Tmax ( hyperoside and rutin cannot be well absorbed into Caco-2 cell, which suggested that most of flavonoids glycosides needed to be transformed into flavonoids aglycone, and then be absorbed into the plasma Fig. 8 , and the real active ingredients in flavonoids may be flavonoids aglycone, not flavonoids glycosides.", [["oral", "ANATOMY", 337, 341], ["extracts", "ANATOMY", 375, 383], ["Caco-2 cell", "ANATOMY", 510, 521], ["plasma", "ANATOMY", 655, 661], ["flavonoids glucoside", "CHEMICAL", 56, 76], ["galuteolin", "CHEMICAL", 82, 92], ["luteolin-7-o-\u2424-d-glucopyranoside", "CHEMICAL", 94, 126], ["luteolin-7-o-\u2424-d-galactoside", "CHEMICAL", 128, 156], ["hyperin", "CHEMICAL", 158, 165], ["chlorogenic acid", "CHEMICAL", 204, 220], ["neochlorogenic acid", "CHEMICAL", 222, 241], ["cryptochlorogenic acid", "CHEMICAL", 243, 265], ["3,4-dicaffeoylquinic acid", "CHEMICAL", 267, 292], ["3,5-dicaffeoylquinic acid", "CHEMICAL", 297, 322], ["Flos Lonicerae", "CHEMICAL", 360, 374], ["Cmax", "CHEMICAL", 441, 445], ["hyperoside", "CHEMICAL", 460, 470], ["rutin", "CHEMICAL", 475, 480], ["flavonoids aglycone", "CHEMICAL", 604, 623], ["flavonoids", "CHEMICAL", 706, 716], ["flavonoids aglycone", "CHEMICAL", 724, 743], ["flavonoids glycosides", "CHEMICAL", 749, 770], ["flavonoids glucoside", "CHEMICAL", 56, 76], ["galuteolin", "CHEMICAL", 82, 92], ["luteolin-7-o-\u2424-d-glucopyranoside", "CHEMICAL", 94, 126], ["luteolin-7-o-\u2424-d-galactoside", "CHEMICAL", 128, 156], ["hyperin", "CHEMICAL", 158, 165], ["chlorogenic acid", "CHEMICAL", 204, 220], ["neochlorogenic acid", "CHEMICAL", 222, 241], ["cryptochlorogenic acid", "CHEMICAL", 243, 265], ["3,4-dicaffeoylquinic acid", "CHEMICAL", 267, 292], ["3,5-dicaffeoylquinic acid", "CHEMICAL", 297, 322], ["hyperoside", "CHEMICAL", 460, 470], ["rutin", "CHEMICAL", 475, 480], ["flavonoids glycosides", "CHEMICAL", 552, 573], ["flavonoids", "CHEMICAL", 604, 614], ["flavonoids", "CHEMICAL", 706, 716], ["flavonoids", "CHEMICAL", 724, 734], ["flavonoids glycosides", "CHEMICAL", 749, 770], ["flavonoids glucoside", "SIMPLE_CHEMICAL", 56, 76], ["galuteolin", "SIMPLE_CHEMICAL", 82, 92], ["luteolin-7-o-\u2424-d-glucopyranoside", "SIMPLE_CHEMICAL", 94, 126], ["luteolin-7-o-\u2424-d-galactoside", "SIMPLE_CHEMICAL", 128, 156], ["hyperin", "SIMPLE_CHEMICAL", 158, 165], ["chlorogenic acid", "SIMPLE_CHEMICAL", 204, 220], ["neochlorogenic acid", "SIMPLE_CHEMICAL", 222, 241], ["cryptochlorogenic acid", "SIMPLE_CHEMICAL", 243, 265], ["3,4-dicaffeoylquinic acid", "SIMPLE_CHEMICAL", 267, 292], ["3,5-dicaffeoylquinic acid", "SIMPLE_CHEMICAL", 297, 322], ["rats", "ORGANISM", 326, 330], ["oral", "ORGANISM_SUBDIVISION", 337, 341], ["Cmax", "SIMPLE_CHEMICAL", 441, 445], ["hyperoside", "SIMPLE_CHEMICAL", 460, 470], ["rutin", "SIMPLE_CHEMICAL", 475, 480], ["Caco-2 cell", "CELL", 510, 521], ["flavonoids glycosides", "SIMPLE_CHEMICAL", 552, 573], ["flavonoids aglycone", "SIMPLE_CHEMICAL", 604, 623], ["plasma", "ORGANISM_SUBSTANCE", 655, 661], ["flavonoids", "SIMPLE_CHEMICAL", 706, 716], ["flavonoids aglycone", "SIMPLE_CHEMICAL", 724, 743], ["flavonoids glycosides", "SIMPLE_CHEMICAL", 749, 770], ["Caco-2 cell", "CELL_LINE", 510, 521], ["rats", "SPECIES", 326, 330], ["flavonoids glucoside", "TEST", 56, 76], ["galuteolin", "TEST", 82, 92], ["luteolin", "TEST", 94, 102], ["glucopyranoside", "TREATMENT", 111, 126], ["luteolin", "TREATMENT", 128, 136], ["d-galactoside", "TREATMENT", 143, 156], ["chlorogenic acid", "TEST", 204, 220], ["neochlorogenic acid", "TEST", 222, 241], ["cryptochlorogenic acid", "TEST", 243, 265], ["dicaffeoylquinic acid", "TEST", 271, 292], ["dicaffeoylquinic acid", "TREATMENT", 301, 322], ["oral administration of Flos Lonicerae extracts", "TREATMENT", 337, 383], ["Cmax", "TEST", 441, 445], ["rutin", "TREATMENT", 475, 480], ["flavonoids glycosides", "TREATMENT", 552, 573], ["flavonoids aglycone", "TREATMENT", 604, 623], ["flavonoids", "TREATMENT", 706, 716], ["flavonoids aglycone", "TREATMENT", 724, 743], ["flavonoids glycosides", "TREATMENT", 749, 770], ["consistent with", "UNCERTAINTY", 15, 30], ["active", "OBSERVATION_MODIFIER", 684, 690], ["ingredients", "OBSERVATION", 691, 702], ["flavonoids aglycone", "OBSERVATION", 724, 743]]], ["However, flavonoids glycosides in vivo can not be quantitative assessed well illustrated by Fig. 8 .", [["flavonoids glycosides", "CHEMICAL", 9, 30], ["flavonoids glycosides", "CHEMICAL", 9, 30], ["flavonoids glycosides", "SIMPLE_CHEMICAL", 9, 30], ["flavonoids glycosides", "TREATMENT", 9, 30], ["flavonoids glycosides", "OBSERVATION", 9, 30]]], ["Meanwhile, as shown in Fig. 7 , treatment with Flos Lonicerae extract with COS improves MDCK cell viability better after influenza virus propagation.", [["MDCK cell", "ANATOMY", 88, 97], ["Flos Lonicerae extract", "CHEMICAL", 47, 69], ["COS", "CHEMICAL", 75, 78], ["Flos Lonicerae", "SIMPLE_CHEMICAL", 47, 61], ["COS", "SIMPLE_CHEMICAL", 75, 78], ["MDCK cell", "CELL", 88, 97], ["influenza virus", "ORGANISM", 121, 136], ["MDCK cell", "CELL_LINE", 88, 97], ["influenza virus", "SPECIES", 121, 136], ["Flos Lonicerae extract", "TREATMENT", 47, 69], ["MDCK cell viability", "TREATMENT", 88, 107], ["influenza virus propagation", "PROBLEM", 121, 148]]], ["All evidence above supporting the hypothesis that phenolic acid can be considered as one of the important marker compounds to control the pharmacology of Flos Lonicerae extract.", [["phenolic acid", "CHEMICAL", 50, 63], ["Flos Lonicerae extract", "CHEMICAL", 154, 176], ["phenolic acid", "CHEMICAL", 50, 63], ["phenolic acid", "SIMPLE_CHEMICAL", 50, 63], ["Flos Lonicerae extract", "ORGANISM", 154, 176], ["phenolic acid", "TREATMENT", 50, 63]]], ["We also found that the absorption enhancing effect of COS for improving the intestinal absorption of phenolic acids was affected by their concentrations, a maximal absorption enhancing effect of COS was observed at a dosage of 25 mg/kg, not higher doses.", [["intestinal", "ANATOMY", 76, 86], ["COS", "CHEMICAL", 54, 57], ["phenolic acids", "CHEMICAL", 101, 115], ["COS", "CHEMICAL", 195, 198], ["phenolic acids", "CHEMICAL", 101, 115], ["COS", "SIMPLE_CHEMICAL", 54, 57], ["intestinal", "ORGAN", 76, 86], ["phenolic acids", "SIMPLE_CHEMICAL", 101, 115], ["COS", "SIMPLE_CHEMICAL", 195, 198], ["the absorption enhancing effect of COS", "PROBLEM", 19, 57], ["the intestinal absorption of phenolic acids", "PROBLEM", 72, 115], ["a maximal absorption enhancing effect of COS", "PROBLEM", 154, 198], ["absorption", "OBSERVATION_MODIFIER", 23, 33], ["enhancing", "OBSERVATION_MODIFIER", 34, 43], ["effect", "OBSERVATION_MODIFIER", 44, 50], ["intestinal", "ANATOMY", 76, 86], ["phenolic acids", "OBSERVATION", 101, 115]]], ["Gao et al. (2008) reported the absorption enhancing effect of chitosan hexamer for FD4 was dependent on its concentration, but its absorption enhancing effect was almost saturable up to 0.5% (w/v) from in situ loop method.", [["chitosan hexamer", "CHEMICAL", 62, 78], ["FD4", "CHEMICAL", 83, 86], ["chitosan hexamer", "SIMPLE_CHEMICAL", 62, 78], ["FD4", "SIMPLE_CHEMICAL", 83, 86], ["chitosan hexamer", "TREATMENT", 62, 78], ["its absorption enhancing effect", "PROBLEM", 127, 158]]], ["Therefore, our present result is consistent with the previous report and chitosan has some optimal concentrations to show the greatest absorption enhancing effects for improving the intestinal absorption of phenolic acids in Flos Lonicerae extract, although the type of chitosan was different.Cmax (ng/ml)The present study also demonstrated that the absorption of phenolic acids in Flos Lonicerae extract can be not only improved greatest, but also safety in gastrointestine by COS at the dosage of 25 mg/kg.", [["intestinal", "ANATOMY", 182, 192], ["gastrointestine", "ANATOMY", 459, 474], ["chitosan", "CHEMICAL", 73, 81], ["phenolic acids", "CHEMICAL", 207, 221], ["Flos Lonicerae extract", "CHEMICAL", 225, 247], ["chitosan", "CHEMICAL", 270, 278], ["Cmax", "CHEMICAL", 293, 297], ["phenolic acids", "CHEMICAL", 364, 378], ["Flos Lonicerae extract", "CHEMICAL", 382, 404], ["COS", "CHEMICAL", 478, 481], ["phenolic acids", "CHEMICAL", 207, 221], ["phenolic acids", "CHEMICAL", 364, 378], ["chitosan", "SIMPLE_CHEMICAL", 73, 81], ["intestinal", "ORGAN", 182, 192], ["phenolic acids", "SIMPLE_CHEMICAL", 207, 221], ["Flos", "SIMPLE_CHEMICAL", 225, 229], ["chitosan", "SIMPLE_CHEMICAL", 270, 278], ["Cmax", "SIMPLE_CHEMICAL", 293, 297], ["phenolic acids", "SIMPLE_CHEMICAL", 364, 378], ["Flos", "SIMPLE_CHEMICAL", 382, 386], ["gastrointestine", "SIMPLE_CHEMICAL", 459, 474], ["COS", "SIMPLE_CHEMICAL", 478, 481], ["chitosan", "TREATMENT", 73, 81], ["the greatest absorption enhancing effects", "PROBLEM", 122, 163], ["phenolic acids", "TREATMENT", 207, 221], ["The present study", "TEST", 305, 322], ["phenolic acids", "TREATMENT", 364, 378], ["Flos Lonicerae extract", "TREATMENT", 382, 404], ["consistent with", "UNCERTAINTY", 33, 48], ["intestinal", "ANATOMY", 182, 192], ["phenolic acids", "OBSERVATION", 207, 221], ["phenolic acids", "OBSERVATION", 364, 378]]], ["Meanwhile, Thanou et al. (2001 Thanou et al. ( , 2007 showed the effect of low viscosity grade Mono-N-Carboxymethyl Chitosan (LMCC), High low viscosity grade N-sulfonato-N,O-carboxymethy-lchitosan (SNOCC-60) on the absorption of low molecular weight heparin (LMWH), and found that the AUC values can be increased by 7 and 18 times, respectively by intraduodenally administration.", [["Mono-N-Carboxymethyl Chitosan", "CHEMICAL", 95, 124], ["LMCC", "CHEMICAL", 126, 130], ["N-sulfonato-N,O-carboxymethy-lchitosan", "CHEMICAL", 158, 196], ["SNOCC-60", "CHEMICAL", 198, 206], ["heparin", "CHEMICAL", 250, 257], ["LMWH", "CHEMICAL", 259, 263], ["Mono-N-Carboxymethyl Chitosan", "CHEMICAL", 95, 124], ["N-sulfonato-N,O-carboxymethy-lchitosan", "CHEMICAL", 158, 196], ["SNOCC-60", "CHEMICAL", 198, 206], ["-N-Carboxymethyl Chitosan", "SIMPLE_CHEMICAL", 99, 124], ["LMCC", "SIMPLE_CHEMICAL", 126, 130], ["N-sulfonato-N", "SIMPLE_CHEMICAL", 158, 171], ["O-carboxymethy-lchitosan", "SIMPLE_CHEMICAL", 172, 196], ["SNOCC-60", "SIMPLE_CHEMICAL", 198, 206], ["low molecular weight heparin", "SIMPLE_CHEMICAL", 229, 257], ["LMWH", "SIMPLE_CHEMICAL", 259, 263], ["low viscosity grade Mono", "PROBLEM", 75, 99], ["Carboxymethyl Chitosan (LMCC", "TREATMENT", 102, 130], ["High low viscosity", "PROBLEM", 133, 151], ["sulfonato", "TREATMENT", 160, 169], ["carboxymethy", "TREATMENT", 174, 186], ["low molecular weight heparin (LMWH", "TREATMENT", 229, 263], ["the AUC values", "TEST", 281, 295], ["low viscosity", "OBSERVATION_MODIFIER", 138, 151]]], ["Therefore, other chitosan derivatives as absorption enhancers need to be further investigated in order to improve the pharmacological effects of Flos Lonicerae extract better.", [["chitosan", "CHEMICAL", 17, 25], ["Flos Lonicerae extract", "CHEMICAL", 145, 167], ["chitosan derivatives", "SIMPLE_CHEMICAL", 17, 37], ["Flos", "SIMPLE_CHEMICAL", 145, 149], ["absorption enhancers", "DNA", 41, 61], ["other chitosan derivatives", "TREATMENT", 11, 37], ["absorption enhancers", "TREATMENT", 41, 61], ["Flos Lonicerae extract", "TREATMENT", 145, 167]]]], "PMC7320529": [["IntroductionThe Hajj is the largest pilgrimage of Muslims around the world that happens once a year in Mecca, Kingdom of Saudi Arabia (KSA).", [["largest", "OBSERVATION_MODIFIER", 28, 35]]], ["Approximately, 2\u20133 million people arrive each year to perform the rituals which are time bound.", [["people", "ORGANISM", 27, 33], ["people", "SPECIES", 27, 33]]], ["The Tawaf (the circumambulation seven times around the Kaaba) can range from 1.4 km to 4.1 km (depending on the crowd and which floor it is performed).", [["The Tawaf (the circumambulation", "TREATMENT", 0, 31]]], ["During the Ramy al-Jamarat (stoning of the pillars), for which the pilgrim walks from his tent in Mina to Jamarat bridge, the walking distance varies depending up on the location of the tent.", [["the pilgrim walks", "TREATMENT", 63, 80], ["his tent", "TREATMENT", 86, 94], ["Jamarat bridge", "TREATMENT", 106, 120], ["the tent", "TREATMENT", 182, 190]]], ["On an average, rituals of Hajj include long distance travel by foot (that involves walking 5\u201315 km some days) [2].", [["foot", "ORGANISM_SUBDIVISION", 63, 67], ["foot", "ANATOMY", 63, 67]]], ["Skin diseases were sparingly studied in the past [3,4] and there is a lack of scientific evidence concerning feet problems among Hajj pilgrims.", [["Skin", "ANATOMY", 0, 4], ["Skin diseases", "DISEASE", 0, 13], ["Skin", "ORGAN", 0, 4], ["feet", "ORGANISM_SUBDIVISION", 109, 113], ["Skin diseases", "PROBLEM", 0, 13], ["feet problems", "PROBLEM", 109, 122], ["diseases", "OBSERVATION", 5, 13]]], ["In 1997, a survey conducted among 1101 pilgrims randomly selected in Mina from all the Hajj pilgrims resulted in a 23% prevalence of cut wounds in their feet [5].", [["wounds", "ANATOMY", 137, 143], ["wounds", "DISEASE", 137, 143], ["wounds", "PATHOLOGICAL_FORMATION", 137, 143], ["cut wounds in their feet", "PROBLEM", 133, 157], ["wounds", "OBSERVATION", 137, 143], ["feet", "ANATOMY", 153, 157]]], ["In a more recent study in 2013, conducted at a mobile podiatric clinic at Mina, 31% of the consulting patients complained of blisters on their feet [2].", [["blisters", "ANATOMY", 125, 133], ["blisters", "DISEASE", 125, 133], ["patients", "ORGANISM", 102, 110], ["blisters", "PATHOLOGICAL_FORMATION", 125, 133], ["patients", "SPECIES", 102, 110], ["blisters on their feet", "PROBLEM", 125, 147], ["blisters", "OBSERVATION", 125, 133]]], ["As a part of a global study measuring the health problems of French pilgrims [6,7], information specific to feet problems with respect to walking during the Hajj was collected.Materials and methodsData were obtained during the 2013 Hajj from a cohort that was traveling from France to Mecca, with a specialized travel agency in Marseille, from October 3 to October 24, 2013.", [["feet", "ORGANISM_SUBDIVISION", 108, 112], ["a global study", "TEST", 13, 27], ["methodsData", "TEST", 190, 201]]], ["Symptoms pertaining to feet were collected by the use of an open-ended question.", [["feet", "ANATOMY", 23, 27], ["feet", "ORGAN", 23, 27], ["Symptoms", "PROBLEM", 0, 8], ["feet", "ANATOMY", 23, 27]]], ["Walking distances during the entire pilgrimage were estimated by the investigator.Materials and methodsAll statistical analyses were performed on STATA12.", [["STATA12", "GENE_OR_GENE_PRODUCT", 146, 153], ["STATA12", "PROTEIN", 146, 153], ["All statistical analyses", "TEST", 103, 127]]], ["Pearson\u2019s Chi-square test and Fisher\u2019s exact test, as appropriate, were applied to analyze the categorical variables.", [["Fisher\u2019s exact test", "TEST", 30, 49]]], ["All p values of 0.05 or less were considered significant.", [["All p values", "TEST", 0, 12]]], ["Body mass index (BMI) was calculated as weight (in kilograms) over square of the height (in meters).", [["Body", "ANATOMY", 0, 4], ["Body mass index", "TEST", 0, 15], ["BMI", "TEST", 17, 20], ["weight", "TEST", 40, 46], ["mass", "OBSERVATION", 5, 9]]], ["It was grouped according to guidelines given by the Center for Disease Control (www.cdc.gov): below 18.5: underweight, 18.5\u201324.9: normal, 25\u201329.9: overweight, above 30: obese.", [["underweight", "DISEASE", 106, 117], ["overweight", "DISEASE", 147, 157], ["overweight", "TEST", 147, 157], ["obese", "PROBLEM", 169, 174], ["obese", "OBSERVATION", 169, 174]]], ["BMI, sex, diabetes and age of the pilgrim were considered as major predictor variables for blisters on feet.ResultsThe cohort consisted of 129 pilgrims with a female to male ratio of 1.5:1 and a mean age of 62 years.", [["blisters", "ANATOMY", 91, 99], ["feet", "ANATOMY", 103, 107], ["diabetes", "DISEASE", 10, 18], ["blisters", "DISEASE", 91, 99], ["blisters", "PATHOLOGICAL_FORMATION", 91, 99], ["feet", "ORGANISM_SUBDIVISION", 103, 107], ["BMI", "PROBLEM", 0, 3], ["diabetes", "PROBLEM", 10, 18], ["the pilgrim", "PROBLEM", 30, 41], ["blisters on feet", "PROBLEM", 91, 107], ["diabetes", "OBSERVATION", 10, 18], ["blisters", "OBSERVATION", 91, 99], ["feet", "ANATOMY", 103, 107]]], ["The prevalence of general chronic diseases was as follows: hypertension (33.3%), diabetes (26.4%), chronic cardiac diseases (8.5%) and chronic respiratory diseases (3.9%).ResultsThe mean BMI for the entire cohort was 27.9 kg/m2 (95% CI = 27.1\u201328.8).", [["cardiac", "ANATOMY", 107, 114], ["respiratory", "ANATOMY", 143, 154], ["chronic diseases", "DISEASE", 26, 42], ["hypertension", "DISEASE", 59, 71], ["diabetes", "DISEASE", 81, 89], ["chronic cardiac diseases", "DISEASE", 99, 123], ["chronic respiratory diseases", "DISEASE", 135, 163], ["cardiac", "ORGAN", 107, 114], ["general chronic diseases", "PROBLEM", 18, 42], ["hypertension", "PROBLEM", 59, 71], ["diabetes", "PROBLEM", 81, 89], ["chronic cardiac diseases", "PROBLEM", 99, 123], ["chronic respiratory diseases", "PROBLEM", 135, 163], ["The mean BMI", "TEST", 178, 190], ["CI", "TEST", 233, 235], ["chronic", "OBSERVATION_MODIFIER", 26, 33], ["diseases", "OBSERVATION", 34, 42], ["hypertension", "OBSERVATION", 59, 71], ["chronic", "OBSERVATION_MODIFIER", 99, 106], ["cardiac", "ANATOMY", 107, 114], ["diseases", "OBSERVATION", 115, 123], ["chronic", "OBSERVATION_MODIFIER", 135, 142], ["respiratory diseases", "OBSERVATION", 143, 163]]], ["None of the pilgrims were underweight or had a BMI below 18.5.", [["underweight", "DISEASE", 26, 37], ["pilgrims", "ORGANISM", 12, 20], ["a BMI", "TEST", 45, 50]]], ["The mean BMI for females (28.9; 95% CI = 27.7\u201330.2) was significantly higher than males (26.5; 95% CI = 25.6\u201327.3).", [["The mean BMI", "TEST", 0, 12], ["females", "TEST", 17, 24], ["CI", "TEST", 36, 38], ["CI", "TEST", 99, 101]]], ["Almost one third (29.5%) of the cohort had a BMI over 30 and slightly more than one third (37.2%) had a BMI in the range of 25\u201330.", [["a BMI", "TEST", 43, 48], ["a BMI", "TEST", 102, 107]]], ["As shown in Fig. 1, the prevalence of obesity in females was 3 times more than in males (p = 0.005).ResultsThe estimated total distance walked during the entire pilgrimage was about 58 km.", [["obesity", "DISEASE", 38, 45], ["obesity", "PROBLEM", 38, 45], ["obesity", "OBSERVATION", 38, 45]]], ["This included Tawaf (total of 1.4 km per Tawaf, done thrice = 4.2 km), Sa\u2019ay (2.8 km per Sa\u2019ay, done twice = 5.6 km), Jamarat (total of 8 km round-trip from the tents to the Jamarat bridge, done 4 times equals 32 km) and miscellaneous walking to get to the pick-up points of the tour (about 16 km).ResultsIn the cohort, 31.8% reported blisters on the feet during the post-Hajj questionnaire (Table 1).", [["blisters", "ANATOMY", 335, 343], ["feet", "ANATOMY", 351, 355], ["blisters", "DISEASE", 335, 343], ["blisters", "PATHOLOGICAL_FORMATION", 335, 343], ["feet", "ORGANISM_SUBDIVISION", 351, 355], ["Sa\u2019ay", "TEST", 71, 76], ["Jamarat", "TEST", 118, 125], ["the Jamarat bridge", "TREATMENT", 170, 188], ["blisters on the feet", "PROBLEM", 335, 355], ["blisters", "OBSERVATION", 335, 343], ["feet", "ANATOMY", 351, 355]]], ["The prevalence was statistically higher in females and in pilgrims who were overweight or obese.", [["overweight or obese", "DISEASE", 76, 95], ["obese", "PROBLEM", 90, 95], ["higher", "OBSERVATION_MODIFIER", 33, 39], ["obese", "OBSERVATION", 90, 95]]], ["The results were significant when the normal BMI group or overweight group was compared with the obese, and not significant between the normal BMI group and the overweight group (Fig. 2).ResultsAmong the diabetic pilgrims, 29.4% reported blisters on their feet as compared with 32.6% among the non-diabetic pilgrims; however, the difference was not statistically significant (Table 1).ResultsOnly one pilgrim, who was female, obese and more than 60 years old, reported an infected blister of the foot.", [["blisters", "ANATOMY", 238, 246], ["blister", "ANATOMY", 481, 488], ["foot", "ANATOMY", 496, 500], ["overweight", "DISEASE", 58, 68], ["overweight", "DISEASE", 161, 171], ["diabetic", "DISEASE", 204, 212], ["blisters", "DISEASE", 238, 246], ["non-diabetic", "DISEASE", 294, 306], ["blister of the foot", "DISEASE", 481, 500], ["blisters", "PATHOLOGICAL_FORMATION", 238, 246], ["feet", "ORGANISM_SUBDIVISION", 256, 260], ["blister", "ORGANISM_SUBDIVISION", 481, 488], ["foot", "ORGANISM_SUBDIVISION", 496, 500], ["the diabetic pilgrims", "PROBLEM", 200, 221], ["blisters on their feet", "PROBLEM", 238, 260], ["the non-diabetic pilgrims", "PROBLEM", 290, 315], ["obese", "PROBLEM", 426, 431], ["an infected blister of the foot", "PROBLEM", 469, 500], ["obese", "OBSERVATION", 97, 102], ["normal", "OBSERVATION", 136, 142], ["diabetic", "OBSERVATION_MODIFIER", 204, 212], ["blisters", "OBSERVATION", 238, 246], ["feet", "ANATOMY", 256, 260], ["non-diabetic", "OBSERVATION_MODIFIER", 294, 306], ["pilgrims", "OBSERVATION", 307, 315], ["obese", "OBSERVATION", 426, 431], ["infected", "OBSERVATION_MODIFIER", 472, 480], ["blister", "OBSERVATION", 481, 488], ["foot", "ANATOMY", 496, 500]]], ["One male pilgrim who was obese and over 60 years old reported mycosis of his feet.", [["feet", "ANATOMY", 77, 81], ["mycosis", "DISEASE", 62, 69], ["pilgrim", "ORGANISM", 9, 16], ["feet", "ORGANISM_SUBDIVISION", 77, 81], ["obese", "PROBLEM", 25, 30], ["mycosis of his feet", "PROBLEM", 62, 81], ["obese", "OBSERVATION", 25, 30], ["mycosis", "OBSERVATION", 62, 69], ["feet", "ANATOMY", 77, 81]]], ["Also, 10.9% of the cohort reported sore legs and feet (Table 2).", [["sore legs", "ANATOMY", 35, 44], ["sore legs", "DISEASE", 35, 44], ["legs", "ORGANISM_SUBDIVISION", 40, 44], ["10.9%", "OBSERVATION_MODIFIER", 6, 11], ["legs", "ANATOMY", 40, 44], ["feet", "ANATOMY", 49, 53]]], ["Two pilgrims reported tendonitis and edema of their legs during Hajj.", [["edema", "ANATOMY", 37, 42], ["legs", "ANATOMY", 52, 56], ["tendonitis", "DISEASE", 22, 32], ["edema", "DISEASE", 37, 42], ["edema", "PATHOLOGICAL_FORMATION", 37, 42], ["legs", "ORGANISM_SUBDIVISION", 52, 56], ["tendonitis", "PROBLEM", 22, 32], ["edema of their legs", "PROBLEM", 37, 56], ["tendonitis", "OBSERVATION", 22, 32], ["edema", "OBSERVATION", 37, 42], ["legs", "ANATOMY", 52, 56]]], ["There was one case of necrotizing diabetic foot that was reported.ResultsOf the 76 pilgrims reporting foot ailments during the post-Hajj questionnaire (58.9%), one consulted the medical doctor during travel for blisters on feet.DiscussionAs far as this study is concerned, this is the first prospective study assessing the prevalence of feet problems in Hajj pilgrims.", [["foot", "ANATOMY", 43, 47], ["blisters", "ANATOMY", 211, 219], ["feet", "ANATOMY", 223, 227], ["necrotizing diabetic foot", "DISEASE", 22, 47], ["blisters", "DISEASE", 211, 219], ["foot", "ORGANISM_SUBDIVISION", 43, 47], ["foot", "ORGANISM_SUBDIVISION", 102, 106], ["blisters", "PATHOLOGICAL_FORMATION", 211, 219], ["feet", "ORGANISM_SUBDIVISION", 223, 227], ["feet", "ORGANISM_SUBDIVISION", 337, 341], ["necrotizing diabetic foot", "PROBLEM", 22, 47], ["foot ailments", "PROBLEM", 102, 115], ["blisters on feet", "PROBLEM", 211, 227], ["this study", "TEST", 248, 258], ["the first prospective study", "TEST", 281, 308], ["feet problems", "PROBLEM", 337, 350], ["necrotizing", "OBSERVATION_MODIFIER", 22, 33], ["diabetic", "OBSERVATION", 34, 42], ["foot", "ANATOMY", 43, 47], ["foot", "ANATOMY", 102, 106], ["ailments", "OBSERVATION", 107, 115], ["blisters", "OBSERVATION", 211, 219], ["feet", "ANATOMY", 223, 227], ["feet", "ANATOMY", 337, 341]]], ["The present report suggests that prevalence of blisters of feet is high among the Hajj pilgrims, which corroborates with the findings of another study conducted in the same year but in a podiatric clinic [2].", [["blisters", "ANATOMY", 47, 55], ["feet", "ANATOMY", 59, 63], ["blisters", "DISEASE", 47, 55], ["blisters", "PATHOLOGICAL_FORMATION", 47, 55], ["feet", "ORGANISM_SUBDIVISION", 59, 63], ["blisters of feet", "PROBLEM", 47, 63], ["another study", "TEST", 137, 150], ["blisters", "OBSERVATION", 47, 55], ["feet", "ANATOMY", 59, 63], ["high", "OBSERVATION_MODIFIER", 67, 71]]], ["However, this study measured the proportion of pilgrims seeking consultation who reported feet-related problems, whereas the present study included all the pilgrims irrespective of their consultation status.", [["this study", "TEST", 9, 19], ["related problems", "PROBLEM", 95, 111]]], ["Another significant finding was the difference in prevalence of blisters in males and females.", [["blisters", "ANATOMY", 64, 72], ["blisters", "DISEASE", 64, 72], ["blisters", "PATHOLOGICAL_FORMATION", 64, 72], ["blisters", "PROBLEM", 64, 72], ["significant", "OBSERVATION_MODIFIER", 8, 19], ["blisters", "OBSERVATION", 64, 72], ["males", "ANATOMY", 76, 81]]], ["This result is also consistent with that of a study conducted among the United States military deployed in Iraq where the overall prevalence of blisters was 33% and higher in females as compared with males [8].", [["blisters", "ANATOMY", 144, 152], ["blisters", "DISEASE", 144, 152], ["blisters", "PATHOLOGICAL_FORMATION", 144, 152], ["a study", "TEST", 44, 51], ["blisters", "PROBLEM", 144, 152], ["consistent with", "UNCERTAINTY", 20, 35], ["blisters", "OBSERVATION", 144, 152], ["higher", "OBSERVATION_MODIFIER", 165, 171]]], ["This might be due to the fact that males and females have different skin types and respond differently to mechanical stress [9].", [["skin", "ANATOMY", 68, 72], ["skin", "ORGAN", 68, 72], ["different skin types", "PROBLEM", 58, 78], ["males", "OBSERVATION", 35, 40]]], ["In addition, obesity has been identified as a key predictor of blisters on feet, and the prevalence of obesity is higher in females in the present study.", [["blisters", "ANATOMY", 63, 71], ["obesity", "DISEASE", 13, 20], ["blisters", "DISEASE", 63, 71], ["obesity", "DISEASE", 103, 110], ["blisters", "PATHOLOGICAL_FORMATION", 63, 71], ["feet", "ORGANISM_SUBDIVISION", 75, 79], ["obesity", "PROBLEM", 13, 20], ["blisters on feet", "PROBLEM", 63, 79], ["obesity", "PROBLEM", 103, 110], ["obesity", "OBSERVATION", 13, 20], ["blisters", "OBSERVATION", 63, 71], ["feet", "ANATOMY", 75, 79], ["obesity", "OBSERVATION", 103, 110], ["higher", "OBSERVATION_MODIFIER", 114, 120]]], ["It is known that excess weight alters the natural anatomy of the foot, thereby increasing the friction and pressure over bony prominences [10].", [["foot", "ANATOMY", 65, 69], ["foot", "ORGANISM_SUBDIVISION", 65, 69], ["excess weight", "PROBLEM", 17, 30], ["pressure over bony prominences", "PROBLEM", 107, 137], ["excess weight", "OBSERVATION", 17, 30], ["foot", "ANATOMY", 65, 69], ["increasing", "OBSERVATION_MODIFIER", 79, 89], ["friction", "OBSERVATION_MODIFIER", 94, 102], ["pressure", "OBSERVATION_MODIFIER", 107, 115]]], ["Finally, this problem might be compounded due to the hot climate in Saudi Arabia and poorly maintained hygienic conditions in the tents at Mina.", [["hygienic conditions", "OBSERVATION", 103, 122]]], ["Of note, 82.5% of the pilgrims with blisters were on antibiotics for either respiratory or gastro-intestinal complaints [6].", [["blisters", "ANATOMY", 36, 44], ["respiratory", "ANATOMY", 76, 87], ["intestinal", "ANATOMY", 98, 108], ["blisters", "DISEASE", 36, 44], ["respiratory or gastro-intestinal complaints", "DISEASE", 76, 119], ["pilgrims", "ORGANISM", 22, 30], ["blisters", "PATHOLOGICAL_FORMATION", 36, 44], ["intestinal", "ORGAN", 98, 108], ["blisters", "PROBLEM", 36, 44], ["antibiotics", "TREATMENT", 53, 64], ["respiratory or gastro-intestinal complaints", "PROBLEM", 76, 119], ["blisters", "OBSERVATION", 36, 44], ["intestinal", "ANATOMY", 98, 108]]], ["This might explain why the occurrence of skin infection was low in the cohort.", [["skin", "ANATOMY", 41, 45], ["skin infection", "DISEASE", 41, 55], ["skin", "ORGAN", 41, 45], ["skin infection", "PROBLEM", 41, 55], ["skin", "ANATOMY", 41, 45], ["infection", "OBSERVATION", 46, 55]]], ["Also, a sizable proportion of the cohort suffered from diabetes, including one case with diabetic foot.", [["diabetes", "DISEASE", 55, 63], ["diabetic foot", "DISEASE", 89, 102], ["foot", "ORGANISM_SUBDIVISION", 98, 102], ["diabetes", "PROBLEM", 55, 63], ["diabetic foot", "PROBLEM", 89, 102], ["sizable", "OBSERVATION_MODIFIER", 8, 15], ["proportion", "OBSERVATION_MODIFIER", 16, 26], ["diabetes", "OBSERVATION", 55, 63], ["diabetic", "OBSERVATION", 89, 97], ["foot", "ANATOMY", 98, 102]]], ["Diabetic foot is one of the leading causes for surgical admissions among pilgrims [11,12] and emphasizes the need for protecting the feet in order to prevent further complications.", [["Diabetic", "DISEASE", 0, 8], ["foot", "ORGANISM_SUBDIVISION", 9, 13], ["feet", "ORGANISM_SUBDIVISION", 133, 137], ["Diabetic foot", "PROBLEM", 0, 13], ["protecting the feet", "TREATMENT", 118, 137], ["further complications", "PROBLEM", 158, 179], ["foot", "ANATOMY", 9, 13], ["feet", "ANATOMY", 133, 137], ["complications", "OBSERVATION", 166, 179]]], ["Other foot complaints like callosity, erythema and dryness and ulcers may also affect the pilgrims as reported by a previous study [2].RecommendationsIt is essential that the sole of the shoe or sandal be flexible to reduce the impact of the ground on the feet.", [["foot", "ANATOMY", 6, 10], ["callosity", "DISEASE", 27, 36], ["erythema", "DISEASE", 38, 46], ["ulcers", "DISEASE", 63, 69], ["foot", "ORGANISM_SUBDIVISION", 6, 10], ["ulcers", "PATHOLOGICAL_FORMATION", 63, 69], ["feet", "ORGANISM_SUBDIVISION", 256, 260], ["Other foot complaints", "PROBLEM", 0, 21], ["callosity", "PROBLEM", 27, 36], ["erythema", "PROBLEM", 38, 46], ["dryness", "PROBLEM", 51, 58], ["ulcers", "PROBLEM", 63, 69], ["a previous study", "TEST", 114, 130], ["foot", "ANATOMY", 6, 10], ["erythema", "OBSERVATION", 38, 46], ["dryness", "OBSERVATION", 51, 58], ["ulcers", "OBSERVATION", 63, 69], ["ground", "ANATOMY_MODIFIER", 242, 248], ["feet", "ANATOMY", 256, 260]]], ["It is preferable for shoes to have soft padding, especially at the heel and at the balls of the feet.", [["heel", "ANATOMY", 67, 71], ["feet", "ANATOMY", 96, 100], ["heel", "ORGANISM_SUBDIVISION", 67, 71], ["feet", "ORGANISM_SUBDIVISION", 96, 100], ["soft padding", "TREATMENT", 35, 47], ["soft padding", "OBSERVATION_MODIFIER", 35, 47], ["heel", "ANATOMY", 67, 71], ["balls", "ANATOMY_MODIFIER", 83, 88], ["feet", "ANATOMY", 96, 100]]], ["Bigger size sandals tend to rub against the skin causing friction blisters, and smaller size sandals cause cramping of the toes and pressure sores.", [["skin", "ANATOMY", 44, 48], ["blisters", "ANATOMY", 66, 74], ["toes", "ANATOMY", 123, 127], ["blisters", "DISEASE", 66, 74], ["cramping of the toes", "DISEASE", 107, 127], ["skin", "ORGAN", 44, 48], ["toes", "ORGANISM_SUBDIVISION", 123, 127], ["Bigger size sandals", "PROBLEM", 0, 19], ["friction blisters", "PROBLEM", 57, 74], ["smaller size sandals", "PROBLEM", 80, 100], ["cramping of the toes", "PROBLEM", 107, 127], ["pressure sores", "PROBLEM", 132, 146], ["size", "OBSERVATION_MODIFIER", 7, 11], ["skin", "ANATOMY", 44, 48], ["friction", "OBSERVATION_MODIFIER", 57, 65], ["blisters", "OBSERVATION", 66, 74], ["smaller", "OBSERVATION_MODIFIER", 80, 87], ["size", "OBSERVATION_MODIFIER", 88, 92], ["cramping", "OBSERVATION", 107, 115], ["toes", "ANATOMY", 123, 127], ["pressure sores", "OBSERVATION", 132, 146]]], ["Wearing socks would definitely reduce the impact on the feet; however, due to religious restrictions, it may not be possible for the pilgrims to wear them.", [["feet", "ORGANISM_SUBDIVISION", 56, 60], ["socks", "TREATMENT", 8, 13], ["the impact on the feet", "PROBLEM", 38, 60], ["feet", "ANATOMY", 56, 60]]], ["Despite these precautions, if blisters occur, it is advisable to keep the feet dry and well-aired, which helps in reducing the chances of infection.", [["blisters", "ANATOMY", 30, 38], ["infection", "DISEASE", 138, 147], ["blisters", "PATHOLOGICAL_FORMATION", 30, 38], ["these precautions", "TREATMENT", 8, 25], ["blisters", "PROBLEM", 30, 38], ["infection", "PROBLEM", 138, 147], ["feet", "ANATOMY", 74, 78], ["dry", "OBSERVATION", 79, 82], ["infection", "OBSERVATION", 138, 147]]], ["A good moisturizer applied three times a day will also help reduce friction during walking [13].", [["A good moisturizer", "TREATMENT", 0, 18]]], ["Any infected blister must be assessed by medical personnel to avoid further complications.", [["blister", "ANATOMY", 13, 20], ["blister", "ORGANISM_SUBSTANCE", 13, 20], ["Any infected blister", "PROBLEM", 0, 20], ["further complications", "PROBLEM", 68, 89], ["infected", "OBSERVATION_MODIFIER", 4, 12], ["blister", "OBSERVATION", 13, 20]]]]}